##4071377
According	according	ii21
to	to	ii22
a	a	at1
recent	recent	jj
article	article	nn1
in	in	ii
the	the	at
New	new	np1
England	england	np1
Journal	journal	nn1
of	of	io
Medicine	medicine	nn1
,	,	y
total	total	jj
pharmaceutical	pharmaceutical	jj
industry	industry	nn1
spending	spend	vvg_nn1
on	on	ii
direct-to-consumer	direct-to-consumer	nn1_jj
(	(	y
DTC	dtc	np1
)	)	y
advertising	advertising	nn1
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
rose	rise	vvd
from	from	ii
$985	$985	nnu
million	million	m
in	in	ii
1996	1996	mc
to	to	ii
$4.2	$4.2	nnu
billion	billion	m
in	in	ii
2005--an		at1
increase	increase	nn1
of	of	io
330%.		fo
n1	n1	fo
As	as	ii
a	a	at1
result	result	nn1
,	,	y
advertisements	advertisement	nn2
for	for	if
prescription	prescription	nn1
drugs	drug	nn2
are	be	vbr
pervasive	pervasive	jj
and	and	cc
consumers	consumer	nn2
regularly	regularly	rr
view	view	vv0@
them	them	ppho2
in	in	ii
magazines	magazine	nn2
and	and	cc
online	online	rr_jj
,	,	y
watch	watch	vv0
them	them	ppho2
on	on	ii
television	television	nn1
,	,	y
and	and	cc
listen	listen	vv0
to	to	ii
them	them	ppho2
on	on	ii
the	the	at
radio	radio	nn1
.	.	y
<p>	<p>	y
This	this	dd1
figure	figure	nn1
,	,	y
however	however	rr
,	,	y
must	must	vm
be	be	vbi
put	put	vvn
in	in	ii
perspective	perspective	nn1
.	.	y
Research	research	vv0@_nn1
also	also	rr
shows	show	vvz
that	that	cst
during	during	ii
the	the	at
same	same	da
period	period	nn1
,	,	y
spending	spend	vvg
on	on	ii_rp@
pharmaceutical	pharmaceutical	jj
marketing	marketing	nn1
increased	increase	vvd_vvn
not	not	xx
only	only	rr
for	for	if
DTC	dtc	np1
advertising	advertising	nn1
,	,	y
but	but	ccb
also	also	rr
across	across	ii
the	the	at
board	board	nn1
,	,	y
from	from	ii
about	about	rg
$11.4	$11.4	nnu
billion	billion	m
to	to	ii
$29.9	$29.9	nnu
billion.	billion	m
n2	n2	fo
In	in	ii
fact	fact	nn1
,	,	y
although	although	cs
DTC	dtc	np1
advertising	advertising	nn1
has	have	vhz
increased	increase	vvn
steadily	steadily	rr
both	both	rr
in	in	ii
absolute	absolute	jj
terms	term	nn2
and	and	cc
as	as	ii_csa
a	a	at1
percentage	percentage	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
sales	sales	nn
,	,	y
promotion	promotion	nn1
of	of	io
drug	drug	nn1
treatments	treatment	nn2
directly	directly	rr
to	to	ii
physicians	physician	nn2
and	and	cc
other	other	jj
health	health	nn1
care	care	nn1
professionals	professional	nn2
still	still	rr
far	far	rr
outweighs	outweigh	vvz
DTC	dtc	np1
advertising.	advertising	nnu
n3	n3	fo
In	in	ii
2005	2005	mc
,	,	y
$7.2	$7.2	nnu
billion	billion	m
was	be	vbdz
spent	spend	vvn
on	on	ii
promotion	promotion	nn1
to	to	ii
physicians	physician	nn2
alone.	alone	nnu
n4	n4	fo
Relatively	relatively	rr
speaking	speak	vvg_jj@
,	,	y
DTC	dtc	np1
advertising	advertising	nn1
is	be	vbz
concentrated	concentrate	vvn
on	on	ii
a	a	at1
small	small	jj
number	number	nn1
of	of	io
brands.	brands	nnu
n5	n5	fo
Its	its	z'
reach	reach	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
subject	subject	nn1
of	of	io
significant	significant	jj
debate	debate	nn1
among	among	ii
courts	court	nn2
and	and	cc
commentators.	commentators	nnu
(	(	y
n6	n6	fo
)	)	y
<p>	<p>	y
In	in	ii31
light	light	ii32
of	of	ii33
these	these	dd2
changes	change	nn2
in	in	ii
the	the	at
marketing	marketing	nn1
environment	environment	nn1
,	,	y
this	this	dd1
Article	article	nn1
examines	examine	vvz
whether	whether	csw
traditional	traditional	jj
legal	legal	jj
principles	principle	nn2
governing	govern	vvg
the	the	at
duty	duty	nn1
to	to	to
warn	warn	vvi
of	of	io
the	the	at
risks	risk	nn2
of	of	io
pharmaceutical	pharmaceutical	jj
products	product	nn2
remain	remain	vv0
sound	sound	jj@_nn1
public	public	jj_nn1
policy	policy	nn1
.	.	y
First	first	md
,	,	y
the	the	at
Article	article	nn1
considers	consider	vvz
the	the	at
early	early	jj
history	history	nn1
of	of	io
the	the	at
sale	sale	nn1
and	and	cc
marketing	marketing	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
products	product	nn2
,	,	y
discussing	discuss	vvg
the	the	at
initial	initial	jj_nn1
tragic	tragic	jj
absence	absence	nn1
of	of	io
regulation	regulation	nn1
,	,	y
followed	follow	vvn
by	by	ii
the	the	at
establishment	establishment	nn1
of	of	io
the	the	at
FDA	fda	nn1_np1
and	and	cc
the	the	at
pre-market	pre-market	jj_nn1
approval	approval	nn1
process	process	nn1
.	.	y
It	it	pph1
then	then	rt
examines	examine	vvz
the	the	at
modern	modern	jj
age	age	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
advertising	advertising	nn1
,	,	y
including	including	ii_vvg@
the	the	at
FDA	fda	nn1_np1
's	's	ge
relatively	relatively	rr
recent	recent	jj
guidance	guidance	nn1
on	on	ii
DTC	dtc	np1
broadcast	broadcast	nn1_vv0_jj@
advertising	advertising	nn1
and	and	cc
the	the	at
extent	extent	nn1
of	of	io
its	its	z'
regulation	regulation	nn1
.	.	y
Finally	finally	rr
,	,	y
the	the	at
Article	article	nn1
examines	examine	vvz
rules	rule	nn2
of	of	io
law	law	nn1
that	that	cst
establish	establish	vv0
the	the	at
legal	legal	jj
landscape	landscape	nn1
for	for	if
warnings	warning	nn2
and	and	cc
advertising	advertising	nn1_vvg@
in	in	ii
the	the	at
pharmaceutical	pharmaceutical	jj
context	context	nn1
.	.	y
This	this	dd1
includes	include	vvz
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
,	,	y
the	the	at
effect	effect	nn1
of	of	io
regulatory	regulatory	jj
compliance	compliance	nn1
on	on	ii
product	product	nn1
liability	liability	nn1
and	and	cc
consumer	consumer	nn1
protection	protection	nn1
claims	claim	nn2_vvz
,	,	y
and	and	cc
the	the	at
application	application	nn1
of	of	io
conflict	conflict	nn1
preemption	preemption	nn1
principles	principle	nn2
to	to	to
tort	tort	vvi
law	law	nn1
claims	claim	nn2_vvz
involving	involve	vvg
FDA-approved	fda-approved	jj_nn1
products	product	nn2
.	.	y
<p>	<p>	y
The	the	at
Article	article	nn1
finds	find	vvz
that	that	cst
the	the	at
two	two	mc
foundational	foundational	jj
tenets	tenet	nn2
underlying	underlie	vvg
these	these	dd2
doctrines	doctrine	nn2
have	have	vh0
not	not	xx
changed	change	vvn
.	.	y
First	first	md
,	,	y
on	on	ii
a	a	at1
societal	societal	jj
level	level	nn1_jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
both	both	rr_db2
in	in	ii
approving	approve	vvg
pharmaceutical	pharmaceutical	jj
products	product	nn2
as	as	csa_rg@_ii@
safe	safe	jj
and	and	cc
effective	effective	jj
for	for	if
certain	certain	jj
classes	class	nn2
of	of	io
patients	patient	nn2
and	and	cc
in	in	ii
mandating	mandate	vvg_jj@
disclosure	disclosure	nn1
of	of	io
risks	risk	nn2
so	so	cs21
that	that	cs22
physicians	physician	nn2
can	can	vm
accurately	accurately	rr
counsel	counsel	vvi
their	their	appge
patients	patient	nn2
.	.	y
Second	second	md
,	,	y
physicians	physician	nn2
remain	remain	vv0
individually	individually	rr
responsible	responsible	jj
for	for	if
diagnosing	diagnose	vvg
each	each	dd1
patient	patient	nn1_jj
regardless	regardless	rr
of	of	io
advertising	advertising	nn1
and	and	cc
for	for	if
helping	help	vvg
each	each	dd1
patient	patient	nn1
make	make	vvi
an	a	at1
educated	educated	jj
treatment	treatment	nn1
decision	decision	nn1
in	in	ii31
light	light	ii32
of	of	ii33
the	the	at
risks	risk	nn2
and	and	cc
benefits	benefit	nn2
of	of	io
a	a	at1
drug	drug	nn1
.	.	y
Because	because	ii21
of	of	ii22
their	their	appge
authority	authority	nn1
to	to	to
write	write	vvi
prescriptions	prescription	nn2
,	,	y
physicians	physician	nn2
have	have	vh0
ultimate	ultimate	jj
responsibility	responsibility	nn1
for	for	if
deciding	decide	vvg
whether	whether	csw
a	a	at1
given	given	jj@
drug	drug	nn1
is	be	vbz
appropriate	appropriate	jj
and	and	cc
beneficial	beneficial	jj
for	for	if
the	the	at
patient	patient	nn1_jj
.	.	y
Prescription	prescription	nn1
drug	drug	nn1
manufacturers	manufacturer	nn2
,	,	y
therefore	therefore	rr
,	,	y
have	have	vh0
obligations	obligation	nn2
to	to	to
report	report	vvi
all	all	db
material	material	jj@_nn1
information	information	nn1
to	to	ii
the	the	at
FDA	fda	nn1_np1
,	,	y
both	both	rr
before	before	cs_ii_rt@
and	and	cc
after	after	ii_cs
approval	approval	nn1
,	,	y
so	so	cs21
that	that	cs22
the	the	at
FDA	fda	nn1_np1
can	can	vm
make	make	vvi
a	a	at1
fully	fully	rr
informed	inform	vvn_jj@_vvd
decision	decision	nn1
about	about	ii
what	what	ddq
products	product	nn2
should	should	vm
be	be	vbi
available	available	jj
to	to	ii
the	the	at
market	market	nn1
and	and	cc
can	can	vm
convey	convey	vvi
adequate	adequate	jj
information	information	nn1
to	to	ii
physicians	physician	nn2
for	for	if
patient	patient	jj_nn1
counseling	counseling	nn1
purposes	purpose	nn2
.	.	y
<p>	<p>	y
The	the	at
Article	article	nn1
concludes	conclude	vvz
that	that	cst_dd1
,	,	y
irrespective	irrespective	ii21
of	of	ii22
the	the	at
rise	rise	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
,	,	y
traditional	traditional	jj
principles	principle	nn2
of	of	io
law	law	nn1
fully	fully	rr
retain	retain	vv0
their	their	appge
viability	viability	nn1
in	in	ii
the	the	at
post-DTC	post-dtc	jj
world	world	nn1
both	both	rr
as	as	ii
a	a	at1
matter	matter	nn1
of	of	io
jurisprudence	jurisprudence	nn1
and	and	cc
sound	sound	jj@_nn1_vv0@
public	public	jj_nn1
policy	policy	nn1
.	.	y
<p>	<p>	y
I.	i	np1
MARKETING	marketing	nn1
AND	and	cc
REGULATION	regulation	nn1
OF	of	io
PHARMACEUTICALS	pharmaceutical	nn2
FROM	from	ii
PAST	past	nn1
TO	to	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
examining	examine	vvg
modern	modern	jj
regulation	regulation	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
products	product	nn2
and	and	cc
their	their	appge
advertising	advertising	nn1
,	,	y
placing	place	vvg
the	the	at
current	current	jj
system	system	nn1
in	in	ii
historical	historical	jj
context	context	nn1
is	be	vbz
useful	useful	jj
.	.	y
Companies	company	nn2
that	that	cst
sell	sell	vv0
medications	medication	nn2
have	have	vh0
advertised	advertise	vvn
their	their	appge
products	product	nn2
directly	directly	rr
to	to	ii
consumers	consumer	nn2
since	since	cs_ii@
the	the	at
beginning	beginning	nn1
of	of	io
medicine	medicine	nn1
.	.	y
The	the	at
increasing	increasing	jj
regulatory	regulatory	jj
scrutiny	scrutiny	nn1
regarding	regarding	ii_vvg
approval	approval	nn1
,	,	y
marketing	marketing	nn1_vvg@
,	,	y
and	and	cc
sale	sale	nn1
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
,	,	y
however	however	rr
,	,	y
is	be	vbz
a	a	at1
relatively	relatively	rr
recent	recent	jj
development	development	nn1
.	.	y
The	the	at
new	new	jj
oversight	oversight	nn1
is	be	vbz
meant	mean	vvn
to	to	to
ensure	ensure	vvi
that	that	cst
drugs	drug	nn2
are	be	vbr
safe	safe	jj
and	and	cc
effective	effective	jj
and	and	cc
that	that	dd1
drug	drug	nn1
advertising	advertising	nn1
does	do	vdz
not	not	xx
mislead	mislead	vvi
the	the	at
public	public	nn1_jj
.	.	y
<p>	<p>	y
During	during	ii
much	much	da1
of	of	io
the	the	at
eighteenth	eighteenth	md
and	and	cc
nineteenth	nineteenth	md
centuries	century	nnt2
,	,	y
companies	company	nn2
regularly	regularly	rr
advertised	advertise	vvn_vvd_jj@
patent	patent	nn1_jj@
medicines	medicine	nn2
,	,	y
which	which	ddq
were	be	vbdr
available	available	jj
without	without	iw
a	a	at1
prescription	prescription	nn1
,	,	y
directly	directly	rr
to	to	ii
consumers	consumer	nn2
in	in	ii
American	american	jj
newspapers	newspaper	nn2
.	.	y
Indeed	indeed	rr
,	,	y
during	during	ii
the	the	at
1800s	1800s	mc2
,	,	y
patent	patent	nn1_jj@
medicine	medicine	nn1
advertisers	advertiser	nn2
spent	spend	vvn_vvd
more	more	rrr_dar
on	on	ii
newspaper	newspaper	nn1
advertisements	advertisement	nn2
than	than	csn
any	any	dd
other	other	jj
group.	group	nnu
n7	n7	fo
At	at	ii
the	the	at
time	time	nnt1
,	,	y
no	no	at
regulatory	regulatory	jj
structure	structure	nn1
existed	exist	vvd
to	to	to
provide	provide	vvi
for	for	if
pre-market	pre-market	jj_nn1
review	review	nn1
of	of	io
these	these	dd2
medicines	medicine	nn2
to	to	to
ensure	ensure	vvi
their	their	appge
safety	safety	nn1
or	or	cc
efficacy	efficacy	nn1
or	or	cc
to	to	to
substantiate	substantiate	vvi
the	the	at
claims	claim	nn2
their	their	appge
producers	producer	nn2
made	make	vvn_vvd
in	in	ii
these	these	dd2
advertisements	advertisement	nn2
.	.	y
The	the	at
grifting	grifting	jj@_nn1@
snake	snake	nn1
oil	oil	nn1
salesman	salesman	nn1
,	,	y
a	a	at1
character	character	nn1
that	that	cst
still	still	rr
pervades	pervade	vvz
the	the	at
mythology	mythology	nn1
of	of	io
the	the	at
American	american	jj
West	west	nd1
,	,	y
dates	date	vvz_nn2
to	to	ii
this	this	dd1
unregulated	unregulated	jj
period	period	nn1
.	.	y
<p>	<p>	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Jungle	jungle	nn1
,	,	y
with	with	iw
its	its	z'
detailed	detailed	jj
account	account	nn1
of	of	io
the	the	at
unsanitary	unsanitary	jj_nn1
conditions	condition	nn2
of	of	io
the	the	at
Chicago	chicago	np1
stockyards.	stockyards	nnu
n8	n8	fo
Prompted	prompt	vvn
by	by	ii
the	the	at
resulting	resulting	jj
public	public	jj_nn1
outcry	outcry	nn1
from	from	ii
the	the	at
book	book	nn1
and	and	cc
public	public	jj_nn1
reaction	reaction	nn1
to	to	ii
similar	similar	jj
disclosures	disclosure	nn2
in	in	ii
the	the	at
nation	nation	nn1
's	's	ge
newspapers	newspaper	nn2
about	about	ii
poisonous	poisonous	jj
preservatives	preservative	nn2
and	and	cc
dyes	dye	nn2
in	in	ii
foods	food	nn2
and	and	cc
cure-all	cure-all	db_rr@
patent	patent	jj@_nn1
medicines	medicine	nn2
,	,	y
Congress	congress	nn1
passed	pass	vvd_vvn
the	the	at
original	original	jj
Pure	pure	jj
Food	food	nn1
and	and	cc
Drugs	drug	nn2
Act.	act	np1
(	(	y
n9	n9	fo
)	)	y
<p>	<p>	y
But	but	ccb
if	if	cs
the	the	at
1906	1906	mc
Act	act	nn1
was	be	vbdz
meant	mean	vvn
to	to	to
curb	curb	vvi
the	the	at
deceptive	deceptive	jj
practices	practice	nn2
of	of	io
snake	snake	nn1
oil	oil	nn1
salesmen	salesman	nn2
,	,	y
it	it	pph1
was	be	vbdz
poorly	poorly	rr
equipped	equip	vvn
for	for	if
the	the	at
task	task	nn1
.	.	y
First	first	md
,	,	y
the	the	at
1906	1906	mc
Act	act	nn1
did	do	vdd
not	not	xx
prevent	prevent	vvi
manufacturers	manufacturer	nn2
from	from	ii
placing	place	vvg
worthless	worthless	jj
medicines	medicine	nn2
on	on	ii
the	the	at
market	market	nn1
because	because	cs
proof	proof	nn1
of	of	io
safety	safety	nn1
or	or	cc
efficacy	efficacy	nn1
was	be	vbdz
not	not	xx
required	require	vvn
.	.	y
Second	second	md
,	,	y
the	the	at
Act	act	nn1
was	be	vbdz
directed	direct	vvn
only	only	rr
at	at	ii
product	product	nn1
labels	label	nn2
,	,	y
not	not	xx
extra-label	extra-label	vv0
advertising.	advertising	nnu
n10	n10	fo
It	it	pph1_nn1@
defined	define	vvd
a	a	at1
drug	drug	nn1
as	as	csa
"	"	y
misbranded	misbranded	vvn@_jj@_vvd
"	"	y
only	only	rr_jj
if	if	cs
the	the	at
stated	stated	jj@
claims	claim	nn2
on	on	ii
the	the	at
label	label	nn1
regarding	regarding	ii_vvg
its	its	z'
curative	curative	nn1_jj
or	or	cc
therapeutic	therapeutic	jj
qualities	quality	nn2
were	be	vbdr
proven	prove	vvn_jj
false	false	jj
or	or	cc
fraudulent.	fraudulent	nnu
(	(	y
n11	n11	fo
)	)	y
<p>	<p>	y
These	these	dd2
inadequacies	inadequacy	nn2
became	become	vvd
tragically	tragically	rr
apparent	apparent	jj
some	some	dd
three	three	mc
decades	decade	nnt2
later	later	rrr
.	.	y
In	in	ii
June	june	npm1
1937	1937	mc
,	,	y
a	a	at1
salesman	salesman	nn1
for	for	if
the	the	at
S.E.	s.e	nd1
Massengill	massengill	np1
Co.	co	np1
reported	report	vvd
that	that	cst
his	his	appge
customers	customer	nn2
sought	seek	vvd_vvn
a	a	at1
liquid	liquid	jj_nn1
version	version	nn1
of	of	io
the	the	at
drug	drug	nn1
sulfanilamide	sulfanilamide	nn1_vv0
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
been	be	vbn
proven	prove	vvn
to	to	to
have	have	vhi
dramatic	dramatic	jj
curative	curative	jj_nn1
effects	effect	nn2
in	in	ii
tablet	tablet	nn1
or	or	cc
powder	powder	vv0@_nn1
form.	form	nnu
n12	n12	fo
Responding	respond	vvg
to	to	ii
the	the	at
market	market	nn1
need	need	nn1_vv0
,	,	y
a	a	at1
chemist	chemist	nn1
and	and	cc
pharmacist	pharmacist	nn1
for	for	if
the	the	at
company	company	nn1
experimented	experiment	vvn_vvd
with	with	iw
sulfanilamide	sulfanilamide	nn1
's	's	ge
solubility	solubility	nn1
and	and	cc
found	find	vvn
that	that	cst
it	it	pph1
would	would	vm
dissolve	dissolve	vvi
in	in	ii
diethylene	diethylene	nn1
glycol.	glycol	nnu
n13	n13	fo
Although	although	cs
the	the	at
company	company	nn1
tested	test	vvd_vvn
the	the	at
product	product	nn1
for	for	if
flavor	flavor	nn1
,	,	y
appearance	appearance	nn1
,	,	y
and	and	cc
fragrance	fragrance	nn1
,	,	y
it	it	pph1
did	do	vdd
not	not	xx
test	test	vvi
the	the	at
product	product	nn1
's	's	ge
toxicity.	toxicity	nnu
n14	n14	fo
In	in	ii
sufficient	sufficient	jj
doses	dose	nn2
,	,	y
diethylene	diethylene	nn1
glycol	glycol	nn1
is	be	vbz
toxic	toxic	jj
to	to	ii
humans	human	nn2
and	and	cc
animals	animal	nn2
,	,	y
causing	cause	vvg
renal	renal	jj
failure	failure	nn1
,	,	y
encephalopathy	encephalopathy	nn1
,	,	y
and	and	cc
death.	death	nnu
n15	n15	fo
A	a	zz1
scientific	scientific	jj
literature	literature	nn1
review	review	nn1
or	or	cc
a	a	at1
few	few	da2
simple	simple	jj
animal	animal	nn1
tests	test	nn2
would	would	vm
have	have	vhi
revealed	reveal	vvn
its	its	z'
lethal	lethal	jj
properties.	properties	nnu
n16	n16	fo
S.E.	s.e	nd1
Massengill	massengill	np1
,	,	y
however	however	rr
,	,	y
shipped	ship	vvd_vvn
the	the	at
product	product	nn1
without	without	iw
taking	take	vvg
these	these	dd2
precautions	precaution	nn2
.	.	y
Between	between	ii
September	september	npm1
and	and	cc
October	october	npm1
1937	1937	mc
,	,	y
more	more	dar
than	than	csn
one	one	mc1
hundred	hundred	m
people	people	nn
across	across	ii
the	the	at
country	country	nn1
obtained	obtain	vvd_vvn
the	the	at
product	product	nn1
from	from	ii
their	their	appge
doctors	doctor	nn2
or	or	cc
bought	buy	vvd
it	it	pph1
from	from	ii
a	a	at1
pharmacy	pharmacy	nn1
and	and	cc
died	die	vvd
after	after	ii
consuming	consume	vvg
it.	it	nnu
(	(	y
n17	n17	fo
)	)	y
<p>	<p>	y
After	after	cs_ii
news	news	nn1
of	of	io
the	the	at
strange	strange	jj
deaths	death	nn2
began	begin	vvd
surfacing	surface	vvg
,	,	y
the	the	at
FDA	fda	nn1_np1
investigated	investigate	vvn_vvd
and	and	cc
intervened	intervene	vvn
,	,	y
seizing	seize	vvg_jj
shipments	shipment	nn2
from	from	ii
pharmacies	pharmacy	nn2
and	and	cc
doctor	doctor	nn1
's	's	ge
offices	office	nn2
across	across	ii
the	the	at
country	country	nn1
.	.	y
But	but	ccb
the	the	at
FDA	fda	np1_nn1
's	's	ge
sole	sole	jj
authority	authority	nn1
for	for	if
these	these	dd2
seizures	seizure	nn2
was	be	vbdz
not--as		csa_rg@
one	one	pn1_mc1
might	might	vm_nn1%
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
toxicity	toxicity	nn1
review	review	nn1
.	.	y
Ironically	ironically	rr
,	,	y
the	the	at
FDA	fda	nn1_np1
only	only	rr
had	have	vhn@_vhd
authority	authority	nn1
to	to	to
intervene	intervene	vvi
through	through	ii
the	the	at
1906	1906	mc
Act	act	nn1
's	's	ge
prohibition	prohibition	nn1
against	against	ii
label	label	nn1
misbranding.		nnu
n18	n18	fo
The	the	at
term	term	nn1
"	"	y
elixir	elixir	nn1
"	"	y
on	on	ii
the	the	at
product	product	nn1
's	's	ge
label	label	nn1
implied	imply	vvd_vvn
that	that	cst
the	the	at
product	product	nn1
was	be	vbdz
an	a	at1
alcohol	alcohol	nn1
solution	solution	nn1
when	when	rrq_cs
,	,	y
in	in	ii
fact	fact	nn1
,	,	y
it	it	pph1
contained	contain	vvd
no	no	at
alcohol.	alcohol	nnu
n19	n19	fo
Had	have	vhd
the	the	at
product	product	nn1
instead	instead	rr
been	be	vbn
labeled	label	vvn@
a	a	at1
"	"	y
solution	solution	nn1
,	,	y
"	"	y
the	the	at
FDA	fda	nn1_np1
would	would	vm
have	have	vhi
had	have	vhn@
no	no	at
authority	authority	nn1
under	under	ii
the	the	at
1906	1906	mc
Act	act	nn1_vv0@
to	to	ii
intervene.	intervene	nnu
(	(	y
n20	n20	fo
)	)	y
<p>	<p>	y
In	in	ii31
response	response	ii32
to	to	ii33
the	the	at
crisis	crisis	nn1
,	,	y
Congress	congress	nn1
repealed	repeal	vvd_vvn
the	the	at
1906	1906	mc
Act	act	nn1
and	and	cc
replaced	replace	vvd_vvn
it	it	pph1
with	with	iw
the	the	at
Federal	federal	jj
Food	food	nn1
,	,	y
Drug	drug	nn1
,	,	y
and	and	cc
Cosmetic	cosmetic	jj
Act	act	nn1
of	of	io
1938	1938	mc
(	(	y
FDCA	fdca	np1
)	)	y
.	.	y
n21	n21	fo
The	the	at
increased	increased	jj
protections	protection	nn2
of	of	io
the	the	at
new	new	jj
act	act	nn1
included	include	vvd_vvn
an	a	at1
FDA	fda	nn1
pre-market	pre-market	nn1_jj
notification	notification	nn1
(	(	y
but	but	ccb
not	not	xx
approval	approval	nn1
)	)	y
requirement	requirement	nn1
for	for	if
all	all	db
"	"	y
new	new	jj
drugs	drug	nn2
.	.	y
"	"	y
n22	n22	fo
In	in	bcl21
order	order	bcl22
to	to	to
market	market	vvi
a	a	at1
new	new	jj
drug	drug	nn1
,	,	y
a	a	at1
manufacturer	manufacturer	nn1
would	would	vm
submit	submit	vvi
a	a	at1
New	new	jj
Drug	drug	nn1
Application	application	nn1
(	(	y
NDA	nda	np1
)	)	y
to	to	ii
the	the	at
FDA	fda	nn1_np1
.	.	y
If	if	cs
the	the	at
FDA	fda	np1_nn1
did	do	vdd
not	not	xx
affirmatively	affirmatively	rr
deny	deny	vvi
the	the	at
application	application	nn1
within	within	ii
sixty	sixty	mc
days	day	nnt2
,	,	y
then	then	rt
the	the	at
manufacturer	manufacturer	nn1
could	could	vm
market	market	vvi
the	the	at
drug	drug	nn1
immediately.	immediately	nnu
n23	n23	fo
Unsurprisingly	unsurprisingly	rr
,	,	y
given	give	vvn
the	the	at
Elixir	elixir	np1_nn1
Sulfanilamide	sulfanilamide	np1_nn1
incident	incident	nn1
,	,	y
this	this	dd1
pre-market	pre-market	jj_nn1
notification	notification	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
safety	safety	nn1
,	,	y
not	not	xx
its	its	z'
efficacy.	efficacy	nnu
n24	n24	fo
Thus	thus	rr
,	,	y
the	the	at
FDA	fda	np1_nn1
retained	retain	vvd_vvn_jj@
jurisdiction	jurisdiction	nn1
over	over	ii
the	the	at
product	product	nn1
label	label	nn1
and	and	cc
it	it	pph1
obtained	obtain	vvd
authority	authority	nn1
under	under	ii
the	the	at
1938	1938	mc
Act	act	nn1_vv0@
to	to	to
conduct	conduct	vvi
a	a	at1
pre-market	pre-market	jj_nn1
safety	safety	nn1
review	review	nn1
.	.	y
<p>	<p>	y
In	in	ii
the	the	at
same	same	da
year	year	nnt1
Congress	congress	nn1
expressly	expressly	rr
vested	vested	jj_vvn
jurisdiction	jurisdiction	nn1
over	over	ii_rp
all	all	db
drug	drug	nn1
advertisements	advertisement	nn2
with	with	iw
the	the	at
Federal	federal	jj
Trade	trade	nn1
Commission	commission	nn1
(	(	y
FTC	ftc	np1
)	)	y
.	.	y
n25	n25	fo
Congress	congress	nn1
had	have	vhd
created	create	vvn
the	the	at
FTC	ftc	np1
in	in	ii
1914	1914	mc
with	with	iw
the	the	at
passage	passage	nn1
of	of	io
the	the	at
Federal	federal	jj
Trade	trade	nn1
Commission	commission	nn1
Act.	act	np1
n26	n26	fo
Under	under	ii
that	that	dd1
Act	act	nn1
,	,	y
Congress	congress	nn1
authorized	authorize	vvn_vvd@
the	the	at
FTC	ftc	np1
to	to	to
regulate	regulate	vvi
advertising	advertising	nn1_vvg@
generally	generally	rr
,	,	y
though	though	cs
the	the	at
Supreme	supreme	jj
Court	court	nn1
's	's	ge
interpretation	interpretation	nn1
of	of	io
the	the	at
statute	statute	nn1
limited	limit	vvn_vvd@
the	the	at
FTC	ftc	np1
's	's	ge
purview	purview	nn1
to	to	ii
deceptive	deceptive	jj
advertising	advertising	nn1
that	that	cst
harmed	harm	vvd
a	a	at1
competitor	competitor	nn1
company.	company	nnu
(	(	y
n27	n27	fo
)	)	y
<p>	<p>	y
Earlier	early	jjr
proposals	proposal	nn2
to	to	to
amend	amend	vvi
the	the	at
1906	1906	mc
Act	act	nn1
had	have	vhd
sought	seek	vvn
to	to	to
regulate	regulate	vvi
DTC	dtc	np1
advertising	advertising	nn1
of	of	io
drugs	drug	nn2
.	.	y
The	the	at
legislative	legislative	jj
history	history	nn1
of	of	io
those	those	dd2
attempts	attempt	nn2
reveals	reveal	vvz
the	the	at
nature	nature	nn1
and	and	cc
extent	extent	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
at	at	ii
the	the	at
time	time	nnt1
.	.	y
Legislation	legislation	nn1
introduced	introduce	vvn_vvd
in	in	ii
1933	1933	mc
named	name	vvd_vvn
some	some	dd
thirty-six	thirty-six	mc
particular	particular	jj
disease	disease	nn1
states	state	nn2_vvz
or	or	cc
conditions	condition	nn2
for	for	if
which	which	ddq
any	any	dd
advertising	advertising	nn1
would	would	vm
be	be	vbi
necessarily	necessarily	rr
deemed	deem	vvn
false	false	jj_rr@
,	,	y
including	including	ii_vvg@
measles	measles	nn
,	,	y
mumps	mumps	nn2_vvz
,	,	y
scarlet	scarlet	jj
fever	fever	nn1
,	,	y
sexual	sexual	jj
impotence	impotence	nn1
,	,	y
tuberculosis	tuberculosis	nn1
,	,	y
and	and	cc
venereal	venereal	jj
diseases.	diseases	nnu
n28	n28	fo
The	the	at
bill	bill	nn1
included	include	vvd_vvn
an	a	at1
exception	exception	nn1
,	,	y
however	however	rr
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
medical	medical	jj
and	and	cc
pharmacological	pharmacological	jj
professions	profession	nn2
only	only	rr_jj
or	or	cc
if	if	cs_csw@
the	the	at
advertisement	advertisement	nn1
appears	appear	vvz
in	in	ii
scientific	scientific	jj
periodicals	periodical	nn2
.	.	y
"	"	y
n29	n29	fo
The	the	at
list	list	nn1
of	of	io
diseases	disease	nn2
and	and	cc
the	the	at
need	need	nn1
for	for	if
a	a	at1
direct-to-physician	direct-to-physician	jj_nn1
exception	exception	nn1
suggest	suggest	vv0
that	that	cst
DTC	dtc	np1
advertising	advertising	nn1
was	be	vbdz
pervasive	pervasive	jj
in	in	ii
the	the	at
early	early	jj
1930s	1930s	mc2
and	and	cc
provide	provide	vv0
clues	clue	nn2
as	as	ii21
to	to	ii22
the	the	at
conditions	condition	nn2
these	these	dd2
products	product	nn2
were	be	vbdr
marketed	market	vvn
to	to	to
address	address	vvi
.	.	y
<p>	<p>	y
B.	b	np1
Establishment	establishment	nn1
of	of	io
the	the	at
Modern	modern	jj
Regulatory	regulatory	jj
Regime	regime	nn1
for	for	if
Approval	approval	nn1
and	and	cc
Marketing	marketing	nn1
of	of	io
Prescription	prescription	nn1
Drugs	drug	nn2
Before	before	ii
1951	1951	mc
,	,	y
there	there	ex
was	be	vbdz
no	no	at
recognized	recognized	jj@
category	category	nn1
under	under	ii_rg@
federal	federal	jj
law	law	nn1
for	for	if
prescription	prescription	nn1
drugs	drug	nn2
.	.	y
That	that	dd1
year	year	nnt1
,	,	y
Congress	congress	nn1
enacted	enact	vvd_vvn
the	the	at
Durham-Humphrey		np1
Amendments	amendment	nn2
to	to	ii
the	the	at
FDCA	fdca	nn1_np1
,	,	y
which	which	ddq
required	require	vvd@_jj
licensed	licensed	jj
pharmacists	pharmacist	nn2
to	to	to
dispense	dispense	vvi
drugs	drug	nn2
that	that	cst_dd1
can	can	vm
not	not	xx
be	be	vbi
safely	safely	rr
used	use	vvn_vvd
without	without	iw
medical	medical	jj
supervision.	supervision	nnu
n30	n30	fo
It	it	pph1
is	be	vbz
uncertain	uncertain	jj
whether	whether	csw
the	the	at
prescription	prescription	nn1
requirement	requirement	nn1
put	put	vvd_vvn_vv0
an	a	at1
immediate	immediate	jj
halt	halt	nn1
to	to	ii
DTC	dtc	np1
advertising	advertising	nn1
.	.	y
If	if	cs
we	we	ppis2
assume	assume	vv0
that	that	cst
the	the	at
history	history	nn1
of	of	io
the	the	at
1933	1933	mc
legislation	legislation	nn1
is	be	vbz
indicative	indicative	jj
of	of	io
the	the	at
nature	nature	nn1
and	and	cc
extent	extent	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
at	at	ii
the	the	at
time	time	nnt1
of	of	io
that	that	dd1
bill	bill	nn1
's	's	ge
consideration	consideration	nn1
,	,	y
then	then	rt
we	we	ppis2
can	can	vm
extrapolate	extrapolate	vvi
on	on	ii
the	the	at
legislative	legislative	jj
history	history	nn1
of	of	io
the	the	at
next	next	md
major	major	jj
alteration	alteration	nn1
to	to	ii
the	the	at
FDCA	fdca	nn1_np1
,	,	y
the	the	at
1962	1962	mc
Kefauver-Harris	kefauver-harris	np1
Drug	drug	nn1
Amendments	amendment	nn2
.	.	y
That	that	dd1
legislative	legislative	jj
history	history	nn1
suggests	suggest	vvz
that	that	dd1_cst
implementation	implementation	nn1
of	of	io
a	a	at1
prescription-drug	prescription-drug	jj
regulatory	regulatory	jj
scheme	scheme	nn1
in	in	ii
1951	1951	mc
curbed	curb	vvd
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
marketing	marketing	nn1
focus	focus	nn1_vv0
to	to	ii
physicians	physician	nn2
and	and	cc
heath	heath	nn1
care	care	nn1
professionals	professional	nn2
.	.	y
<p>	<p>	y
In	in	ii
1962	1962	mc
,	,	y
the	the	at
Kefauver-Harris	kefauver-harris	np1
Drug	drug	nn1
Amendments	amendment	nn2
authorized	authorize	vvn_vvd@
the	the	at
FDA	fda	nn1_np1
to	to	to
regulate	regulate	vvi
the	the	at
marketing	marketing	nn1
of	of	io
prescription	prescription	nn1
drugs.	drug	nnu
n31	n31	fo
By	by	ii
this	this	dd1
time	time	nnt1
,	,	y
Congress	congress	nn1
was	be	vbdz
drawing	draw	vvg
a	a	at1
distinction	distinction	nn1
between	between	ii
the	the	at
advertising	advertising	nn1
of	of	io
over-the-counter	over-the-counter	nn1_jj
(	(	y
OTC	otc	np1
)	)	y
medicines	medicine	nn2
,	,	y
which	which	ddq
are	be	vbr
directed	direct	vvn
at	at	ii
consumers	consumer	nn2
,	,	y
and	and	cc
the	the	at
marketing	marketing	nn1
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
,	,	y
the	the	at
bulk	bulk	nn1
of	of	io
which	which	ddq
,	,	y
in	in	ii
Congress	congress	nn1
's	's	ge
estimation	estimation	nn1
,	,	y
was	be	vbdz
already	already	rr
directed	direct	vvn_vvd
at	at	ii
the	the	at
medical	medical	jj
community.	community	nnu
n32	n32	fo
A	a	zz1
memorandum	memorandum	nn1
of	of	io
understanding	understand	vvg_nn1
between	between	ii
the	the	at
two	two	mc
agencies	agency	nn2
governs	govern	vvz
this	this	dd1
allocation	allocation	nn1
of	of	io
responsibilities	responsibility	nn2
in	in	ii
which	which	ddq
the	the	at
FTC	ftc	np1
continues	continue	vvz
to	to	to
regulate	regulate	vvi
OTC	otc	nn1_np1
advertising	advertising	nn1
,	,	y
whereas	whereas	cs
the	the	at
FDA	fda	nn1_np1
regulates	regulate	vvz
the	the	at
marketing	marketing	nn1
of	of	io
prescription	prescription	nn1
drugs.	drug	nnu
(	(	y
n33	n33	fo
)	)	y
<p>	<p>	y
The	the	at
1962	1962	mc
Amendments	amendment	nn2
and	and	cc
their	their	appge
implementing	implement	vvg_nn1%
regulations	regulation	nn2
set	set	vvd_vv0_vvn
two	two	mc
major	major	jj
requirements	requirement	nn2
for	for	if
all	all	db
prescription	prescription	nn1
drug	drug	nn1
advertising.	advertising	nnu
n34	n34	fo
First	first	md
,	,	y
advertisements	advertisement	nn2
must	must	vm
contain	contain	vvi
a	a	at1
"	"	y
summary	summary	nn1
"	"	y
that	that	cst_dd1
provides	provide	vvz
a	a	at1
description	description	nn1
of	of	io
the	the	at
drug	drug	nn1
's	's	ge
side	side	nn1
effects	effect	nn2
,	,	y
contraindications	contraindication	nn2
,	,	y
warnings	warning	nn2
,	,	y
and	and	cc
precautions	precaution	nn2
,	,	y
as	as	ii31
well	well	ii32
as	as	ii33
its	its	z'
directions	direction	nn2
for	for	if
use.	use	nnu
n35	n35	fo
Second	second	md
,	,	y
the	the	at
advertisement	advertisement	nn1
,	,	y
when	when	cs_rrq
viewed	view	vvn
in	in	ii
its	its	z'
entirety	entirety	nn1
,	,	y
must	must	vm
present	present	vvi
a	a	at1
"	"	y
fair	fair	jj
balance	balance	nn1
"	"	y
between	between	ii
the	the	at
information	information	nn1
relating	relate	vvg
to	to	ii
the	the	at
drug	drug	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
profile.	profile	nnu
(	(	y
n36	n36	fo
)	)	y
<p>	<p>	y
The	the	at
1962	1962	mc
Amendments	amendment	nn2
also	also	rr
strengthened	strengthen	vvd_vvn
the	the	at
FDA	fda	np1_nn1
's	's	ge
pre-market	pre-market	jj_nn1
review	review	nn1
process	process	nn1_vv0
,	,	y
implementing	implement	vvg
the	the	at
procedure	procedure	nn1
that	that	cst_dd1
remains	remain	vvz
largely	largely	rr
in	in	ii
effect	effect	nn1
today	today	rt
.	.	y
Once	once	rr21
again	again	rr22
,	,	y
the	the	at
prompt	prompt	nn1_jj
for	for	if
regulation	regulation	nn1
arose	arise	vvd
out	out	ii21
of	of	ii22
a	a	at1
public	public	jj_nn1
health	health	nn1
crisis	crisis	nn1
.	.	y
Thalidomide	thalidomide	vv0_nn1_np1@
,	,	y
a	a	at1
drug	drug	nn1
approved	approve	vvn_vvd
for	for	if
marketing	marketing	nn1_vvg@
in	in	ii
various	various	jj
European	european	jj
countries	country	nn2
,	,	y
was	be	vbdz
discovered	discover	vvn@
to	to	to
be	be	vbi
a	a	at1
teratogen	teratogen	nn1
,	,	y
an	a	at1
agent	agent	nn1
that	that	cst_dd1
can	can	vm
cause	cause	vvi
malformations	malformation	nn2
of	of	io
an	a	at1
embryo	embryo	nn1
or	or	cc
fetus.	fetus	nnu
n37	n37	fo
A	a	zz1
manufacturer	manufacturer	nn1
had	have	vhd
submitted	submit	vvn
an	a	at1
NDA	nda	nn1
to	to	to
market	market	vvi
the	the	at
drug	drug	nn1
for	for	if
use	use	nn1
in	in	ii
the	the	at
United	united	np1
States	state	np1
,	,	y
which	which	ddq
was	be	vbdz
pending	pending	jj
at	at	ii
the	the	at
time	time	nnt1
of	of	io
this	this	dd1
discovery	discovery	nn1
.	.	y
Congress	congress	nn1
responded	respond	vvn
by	by	ii
amending	amend	vvg
the	the	at
FDCA	fdca	nn1_np1
to	to	to
require	require	vvi
affirmative	affirmative	jj_nn1
approval	approval	nn1
by	by	ii
the	the	at
FDA	fda	nn1
for	for	if
NDAs		nn2
,	,	y
replacing	replace	vvg
the	the	at
notification	notification	nn1
and	and	cc
automatic-approval	automatic-approval	jj_nn1
system	system	nn1
put	put	vvn_vvd
in	in	ii
place	place	nn1
by	by	ii
the	the	at
1938	1938	mc
Act.	act	np1
n38	n38	fo
In	in	rr21
addition	addition	rr22
,	,	y
Congress	congress	nn1
required	required	jj_vvn
manufacturers	manufacturer	nn2
submitting	submit	vvg
NDAs		nn2
to	to	to
prove	prove	vvi
not	not	xx
only	only	rr
that	that	cst
a	a	at1
drug	drug	nn1
was	be	vbdz
safe	safe	jj
,	,	y
n39	n39	fo
but	but	ccb
also	also	rr
that	that	cst
the	the	at
product	product	nn1
was	be	vbdz
effective.	effective	nnu
n40	n40	fo
For	for	if
its	its	z'
part	part	nn1
,	,	y
the	the	at
FDA	fda	nn1_np1
now	now	rt
had	have	vhd
to	to	to
reach	reach	vvi
an	a	at1
affirmative	affirmative	jj_nn1
conclusion	conclusion	nn1
that	that	cst
the	the	at
drug	drug	nn1
was	be	vbdz
both	both	rr
safe	safe	jj
and	and	cc
effective	effective	jj
before	before	ii_cs
the	the	at
drug	drug	nn1
could	could	vm
be	be	vbi
marketed.		nnu
n41	n41	fo
The	the	at
standards	standard	nn2
for	for	if
approval	approval	nn1
have	have	vh0
remained	remain	vvn
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	to
guide	guide	vvi
both	both	db2_rr
the	the	at
industry	industry	nn1
and	and	cc
the	the	at
FDA	fda	nn1_np1
in	in	ii
their	their	appge
daily	daily	jj
decisions	decision	nn2
to	to	ii
the	the	at
present.	present	nnu
(	(	y
n42	n42	fo
)	)	y
<p>	<p>	y
Procedurally	procedurally	rr_np1@
,	,	y
the	the	at
FDA	fda	np1_nn1
's	's	ge
Center	center	nn1
for	for	if
Drug	drug	nn1
Evaluation	evaluation	nn1
and	and	cc
Research	research	nn1
(	(	y
CDER	cder	np1
)	)	y
reviews	review	nn2_vvz
and	and	cc
approves	approve	vvz
NDAs	ndas	np2_nn2
,	,	y
n43	n43	fo
and	and	cc
then	then	rt
evalutes		vvz
the	the	at
drug	drug	nn1
's	be	vbz_ge_vhz@
proposed	propose	vvn_jj
labeling.	labeling	nnu
n44	n44	fo
The	the	at
FDA	fda	nn1_np1
must	must	vm
find	find	vvi
that	that	cst
the	the	at
results	result	nn2
and	and	cc
data	data	nn
submitted	submit	vvn_vvd
in	in	ii
the	the	at
NDA	nda	nn1_np1
justify	justify	vv0
each	each	dd1
statement	statement	nn1
proposed	propose	vvn_vvd
for	for	if
drug	drug	nn1
labeling.	labeling	nnu
n45	n45	fo
Federal	federal	jj
regulations	regulation	nn2
require	require	vv0
dividing	divide	vvg
the	the	at
label	label	nn1
's	's	ge
content	content	nn1_jj
into	into	ii
sections	section	nn2
,	,	y
including	including	ii_vvg@
a	a	at1
list	list	nn1
of	of	io
the	the	at
drug	drug	nn1
's	's	ge
approved	approved	jj_vvn
indications	indication	nn2
and	and	cc
usage	usage	nn1
,	,	y
n46	n46	fo
contraindications	contraindication	nn2
,	,	y
n47	n47	fo
warnings	warning	nn2
,	,	y
n48	n48	fo
precautions	precaution	nn2
,	,	y
n49	n49	fo
and	and	cc
adverse	adverse	jj
reactions.	reactions	nnu
n50	n50	fo
The	the	at
FDA	fda	nn1_np1
must	must	vm
approve	approve	vvi
the	the	at
label	label	nn1
's	's	ge
content	content	nn1_jj
before	before	cs
it	it	pph1
accepts	accept	vvz
the	the	at
NDA	nda	nn1_np1
and	and	cc
the	the	at
company	company	nn1
begins	begin	vvz
marketing	market	vvg
the	the	at
drug	drug	nn1
.	.	y
<p>	<p>	y
C.	c	np1
DTC	dtc	np1
Advertising	advertising	nn1
and	and	cc
Its	its	z'
Regulation	regulation	nn1
Today	today	rt
The	the	at
Division	division	nn1
of	of	io
Drug	drug	nn1
Marketing	marketing	nn1
,	,	y
Advertising	advertising	nn1_vvg@
,	,	y
and	and	cc
Communications	communication	nn2
(	(	y
DDMAC		np1
)	)	y
,	,	y
a	a	at1
separate	separate	jj
component	component	nn1
of	of	io
CDER	cder	np1_nn1
,	,	y
reviews	review	vvz
pharmaceutical	pharmaceutical	jj
marketing	marketing	nn1
practices	practice	nn2
.	.	y
There	there	ex
are	be	vbr
no	no	at
formal	formal	jj
regulations	regulation	nn2
that	that	cst
distinguish	distinguish	vv0
DTC	dtc	np1
advertising	advertising	nn1
from	from	ii
direct-to-physician	direct-to-physician	jj_nn1
advertising.	advertising	nnu
n51	n51	fo
Rather	rather	rr@_rg
,	,	y
the	the	at
FDA	fda	nn1_np1
recognizes	recognize	vvz
three	three	mc
distinct	distinct	jj
types	type	nn2
of	of	io
advertising	advertising	nn1
,	,	y
based	base	vvn
on	on	ii
the	the	at
advertisements	advertisement	nn2
'	'	ge
content	content	nn1_jj
.	.	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
call	call	vv0_nn1
attention	attention	nn1
to	to	ii
a	a	at1
product	product	nn1
or	or	cc
brand	brand	nn1_vv0@
name	name	nn1
,	,	y
but	but	ccb
contain	contain	vv0
no	no	at
reference	reference	nn1
to	to	ii
the	the	at
purpose	purpose	nn1
of	of	io
the	the	at
drug	drug	nn1
,	,	y
its	its	z'
benefits	benefit	nn2
,	,	y
or	or	cc
risks.	risk	nnu
n52	n52	fo
Reminder	reminder	nn1
advertisements	advertisement	nn2
are	be	vbr
exempt	exempt	jj
from	from	ii
the	the	at
brief-summary	brief-summary	nn1
requirement.	requirement	nnu
n53	n53	fo
Second	second	md
,	,	y
"	"	y
help-seeking	help-seeking	jj_nn1
"	"	y
advertisements	advertisement	nn2
describe	describe	vv0
a	a	at1
disease	disease	nn1
or	or	cc
condition	condition	nn1
and	and	cc
direct	direct	vv0@_rr@
the	the	at
consumer	consumer	nn1
to	to	to
see	see	vvi
his	his	appge
doctor	doctor	nn1
,	,	y
but	but	ccb
do	do	vd0
not	not	xx
mention	mention	vvi
the	the	at
drug	drug	nn1
's	's	ge
name.	name	nnu
n54	n54	fo
Finally	finally	rr
,	,	y
product-claim	product-claim	jj_nn1
advertisements	advertisement	nn2
reveal	reveal	vv0
both	both	rr
the	the	at
product	product	nn1
's	's	ge
name	name	nn1
and	and	cc
its	its	z'
contraindications.	contraindications	nnu
n55	n55	fo
These	these	dd2
product-claim	product-claim	jj
advertisements	advertisement	nn2
must	must	vm
satisfy	satisfy	vvi
the	the	at
"	"	y
brief	brief	jj
summary	summary	nn1
"	"	y
and	and	cc
"	"	y
fair	fair	jj
balance	balance	nn1
"	"	y
requirements.	requirements	nnu
(	(	y
n56	n56	fo
)	)	y
<p>	<p>	y
In	in	ii
the	the	at
twenty	twenty	mc
years	year	nnt2
following	following	ra@_vvg_ii@
enactment	enactment	nn1
of	of	io
the	the	at
1962	1962	mc
Amendments	amendment	nn2
,	,	y
pharmaceutical	pharmaceutical	jj
manufacturers	manufacturer	nn2
directed	direct	vvd_vvn
advertisements	advertisement	nn2
and	and	cc
promotional	promotional	jj
practices	practice	nn2
almost	almost	rr
exclusively	exclusively	rr
toward	toward	ii
physicians.	physicians	nnu
n57	n57	fo
It	it	pph1
was	be	vbdz
not	not	xx
until	until	cs_ii@
the	the	at
early	early	jj
1980s	1980s	mc2
that	that	cst
manufacturers	manufacturer	nn2
began	begin	vvd
to	to	to
place	place	vvi
advertisements	advertisement	nn2
for	for	if
prescription	prescription	nn1
medicines	medicine	nn2
in	in	ii
mainstream	mainstream	jj
print	print	nn1
media	media	nn
n58	n58	fo
Soon	soon	rr
after	after	cs_ii
these	these	dd2
advertisements	advertisement	nn2
began	begin	vvd
to	to	to
run	run	vvi
,	,	y
the	the	at
FDA	fda	np1_nn1
asked	ask	vvd
for	for	if
a	a	at1
voluntary	voluntary	jj
moratorium	moratorium	nn1
of	of	io
the	the	at
practice.	practice	nnu
(	(	y
n59	n59	fo
)	)	y
<p>	<p>	y
In	in	ii
1985	1985	mc
,	,	y
the	the	at
FDA	fda	np1_nn1
decided	decide	vvd_vvn
to	to	to
permit	permit	vvi
DTC	dtc	np1
advertising	advertising	nn1_vvg@
so	so	rg
long	long	rr_jj
as	as	csa
the	the	at
manufacturer	manufacturer	nn1
complied	comply	vvn_vvd
with	with	iw
the	the	at
"	"	y
brief	brief	jj
summary	summary	nn1
"	"	y
and	and	cc
"	"	y
fair	fair	jj
balance	balance	nn1
"	"	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
media	media	nn
,	,	y
the	the	at
product	product	nn1
's	's	ge
approved	approved	jj_vvn
physician	physician	nn1
labeling	labeling	nn1@_vvg
was	be	vbdz
reprinted	reprint	vvn
in	in	ii
the	the	at
advertisement	advertisement	nn1
to	to	to
satisfy	satisfy	vvi
the	the	at
"	"	y
brief	brief	jj
summary	summary	nn1
"	"	y
requirement	requirement	nn1
.	.	y
This	this	dd1
practice	practice	nn1
,	,	y
however	however	rr
,	,	y
presented	present	vvd_jj@_vvn
challenges	challenge	nn2
for	for	if
broadcast	broadcast	nn1_jj@
advertising	advertising	nn1
.	.	y
A	a	at1_zz1
thirty-second	thirty-second	md_nnu
TV	tv	nn1
spot	spot	nn1
was	be	vbdz
both	both	rr
too	too	rg
expensive	expensive	jj
and	and	cc
too	too	rg
short	short	jj_rr@
for	for	if
a	a	at1
manufacturer	manufacturer	nn1
to	to	to
read	read	vvi
the	the	at
brief	brief	jj
summary	summary	nn1
or	or	cc
scroll	scroll	vv0_nn1
through	through	ii
the	the	at
product	product	nn1
's	's	ge
package	package	nn1
insert.	insert	nnu
(	(	y
n61	n61	fo
)	)	y
<p>	<p>	y
In	in	ii31
response	response	ii32
to	to	ii33
industry	industry	nn1
inquiry	inquiry	nn1
,	,	y
the	the	at
FDA	fda	np1_nn1
held	hold	vvd_vvn
public	public	jj
hearings	hearing	nn2
on	on	ii
DTC	dtc	np1
broadcast	broadcast	nn1_vv0_jj@
advertising	advertising	nn1_vvg@
in	in	ii
1995	1995	mc
.	.	y
The	the	at
agency	agency	nn1
issued	issue	vvd_vvn
a	a	at1
Draft	draft	nn1
Guidance	guidance	nn1
document	document	nn1
in	in	ii
1997	1997	mc
,	,	y
which	which	ddq
became	become	vvd
its	its	z'
final	final	jj_nn1
position	position	nn1
in	in	ii
1999.	1999	mc
n62	n62	fo
The	the	at
Guidance	guidance	nn1
document	document	nn1
removed	remove	vvd_vvn
barriers	barrier	nn2
to	to	to
broadcast	broadcast	vvi
advertising	advertising	nn1_vvg@
largely	largely	rr
by	by	ii
transforming	transform	vvg
the	the	at
"	"	y
brief	brief	jj
summary	summary	nn1
"	"	y
requirement	requirement	nn1
for	for	if
print	print	nn1
advertising	advertising	nn1_vvg@
into	into	ii
what	what	ddq
is	be	vbz
now	now	rt
known	know	vvn
as	as	ii
the	the	at
"	"	y
major	major	jj
statement	statement	nn1
"	"	y
requirement	requirement	nn1
for	for	if
broadcast	broadcast	nn1_jj@_vvn
advertising.	advertising	nnu
n63	n63	fo
Under	under	ii
that	that	dd1
requirement	requirement	nn1
,	,	y
the	the	at
advertisement	advertisement	nn1
need	need	vm@
not	not	xx
repeat	repeat	vvi
all	all	db
potential	potential	jj
side	side	nn1
effects	effect	nn2
,	,	y
contraindications	contraindication	nn2
,	,	y
warnings	warning	nn2
,	,	y
and	and	cc
precautions	precaution	nn2
associated	associate	vvn
with	with	iw
the	the	at
product	product	nn1
,	,	y
but	but	ccb
it	it	pph1
must	must	vm
,	,	y
in	in	ii
consumer-friendly	consumer-friendly	jj
language	language	nn1
,	,	y
disclose	disclose	vv0
the	the	at
drug	drug	nn1
's	's	ge
major	major	jj
risks	risk	nn2
in	in	ii_rp@
either	either	rr
the	the	at
audio	audio	nn1_jj
or	or	cc
visual	visual	jj
component.	component	nnu
n64	n64	fo
Further	far	rrr@
,	,	y
to	to	to
make	make	vvi
"	"	y
adequate	adequate	jj
provision	provision	nn1
"	"	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
clear	clear	jj
that	that	cst
the	the	at
advertisement	advertisement	nn1
must	must	vm
publicize	publicize	vvi
a	a	at1
toll-free	toll-free	jj
telephone	telephone	nn1
number	number	nn1
through	through	ii
which	which	ddq
the	the	at
patient	patient	nn1
can	can	vm
obtain	obtain	vvi
a	a	at1
copy	copy	nn1
of	of	io
the	the	at
product	product	nn1
's	's	ge
label	label	nn1
refer	refer	vv0
the	the	at
patient	patient	nn1_jj
to	to	ii
a	a	at1
print	print	nn1
advertisement	advertisement	nn1
or	or	cc
other	other	jj
non-web-based	non-web-based	jj_nn1
resource	resource	nn1_vv0
for	for	if
additional	additional	jj
information	information	nn1
,	,	y
include	include	vv0
a	a	at1
web	web	nn1
address	address	nn1
providing	provide	vvg
access	access	nn1
to	to	ii
the	the	at
product	product	nn1
's	's	ge
labeling	label	vvg_nn1@_jj@
,	,	y
and	and	cc
refer	refer	vv0
the	the	at
patient	patient	nn1_jj
to	to	ii
his	his	appge
doctor	doctor	nn1
or	or	cc
pharmacist.		nnu
n65	n65	fo
Although	although	cs
the	the	at
Guidance	guidance	nn1
document	document	nn1
does	do	vdz
not	not	xx
have	have	vhi
binding	binding	jj
legal	legal	jj
effect	effect	nn1
,	,	y
the	the	at
FDA	fda	nn1_np1
essentially	essentially	rr
placed	place	vvn
manufacturers	manufacturer	nn2
on	on	ii
notice	notice	nn1
that	that	cst
it	it	pph1
would	would	vm
not	not	xx
take	take	vvi
regulatory	regulatory	jj
action	action	nn1
when	when	cs_rrq
a	a	at1
broadcast	broadcast	nn1_jj@
advertisement	advertisement	nn1
complies	comply	vvz
with	with	iw
the	the	at
Guidance	guidance	nn1
document	document	nn1
's	's	ge
terms.	terms	nnu
(	(	y
n66	n66	fo
)	)	y
<p>	<p>	y
Additionally	additionally	rr
,	,	y
as	as	csa
with	with	iw
all	all	db
advertisements	advertisement	nn2
,	,	y
the	the	at
broadcast	broadcast	nn1_jj@
messaging	messaging	nn1
must	must	vm
not	not	xx
be	be	vbi
false	false	jj
or	or	cc
misleading	misleading	jj
in	in	ii
any	any	dd
respect	respect	nn1
.	.	y
Beyond	beyond	ii
assessing	assess	vvg
the	the	at
pure	pure	jj
content	content	nn1_jj
,	,	y
DDMAC		np1_nn1
may	may	vm
also	also	rr
consider	consider	vvi
the	the	at
form	form	nn1
of	of	io
the	the	at
audio	audio	nn1_jj
and	and	cc
video	video	nn1_vv0@
production	production	nn1
and	and	cc
presentation	presentation	nn1
(	(	y
for	for	rex21
example	example	rex22
,	,	y
the	the	at
graphics	graphic	nn
and	and	cc
superimposition	superimposition	nn1
of	of	io
text	text	nn1
,	,	y
the	the	at
pacing	pace	vvg
and	and	cc
clarity	clarity	nn1
of	of	io
voiceovers	voiceovers	vvz
,	,	y
the	the	at
visual	visual	jj
editing	editing	nn1
,	,	y
and	and	cc
sound	sound	nn1
effects	effect	nn2
or	or	cc
music	music	nn1
)	)	y
to	to	to
ensure	ensure	vvi
that	that	cst
the	the	at
advertisement	advertisement	nn1
is	be	vbz
"	"	y
fairly	fairly	rr
balanced	balance	vvn_jj
"	"	y
and	and	cc
that	that	dd1_cst
risk	risk	nn1_vv0
information	information	nn1
is	be	vbz
adequately	adequately	rr
communicated.	communicated	nnu
(	(	y
n67	n67	fo
)	)	y
<p>	<p>	y
Should	should	vm
DDMAC		np1_nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
law	law	nn1
or	or	cc
FDA	fda	nn1_np1
guidelines	guideline	nn2
,	,	y
it	it	pph1
sends	send	vvz
one	one	mc1
of	of	io
two	two	mc
types	type	nn2
of	of	io
letters	letter	nn2
to	to	ii
the	the	at
offender.	offender	nnu
n68	n68	fo
Minor	minor	jj
violations	violation	nn2
are	be	vbr
noted	note	vvn
in	in	ii
a	a	at1
Notice	notice	nn1
of	of	io
Violation	violation	nn1
(	(	y
NOV	nov	npm1
)	)	y
letter.	letter	nnu
n69	n69	fo
A	a	zz1
recipient	recipient	nn1
of	of	io
an	a	at1
NOV	nov	npm1
letter	letter	nn1
typically	typically	rr
discontinues	discontinue	vvz
the	the	at
offending	offending	jj_nn1
marketing	marketing	nn1
practice	practice	nn1
and	and	cc
responds	respond	vvz
to	to	ii
DDMAC		np1_nn1_jj
in	in	ii
writing	write	vvg_nn1
within	within	ii
ten	ten	m
days	day	nnt2
,	,	y
informing	inform	vvg
it	it	pph1
of	of	io
the	the	at
discontinuation.		nnu
n70	n70	fo
For	for	if
more	more	rgr_dar
serious	serious	jj
violations	violation	nn2
,	,	y
DDMAC		np1_nn1
sends	send	vvz
a	a	at1
warning	warning	nn1
letter.	letter	nnu
n71	n71	fo
These	these	dd2
letters	letter	nn2
put	put	vv0_vvd
the	the	at
recipient	recipient	nn1
on	on	ii
notice	notice	nn1
of	of	io
the	the	at
FDA	fda	np1_nn1
's	's	ge
intent	intent	nn1_jj
to	to	to
initiate	initiate	vvi
further	far	rrr_jjr@
regulatory	regulatory	jj
action	action	nn1
against	against	ii
the	the	at
recipient	recipient	nn1
if	if	cs
it	it	pph1
refuses	refuse	vvz
to	to	to
rectify	rectify	vvi
the	the	at
offending	offending	jj_nn1
practice	practice	nn1
promptly	promptly	rr
.	.	y
Manufacturers	manufacturer	nn2
have	have	vh0
consistently	consistently	rr
taken	take	vvn
the	the	at
appropriate	appropriate	jj
corrective	corrective	jj_nn1
action	action	nn1
indicated	indicate	vvn_vvd
in	in	ii
such	such	da
letters	letter	nn2
,	,	y
without	without	iw
the	the	at
need	need	nn1
for	for	if
further	far	jjr@
action	action	nn1
from	from	ii
the	the	at
FDA.	fda	np1
n72	n72	fo
In	in	rr21
addition	addition	rr22
,	,	y
the	the	at
Food	food	nn1
and	and	cc
Drug	drug	nn1
Administration	administration	nn1
Amendments	amendment	nn2
Act	act	nn1
of	of	io
2007	2007	mc
(	(	y
FDAAA		np1
)	)	y
gave	give	vvd
the	the	at
FDA	fda	nn1_np1
the	the	at
authority	authority	nn1
to	to	to
impose	impose	vvi
civil	civil	jj
penalties	penalty	nn2
directly	directly	rr
for	for	if
false	false	jj
or	or	cc
misleading	misleading	jj
advertisements.	advertisements	nnu
(	(	y
n73	n73	fo
)	)	y
<p>	<p>	y
Federal	federal	jj
law	law	nn1
does	do	vdz
not	not	xx
currently	currently	rr
mandate	mandate	nn1
pre-market	pre-market	nn1_jj
review	review	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
.	.	y
Rather	rather	rr@_rg
,	,	y
unless	unless	cs
the	the	at
FDA	fda	nn1_np1
provides	provide	vvz
otherwise	otherwise	rr
,	,	y
n74	n74	fo
manufacturers	manufacturer	nn2
are	be	vbr
required	require	vvn
to	to	to
submit	submit	vvi
their	their	appge
marketing	marketing	nn1
materials	material	nn2
to	to	ii
the	the	at
agency	agency	nn1
at	at	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
n75	n75	fo
Many	many	da2
manufacturers	manufacturer	nn2
,	,	y
however	however	rr
,	,	y
routinely	routinely	rr
submit	submit	vv0
proposed	proposed	jj
advertisements	advertisement	nn2
before	before	ii_cs
dissemination	dissemination	nn1
on	on	ii
a	a	at1
voluntary	voluntary	jj
basis	basis	nn1
.	.	y
This	this	dd1
provides	provide	vvz
the	the	at
FDA	fda	nn1
with	with	iw
an	a	at1
opportunity	opportunity	nn1
to	to	to
review	review	vvi
advertisements	advertisement	nn2
before	before	cs
they	they	pphs2
are	be	vbr
released	release	vvn
publicly	publicly	rr
and	and	cc
to	to	to
suggest	suggest	vvi
improvements.	improvement	nnu
n76	n76	fo
For	for	rex21
example	example	rex22
,	,	y
between	between	ii
2000	2000	mc
and	and	cc
2006	2006	mc
,	,	y
the	the	at
FDA	fda	np1_nn1
received	receive	vvd_vvn
an	a	at1
average	average	nn1
of	of	io
approximately	approximately	rr
150	150	mc
television	television	nn1
advertisements	advertisement	nn2
each	each	dd1
year	year	nnt1
for	for	if
advisory	advisory	jj
review.	review	nnu
n77	n77	fo
In	in	ii
fact	fact	nn1
,	,	y
the	the	at
Pharmaceutical	pharmaceutical	jj
Research	research	nn1
and	and	cc
Manufacturers	manufacturer	nn2
of	of	io
America	america	np1
(	(	y
PhRMA	phrma	np1
)	)	y
,	,	y
the	the	at
leading	leading	jj
industry	industry	nn1
group	group	nn1
of	of	io
drug	drug	nn1
manufacturers	manufacturer	nn2
,	,	y
encourages	encourage	vvz
its	its	z'
members	member	nn2
to	to	to
submit	submit	vvi
all	all	db
television	television	nn1
advertising	advertising	nn1_vvg@
to	to	ii
the	the	at
FDA	fda	nn1
for	for	if
review	review	nn1
before	before	ii
airing.		nnu
n78	n78	fo
Manufacturers	manufacturer	nn2
have	have	vh0
widely	widely	rr
adopted	adopt	vvn
the	the	at
PhRMA	phrma	np1_nn1@
code	code	nn1
and	and	cc
continue	continue	vv0
the	the	at
longstanding	long-standing	jj
practice	practice	nn1
of	of	io
submitting	submit	vvg
DTC	dtc	np1
advertisements	advertisement	nn2
to	to	ii
the	the	at
FDA	fda	nn1_np1
before	before	ii
dissemination.	dissemination	nnu
(	(	y
n79	n79	fo
)	)	y
<p>	<p>	y
Some	some	dd
critics	critic	nn2
,	,	y
including	including	ii_vvg@
the	the	at
General	general	jj_nn1
Accounting	accounting	nn1_vvg_jj@
Office	office	nn1
(	(	y
GAO	gao	np1
)	)	y
,	,	y
have	have	vh0
highlighted	highlight	vvn
shortcomings	shortcoming	nn2
in	in	ii
the	the	at
regulatory	regulatory	jj
process	process	nn1
overseeing	oversee	vvg
pharmaceutical	pharmaceutical	jj
marketing	marketing	nn1
and	and	cc
have	have	vh0
suggested	suggest	vvn
that	that	cst_dd1
DDMAC		np1_nn1_jj
needs	need	vvz_nn2
additional	additional	jj
resources	resource	nn2
.	.	y
In	in	ii
2002	2002	mc
,	,	y
a	a	at1
GAO	gao	np1
study	study	nn1
examined	examine	vvd_vvn
two	two	mc
deficiencies	deficiency	nn2
in	in	ii
the	the	at
regulation	regulation	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
:	:	y
the	the	at
FDA	fda	np1_nn1
's	's	ge
inability	inability	nn1
to	to	to
be	be	vbi
certain	certain	jj
that	that	cst
manufacturers	manufacturer	nn2
submit	submit	vv0
their	their	appge
advertisements	advertisement	nn2
to	to	ii
the	the	at
agency	agency	nn1
and	and	cc
the	the	at
lengthy	lengthy	jj
period	period	nn1
before	before	ii_cs
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
information.	information	nnu
n80	n80	fo
When	when	rrq_cs
the	the	at
GAO	gao	np1
revisited	revisit	vvd
the	the	at
issue	issue	nn1
four	four	mc
years	year	nnt2
later	later	rrr
,	,	y
it	it	pph1
found	find	vvd
that	that	cst
this	this	dd1
lag	lag	nn1
time	time	nnt1
had	have	vhd
worsened	worsen	vvn
considerably	considerably	rr
,	,	y
leading	lead	vvg
to	to	ii
a	a	at1
situation	situation	nn1
where	where	rrq
,	,	y
more	more	rgr
often	often	rr
than	than	csn
not	not	xx
,	,	y
the	the	at
publication	publication	nn1
or	or	cc
broadcast	broadcast	nn1
of	of	io
the	the	at
misleading	misleading	jj
advertisement	advertisement	nn1
had	have	vhd
already	already	rr
concluded	conclude	vvn
before	before	ii_cs
the	the	at
FDA	fda	np1_nn1
issued	issue	vvd
its	its	z'
violation	violation	nn1
letter.	letter	nnu
n81	n81	fo
It	it	pph1_nn1@
also	also	rr
noted	note	vvn_vvd
that	that	cst
the	the	at
FDA	fda	nn1_np1
had	have	vhd
the	the	at
capacity	capacity	nn1
to	to	to
review	review	vvi
only	only	rr
a	a	at1
small	small	jj
portion	portion	nn1
of	of	io
the	the	at
increasingly	increasingly	rr
large	large	jj
amount	amount	nn1
of	of	io
the	the	at
DTC	dtc	np1
materials	material	nn2
submitted	submit	vvd_vvn
.	.	y
Therefore	therefore	rr
,	,	y
the	the	at
FDA	fda	nn1_np1
closely	closely	rr
examined	examine	vvn_vvd
only	only	jj
advertisements	advertisement	nn2
for	for	if
those	those	dd2
drugs	drug	nn2
with	with	iw
the	the	at
greatest	greatest	jjt
potential	potential	nn1_jj
to	to	ii
impact	impact	nn1
the	the	at
public	public	jj_nn1
health.	health	nnu
n82	n82	fo
As	as	ii_csa
the	the	at
FDA	fda	nn1_np1
recently	recently	rr
noted	note	vvn_vvd
,	,	y
"	"	y
the	the	at
lack	lack	nn1
of	of	io
timely	timely	jj
,	,	y
predictable	predictable	jj
FDA	fda	nn1
review	review	nn1
times	time	nnt2_vvz%
for	for	if
DTC	dtc	np1
television	television	nn1
advertisements	advertisement	nn2
has	have	vhz
hindered	hinder	vvn
companies	company	nn2
'	'	ge
ability	ability	nn1
to	to	to
accurately	accurately	rr
set	set	vvi
timeframes	timeframe	nn2
for	for	if
their	their	appge
marketing	marketing	nn1
campaigns	campaign	nn2
and	and	cc
has	have	vhz
discouraged	discourage	vvn
companies	company	nn2
from	from	ii
taking	take	vvg
advantage	advantage	nn1
of	of	io
the	the	at
DTC	dtc	np1
advisory	advisory	jj
review	review	nn1
process	process	nn1
.	.	y
"	"	y
(	(	y
n83	n83	fo
)	)	y
<p>	<p>	y
Congress	congress	nn1
attempted	attempt	vvd_vvn
to	to	to
address	address	vvi
the	the	at
inability	inability	nn1
of	of	io
the	the	at
FDA	fda	nn1_np1
to	to	to
keep	keep	vvi
pace	pace	nn1
with	with	iw
the	the	at
increasing	increasing	jj
number	number	nn1
of	of	io
DTC	dtc	np1
advertisements	advertisement	nn2
submitted	submit	vvn_vvd
for	for	if
its	its	z'
review	review	nn1
when	when	cs_rrq
it	it	pph1
enacted	enact	vvd
FDAAA		np1_nn1
,	,	y
which	which	ddq
included	include	vvd
a	a	at1
new	new	jj
user	user	nn1
's	's	ge
fee	fee	nn1
program	program	nn1
to	to	to
provide	provide	vvi
the	the	at
agency	agency	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
program.	program	nnu
n84	n84	fo
The	the	at
program	program	nn1
would	would	vm
have	have	vhi
required	require	vvn
any	any	dd
company	company	nn1
that	that	cst
intended	intend	vvd
to	to	to
submit	submit	vvi
DTC	dtc	np1
television	television	nn1
advertisements	advertisement	nn2
for	for	if
voluntary	voluntary	jj
FDA	fda	nn1_np1
review	review	nn1_vv0
to	to	to
pay	pay	vvi
an	a	at1
annual	annual	jj
fee	fee	nn1
to	to	to
help	help	vvi
maintain	maintain	vvi
the	the	at
program.	program	nnu
n85	n85	fo
The	the	at
Act	act	nn1
provided	provide	vvd_vvn_cs
,	,	y
however	however	rr
,	,	y
that	that	cst
this	this	dd1
new	new	jj
program	program	nn1
would	would	vm
not	not	xx
go	go	vvi
into	into	ii
effect	effect	nn1
unless	unless	cs
the	the	at
FDA	fda	np1_nn1
received	receive	vvd
$11,250,000		nnu
in	in	ii
fees	fee	nn2
within	within	ii
120	120	mc
days	day	nnt2
of	of	io
enactment	enactment	nn1
(	(	y
that	that	rex21
is	is	rex22
,	,	y
by	by	ii
January	january	npm1
25	25	mc
,	,	y
2008	2008	mc
)	)	y
.	.	y
n86	n86	fo
In	in	ii
January	january	npm1
2008	2008	mc
,	,	y
the	the	at
FDA	fda	np1_nn1
announced	announce	vvd_vvn
that	that	cst
because	because	cs
a	a	at1
subsequent	subsequent	jj
appropriation	appropriation	nn1
bill	bill	nn1
did	do	vdd
not	not	xx
include	include	vvi
a	a	at1
corresponding	corresponding	jj
authorization	authorization	nn1
for	for	if
the	the	at
FDA	fda	nn1_np1
to	to	to
collect	collect	vvi
and	and	cc
spend	spend	vvi
user	user	nn1
fees	fee	nn2
for	for	if
the	the	at
purposes	purpose	nn2
of	of	io
the	the	at
program	program	nn1
,	,	y
and	and	cc
because	because	cs
the	the	at
FDA	fda	nn1_np1
had	have	vhd
not	not	xx
collected	collect	vvn
the	the	at
mandated	mandated	jj@
minimum	minimum	jj_nn1
level	level	nn1
of	of	io
funds	fund	nn2
,	,	y
it	it	pph1
would	would	vm
not	not	xx
implement	implement	vvi
the	the	at
new	new	jj
program.	program	nnu
n87	n87	fo
Therefore	therefore	rr
,	,	y
the	the	at
FDA	fda	nn1_np1
continues	continue	vvz
to	to	to
review	review	vvi
advertisements	advertisement	nn2
voluntarily	voluntarily	rr
submitted	submit	vvn_vvd
for	for	if
review	review	nn1
"	"	y
in	in	ii_rp@
as	as	rg@_csa
timely	timely	jj
a	a	at1
manner	manner	nn1
as	as	csa_ii@
resources	resource	nn2
permit	permit	vv0
.	.	y
"	"	y
(	(	y
n88	n88	fo
)	)	y
<p>	<p>	y
D.	d	np1
The	the	at
Relevance	relevance	nn1
of	of	io
History	history	nn1
to	to	ii
DTC	dtc	np1
Advertising	advertising	nn1
Today	today	rt
The	the	at
previously	previously	rr
discussed	discuss	vvn_vvd
history	history	nn1
and	and	cc
development	development	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
regulation	regulation	nn1
reveals	reveal	vvz
some	some	dd
interesting	interesting	jj
insights	insight	nn2
.	.	y
First	first	md
,	,	y
DTC	dtc	np1
advertising	advertising	nn1
is	be	vbz
not	not	xx
a	a	at1
new	new	jj
phenomenon	phenomenon	nn1
;	;	y
in	in	ii
fact	fact	nn1
,	,	y
it	it	pph1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
in	in	ii
early	early	jj_rr
pharmaceutical	pharmaceutical	jj
regulation	regulation	nn1
,	,	y
the	the	at
1906	1906	mc
Pure	pure	jj
Food	food	nn1
and	and	cc
Drugs	drug	nn2
Act	act	nn1_vv0@
and	and	cc
the	the	at
Federal	federal	jj
Food	food	nn1
,	,	y
Drug	drug	nn1
,	,	y
and	and	cc
Cosmetic	cosmetic	jj
Act	act	nn1
of	of	io
1938	1938	mc
,	,	y
were	be	vbdr
born	born	vvn
out	out	ii21
of	of	ii22
responses	response	nn2
to	to	ii
public	public	jj_nn1
health	health	nn1
crises	crisis	nn2
resulting	result	vvg
from	from	ii
inadequate	inadequate	jj
testing	testing	nn1
,	,	y
not	not	xx
deficiencies	deficiency	nn2
specific	specific	jj
to	to	ii
DTC	dtc	np1
advertising.	advertising	nnu
n90	n90	fo
Third	third	md
,	,	y
regulation	regulation	nn1
discouraging	discourage	vvg_jj
DTC	dtc	np1
advertising	advertising	nn1
(	(	y
by	by	ii
deeming	deem	vvg
it	it	pph1
false	false	rr@_jj
)	)	y
was	be	vbdz
initially	initially	rr
proposed	propose	vvn_jj_vvd
and	and	cc
rejected	reject	vvn
by	by	ii
Congress	congress	nn1
in	in	ii
an	a	at1
age	age	nn1
when	when	cs_rrq
the	the	at
advertisements	advertisement	nn2
were	be	vbdr
likely	likely	jj_rr@
to	to	to
have	have	vhi
been	be	vbn
in	in	ii
printed	printed	jj
materials.	materials	nnu
n91	n91	fo
This	this	dd1
history	history	nn1
implies	imply	vvz
that	that	dd1_cst
Congress	congress	nn1
did	do	vdd
not	not	xx
find	find	vvi
DTC	dtc	np1
advertising	advertise	vvg@_nn1
a	a	at1
significant	significant	jj
threat	threat	nn1
to	to	ii
consumer	consumer	nn1
safety	safety	nn1
,	,	y
given	give	vvn
the	the	at
need	need	nn1
for	for	if
a	a	at1
prescribing	prescribing	nn1@_vvg
physician.	physician	nnu
(	(	y
n92	n92	fo
)	)	y
<p>	<p>	y
Modern	modern	jj
regulation	regulation	nn1
of	of	io
pharmaceuticals	pharmaceutical	nn2
follows	follow	vvz
such	such	da
sentiment	sentiment	nn1
.	.	y
In	in	ii
developing	develop	vvg_jj
comprehensive	comprehensive	jj
regulation	regulation	nn1
regarding	regarding	ii_vvg
the	the	at
safety	safety	nn1
,	,	y
efficacy	efficacy	nn1
,	,	y
and	and	cc
marketing	marketing	nn1
of	of	io
a	a	at1
drug	drug	nn1
,	,	y
the	the	at
FDA	fda	nn1_np1
has	have	vhz
refrained	refrain	vvn
from	from	ii
regulation	regulation	nn1
specific	specific	jj_nn1%
to	to	ii
DTC	dtc	np1
advertising	advertising	nn1
and	and	cc
has	have	vhz
instead	instead	rr
approached	approach	vvn
this	this	dd1
form	form	nn1
of	of	io
marketing	marketing	nn1_vvg@
under	under	ii
the	the	at
same	same	da
analysis	analysis	nn1
as	as	csa
direct-to-physician	direct-to-physician	jj_nn1
advertising.	advertising	nnu
n93	n93	fo
As	as	csa
DTC	dtc	np1
advertising	advertising	nn1
resurfaced	resurface	vvd_vvn@
from	from	ii
dormancy	dormancy	nn1
and	and	cc
became	become	vvd
more	more	rgr_dar
mainstream	mainstream	jj
in	in	ii
the	the	at
early	early	jj
1980s	1980s	mc2
,	,	y
the	the	at
FDA	fda	np1_nn1
instituted	institute	vvd_vvn
a	a	at1
voluntary	voluntary	jj
moratorium	moratorium	nn1
to	to	to
examine	examine	vvi
again	again	rt
whether	whether	csw
DTC	dtc	np1
advertising	advertising	nn1
posed	pose	vvd_vvn
a	a	at1
legitimate	legitimate	jj
concern	concern	nn1
to	to	ii
consumers	consumer	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
FDA	fda	nn1_np1
has	have	vhz
clearly	clearly	rr
recognized	recognize	vvn
,	,	y
through	through	ii
its	its	z'
Guidance	guidance	nn1
document	document	nn1
and	and	cc
other	other	jj
agency	agency	nn1
statements	statement	nn2
,	,	y
that	that	cst
DTC	dtc	np1
marketing	marketing	nn1
does	do	vdz
not	not	xx
pose	pose	vvi
a	a	at1
heightened	heightened	jj
risk	risk	nn1
to	to	ii
consumers	consumer	nn2
,	,	y
and	and	cc
may	may	vm
actually	actually	rr
prove	prove	vvi
beneficial.	beneficial	nnu
(	(	y
n95	n95	fo
)	)	y
<p>	<p>	y
There	there	ex
is	be	vbz
,	,	y
however	however	rr
,	,	y
a	a	at1
recognized	recognized	jj@
need	need	nn1
to	to	to
provide	provide	vvi
the	the	at
FDA	fda	nn1
with	with	iw
additional	additional	jj
staffing	staffing	nn1
so	so	cs21
that	that	cs22
it	it	pph1
may	may	vm
more	more	rgr_rrr
promptly	promptly	rr
review	review	vvi
advertisements	advertisement	nn2
and	and	cc
suggest	suggest	vvi
improvements	improvement	nn2
.	.	y
Such	such	da
action	action	nn1
can	can	vm
only	only	rr
come	come	vvi
from	from	ii
Congress	congress	nn1
.	.	y
Despite	despite	ii
that	that	dd1
particular	particular	jj
criticism	criticism	nn1
regarding	regarding	ii_vvg
the	the	at
regulatory	regulatory	jj
review	review	nn1
of	of	io
DTC	dtc	np1
advertisements	advertisement	nn2
,	,	y
repeated	repeat	vvd_jj@_vvn
examination	examination	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1_vvg@
over	over	ii_rp
the	the	at
past	past	jj_nn1
century	century	nnt1
has	have	vhz
not	not	xx
found	find	vvn
that	that	cst
it	it	pph1
interferes	interfere	vvz
with	with	iw
the	the	at
doctor-patient	doctor-patient	jj_nn1
relationship	relationship	nn1
or	or	cc
diminishes	diminish	vvz
the	the	at
role	role	nn1
of	of	io
the	the	at
FDA	fda	nn1_np1
in	in	ii_rp@
closely	closely	rr
regulating	regulate	vvg
the	the	at
safety	safety	nn1
and	and	cc
efficacy	efficacy	nn1
of	of	io
the	the	at
drug	drug	nn1
.	.	y
Because	because	cs
DTC	dtc	np1
marketing	marketing	nn1
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
has	have	vhz
not	not	xx
fundamentally	fundamentally	rr
altered	alter	vvn
the	the	at
playing	playing	jj%_vvg_nn1%
field	field	nn1
,	,	y
traditional	traditional	jj
rules	rule	nn2
of	of	io
law	law	nn1
should	should	vm
remain	remain	vvi
fully	fully	rr
viable	viable	jj
.	.	y
<p>	<p>	y
II	ii	mc
.	.	y
THE	the	at
POTENTIAL	potential	jj_nn1
BENEFITS	benefit	nn2
AND	and	cc
PITFALLS	pitfall	nn2
OF	of	io
DTC	dtc	np1
ADVERTISING	advertising	nn1
Reaction	reaction	nn1
to	to	ii
the	the	at
resurgence	resurgence	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
within	within	ii
the	the	at
modern	modern	jj
regulated	regulated	jj@_vvd_vvn
pharmaceutical	pharmaceutical	jj
environment	environment	nn1
is	be	vbz
mixed	mix	vvn
.	.	y
Critics	critic	nn2
argue	argue	vv0
that	that	cst
DTC	dtc	np1
advertising	advertising	nn1
overemphasizes	overemphasize	vvz
benefits	benefit	nn2
and	and	cc
downplays	downplay	vvz_nn2
risks	risk	nn2
,	,	y
which	which	ddq
might	might	vm
cause	cause	vvi
patients	patient	nn2
to	to	to
believe	believe	vvi
that	that	cst
a	a	at1
particular	particular	jj
medicine	medicine	nn1
works	work	vvz
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
critics	critic	nn2
express	express	vv0
concern	concern	nn1_vv0@
that	that	cst
the	the	at
presence	presence	nn1
of	of	io
DTC	dtc	np1
campaigns	campaign	nn2
negatively	negatively	rr
affect	affect	vv0
the	the	at
doctor-patient	doctor-patient	jj_nn1
relationship	relationship	nn1
,	,	y
prompting	prompt	vvg
patients	patient	nn2
to	to	ii
pressure	pressure	nn1
their	their	appge
physicians	physician	nn2
to	to	to
prescribe	prescribe	vvi
unneeded	unneeded	jj
medications	medication	nn2
or	or	cc
to	to	to
demand	demand	vvi
a	a	at1
brand	brand	nn1
name	name	nn1_vv0@
pharmaceutical	pharmaceutical	jj
over	over	ii
cheaper	cheap	jjr
or	or	cc
safer	safer	rrr_jjr
generic	generic	jj
alternatives.	alternative	nnu
n97	n97	fo
Beyond	beyond	ii
issues	issue	nn2
with	with	iw
the	the	at
message	message	nn1
itself	itself	ppx1
,	,	y
critics	critic	nn2
cite	cite	vv0
the	the	at
rapid	rapid	jj
increase	increase	nn1
in	in	ii
industry	industry	nn1
spending	spend	vvg_nn1
on	on	ii
DTC	dtc	np1
advertising--a		nn1_vvg@
330%	330%	nnu
rise	rise	nn1_vv0
from	from	ii
$985	$985	nnu
million	million	m
in	in	ii
1996	1996	mc
to	to	ii
$4.2	$4.2	nnu
billion	billion	m
in	in	ii
2005--as		csa_rg@_ii@
contributing	contribute	vvg_jj@
to	to	ii
a	a	at1
contemporaneous	contemporaneous	jj
rise	rise	nn1
in	in	ii
drug	drug	nn1
spending.	spending	nnu
n98	n98	fo
Critics	critic	nn2
also	also	rr
perceive	perceive	vv0
an	a	at1
inverse	inverse	jj_nn1
relationship	relationship	nn1
between	between	ii
this	this	dd1
increased	increased	jj
spending	spending	nn1
and	and	cc
decreasing	decreasing	jj_vvg
regulatory	regulatory	jj
action	action	nn1
documenting	document	vvg_nn1@_jj@
noncompliance	noncompliance	nn1
,	,	y
such	such	ii21
as	as	ii22
NOV	nov	npm1
or	or	cc
warning	warning	nn1_vvg@
letters	letter	nn2
,	,	y
as	as	csa
evidence	evidence	nn1
of	of	io
an	a	at1
overworked	overworked	jj
and	and	cc
inefficient	inefficient	jj
FDA.	fda	np1
(	(	y
n99	n99	fo
)	)	y
<p>	<p>	y
Proponents	proponent	nn2
counter	counter	vv0
that	that	cst
DTC	dtc	np1
advertising	advertising	nn1
fosters	foster	vvz
healthy	healthy	jj
physician-patient	physician-patient	jj_nn1
relationships	relationship	nn2
by	by	ii
providing	provide	vvg
information	information	nn1
to	to	ii
patients	patient	nn2
that	that	cst_dd1
prompts	prompt	vvz
discussion	discussion	nn1
with	with	iw
their	their	appge
physicians	physician	nn2
.	.	y
When	when	cs
first	first	md
surveyed	survey	vvn_vvd
in	in	ii
the	the	at
1980s	1980s	mc2
about	about	ii
whether	whether	csw
they	they	pphs2
would	would	vm
value	value	nn1
DTC	dtc	np1
advertising	advertising	nn1
,	,	y
patients	patient	nn2
responded	respond	vvd_vvn
that	that	cst
they	they	pphs2
believed	believe	vvd
DTC	dtc	np1
advertising	advertising	nn1
would	would	vm
be	be	vbi
useful	useful	jj
,	,	y
but	but	ccb
they	they	pphs2
would	would	vm
still	still	rr
prefer	prefer	vvi
that	that	cst
physicians	physician	nn2
control	control	vv0
prescribing	prescribe	vvg
decisions.	decision	nnu
n100	n100	fo
Twenty	twenty	mc
years	year	nnt2
later	later	rrr
,	,	y
in	in	ii31
response	response	ii32
to	to	ii33
one	one	mc1
study	study	nn1
on	on	ii
consumer	consumer	nn1
perceptions	perception	nn2
,	,	y
the	the	at
majority	majority	nn1
of	of	io
patients	patient	nn2
reported	report	vvd_vvn
that	that	cst
DTC	dtc	np1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
in	in	ii
their	their	appge
own	own	da
health	health	nn1
care	care	nn1
and	and	cc
encouraged	encourage	vvd
them	them	ppho2
to	to	to
seek	seek	vvi
medical	medical	jj
care	care	nn1
from	from	ii
their	their	appge
physicians.	physicians	nnu
n101	n101	fo
Nevertheless	nevertheless	rr
,	,	y
DTC	dtc	np1
advertising	advertising	nn1
ranked	rank	vvn_vvd@
dead	dead	jj_rg@
last	last	md_nn1%
in	in	ii
a	a	at1
recent	recent	jj
poll	poll	nn1
of	of	io
which	which	ddq
sources	source	nn2
consumers	consumer	nn2
report	report	vv0@_nn1
relying	rely	vvg
upon	upon	ii
to	to	to
provide	provide	vvi
accurate	accurate	jj
information	information	nn1
about	about	ii
prescription	prescription	nn1
medications	medication	nn2
.	.	y
Internet	internet	nn1_np1@
websites	website	nn2
,	,	y
family	family	nn1
and	and	cc
friends	friend	nn2
,	,	y
the	the	at
FDA	fda	nn1_np1
,	,	y
the	the	at
package	package	nn1
label	label	nn1
and	and	cc
pharmacists	pharmacist	nn2
all	all	rr@_db
ranked	rank	vvn
progressively	progressively	rr
higher	high	jjr_rrr@
on	on	ii
the	the	at
list	list	nn1
.	.	y
In	in	ii
fact	fact	nn1
,	,	y
"	"	y
Your	your	appge
doctor	doctor	nn1
"	"	y
topped	top	vvd_vvn
the	the	at
list	list	nn1
overwhelmingly.	overwhelmingly	nnu
(	(	y
n102	n102	fo
)	)	y
<p>	<p>	y
Doctors	doctor	nn2
,	,	y
for	for	if
their	their	appge
part	part	nn1
,	,	y
greeted	greet	vvd
DTC	dtc	np1
advertising	advertising	nn1
with	with	iw
skepticism	skepticism	nn1
,	,	y
but	but	ccb
by	by	ii
the	the	at
early	early	jj
1990s	1990s	mc2
,	,	y
the	the	at
American	american	jj
Academy	academy	nn1
of	of	io
Family	family	nn1
Physicians	physician	nn2
expressed	express	vvd_vvn
an	a	at1
opinion	opinion	nn1
that	that	cst
DTC	dtc	np1
advertising	advertising	nn1
encourages	encourage	vvz
patients	patient	nn2
to	to	to
seek	seek	vvi
needed	needed	jj@_vvn
medical	medical	jj
care.	care	nnu
n103	n103	fo
Later	later	rrr
,	,	y
the	the	at
American	american	jj
Medical	medical	jj
Association	association	nn1
reversed	reverse	vvd_vvn
its	its	z'
blanket	blanket	nn1
policy	policy	nn1
against	against	ii
DTC	dtc	np1
advertising	advertising	nn1
in	in	ii31
favor	favor	ii32
of	of	ii33
a	a	at1
case-by-case	case-by-case	jj_nn1
approach.	approach	nnu
n104	n104	fo
By	by	ii
2002	2002	mc
,	,	y
one	one	mc1
report	report	nn1
showed	show	vvd
that	that	cst
the	the	at
"	"	y
overwhelming	overwhelming	jj
"	"	y
majority	majority	nn1
of	of	io
physicians	physician	nn2
polled	poll	vvd_vvn
believed	believe	vvn_vvd
that	that	cst
DTC	dtc	np1
advertising	advertising	nn1
has	have	vhz
had	have	vhn
a	a	at1
beneficial	beneficial	jj
effect	effect	nn1
on	on	ii
the	the	at
doctor-patient	doctor-patient	jj_nn1
relationship.	relationship	nnu
(	(	y
n105	n105	fo
)	)	y
<p>	<p>	y
In	in	ii
2003	2003	mc
,	,	y
the	the	at
FDA	fda	np1_nn1
published	publish	vvd_vvn
results	result	nn2
from	from	ii
what	what	ddq
is	be	vbz
perhaps	perhaps	rr
the	the	at
most	most	rgt
comprehensive	comprehensive	jj
survey	survey	nn1
to	to	ii
date	date	nn1
of	of	io
physician	physician	nn1
attitudes	attitude	nn2
toward	toward	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
and	and	cc
250	250	mc
specialists	specialist	nn2
in	in	ii
the	the	at
fields	field	nn2
of	of	io
dermatology	dermatology	nn1
,	,	y
allergy	allergy	nn1
,	,	y
endocrinology	endocrinology	nn1
,	,	y
and	and	cc
psychiatry.	psychiatry	nnu
n107	n107	fo
Most	most	dat
doctors	doctor	nn2
polled	poll	vvd_vvn
believed	believe	vvn_vvd
that	that	cst
DTC	dtc	np1
advertising	advertising	nn1
led	lead	vvd_vvn
patients	patient	nn2
to	to	to
ask	ask	vvi
more	more	rgr_dar
thoughtful	thoughtful	jj
questions	question	nn2
,	,	y
made	make	vvd_vvn
patients	patient	nn2
more	more	rgr
aware	aware	jj
of	of	io
possible	possible	jj
treatments	treatment	nn2
,	,	y
made	make	vvd_vvn
patients	patient	nn2
more	more	rgr
concerned	concerned	jj
about	about	ii
their	their	appge
health	health	nn1
care	care	nn1
,	,	y
prompted	prompt	vvd_vvn
better	better	jjr
discussions	discussion	nn2
between	between	ii
patients	patient	nn2
and	and	cc
physicians	physician	nn2
about	about	ii
health	health	nn1
,	,	y
and	and	cc
thus	thus	rr
helped	help	vvn_vvd
educate	educate	vvi
patients	patient	nn2
about	about	ii
their	their	appge
health	health	nn1
problems.	problems	nnu
n108	n108	fo
The	the	at
survey	survey	nn1
also	also	rr
found	find	vvn_vvd
that	that	cst
doctors	doctor	nn2
believe	believe	vv0
patients	patient	nn2
understand	understand	vv0
that	that	cst
they	they	pphs2
need	need	vv0
to	to	to
consult	consult	vvi
a	a	at1
healthcare	health-care	nn1
professional	professional	nn1@_jj
about	about	ii
appropriate	appropriate	jj
treatment.	treatment	nnu
(	(	y
n109	n109	fo
)	)	y
<p>	<p>	y
This	this	dd1
Article	article	nn1
does	do	vdz
not	not	xx
attempt	attempt	vvi
to	to	to
resolve	resolve	vvi
this	this	dd1
debate	debate	nn1
or	or	cc
answer	answer	vv0
whether	whether	csw
DTC	dtc	np1
advertising	advertising	nn1
is	be	vbz
good	good	jj
or	or	cc
bad	bad	jj
for	for	if
the	the	at
industry	industry	nn1
,	,	y
patients	patient	nn2
,	,	y
or	or	cc
physicians	physician	nn2
.	.	y
But	but	ccb
however	however	rgqv
valid	valid	jj
the	the	at
arguments	argument	nn2
are	be	vbr
on	on	ii
both	both	db2
sides	side	nn2
,	,	y
neither	neither	rr
the	the	at
available	available	jj
data	data	nn
nor	nor	cc
current	current	jj
medical	medical	jj
practice	practice	nn1
supports	support	vvz
the	the	at
notion	notion	nn1
that	that	cst
DTC	dtc	np1
advertising	advertising	nn1
alters	alter	vvz
a	a	at1
physician	physician	nn1
's	's	ge
control	control	nn1
of	of	io
,	,	y
or	or	cc
ethical	ethical	jj
and	and	cc
legal	legal	jj
responsibility	responsibility	nn1
for	for	if
,	,	y
the	the	at
ultimate	ultimate	jj
decision	decision	nn1
to	to	to
prescribe	prescribe	vvi
medicines	medicine	nn2
to	to	ii
a	a	at1
patient	patient	nn1_jj
.	.	y
For	for	rex21
example	example	rex22
,	,	y
the	the	at
FDA	fda	nn1_np1
responded	respond	vvn_vvd
to	to	ii
concerns	concern	nn2
of	of	io
undue	undue	jj
influence	influence	nn1
in	in	ii
prescribing	prescribe	vvg
decisions	decision	nn2
by	by	ii
asking	ask	vvg
doctors	doctor	nn2
in	in	ii
its	its	z'
2003	2003	mc
survey	survey	vv0@_nn1
whether	whether	csw
a	a	at1
patient	patient	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
doctor	doctor	nn1
when	when	cs
interacting	interact	vvg_jj
with	with	iw
that	that	dd1
patient	patient	nn1
.	.	y
Overwhelmingly	overwhelmingly	rr
,	,	y
those	those	dd2
polled	poll	vvn_vvd
responded	respond	vvd_vvn
that	that	cst
it	it	pph1
did	do	vdd
not.	not	nnu
n110	n110	fo
Of	of	io
the	the	at
18%	18%	nnu
who	who	pnqs
did	do	vdd
believe	believe	vvi
that	that	cst
problems	problem	nn2
arose	arise	vvd
,	,	y
most	most	rrt@_dat_rgt
reported	report	vvn_vvd_jj@
that	that	cst
the	the	at
problem	problem	nn1
either	either	rr
stemmed	stem	vvd_vvn@_jj
from	from	ii
additional	additional	jj
time	time	nnt1
spent	spend	vvn
with	with	iw
the	the	at
patient	patient	nn1_jj
correcting	correct	vvg_jj@
misperceptions	misperception	nn2
about	about	ii
the	the	at
product	product	nn1
or	or	cc
confirming	confirm	vvg
that	that	cst
the	the	at
patient	patient	nn1
did	do	vdd
not	not	xx
have	have	vhi
the	the	at
condition	condition	nn1
the	the	at
drug	drug	nn1
was	be	vbdz
designed	design	vvn
to	to	ii
treat.	treat	nnu
n111	n111	fo
When	when	rrq_cs
asked	ask	vvd_vvn@
whether	whether	csw
the	the	at
patient	patient	nn1
tried	try	vvd
"	"	y
to	to	to
influence	influence	vvi
the	the	at
course	course	nn1
of	of	io
treatment	treatment	nn1
in	in	ii
a	a	at1
way	way	nn1
that	that	cst_dd1
would	would	vm
have	have	vhi
been	be	vbn
harmful	harmful	jj
to	to	ii
him	him	ppho1
or	or	cc
her	her	ppho1
,	,	y
"	"	y
91%	91%	nnu
of	of	io
doctors	doctor	nn2
polled	poll	vvn_vvd
said	say	vvd
no.	no	uh
n112	n112	fo
Furthermore	furthermore	rr
,	,	y
although	although	cs
some	some	dd
doctors	doctor	nn2
reported	report	vvd_vvn
moderate	moderate	jj
to	to	ii
heavy	heavy	jj
pressure	pressure	nn1
to	to	to
prescribe	prescribe	vvi
medications	medication	nn2
to	to	ii
their	their	appge
patients	patient	nn2
,	,	y
the	the	at
majority	majority	nn1
of	of	io
doctors	doctor	nn2
polled	poll	vvd_vvn
reported	report	vvn_vvd_jj@
that	that	cst
they	they	pphs2
felt	feel	vvd
"	"	y
not	not	xx
at	at	rr21
all	all	rr22
pressured	pressure	vvd_vvn@
"	"	y
to	to	to
do	do	vdi
so.	so	nnu
n113	n113	fo
In	in	ii
any	any	dd
event	event	nn1
,	,	y
even	even	rr
those	those	dd2
reporting	report	vvg
some	some	dd
level	level	nn1
of	of	io
pressure	pressure	nn1
to	to	to
prescribe	prescribe	vvi
still	still	rr
ultimately	ultimately	rr
had	have	vhn@_vhd
to	to	to
make	make	vvi
the	the	at
decision	decision	nn1
whether	whether	csw
to	to	to
prescribe	prescribe	vvi
individually	individually	rr
.	.	y
Thus	thus	rr
,	,	y
the	the	at
results	result	nn2
of	of	io
the	the	at
survey	survey	nn1
demonstrate	demonstrate	vv0
that	that	cst_dd1
prescribing	prescribe	vvg_nn1@
decisions	decision	nn2
still	still	rr
rest	rest	vv0
firmly	firmly	rr
with	with	iw
the	the	at
physician	physician	nn1
and	and	cc
that	that	cst
the	the	at
patient	patient	nn1
relies	rely	vvz
necessarily	necessarily	rr
upon	upon	ii
his	his	appge
physician	physician	nn1
's	's	ge
medical	medical	jj
judgment	judgment	nn1
.	.	y
<p>	<p>	y
III	iii	mc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
POLICY	policy	nn1
TODAY	today	rt
Three	three	mc
traditional	traditional	jj
rules--the		nn2
learned	learn	vvd_vvn
intermediary	intermediary	nn1
doctrine	doctrine	nn1
,	,	y
regulatory	regulatory	jj
compliance	compliance	nn1
exemptions	exemption	nn2
to	to	ii
consumer	consumer	nn1
protection	protection	nn1
statutes	statute	nn2
,	,	y
and	and	cc
federal	federal	jj
preemption--are		vbr
particularly	particularly	rr
relevant	relevant	jj
in	in	ii
evaluating	evaluate	vvg
liability	liability	nn1
related	relate	vvn_vvd
to	to	ii
drug	drug	nn1
warnings	warning	nn2
.	.	y
The	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
is	be	vbz
a	a	at1
judicial	judicial	jj
doctrine	doctrine	nn1
,	,	y
regulatory	regulatory	jj
compliance	compliance	nn1
is	be	vbz
a	a	at1
statutory	statutory	jj
policy	policy	nn1
rooted	root	vvn
in	in	ii_rr21
common	common	jj_rr22
law	law	nn1
,	,	y
and	and	cc
federal	federal	jj
preemption	preemption	nn1
is	be	vbz
a	a	at1
constitutional	constitutional	jj
principle	principle	nn1
deriving	derive	vvg
from	from	ii
the	the	at
Supremacy	supremacy	nn1
Clause	clause	nn1
of	of	io
the	the	at
Constitution	constitution	nn1
.	.	y
Although	although	cs
each	each	dd1
originates	originate	vvz
from	from	ii
a	a	at1
different	different	jj
source	source	nn1
,	,	y
they	they	pphs2
share	share	vv0
a	a	at1
common	common	jj
underlying	underlying	jj
policy	policy	nn1
.	.	y
That	that	dd1
policy	policy	nn1
recognizes	recognize	vvz
that	that	cst_dd1
close	close	jj_vv0
regulation	regulation	nn1
by	by	ii
the	the	at
FDA	fda	nn1_np1
and	and	cc
oversight	oversight	vv0_nn1
by	by	ii
individual	individual	jj_nn1
doctors	doctor	nn2
appropriately	appropriately	rr
preclude	preclude	vv0
holding	hold	vvg
pharmaceutical	pharmaceutical	jj
manufacturers	manufacturer	nn2
liable	liable	jj
for	for	if
alleged	alleged	jj
flaws	flaw	nn2
in	in	ii
communicating	communicating	jj_vvg_nn1
information	information	nn1
to	to	ii
individual	individual	jj_nn1
patients	patient	nn2
.	.	y
<p>	<p>	y
A.	a	zz
Ask	ask	vv0
Your	your	appge
Doctor	doctor	nn1
:	:	y
The	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Doctrine	doctrine	nn1
1	1	mc1
.	.	y
Learned	learned	jj@_vvn
Intermediary	intermediary	nn1
Fundamentals	fundamentals	np1
The	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
provides	provide	vvz
that	that	cst
manufacturers	manufacturer	nn2
or	or	cc
suppliers	supplier	nn2
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
fulfill	fulfill	vv0
their	their	appge
duty	duty	nn1
to	to	to
warn	warn	vvi
consumers	consumer	nn2
of	of	io
the	the	at
dangerous	dangerous	jj
propensities	propensity	nn2
of	of	io
their	their	appge
products	product	nn2
by	by	ii
conveying	convey	vvg
accurate	accurate	jj
warning	warning	nn1
information	information	nn1
to	to	ii
prescribing	prescribe	vvg
physicians.	physicians	nnu
n114	n114	fo
It	it	pph1
is	be	vbz
the	the	at
physician	physician	nn1
's	's	ge
duty	duty	nn1
to	to	to
evaluate	evaluate	vvi
the	the	at
benefits	benefit	nn2
and	and	cc
risks	risk	nn2
of	of	io
the	the	at
medication	medication	nn1
as	as	csa
they	they	pphs2
apply	apply	vv0
to	to	ii
the	the	at
individual	individual	jj_nn1
patient.	patient	nnu
n115	n115	fo
The	the	at
rule	rule	nn1
establishes	establish	vvz
a	a	at1
manufacturer	manufacturer	nn1
's	's	ge
legal	legal	jj
duty	duty	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
n116	n116	fo
)	)	y
<p>	<p>	y
Several	several	da2
commonsense	commonsense	jj
rationales	rationale	nn2
support	support	vv0
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
.	.	y
First	first	md
,	,	y
training	training	nn1_vvg@
and	and	cc
experience	experience	nn1_vv0
place	place	nn1_vv0
physicians	physician	nn2
in	in	ii
a	a	at1
better	better	jjr
position	position	nn1
than	than	csn
the	the	at
manufacturer	manufacturer	nn1
to	to	to
convey	convey	vvi
complex	complex	jj
medical	medical	jj
information	information	nn1
and	and	cc
terminology	terminology	nn1
to	to	ii
patients.	patient	nnu
n117	n117	fo
Second	second	md
,	,	y
the	the	at
physician	physician	nn1
has	have	vhz
a	a	at1
relationship	relationship	nn1
with	with	iw
the	the	at
individual	individual	jj_nn1
patient	patient	nn1_jj
,	,	y
making	make	vvg
it	it	pph1
possible	possible	jj
to	to	to
evaluate	evaluate	vvi
the	the	at
patient	patient	nn1
's	's	ge
treatment	treatment	nn1
needs	need	nn2_vvz
and	and	cc
provide	provide	vv0
an	a	at1
assessment	assessment	nn1
of	of	io
the	the	at
potential	potential	jj_nn1
benefits	benefit	nn2
and	and	cc
likely	likely	jj
risks	risk	nn2
specific	specific	jj
to	to	ii
the	the	at
patient	patient	nn1
's	's	ge_vbz
medical	medical	jj
and	and	cc
family	family	nn1
history.	history	nnu
n118	n118	fo
Third	third	md
,	,	y
it	it	pph1
is	be	vbz
more	more	rgr
effective	effective	jj
and	and	cc
efficient	efficient	jj
for	for	if
manufacturers	manufacturer	nn2
to	to	to
provide	provide	vvi
a	a	at1
common	common	jj
set	set	nn1
of	of	io
warnings	warning	nn2
to	to	ii
an	a	at1
intermediary	intermediary	nn1
with	with	iw
more	more	rgr_dar
definable	definable	jj
knowledge	knowledge	nn1
and	and	cc
skill	skill	nn1
characteristics	characteristic	nn2
than	than	csn
to	to	ii
a	a	at1
broad	broad	jj
spectrum	spectrum	nn1
of	of	io
consumers	consumer	nn2
.	.	y
In	in	ii
fact	fact	nn1
,	,	y
it	it	pph1
is	be	vbz
difficult	difficult	jj
,	,	y
if	if	cs
not	not	xx
impossible	impossible	jj
,	,	y
to	to	to
convey	convey	vvi
comprehensive	comprehensive	jj
drug	drug	nn1
warnings	warning	nn2
to	to	ii
consumers	consumer	nn2
because	because	ii21
of	of	ii22
the	the	at
highly	highly	rr
technical	technical	jj
nature	nature	nn1
of	of	io
the	the	at
information	information	nn1
and	and	cc
the	the	at
various	various	jj
needs	need	nn2
of	of	io
individual	individual	jj_nn1
patients.	patient	nnu
n119	n119	fo
The	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
was	be	vbdz
established	establish	vvn
,	,	y
therefore	therefore	rr
,	,	y
in	in	ii
recognition	recognition	nn1
of	of	io
these	these	dd2
significant	significant	jj
challenges	challenge	nn2
and	and	cc
the	the	at
physician	physician	nn1
's	's	ge
superior	superior	jj
position	position	nn1
and	and	cc
ability	ability	nn1
to	to	to
communicate	communicate	vvi
warnings.	warnings	nnu
(	(	y
n120	n120	fo
)	)	y
<p>	<p>	y
Almost	almost	rr
all	all	db
jurisdictions	jurisdiction	nn2
follow	follow	vv0
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
with	with	ii31
regard	regard	ii32
to	to	ii33
claims	claim	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
by	by	ii
the	the	at
Eighth	eighth	md
Circuit	circuit	nn1
,	,	y
which	which	ddq
recognized	recognize	vvd
that	that	cst_dd1
pharmaceutical	pharmaceutical	jj
companies	company	nn2
have	have	vh0
a	a	at1
duty	duty	nn1
to	to	to
warn	warn	vvi
physicians	physician	nn2
directly	directly	rr
about	about	ii_rg%
potential	potential	jj_nn1
risks	risk	nn2
of	of	io
their	their	appge
products	product	nn2
,	,	y
whereas	whereas	cs
physicians	physician	nn2
must	must	vm
serve	serve	vvi
as	as	rg@_csa
"	"	y
learned	learned	jj@_vvn
intermediaries	intermediary	nn2
"	"	y
who	who	pnqs
interpret	interpret	vv0
this	this	dd1
information	information	nn1
and	and	cc
advise	advise	vv0
patients	patient	nn2
appropriately.	appropriately	nnu
n122	n122	fo
It	it	pph1
was	be	vbdz
embraced	embrace	vvn
quickly	quickly	rr
by	by	ii
other	other	jj
jurisdictions.	jurisdiction	nnu
n123	n123	fo
The	the	at
doctrine	doctrine	nn1
has	have	vhz
also	also	rr
come	come	vvn
to	to	to
include	include	vvi
prescription	prescription	nn1
medical	medical	jj
devices	device	nn2
under	under	ii
the	the	at
same	same	da
rationale.	rationale	nnu
n124	n124	fo
Although	although	cs
the	the	at
doctrine	doctrine	nn1
finds	find	vvz
support	support	nn1_vv0
in	in	ii
the	the	at
Restatement	restatement	nn1
(	(	y
Second	second	md_nnt1
)	)	y
of	of	io
Torts	torts	np1_nn2
388	388	mc
,	,	y
n125	n125	fo
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
of	of	io
Torts	torts	np1_nn2
:	:	y
Products	product	nn2
Liability	liability	nn1
6	6	mc
sets	set	vvz_nn2
forth	forth	rr
its	its	z'
underpinnings	underpinning	nn2
more	more	rrr_rgr
completely.	completely	nnu
n126	n126	fo
The	the	at
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
specifically	specifically	rr
addresses	address	vvz
liability	liability	nn1
for	for	if
sellers	seller	nn2
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
and	and	cc
medical	medical	jj
devices	device	nn2
,	,	y
deals	deal	vvz_nn2
with	with	iw
the	the	at
application	application	nn1
of	of	io
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
,	,	y
and	and	cc
sets	set	vvz_nn2
forth	forth	rr
narrow	narrow	jj
exceptions	exception	nn2
to	to	ii
the	the	at
doctrine	doctrine	nn1
's	's	ge
application.	application	nnu
n127	n127	fo
It	it	pph1
presents	present	vvz
the	the	at
rule	rule	nn1
as	as	csa
adopted	adopt	vvn
by	by	ii
the	the	at
majority	majority	nn1
of	of	io
jurisdictions	jurisdiction	nn2
,	,	y
either	either	rr
through	through	ii
judicial	judicial	jj
pronouncement	pronouncement	nn1
or	or	cc
statutory	statutory	jj
enactment.	enactment	nnu
(	(	y
n128	n128	fo
)	)	y
<p>	<p>	y
2	2	mc
.	.	y
Traditional	traditional	jj
Limited	limited	jj
Exceptions	exception	nn2
to	to	ii
the	the	at
Rule	rule	nn1
The	the	at
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
,	,	y
recognizes	recognize	vvz
a	a	at1
limited	limited	jj
set	set	nn1
of	of	io
circumstances	circumstance	nn2
in	in	ii
which	which	ddq
applying	apply	vvg
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
may	may	vm
be	be	vbi
inappropriate.	inappropriate	nnu
n129	n129	fo
This	this	dd1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
personal	personal	jj
intervention	intervention	nn1
or	or	cc
evaluation	evaluation	nn1
of	of	io
a	a	at1
health-care	health-care	nn1
provider	provider	nn1
.	.	y
"	"	y
n130	n130	fo
In	in	ii
such	such	da
situations	situation	nn2
,	,	y
manufacturers	manufacturer	nn2
are	be	vbr
directly	directly	rr
responsible	responsible	jj
for	for	if
providing	provide	vvg
patients	patient	nn2
with	with	iw
warnings	warning	nn2
and	and	cc
instructions	instruction	nn2
.	.	y
<p>	<p>	y
Vaccines	vaccine	nn2
and	and	cc
other	other	jj
immunizations	immunization	nn2
administered	administer	vvn_vvd@
en	en	rr21
masse	masse	rr22
or	or	cc
to	to	ii
the	the	at
general	general	jj_nn1
public	public	jj_nn1
present	present	nn1_vv0@
the	the	at
most	most	rgt
common	common	jj
example	example	nn1
of	of	io
this	this	dd1
exception	exception	nn1
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule.	rule	nnu
n131	n131	fo
Health	health	nn1
care	care	nn1
providers	provider	nn2
typically	typically	rr
dispense	dispense	vv0
these	these	dd2
treatments	treatment	nn2
in	in	ii
an	a	at1
expedited	expedited	jj@
manner	manner	nn1
without	without	iw
establishing	establish	vvg
a	a	at1
doctor-patient	doctor-patient	jj_nn1
relationship	relationship	nn1
or	or	cc
evaluating	evaluate	vvg
risks	risk	nn2
given	give	vvn
the	the	at
patient	patient	nn1
's	's	ge
medical	medical	jj
history	history	nn1
.	.	y
In	in	ii
some	some	dd
instances	instance	nn2
,	,	y
the	the	at
role	role	nn1
of	of	io
the	the	at
physician	physician	nn1
may	may	vm
be	be	vbi
reduced	reduce	vvn
to	to	ii
that	that	dd1
of	of	io
a	a	at1
delivery	delivery	nn1
mechanism	mechanism	nn1
,	,	y
leaving	leave	vvg
the	the	at
position	position	nn1
of	of	io
learned	learned	jj@
intermediary	intermediary	nn1
vacant	vacant	jj
.	.	y
Thus	thus	rr
,	,	y
in	in	ii
such	such	da
rare	rare	jj
instances	instance	nn2
,	,	y
the	the	at
manufacturer	manufacturer	nn1
may	may	vm
reemerge	re-emerge	vvi
as	as	ii
the	the	at
entity	entity	nn1
best	best	rrt
suited	suit	vvn
to	to	to
warn	warn	vvi
consumers	consumer	nn2
directly	directly	rr
of	of	io
the	the	at
risks	risk	nn2
associated	associate	vvn
with	with	iw
its	its	z'
vaccine.	vaccine	nnu
(	(	y
n132	n132	fo
)	)	y
<p>	<p>	y
Courts	court	nn2
deciding	decide	vvg
whether	whether	csw
to	to	to
apply	apply	vvi
the	the	at
exception	exception	nn1
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
for	for	if
mass	mass	jj_nn1
immunizations	immunization	nn2
have	have	vh0
tread	tread	nn1%_vv0
carefully	carefully	rr
,	,	y
resisting	resist	vvg
hard-line	hard-line	jj
rules	rule	nn2
or	or	cc
blanket	blanket	nn1_vv0@
policy	policy	nn1
exemptions.	exemptions	nnu
n133	n133	fo
For	for	rex21
example	example	rex22
,	,	y
a	a	at1
federal	federal	jj
court	court	nn1
applying	apply	vvg
Georgia	georgia	np1
law	law	nn1
held	hold	vvd_vvn
that	that	cst
manufacturers	manufacturer	nn2
of	of	io
a	a	at1
measles	measles	nn
,	,	y
mumps	mumps	nn2_vvz
,	,	y
and	and	cc
rubella	rubella	nn1
vaccine	vaccine	nn1
were	be	vbdr
not	not	xx
required	require	vvn
to	to	to
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
administered	administer	vvn
as	as	ii
part	part	nn1
of	of	io
a	a	at1
massive	massive	jj
,	,	y
nationwide	nationwide	jj
immunization	immunization	nn1
program.	program	nnu
n134	n134	fo
In	in	ii
that	that	dd1
case	case	nn1
,	,	y
the	the	at
court	court	nn1
found	find	vvd_vvn
that	that	cst
a	a	at1
vaccination	vaccination	nn1
program	program	nn1
aimed	aim	vvd_vvn
only	only	rr
at	at	ii
select	select	jj
students	student	nn2
throughout	throughout	ii
a	a	at1
county	county	nn1
was	be	vbdz
enough	enough	dd
to	to	to
retain	retain	vvi
application	application	nn1
of	of	io
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
defense.	defense	nnu
n135	n135	fo
Similarly	similarly	rr
,	,	y
a	a	at1
federal	federal	jj
court	court	nn1
in	in	ii
Oklahoma	oklahoma	np1
avoided	avoid	vvd
adopting	adopt	vvg
an	a	at1
over-expansive	over-expansive	jj
exception	exception	nn1
to	to	ii
the	the	at
rule	rule	nn1
after	after	ii_cs
a	a	at1
child	child	nn1
developed	develop	vvd_vvn_jj
permanent	permanent	jj
neurological	neurological	jj
damage	damage	nn1
after	after	ii
receiving	receive	vvg
a	a	at1
diphtheria	diphtheria	nn1
vaccine.	vaccine	nnu
n136	n136	fo
Because	because	cs
the	the	at
child	child	nn1
's	's	ge
personal	personal	jj
physician	physician	nn1
administered	administer	vvn_vvd@
the	the	at
vaccine	vaccine	nn1
at	at	ii
her	her	appge
office	office	nn1
,	,	y
it	it	pph1
was	be	vbdz
impermissible	impermissible	jj
to	to	to
apply	apply	vvi
the	the	at
exception.	exception	nnu
n137	n137	fo
Moreover	moreover	rr
,	,	y
as	as	csa
these	these	dd2
cases	case	nn2
illustrate	illustrate	vv0
,	,	y
courts	court	nn2
have	have	vh0
shown	show	vvn
great	great	jj
reluctance	reluctance	nn1
to	to	to
define	define	vvi
exceptions	exception	nn2
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
broadly	broadly	rr
,	,	y
and	and	cc
apply	apply	vv0
this	this	dd1
exception	exception	nn1
only	only	rr
where	where	cs_rrq
immunizations	immunization	nn2
are	be	vbr
conducted	conduct	vvn
in	in	ii
an	a	at1
"	"	y
assembly-line	assembly-line	nn1
"	"	y
or	or	cc
"	"	y
clinic-like		jj
"	"	y
fashion	fashion	nn1
where	where	cs_rrq
no	no	at
individualized	individualized	jj@
medical	medical	jj
judgment	judgment	nn1
is	be	vbz
rendered.	rendered	nnu
n138	n138	fo
An	a	at1
additional	additional	jj
consideration	consideration	nn1
arises	arise	vvz
because	because	cs
,	,	y
as	as	ii
a	a	at1
matter	matter	nn1
of	of	io
public	public	jj_nn1
policy	policy	nn1
,	,	y
placing	place	vvg
special	special	jj
liability	liability	nn1
on	on	ii
manufacturers	manufacturer	nn2
who	who	pnqs
develop	develop	vv0
vaccines	vaccine	nn2
might	might	vm
have	have	vhi
adverse	adverse	jj
consequences	consequence	nn2
for	for	if
public	public	jj_nn1_rr@
health.	health	nnu
(	(	y
n139	n139	fo
)	)	y
<p>	<p>	y
A	a	at1
minority	minority	nn1
of	of	io
courts	court	nn2
have	have	vh0
adopted	adopt	vvn
an	a	at1
even	even	rr
narrower	narrow	jjr
exception	exception	nn1
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
with	with	ii31
regard	regard	ii32
to	to	ii33
oral	oral	jj_nn1
contraceptives.	contraceptive	nnu
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
pills	pill	nn2
because	because	cs
they	they	pphs2
believe	believe	vv0
that	that	cst
a	a	at1
unique	unique	jj
set	set	nn1
of	of	io
circumstances	circumstance	nn2
separates	separate	vvz
oral	oral	jj
contraceptives	contraceptive	nn2
from	from	ii
other	other	jj
prescription	prescription	nn1
drugs.	drug	nnu
n141	n141	fo
For	for	rex21
instance	instance	rex22
,	,	y
the	the	at
Massachusetts	massachusetts	np1
Supreme	supreme	jj
Judicial	judicial	jj
Court	court	nn1
reasoned	reason	vvd
that	that	cst
:	:	y
<p>	<p>	y
Whereas	whereas	cs
a	a	at1
patient	patient	nn1
's	's	ge
involvement	involvement	nn1
in	in	ii
decision-making	decision-making	nn1_jj
concerning	concerning	ii_vvg
use	use	nn1
of	of	io
a	a	at1
prescription	prescription	nn1
drug	drug	nn1
necessary	necessary	jj
to	to	to
treat	treat	vvi
a	a	at1
malady	malady	nn1
is	be	vbz
typically	typically	rr
minimal	minimal	jj
or	or	cc
nonexistent	nonexistent	jj
,	,	y
the	the	at
healthy	healthy	jj
,	,	y
young	young	jj
consumer	consumer	nn1
of	of	io
oral	oral	jj_nn1
contraceptives	contraceptive	nn2
is	be	vbz
usually	usually	rr
actively	actively	rr
involved	involved	jj
in	in	ii
the	the	at
decision	decision	nn1
to	to	to
use	use	vvi
"	"	y
the	the	at
pill	pill	nn1
,	,	y
"	"	y
as	as	ii31
opposed	opposed	ii32
to	to	ii33
other	other	jj
available	available	jj
birth	birth	nn1
control	control	nn1
products	product	nn2
,	,	y
and	and	cc
the	the	at
prescribing	prescribing	nn1@
physician	physician	nn1
is	be	vbz
relegated	relegate	vvn
to	to	ii
a	a	at1
relatively	relatively	rr
passive	passive	jj
role.	role	nnu
(	(	y
n142	n142	fo
)	)	y
<p>	<p>	y
The	the	at
court	court	nn1
went	go	vvd
on	on	rp
to	to	to
conclude	conclude	vvi
that	that	dd1_cst
oral	oral	jj_nn1
contraceptives	contraceptive	nn2
"	"	y
stand	stand	vv0
apart	apart	rl
"	"	y
from	from	ii
ordinary	ordinary	jj
prescription	prescription	nn1
drugs	drug	nn2
,	,	y
permitting	permit	vvg
liability	liability	nn1
when	when	cs_rrq
a	a	at1
manufacturer	manufacturer	nn1
fails	fail	vvz
to	to	to
convey	convey	vvi
an	a	at1
adequate	adequate	jj
warning	warning	nn1
directly	directly	rr
to	to	ii
consumers.	consumers	nnu
(	(	y
n143	n143	fo
)	)	y
<p>	<p>	y
There	there	ex
is	be	vbz
considerable	considerable	jj
judicial	judicial	jj
disagreement	disagreement	nn1
over	over	ii
the	the	at
merits	merit	nn2
of	of	io
allowing	allow	vvg
an	a	at1
exception	exception	nn1
for	for	if
oral	oral	jj_nn1
contraceptives.	contraceptive	nnu
n144	n144	fo
This	this	dd1
debate	debate	nn1
has	have	vhz
also	also	rr
spread	spread	vvn
to	to	ii
contraceptive	contraceptive	jj_nn1
intrauterine	intrauterine	jj_nn1
devices	device	nn2
(	(	y
IUDs	iud	nn2
)	)	y
,	,	y
which	which	ddq
a	a	at1
few	few	da2
jurisdictions	jurisdiction	nn2
have	have	vh0
exempted	exempt	vvn
from	from	ii
the	the	at
doctrine	doctrine	nn1
by	by	ii
applying	apply	vvg
a	a	at1
similar	similar	jj
rationale	rationale	nn1
as	as	csa
that	that	cst_dd1
used	use	vmk_vvn
to	to	to
exclude	exclude	vvi
drug	drug	nn1
contraceptives.	contraceptive	nnu
n145	n145	fo
Courts	court	nn2
opposed	oppose	vvn_vvd
to	to	ii
this	this	dd1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
nature	nature	nn1
of	of	io
treatment	treatment	nn1
for	for	if
contraceptives	contraceptive	nn2
,	,	y
yet	yet	rr
strongly	strongly	rr
relied	rely	vvn_vvd
on	on	ii
the	the	at
principle	principle	nn1
that	that	cst
"	"	y
in	in	ii
the	the	at
final	final	jj_nn1
analysis	analysis	nn1
it	it	pph1
is	be	vbz
the	the	at
physician	physician	nn1
who	who	pnqs
ultimately	ultimately	rr
prescribes	prescribe	vvz
the	the	at
drug	drug	nn1
or	or	cc
device	device	nn1
.	.	y
"	"	y
n146	n146	fo
For	for	if
this	this	dd1
reason	reason	nn1
,	,	y
courts	court	nn2
have	have	vh0
rejected	reject	vvn
further	far	rrr_jjr@
exceptions	exception	nn2
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
for	for	if
other	other	jj
prescription	prescription	nn1
treatments	treatment	nn2
with	with	iw
characteristics	characteristic	nn2
arguably	arguably	rr
similar	similar	jj
to	to	ii
prescription	prescription	nn1
contraceptives	contraceptive	nn2
,	,	y
n147	n147	fo
while	while	cs
declining	decline	vvg_jj
to	to	to
apply	apply	vvi
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
to	to	ii
nonprescription	nonprescription	nn1
contraceptives.	contraceptive	nnu
(	(	y
n148	n148	fo
)	)	y
<p>	<p>	y
3	3	mc
.	.	y
A	a	at1
Few	few	da2
Recent	recent	jj
Decisions	decision	nn2
Chip	chip	nn1
Away	away	rl
at	at	ii
the	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Rule	rule	nn1
Jurisprudence	jurisprudence	np1_nn1@
keeping	keep	vvg_nn1@
exceptions	exception	nn2
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
very	very	rg
limited	limited	jj
has	have	vhz
remained	remain	vvn
remarkably	remarkably	rr
consistent	consistent	jj
since	since	cs_ii@
the	the	at
rule	rule	nn1
's	's	ge
inception	inception	nn1
.	.	y
The	the	at
debate	debate	nn1
over	over	ii
the	the	at
scope	scope	nn1
of	of	io
the	the	at
traditional	traditional	jj
exceptions	exception	nn2
is	be	vbz
more	more	rrr
a	a	at1
product	product	nn1
of	of	io
reasonable	reasonable	jj
disagreement	disagreement	nn1
over	over	ii
the	the	at
physician	physician	nn1
's	's	ge
role	role	nn1
in	in	ii
issuing	issue	vvg_jj
one	one	mc1
unique	unique	jj
type	type	nn1
of	of	io
prescription	prescription	nn1
than	than	csn
any	any	dd
challenge	challenge	nn1_vv0
to	to	ii
the	the	at
basic	basic	jj
functioning	functioning	nn1@
of	of	io
the	the	at
doctrine.	doctrine	nnu
n149	n149	fo
In	in	ii
fact	fact	nn1
,	,	y
the	the	at
debate	debate	nn1
regarding	regarding	ii_vvg
courts	court	nn2
'	'	ge
aversion	aversion	nn1
to	to	ii
expanding	expanding	jj_vvg
exceptions	exception	nn2
for	for	if
mass	mass	jj_nn1
immunizations	immunization	nn2
not	not	xx
conducted	conduct	vvn
in	in	ii
"	"	y
clinic	clinic	nn1
like	like	ii
"	"	y
conditions	condition	nn2
and	and	cc
contraceptives	contraceptive	nn2
illustrates	illustrate	vvz
just	just	rr
how	how	rrq
solidified	solidify	vvd
the	the	at
doctrine	doctrine	nn1
has	have	vhz
become	become	vvn@
.	.	y
In	in	ii
the	the	at
past	past	jj_nn1
decade	decade	nnt1
,	,	y
however	however	rr
,	,	y
Oklahoma	oklahoma	np1
has	have	vhz
recognized	recognize	vvn
a	a	at1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
New	new	np1
Jersey	jersey	np1
and	and	cc
West	west	np1
Virginia	virginia	np1
have	have	vh0
made	make	vvn
a	a	at1
sudden	sudden	jj
,	,	y
radical	radical	jj_nn1
departure	departure	nn1
from	from	ii
this	this	dd1
long-established	long-established	jj
judicial	judicial	jj
rule	rule	nn1
.	.	y
<p>	<p>	y
In	in	ii
1997	1997	mc
,	,	y
Oklahoma	oklahoma	np1
recognized	recognize	vvd
a	a	at1
very	very	rg
limited	limited	jj
exception	exception	nn1
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
in	in	ii
a	a	at1
failure-to-warn	failure-to-warn	vv0
claim	claim	nn1_vv0
involving	involve	vvg
a	a	at1
prescription	prescription	nn1
nicotine	nicotine	nn1
patch	patch	nn1
.	.	y
In	in	ii
Edwards	edwards	np1
v.	xx_v	ii
Basel	basel	np1
Pharmaceuticals	pharmaceutical	nn2
,	,	y
the	the	at
Oklahoma	oklahoma	np1
Supreme	supreme	jj
Court	court	nn1
held	hold	vvd_vvn
that	that	cst
an	a	at1
exception	exception	nn1
to	to	ii
the	the	at
rule	rule	nn1
applied	apply	vvn_vvd
where	where	cs_rrq
the	the	at
FDA	fda	nn1
mandated	mandate	vvn
that	that	cst
manufacturers	manufacturer	nn2
,	,	y
through	through	ii
labeling	label	vvg
their	their	appge
products	product	nn2
,	,	y
directly	directly	rr
communicate	communicate	vv0
warnings	warning	nn2
to	to	ii
patients.	patient	nnu
n150	n150	fo
In	in	ii
such	such	da
situations	situation	nn2
,	,	y
the	the	at
court	court	nn1
ruled	rule	vvd_vvn
,	,	y
"	"	y
an	a	at1
exception	exception	nn1
to	to	ii
the	the	at
'	'	ge
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
'	'	ge
has	have	vhz
occurred	occur	vvn
and	and	cc
the	the	at
manufacturer	manufacturer	nn1
is	be	vbz
not	not	xx
automatically	automatically	rr
shielded	shield	vvn_vvd
from	from	ii
any	any	dd
liability	liability	nn1
by	by	ii
properly	properly	rr
warning	warn	vvg@
the	the	at
prescribing	prescribing	nn1@
physician	physician	nn1
.	.	y
"	"	y
n151	n151	fo
Rather	rather	rr@_rg
,	,	y
the	the	at
court	court	nn1
declared	declare	vvd_vvn
that	that	cst
when	when	cs
the	the	at
FDA	fda	nn1_np1
requires	require	vvz
manufacturers	manufacturer	nn2
to	to	to
provide	provide	vvi
DTC	dtc	np1
information	information	nn1
,	,	y
the	the	at
warning	warning	nn1
must	must	vm
adequately	adequately	rr
explain	explain	vvi
to	to	ii
the	the	at
user	user	nn1
the	the	at
possible	possible	jj
danger	danger	nn1
associated	associate	vvn
with	with	iw
the	the	at
product.	product	nnu
n152	n152	fo
The	the	at
Oklahoma	oklahoma	np1
Supreme	supreme	jj
Court	court	nn1
's	's	ge
decision	decision	nn1
does	do	vdz
not	not	xx
abrogate	abrogate	vvi
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
on	on	ii
the	the	at
basis	basis	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
,	,	y
but	but	ccb
only	only	rr
in	in	ii
those	those	dd2
rare	rare	jj
instances	instance	nn2
in	in	ii
which	which	ddq
the	the	at
FDA	fda	nn1_np1
mandates	mandate	nn2
communication	communication	nn1
of	of	io
warnings	warning	nn2
directly	directly	rr
from	from	ii
manufacturer	manufacturer	nn1
to	to	ii
patient	patient	nn1
.	.	y
<p>	<p>	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Jersey	jersey	np1
Supreme	supreme	jj
Court	court	nn1
's	's	ge
decision	decision	nn1
in	in	ii
Perez	perez	np1
v.	xx_v	ii
Wyeth	wyeth	np1
Labs.	lab	zz
,	,	y
Inc.	inc	jj
n153	n153	fo
Perez	perez	np1
involved	involve	vvd
a	a	at1
prescription	prescription	nn1
contraceptive	contraceptive	nn1
called	call	vvn
Norplant	norplant	np1
,	,	y
a	a	at1
"	"	y
hybrid	hybrid	jj
"	"	y
medical	medical	jj
device	device	nn1
consisting	consist	vvg
of	of	io
a	a	at1
drug	drug	nn1
capsule	capsule	nn1
that	that	cst_dd1
is	be	vbz
surgically	surgically	rr
implanted	implant	vvn
in	in	ii
the	the	at
patient.	patient	nnu
n154	n154	fo
The	the	at
plaintiffs	plaintiff	nn2
alleged	allege	vvd_vvn_jj
inadequate	inadequate	jj
DTC	dtc	np1
warnings	warning	nn2
concerning	concerning	ii_vvg
the	the	at
possibility	possibility	nn1
of	of	io
pain	pain	nn1
and	and	cc
other	other	jj
side	side	nn1
effects.	effects	nnu
n155	n155	fo
In	in	ii
reversing	reverse	vvg
an	a	at1
intermediate	intermediate	jj
appellate	appellate	jj
court	court	nn1
ruling	ruling	nn1
,	,	y
the	the	at
New	new	np1
Jersey	jersey	np1
Supreme	supreme	jj
Court	court	nn1
went	go	vvd
beyond	beyond	ii
adopting	adopt	vvg
the	the	at
minority	minority	nn1
approach	approach	nn1
of	of	io
exempting	exempt	vvg
contraceptives	contraceptive	nn2
,	,	y
and	and	cc
created	create	vvd_vvn
a	a	at1
broader	broad	jjr
exception	exception	nn1
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
for	for	if
prescription	prescription	nn1
drugs	drug	nn2
or	or	cc
devices	device	nn2
marketed	market	vvn_vvd
through	through	ii
DTC	dtc	np1
advertising.	advertising	nnu
n156	n156	fo
This	this	dd1
about-face	about-face	nn1
was	be	vbdz
largely	largely	rr
premised	premise	vvn_vvd
on	on	ii
the	the	at
court	court	nn1
's	's	ge
belief	belief	nn1
that	that	cst
"	"	y
our	our	appge
medical-legal	medical-legal	jj
jurisprudence	jurisprudence	nn1
is	be	vbz
based	base	vvn
on	on	ii
images	image	nn2
of	of	io
health	health	nn1
care	care	nn1_vv0
that	that	cst
no	no	rr21
longer	long	rr22
exist	exist	vv0
.	.	y
"	"	y
n157	n157	fo
DTC	dtc	np1
marketing	marketing	nn1
,	,	y
the	the	at
court	court	nn1
explained	explain	vvd_vvn
,	,	y
fundamentally	fundamentally	rr
changed	change	vvd_vvn
the	the	at
medical	medical	jj
landscape	landscape	nn1
through	through	ii
radio	radio	nn1
,	,	y
television	television	nn1
,	,	y
internet	internet	nn1
,	,	y
and	and	cc
print	print	vv0_nn1
advertisements	advertisement	nn2
such	such	cs21
that	that	cs22
it	it	pph1
was	be	vbdz
no	no	rr21
longer	long	rr22
justified	justify	vvn
for	for	if
consumers	consumer	nn2
to	to	to
rely	rely	vvi
exclusively	exclusively	rr
on	on	ii
their	their	appge
physicians	physician	nn2
for	for	if
risk	risk	nn1
information	information	nn1
concerning	concerning	ii_vvg
a	a	at1
prescription	prescription	nn1
drug	drug	nn1
or	or	cc
device.	device	nnu
n158	n158	fo
As	as	ii
a	a	at1
result	result	nn1
,	,	y
the	the	at
court	court	nn1
held	hold	vvd_vvn
that	that	cst
the	the	at
doctrine	doctrine	nn1
no	no	rr21
longer	long	rr22
provided	provide	vvn_vvd_cs
full	full	jj
protection	protection	nn1
for	for	if
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
benefits	benefit	nn2
and	and	cc
risks	risk	nn2
of	of	io
a	a	at1
drug	drug	nn1
.	.	y
<p>	<p>	y
For	for	if
almost	almost	rr
a	a	at1
decade	decade	nnt1
,	,	y
Oklahoma	oklahoma	np1
and	and	cc
New	new	np1
Jersey	jersey	np1
stood	stand	vvd
alone	alone	rr_jj
in	in	ii
permitting	permit	vvg
a	a	at1
DTC-marketing	dtc-marketing	jj_nn1
exception	exception	nn1
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine.	doctrine	nnu
n159	n159	fo
Courts	court	nn2
applying	apply	vvg
the	the	at
doctrine	doctrine	nn1
during	during	ii
this	this	dd1
period	period	nn1
repeatedly	repeatedly	rr
rejected	reject	vvn_vvd_jj@
attempts	attempt	nn2
to	to	to
create	create	vvi
such	such	da
an	a	at1
exception.	exception	nnu
n160	n160	fo
Then	then	rt
,	,	y
in	in	ii
2007	2007	mc
,	,	y
another	another	dd1
crack	crack	nn1
appeared	appear	vvd_vvn@
in	in	ii
the	the	at
dam	dam	nn1
.	.	y
In	in	ii
State	state	nn1_np1@
ex	ex	ii
rel	rel	nn1
.	.	y
Johnson	johnson	np1
&;		null
Johnson	johnson	np1
Corp	corp	npx
.	.	y
v.	xx_v	ii
Karl	karl	np1
,	,	y
the	the	at
West	west	np1
Virginia	virginia	np1
Supreme	supreme	jj
Court	court	nn1
of	of	io
Appeals	appeal	nn2
arrived	arrive	vvn_vvd
at	at	ii
the	the	at
same	same	da
result	result	nn1
as	as	csa
the	the	at
New	new	np1
Jersey	jersey	np1
Supreme	supreme	jj
Court	court	nn1
with	with	ii31
regard	regard	ii32
to	to	ii33
DTC	dtc	np1
marketing	marketing	nn1
,	,	y
but	but	ccb
followed	follow	vvd
a	a	at1
different	different	jj
approach	approach	nn1
,	,	y
wholly	wholly	rr
rejecting	reject	vvg
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine.	doctrine	nnu
(	(	y
n161	n161	fo
)	)	y
<p>	<p>	y
Before	before	ii_cs
2007	2007	mc
,	,	y
the	the	at
West	west	np1
Virginia	virginia	np1
high	high	jj
court	court	nn1
had	have	vhd
not	not	xx
considered	consider	vvn
application	application	nn1
of	of	io
the	the	at
doctrine	doctrine	nn1
.	.	y
Deciding	decide	vvg
the	the	at
case	case	nn1
as	as	csa_ii@
one	one	mc1
of	of	io
first	first	md
impression	impression	nn1
,	,	y
the	the	at
court	court	nn1
found	find	vvd_vvn
the	the	at
"	"	y
justifications	justification	nn2
for	for	if
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
to	to	to
be	be	vbi
largely	largely	rr
outdated	outdated	jj_vvn@
and	and	cc
unpersuasive.		nnu
"	"	y
n162	n162	fo
Specifically	specifically	rr
,	,	y
the	the	at
court	court	nn1
named	name	vvd
DTC	dtc	np1
marketing	marketing	nn1
as	as	ii_csa
the	the	at
impetus	impetus	nn1
for	for	if
its	its	z'
holding	holding	nn1@_jj@
,	,	y
stating	state	vvg
that	that	cst
the	the	at
"	"	y
Norman	norman	np1_jj
Rockwell	rockwell	np1_nn1@
image	image	nn1
of	of	io
the	the	at
family	family	nn1
doctor	doctor	nn1
no	no	rr21
longer	long	rr22
exists	exist	vvz
"	"	y
n163	n163	fo
and	and	cc
that	that	cst
the	the	at
doctor-patient	doctor-patient	jj_nn1
relationship	relationship	nn1
has	have	vhz
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
premises	premise	nn2
are	be	vbr
absent	absent	jj
.	.	y
"	"	y
n164	n164	fo
Although	although	cs
the	the	at
court	court	nn1
acknowledged	acknowledge	vvd_vvn
that	that	cst_dd1
four	four	mc
state	state	vv0_nn1
supreme	supreme	jj
courts	court	nn2
had	have	vhd
adopted	adopt	vvn
the	the	at
now	now	rt
"	"	y
widely	widely	rr
accepted	accepted	jj_vvn
"	"	y
doctrine	doctrine	nn1
during	during	ii
the	the	at
very	very	rg
same	same	da
decade	decade	nnt1
in	in	ii
which	which	ddq
DTC	dtc	np1
advertising	advertising	nn1
proliferated	proliferate	vvd
,	,	y
it	it	pph1
determined	determine	vvd@_vvn_jj
that	that	cst
these	these	dd2
decisions	decision	nn2
did	do	vdd
not	not	xx
adequately	adequately	rr
consider	consider	vvi
changes	change	nn2
occurring	occur	vvg
in	in	ii
the	the	at
pharmaceutical	pharmaceutical	jj
industry.	industry	nnu
(	(	y
n165	n165	fo
)	)	y
<p>	<p>	y
In	in	rr21
addition	addition	rr22
,	,	y
the	the	at
West	west	np1
Virginia	virginia	np1
court	court	nn1
found	find	vvd_vvn
traditional	traditional	jj
exceptions	exception	nn2
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
to	to	to
be	be	vbi
unwieldy	unwieldy	jj
,	,	y
stating	state	vvg
,	,	y
"	"	y
Given	give	vvn
the	the	at
plethora	plethora	nn1
of	of	io
exceptions	exception	nn2
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
,	,	y
we	we	ppis2
ascertain	ascertain	vv0
no	no	at
benefit	benefit	nn1
in	in	ii
adopting	adopt	vvg
a	a	at1
doctrine	doctrine	nn1
that	that	cst_dd1
would	would	vm
require	require	vvi
the	the	at
simultaneous	simultaneous	jj
adoption	adoption	nn1
of	of	io
numerous	numerous	jj
exceptions	exception	nn2
in	in	bcl21
order	order	bcl22
to	to	to
be	be	vbi
justly	justly	rr
utilized	utilize	vvn_vvd
.	.	y
"	"	y
n166	n166	fo
Based	base	vvn
on	on	ii
these	these	dd2
rationales	rationale	nn2
,	,	y
the	the	at
court	court	nn1
concluded	conclude	vvd_vvn
that	that	cst_dd1
,	,	y
under	under	ii
West	west	np1
Virginia	virginia	np1
law	law	nn1
,	,	y
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
did	do	vdd
not	not	xx
apply	apply	vvi
to	to	ii
warnings	warning	nn2
relating	relate	vvg
to	to	ii
pharmaceutical	pharmaceutical	jj
products	product	nn2
.	.	y
West	west	np1
Virginia	virginia	np1
law	law	nn1
provides	provide	vvz
,	,	y
therefore	therefore	rr
,	,	y
that	that	cst
manufacturers	manufacturer	nn2
are	be	vbr
directly	directly	rr
liable	liable	jj
for	for	if
conveying	convey	vvg
warnings	warning	nn2
and	and	cc
may	may	vm
not	not	xx
rely	rely	vvi
on	on	ii_rp@
physicians	physician	nn2
to	to	to
transmit	transmit	vvi
correct	correct	jj
drug	drug	nn1
information	information	nn1
to	to	ii
patients	patient	nn2
.	.	y
<p>	<p>	y
The	the	at
court	court	nn1
clearly	clearly	rr
was	be	vbdz
incorrect	incorrect	jj
,	,	y
however	however	rr
,	,	y
when	when	cs_rrq
it	it	pph1
spoke	speak	vvd
of	of	io
a	a	at1
"	"	y
plethora	plethora	nn1
"	"	y
of	of	io
exceptions	exception	nn2
to	to	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
immunizations	immunization	nn2
,	,	y
prescription	prescription	nn1
contraceptives--followed		nn2
by	by	ii
only	only	rr
a	a	at1
minority	minority	nn1
of	of	io
courts--and		nn2
the	the	at
uncommon	uncommon	jj
situation	situation	nn1
where	where	rrq
the	the	at
FDA	fda	nn1_np1
explicitly	explicitly	rr
requires	require	vvz
a	a	at1
DTC	dtc	np1
warning	warning	nn1
.	.	y
The	the	at
absolute	absolute	jj
rule	rule	nn1
drastically	drastically	rr
expands	expand	vvz
the	the	at
analysis	analysis	nn1
of	of	io
Perez	perez	np1
by	by	ii
making	make	vvg
West	west	np1
Virginia	virginia	np1
the	the	at
only	only	jj
state	state	nn1
expressly	expressly	rr
to	to	to
reject	reject	vvi
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
.	.	y
<p>	<p>	y
4	4	mc
.	.	y
Exceptions	exception	nn2
for	for	if
DTC	dtc	np1
Marketing	marketing	nn1
Represent	represent	vv0
Unsound	unsound	jj
Policy	policy	nn1
Perez	perez	np1
and	and	cc
Karl	karl	np1
each	each	dd1
dramatically	dramatically	rr
depart	depart	vv0
from	from	ii
the	the	at
traditional	traditional	jj
rule	rule	nn1
of	of	io
law	law	nn1
relating	relate	vvg
to	to	ii
prescription	prescription	nn1
drug	drug	nn1
warnings	warning	nn2
.	.	y
These	these	dd2
departures	departure	nn2
are	be	vbr
unsupported	unsupported	jj
by	by	ii
precedent	precedent	nn1
,	,	y
practice	practice	nn1
,	,	y
or	or	cc
sound	sound	jj@_nn1_vv0@
public	public	jj_nn1
policy	policy	nn1
.	.	y
Established	established	jj@_vvn
exceptions	exception	nn2
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
remain	remain	vv0
few	few	da2
and	and	cc
narrowly	narrowly	rr
designed	design	vvn_vvd
.	.	y
Perez	perez	np1
,	,	y
however	however	rr
,	,	y
creates	create	vvz
a	a	at1
gaping	gaping	jj
exception	exception	nn1
for	for	if
DTC	dtc	np1
marketing	marketing	nn1
.	.	y
The	the	at
primary	primary	jj_nn1
justification	justification	nn1
for	for	if
this	this	dd1
exception	exception	nn1
is	be	vbz
that	that	cst_dd1_rg%
increasingly	increasingly	rr
common	common	jj
DTC	dtc	np1
advertisements	advertisement	nn2
fundamentally	fundamentally	rr
change	change	vv0
the	the	at
physician-patient	physician-patient	jj_nn1
relationship.	relationship	nnu
n167	n167	fo
Yet	yet	rr
the	the	at
ethical	ethical	jj
and	and	cc
legal	legal	jj
obligations	obligation	nn2
of	of	io
the	the	at
medical	medical	jj
community	community	nn1
with	with	ii31
regard	regard	ii32
to	to	ii33
communicating	communicating	jj_vvg_nn1
drug	drug	nn1
warnings	warning	nn2
are	be	vbr
unchanged	unchanged	jj
and	and	cc
show	show	vv0
no	no	at
indication	indication	nn1
of	of	io
abrogation	abrogation	nn1
.	.	y
As	as	ii_csa
the	the	at
dissent	dissent	nn1
in	in	ii
Karl	karl	np1
further	far	rrr
explained	explain	vvd_vvn
:	:	y
"	"	y
By	by	ii
attaching	attach	vvg
undue	undue	jj
importance	importance	nn1
to	to	ii
the	the	at
effects	effect	nn2
of	of	io
direct	direct	jj
marketing	marketing	nn1
,	,	y
the	the	at
majority	majority	nn1
downplays	downplay	vvz
the	the	at
continuing	continuing	jj
and	and	cc
vital	vital	jj
role	role	nn1
that	that	cst
a	a	at1
physician	physician	nn1
plays	play	vvz_nn2
in	in	ii
the	the	at
decision	decision	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
patient	patient	nn1
based	base	vvn
upon	upon	ii
that	that	dd1
particular	particular	jj
individual	individual	nn1
's	's	ge_vbz
specific	specific	jj
medical	medical	jj
needs	need	nn2
.	.	y
"	"	y
(	(	y
n168	n168	fo
)	)	y
<p>	<p>	y
Comparatively	comparatively	rr
,	,	y
a	a	at1
DTC	dtc	np1
marketing	marketing	nn1
exception	exception	nn1
does	do	vdz
not	not	xx
comport	comport	vvi
with	with	iw
the	the	at
traditional	traditional	jj
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
exceptions	exception	nn2
.	.	y
A	a	zz1_at1
DTC	dtc	np1
marketing	marketing	nn1
exception	exception	nn1
is	be	vbz
open-ended	open-ended	jj
,	,	y
theoretically	theoretically	rr
encompassing	encompass	vvg
all	all	db
drugs	drug	nn2
.	.	y
The	the	at
three	three	mc
established	established	jj@_vvd
exceptions	exception	nn2
represent	represent	vv0
a	a	at1
small	small	jj
fraction	fraction	nn1
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
where	where	cs_rrq
it	it	pph1
is	be	vbz
apparent	apparent	jj
the	the	at
physician	physician	nn1
does	do	vdz
not	not	xx
provide	provide	vvi
an	a	at1
individualized	individualized	jj@
medical	medical	jj
assessment	assessment	nn1
.	.	y
This	this	dd1
is	be	vbz
simply	simply	rr
not	not	xx
the	the	at
case	case	nn1
with	with	iw
all	all	db
DTC-marketed	dtc-marketed	jj
prescription	prescription	nn1
drugs	drug	nn2
.	.	y
Physicians	physician	nn2
have	have	vh0
a	a	at1
legal	legal	jj
and	and	cc
ethical	ethical	jj
duty	duty	nn1
to	to	to
provide	provide	vvi
an	a	at1
individualized	individualized	jj@
medical	medical	jj
assessment	assessment	nn1
before	before	ii
prescribing	prescribe	vvg
a	a	at1
drug	drug	nn1
regardless	regardless	rr
of	of	io
how	how	rgq
often	often	rr
it	it	pph1
is	be	vbz
advertised	advertise	vvn
on	on	ii
television	television	nn1
,	,	y
radio	radio	nn1
,	,	y
or	or	cc
any	any	dd
other	other	jj
media.	media	nnu
n169	n169	fo
Suggesting	suggest	vvg
that	that	cst
the	the	at
playing	playing	jj%_vvg_nn1%
field	field	nn1
has	have	vhz
changed	change	vvn
to	to	ii
the	the	at
extent	extent	nn1
physicians	physician	nn2
can	can	vm
no	no	rr21
longer	long	rr22
be	be	vbi
fully	fully	rr
relied	rely	vvn_vvd
upon	upon	ii
to	to	to
discuss	discuss	vvi
with	with	iw
their	their	appge
patients	patient	nn2
the	the	at
benefits	benefit	nn2
and	and	cc
risks	risk	nn2
of	of	io
a	a	at1
drug	drug	nn1
presents	present	vvz
an	a	at1
untenable	untenable	jj
and	and	cc
illogical	illogical	jj
assertion	assertion	nn1
when	when	cs_rrq
juxtaposed	juxtapose	vvn_jj
with	with	iw
the	the	at
fact	fact	nn1
that	that	cst
no	no	at
court	court	nn1
has	have	vhz
made	make	vvn
any	any	dd
attempt	attempt	nn1_vv0
to	to	to
modify	modify	vvi
this	this	dd1
basic	basic	jj
duty	duty	nn1
of	of	io
physicians	physician	nn2
.	.	y
<p>	<p>	y
The	the	at
relatively	relatively	rr
recent	recent	jj
development	development	nn1
of	of	io
the	the	at
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
of	of	io
Torts	torts	np1_nn2
:	:	y
Products	product	nn2
Liability	liability	nn1
,	,	y
6	6	mc
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
's	's	ge
application	application	nn1
to	to	ii
DTC-marketed	dtc-marketed	jj_nn1
prescription	prescription	nn1
drugs	drug	nn2
.	.	y
An	a	at1
early	early	jj
draft	draft	nn1
of	of	io
the	the	at
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
section	section	nn1
relating	relate	vvg
to	to	ii
pharmaceutical	pharmaceutical	jj
manufacturer	manufacturer	nn1
liability	liability	nn1
included	include	vvd_vvn
an	a	at1
exception	exception	nn1
to	to	ii
the	the	at
doctrine	doctrine	nn1
where	where	cs_rrq
"	"	y
the	the	at
manufacturer	manufacturer	nn1
advertised	advertise	vvn_vvd
or	or	cc
otherwise	otherwise	rr
promoted	promote	vvn_vvd@
the	the	at
drug	drug	nn1
or	or	cc
medical	medical	jj
device	device	nn1
directly	directly	rr
to	to	ii
users	user	nn2
and	and	cc
consumers	consumer	nn2
.	.	y
"	"	y
n170	n170	fo
This	this	dd1
black	black	jj
letter	letter	nn1
exception	exception	nn1
in	in	ii
Council	council	nn1
Draft	draft	vv0_nn1
I	i	ppis1
was	be	vbdz
promptly	promptly	rr
deleted	delete	vvn_vvd
a	a	at1
few	few	da2
months	month	nnt2
later	later	rrr
by	by	ii
the	the	at
Reporters	reporter	nn2
in	in	ii
Council	council	nn1
Draft	draft	nn1_vv0
1A.	1a	fo
n171	n171	fo
The	the	at
Reporters	reporter	nn2
explained	explain	vvd_vvn
that	that	cst
the	the	at
change	change	nn1
was	be	vbdz
a	a	at1
result	result	nn1
of	of	io
Council	council	nn1
discussions	discussion	nn2
that	that	cst
"	"	y
demonstrated	demonstrate	vvd_jj@
concern	concern	nn1
about	about	ii
creating	create	vvg
a	a	at1
wholly	wholly	rr
new	new	jj
common	common	jj
law	law	nn1
duty	duty	nn1
to	to	to
warn	warn	vvi
when	when	rrq_cs
there	there	ex
was	be	vbdz
no	no	at
case	case	nn1
law	law	nn1
to	to	to
support	support	vvi
it	it	pph1
.	.	y
"	"	y
(	(	y
n172	n172	fo
)	)	y
<p>	<p>	y
Comment	comment	vv0
e	e	zz1
accompanying	accompany	vvg
the	the	at
amended	amended	jj
draft	draft	nn1
explained	explain	vvd_vvn
that	that	cst
the	the	at
DTC	dtc	np1
marketing	marketing	nn1
exception	exception	nn1
merged	merge	vvn_vvd
into	into	ii
the	the	at
draft	draft	nn1
's	be	vbz_ge_vhz@
learned	learn	vvn_jj@
intermediary	intermediary	nn1
exception	exception	nn1
for	for	if
FDA-required	fda-required	jj_nn1
warnings.	warnings	nnu
n173	n173	fo
Practically	practically	rr
speaking	speak	vvg_jj@
,	,	y
however	however	rr
,	,	y
the	the	at
deletion	deletion	nn1
marked	mark	vvn_vvd@
a	a	at1
clear	clear	jj
retreat	retreat	nn1
from	from	ii
acknowledging	acknowledge	vvg
the	the	at
third	third	md
exception	exception	nn1
to	to	ii
the	the	at
rule	rule	nn1
.	.	y
By	by	ii
the	the	at
time	time	nnt1
the	the	at
Council	council	nn1
issued	issue	vvd_vvn
Tentative	tentative	jj
Draft	draft	nn1
No.	no	xx
1	1	mc1
later	later	jjr
that	that	cst_dd1
year--four	year--four	mc
years	year	nnt2
before	before	ii_cs
the	the	at
final	final	jj_nn1
Restatement	restatement	nn1
draft	draft	nn1
was	be	vbdz
published--both	published--both	rr
the	the	at
DTC-marketing	dtc-marketing	jj_nn1
exception	exception	nn1
and	and	cc
the	the	at
doctrine	doctrine	nn1
's	's	ge
inapplicability	inapplicability	nn1
where	where	cs_rrq
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Only	only	rr
the	the	at
exception	exception	nn1
for	for	if
mass	mass	jj_nn1
immunizations	immunization	nn2
withstood	withstand	vvd_vvn
the	the	at
scrutiny	scrutiny	nn1
of	of	io
the	the	at
Council	council	nn1
.	.	y
There	there	ex
was	be	vbdz
also	also	rr
no	no	at
revival	revival	nn1
by	by	ii
the	the	at
Reporters	reporter	nn2
of	of	io
the	the	at
Restatement	restatement	nn1
,	,	y
the	the	at
Advisory	advisory	jj
Committee	committee	nn1
,	,	y
or	or	cc
the	the	at
articulate	articulate	jj
plaintiffs	plaintiff	nn2
'	'	ge
and	and	cc
defense	defense	nn1
counsel	counsel	nn1_vv0
membership	membership	nn1
at	at	ii
the	the	at
ALI	ali	np1
of	of	io
the	the	at
express	express	jj@
DTC	dtc	np1
marketing	marketing	nn1
exception	exception	nn1
in	in	ii
any	any	dd
of	of	io
the	the	at
subsequent	subsequent	jj
Restatement	restatement	nn1
drafts.	drafts	nnu
n175	n175	fo
Instead	instead	rr
,	,	y
the	the	at
final	final	jj_nn1
version	version	nn1
of	of	io
comment	comment	nn1
e	e	zz1
inserts	insert	vvz
a	a	at1
catch-all	catch-all	jj
that	that	cst
"	"	y
leaves	leave	vvz_nn2
to	to	ii
developing	developing	jj_vvg
case	case	nn1
law	law	nn1
"	"	y
the	the	at
determination	determination	nn1
of	of	io
whether	whether	csw
any	any	dd
other	other	jj
exceptions	exception	nn2
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
exist.	exist	nnu
(	(	y
n176	n176	fo
)	)	y
<p>	<p>	y
In	in	ii
the	the	at
decade	decade	nnt1
following	follow	vvg_ii@_ra@
the	the	at
issuance	issuance	nn1
of	of	io
the	the	at
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
,	,	y
it	it	pph1
is	be	vbz
notable	notable	jj
that	that	cst
no	no	at
state	state	nn1
court	court	nn1
except	except	ii_cs
the	the	at
New	new	np1
Jersey	jersey	np1
Supreme	supreme	jj
Court	court	nn1
in	in	ii
Perez	perez	np1
created	create	vvd
an	a	at1
express	express	jj@
DTC	dtc	np1
marketing	marketing	nn1
exception	exception	nn1
to	to	ii
its	its	z'
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
.	.	y
On	on	ii
the	the	at
contrary	contrary	nn1_jj
,	,	y
over	over	ii
the	the	at
same	same	da
period	period	nn1
,	,	y
four	four	mc
state	state	vv0_nn1
supreme	supreme	jj
courts	court	nn2
joined	join	vvd_vvn
the	the	at
growing	growing	jj
list	list	nn1
of	of	io
high	high	jj
courts	court	nn2
to	to	to
adopt	adopt	vvi
expressly	expressly	rr
the	the	at
Restatement	restatement	nn1
version	version	nn1
of	of	io
the	the	at
rule.	rule	nnu
n177	n177	fo
Further	far	rrr@
,	,	y
sound	sound	vv0@_jj@_nn1
public	public	jj_nn1
policy	policy	nn1
supporting	support	vvg
the	the	at
doctrine	doctrine	nn1
has	have	vhz
led	lead	vvn
to	to	ii
its	its	z'
significant	significant	jj
expansion	expansion	nn1
in	in	ii
other	other	jj
ways	way	nn2
.	.	y
For	for	rex21
example	example	rex22
,	,	y
some	some	dd
courts	court	nn2
have	have	vh0
extended	extend	vvn
the	the	at
doctrine	doctrine	nn1
beyond	beyond	ii
the	the	at
doctor-patient	doctor-patient	jj_nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
it	it	pph1
to	to	ii
veterinarians.	veterinarians	nnu
n179	n179	fo
The	the	at
doctrine	doctrine	nn1
has	have	vhz
also	also	rr
expanded	expand	vvn
outside	outside	ii
the	the	at
medical	medical	jj
community	community	nn1
and	and	cc
into	into	ii
the	the	at
workplace	workplace	nn1
where	where	rrq_cs
courts	court	nn2
routinely	routinely	rr
analyze	analyze	vv0
the	the	at
rule	rule	nn1
in	in	ii31
conjunction	conjunction	ii32
with	with	ii33
the	the	at
bulk-supplier	bulk-supplier	nn1_jj
and	and	cc
sophisticated-user	sophisticated-user	jj_nn1
defenses	defense	nn2
.	.	y
These	these	dd2
defenses	defense	nn2
incorporate	incorporate	vv0
similar	similar	jj
rationales	rationale	nn2
to	to	to
relieve	relieve	vvi
industrial	industrial	jj
manufacturers	manufacturer	nn2
and	and	cc
intermediaries	intermediary	nn2
of	of	io
a	a	at1
duty	duty	nn1
to	to	to
warn	warn	vvi
directly	directly	rr
end-user	end-user	jj@_nn1
workers	worker	nn2
and	and	cc
to	to	to
impart	impart	vvi
that	that	dd1_cst
duty	duty	nn1
on	on	ii
the	the	at
most	most	rgt
knowledgeable	knowledgeable	jj
party	party	nn1
.	.	y
That	that	dd1
party	party	nn1
is	be	vbz
usually	usually	rr
the	the	at
purchaser	purchaser	nn1
or	or	cc
employer	employer	nn1
who	who	pnqs
knows	know	vvz
the	the	at
use	use	nn1
for	for	if
the	the	at
materials	material	nn2
and	and	cc
the	the	at
associated	associated	jj
risks	risk	nn2
and	and	cc
can	can	vm
best	best	rrt
communicate	communicate	vvi
the	the	at
warning	warning	nn1
and	and	cc
provide	provide	vvi
protective	protective	jj
equipment.	equipment	nnu
(	(	y
n180	n180	fo
)	)	y
<p>	<p>	y
Such	such	da
extensions	extension	nn2
of	of	io
the	the	at
principles	principle	nn2
underlying	underlie	vvg
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
,	,	y
in	in	ii31
addition	addition	ii32
to	to	ii33
courts	court	nn2
'	'	ge
general	general	jj_nn1
repudiation	repudiation	nn1
of	of	io
additional	additional	jj
exceptions	exception	nn2
when	when	cs_rrq
left	leave	vvn
to	to	ii
"	"	y
developing	developing	jj_vvg
case	case	nn1
law	law	nn1
,	,	y
"	"	y
clearly	clearly	rr
support	support	vv0
the	the	at
continued	continued	jj
viability	viability	nn1
of	of	io
the	the	at
rule	rule	nn1
.	.	y
Courts	court	nn2
and	and	cc
commentators	commentator	nn2
have	have	vh0
long	long	rr
recognized	recognize	vvn
that	that	cst
physicians	physician	nn2
are	be	vbr
in	in	ii
the	the	at
best	best	jjt
position	position	nn1_vv0@
to	to	to
determine	determine	vvi
the	the	at
appropriateness	appropriateness	nn1
,	,	y
effectiveness	effectiveness	nn1
,	,	y
and	and	cc
risks	risk	nn2
of	of	io
a	a	at1
drug	drug	nn1
based	base	vvn
on	on	ii
a	a	at1
patient	patient	nn1
's	's	ge_vbz
medical	medical	jj
and	and	cc
family	family	nn1
history.	history	nnu
n181	n181	fo
Physicians	physician	nn2
'	'	ge
legal	legal	jj
and	and	cc
ethical	ethical	jj
duty	duty	nn1
to	to	to
warn	warn	vvi
patients	patient	nn2
adequately	adequately	rr
about	about	ii
any	any	dd
treatment	treatment	nn1
,	,	y
including	including	ii_vvg@
prescription	prescription	nn1
drugs	drug	nn2
,	,	y
extends	extend	vvz
from	from	ii
this	this	dd1
relationship	relationship	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
find	find	vvi
otherwise	otherwise	rr
would	would	vm
presume	presume	vvi
that	that	cst
the	the	at
physician	physician	nn1
's	's	ge_vbz
legal	legal	jj
and	and	cc
ethical	ethical	jj
duties	duty	nn2
to	to	to
warn	warn	vvi
either	either	rr_dd1
no	no	rr21
longer	long	rr22
exist	exist	vv0
or	or	cc
are	be	vbr
so	so	rr_rg
altered	alter	vvn_vvd_jj
that	that	cst
a	a	at1
physician	physician	nn1
need	need	vm@
not	not	xx
exercise	exercise	vvi
any	any	dd
individualized	individualized	jj@_vvd
medical	medical	jj
judgment	judgment	nn1
when	when	cs
determining	determine	vvg
a	a	at1
treatment	treatment	nn1
course.	course	nnu
n182	n182	fo
This	this	dd1
proposition	proposition	nn1
would	would	vm
turn	turn	vvi
the	the	at
law	law	nn1
,	,	y
and	and	cc
medical	medical	jj
practice	practice	nn1
,	,	y
on	on	ii
its	its	z'
head	head	nn1
.	.	y
It	it	pph1
would	would	vm
require	require	vvi
redefining	redefine	vvg
the	the	at
physician	physician	nn1
's	's	ge
duty	duty	nn1
to	to	to
warn	warn	vvi
and	and	cc
effectively	effectively	rr
lessen	lessen	vvi
the	the	at
duty	duty	nn1
requirements	requirement	nn2
and	and	cc
ethical	ethical	jj
obligations	obligation	nn2
of	of	io
doctors	doctor	nn2
in	in	ii
the	the	at
name	name	nn1
of	of	io
strengthening	strengthen	vvg_nn1
patient	patient	nn1
care	care	nn1
.	.	y
Not	not	xx
surprisingly	surprisingly	rr
,	,	y
no	no	at
case	case	nn1
law	law	nn1
appears	appear	vvz
to	to	to
advocate	advocate	vvi
lessening	lessen	vvg
the	the	at
duty	duty	nn1
of	of	io
physicians	physician	nn2
to	to	to
warn	warn	vvi
;	;	y
if	if	cs
anything	anything	pn1
,	,	y
the	the	at
physician	physician	nn1
's	's	ge
duty	duty	nn1
to	to	to
warn	warn	vvi
has	have	vhz
become	become	vvn@
more	more	rrr_rgr_dar
comprehensive.		nnu
(	(	y
n183	n183	fo
)	)	y
<p>	<p>	y
In	in	ii31
addition	addition	ii32
to	to	ii33
placing	place	vvg
the	the	at
responsibility	responsibility	nn1
of	of	io
translating	translate	vvg
drug	drug	nn1
warnings	warning	nn2
on	on	ii
the	the	at
more	more	rgr
able	able	jj
physician	physician	nn1
,	,	y
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
achieves	achieve	vvz
other	other	jj
important	important	jj
practical	practical	jj
policy	policy	nn1
objectives	objective	nn2
.	.	y
The	the	at
broad	broad	jj
range	range	nn1
and	and	cc
complexities	complexity	nn2
of	of	io
potential	potential	jj_nn1
prescription	prescription	nn1
drug	drug	nn1
users	user	nn2
make	make	vv0
it	it	pph1
ill-advised	ill-advised	jj
,	,	y
and	and	cc
perhaps	perhaps	rr
impossible	impossible	jj
,	,	y
to	to	to
tailor	tailor	vvi
comprehensive	comprehensive	jj
warnings	warning	nn2
to	to	ii
consumers	consumer	nn2
.	.	y
Differences	difference	nn2
in	in	ii
patients	patient	nn2
'	'	ge
medical	medical	jj
histories	history	nn2
,	,	y
ages	age	nn2
,	,	y
education	education	nn1
levels	level	nn2
,	,	y
and	and	cc
drug	drug	nn1
interactions	interaction	nn2
with	with	iw
current	current	jj
treatments	treatment	nn2
are	be	vbr
only	only	rr
a	a	at1
few	few	da2
of	of	io
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	to
overcome	overcome	vvi
if	if	cs_csw@
directly	directly	rr
liable	liable	jj
for	for	if
warnings	warning	nn2
both	both	rr
to	to	ii
doctors	doctor	nn2
and	and	cc
to	to	ii
consumers	consumer	nn2
.	.	y
Liability	liability	nn1
for	for	if
two	two	mc
types	type	nn2
of	of	io
warnings	warning	nn2
could	could	vm
serve	serve	vvi
to	to	to
eliminate	eliminate	vvi
DTC	dtc	np1
marketing	marketing	nn1
because	because	cs
no	no	at
prescription	prescription	nn1
drug	drug	nn1
company	company	nn1
could	could	vm
warn	warn	vvi
effectively	effectively	rr
.	.	y
The	the	at
result	result	nn1
would	would	vm
impede	impede	vvi
the	the	at
attempts	attempt	nn2
of	of	io
many	many	da2
consumers	consumer	nn2
to	to	to
take	take	vvi
a	a	at1
more	more	rgr
active	active	jj
role	role	nn1
in	in	ii
their	their	appge
personal	personal	jj
health	health	nn1
.	.	y
The	the	at
extended	extended	jj@
liability	liability	nn1
would	would	vm
also	also	rr
likely	likely	rr@
increase	increase	vvi
drug	drug	nn1
prices	price	nn2
,	,	y
hampering	hamper	vvg
the	the	at
accessibility	accessibility	nn1
of	of	io
the	the	at
drugs.	drug	nnu
n184	n184	fo
Worse	bad	rrr@
,	,	y
if	if	cs
a	a	at1
majority	majority	nn1
of	of	io
courts	court	nn2
held	hold	vvd_vvn
drug	drug	nn1
manufacturers	manufacturer	nn2
liable	liable	jj
for	for	if
DTC	dtc	np1
advertisements	advertisement	nn2
,	,	y
it	it	pph1
could	could	vm
create	create	vvi
a	a	at1
self-fulfilling	self-fulfilling	jj_nn1
prophecy	prophecy	nn1
whereby	whereby	rrq
consumers	consumer	nn2
,	,	y
aware	aware	jj
of	of	io
this	this	dd1
obligation	obligation	nn1
,	,	y
begin	begin	vv0
to	to	to
rely	rely	vvi
solely	solely	rr
on	on	ii
the	the	at
less	less	rgr
comprehensive	comprehensive	jj
DTC	dtc	np1
warnings	warning	nn2
and	and	cc
physicians	physician	nn2
take	take	vv0
fewer	fewer	dar
steps	step	nn2
to	to	to
evaluate	evaluate	vvi
treatments	treatment	nn2
individually	individually	rr
because	because	cs
there	there	ex
is	be	vbz
shared	shared	jj_vvn
liability	liability	nn1
with	with	iw
manufacturers	manufacturer	nn2
.	.	y
<p>	<p>	y
As	as	ii_csa
the	the	at
saying	saying	nn1@
goes	go	vvz
,	,	y
"	"	y
A	a	at1
little	little	jj
knowledge	knowledge	nn1
can	can	vm
be	be	vbi
a	a	at1
dangerous	dangerous	jj
thing	thing	nn1
.	.	y
"	"	y
With	with	iw
prescription	prescription	nn1
drugs	drug	nn2
,	,	y
it	it	pph1
can	can	vm
turn	turn	vvi
into	into	ii
a	a	at1
deadly	deadly	jj
thing	thing	nn1
.	.	y
For	for	if
that	that	dd1
reason	reason	nn1
,	,	y
liability	liability	nn1
for	for	if
prescription	prescription	nn1
drug	drug	nn1
warnings	warning	nn2
to	to	ii
consumers	consumer	nn2
is	be	vbz
entrusted	entrust	vvn
to	to	ii
physicians	physician	nn2
and	and	cc
not	not	xx
to	to	ii
less	less	rgr_dar
comprehensive	comprehensive	jj
DTC	dtc	np1
advertisements	advertisement	nn2
.	.	y
Rather	rather	rr@_rg
,	,	y
DTC	dtc	np1
advertisements	advertisement	nn2
caution	caution	vv0@_nn1
to	to	to
"	"	y
see	see	vvi
your	your	appge
doctor	doctor	nn1
"	"	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
can	can	vm
take	take	vvi
on	on	rp
a	a	at1
more	more	rgr
active	active	jj
role	role	nn1
while	while	cs
the	the	at
doctor	doctor	nn1
calculates	calculate	vvz
the	the	at
array	array	nn1
of	of	io
treatment	treatment	nn1
risks	risk	nn2
.	.	y
Because	because	cs
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
establishes	establish	vvz
liability	liability	nn1
rules	rule	nn2_vvz@
to	to	to
facilitate	facilitate	vvi
this	this	dd1
practice	practice	nn1
and	and	cc
improve	improve	vvi
health	health	nn1
care	care	nn1
,	,	y
it	it	pph1
is	be	vbz
as	as	rg@
viable	viable	jj
in	in	ii
today	today	rt
's	's	ge
world	world	nn1
of	of	io
DTC	dtc	np1
marketing	marketing	nn1
as	as	csa
it	it	pph1
ever	ever	rr
was	be	vbdz
.	.	y
<p>	<p>	y
B.	b	np1
Effect	effect	nn1
of	of	io
Compliance	compliance	nn1
with	with	iw
FDA	fda	nn1_np1
Requirements	requirement	nn2
on	on	ii
Liability	liability	nn1
Whereas	whereas	cs
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
places	place	vvz@_nn2
the	the	at
duty	duty	nn1
to	to	to
warn	warn	vvi
patients	patient	nn2
of	of	io
the	the	at
risks	risk	nn2
of	of	io
drugs	drug	nn2
on	on	ii
physicians	physician	nn2
,	,	y
other	other	jj
common	common	jj
law	law	nn1
and	and	cc
statutory	statutory	jj
enactments	enactment	nn2
consider	consider	vv0
the	the	at
deference	deference	nn1
warnings	warning	nn2
should	should	vm
receive	receive	vvi
when	when	rrq_cs
they	they	pphs2
are	be	vbr
reviewed	review	vvn
and	and	cc
approved	approve	vvn
by	by	ii
government	government	nn1
regulators	regulator	nn2
.	.	y
<p>	<p>	y
1	1	mc1
.	.	y
Common	common	jj
Law	law	nn1
Principles	principle	nn2
In	in	ii
the	the	at
absence	absence	nn1
of	of	io
a	a	at1
statute	statute	nn1
instructing	instruct	vvg_nn1@
courts	court	nn2
how	how	rrq
to	to	to
weigh	weigh	vvi
compliance	compliance	nn1
with	with	iw
a	a	at1
government	government	nn1
safety	safety	nn1
standard	standard	nn1_jj
or	or	cc
government	government	nn1
approval	approval	nn1
of	of	io
a	a	at1
product	product	nn1
or	or	cc
service	service	nn1
,	,	y
states	state	nn2
vary	vary	vv0
on	on	ii_rp@
how	how	rrq
they	they	pphs2
consider	consider	vv0
such	such	da
evidence	evidence	nn1
.	.	y
Most	most	dat
courts	court	nn2
find	find	vv0
that	that	dd1_cst
compliance	compliance	nn1
with	with	iw
government	government	nn1
standards	standard	nn2
is	be	vbz
one	one	mc1
of	of	io
many	many	da2
factors	factor	nn2
to	to	to
be	be	vbi
considered	consider	vvn
by	by	ii
the	the	at
jury	jury	nn1
in	in	ii
determining	determine	vvg
whether	whether	csw31
or	or	csw32
not	not	csw33
a	a	at1
product	product	nn1
is	be	vbz
unreasonably	unreasonably	rr
dangerous.	dangerous	nnu
n185	n185	fo
These	these	dd2
courts	court	nn2
reason	reason	vv0@
that	that	dd1_cst
government	government	nn1
regulations	regulation	nn2
provide	provide	vv0
only	only	rr_jj
"	"	y
minimum	minimum	jj_nn1
standards	standard	nn2
,	,	y
"	"	y
and	and	cc
,	,	y
therefore	therefore	rr
,	,	y
are	be	vbr
not	not	xx
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	ii
warn.	warn	nnu
n186	n186	fo
Although	although	cs
most	most	dat
jurisdictions	jurisdiction	nn2
consider	consider	vv0
a	a	at1
violation	violation	nn1
of	of	io
a	a	at1
safety	safety	nn1
regulation	regulation	nn1
as	as	csa_ii@
evidence	evidence	nn1
that	that	cst
a	a	at1
product	product	nn1
is	be	vbz
defective	defective	jj
as	as	ii
a	a	at1
matter	matter	nn1
of	of	io
law	law	nn1
,	,	y
they	they	pphs2
do	do	vd0
not	not	xx
accord	accord	vvi
evidence	evidence	nn1
of	of	io
compliance	compliance	nn1
with	with	iw
government	government	nn1
regulations	regulation	nn2
similarly	similarly	rr
deferential	deferential	jj
treatment.	treatment	nnu
(	(	y
n187	n187	fo
)	)	y
<p>	<p>	y
In	in	ii
1991	1991	mc
,	,	y
the	the	at
American	american	jj
Law	law	nn1
Institute	institute	nn1
(	(	y
ALI	ali	np1
)	)	y
published	publish	vvd
a	a	at1
Reporter	reporter	nn1
's	's	ge
study	study	nn1
recommending	recommend	vvg
that	that	dd1_cst
compliance	compliance	nn1
with	with	iw
regulatory	regulatory	jj
requirements	requirement	nn2
imposed	impose	vvn
by	by	ii
a	a	at1
government	government	nn1
agency	agency	nn1
preclude	preclude	vv0
tort	tort	nn1_vv0
liability	liability	nn1
in	in	ii
certain	certain	jj
situations	situation	nn2
.	.	y
Under	under	ii
the	the	at
Reporter	reporter	nn1
's	's	ge
study	study	nn1
recommendations	recommendation	nn2
,	,	y
tort	tort	vv0_nn1
liability	liability	nn1
would	would	vm
be	be	vbi
precluded	preclude	vvn
when	when	cs_rrq
:	:	y
(	(	y
1	1	mc1
)	)	y
a	a	at1
legislature	legislature	nn1
has	have	vhz
placed	place	vvn
the	the	at
risk	risk	nn1
at	at	ii
issue	issue	nn1
under	under	ii
the	the	at
authority	authority	nn1
of	of	io
a	a	at1
specialized	specialized	jj
administrative	administrative	jj
agency	agency	nn1
;	;	y
(	(	y
2	2	mc
)	)	y
that	that	dd1_cst
agency	agency	nn1
has	have	vhz
established	establish	vvn
and	and	cc
periodically	periodically	rr
revises	revise	vvz
regulatory	regulatory	jj
safety	safety	nn1
controls	control	nn2_vvz
;	;	y
(	(	y
3	3	mc
)	)	y
the	the	at
manufacturer	manufacturer	nn1
or	or	cc
other	other	jj
entity	entity	nn1
complied	comply	vvn_vvd
with	with	iw
the	the	at
relevant	relevant	jj
regulatory	regulatory	jj
standards	standard	nn2
;	;	y
and	and	cc
(	(	y
4	4	mc
)	)	y
the	the	at
manufacturer	manufacturer	nn1
or	or	cc
other	other	jj
entity	entity	nn1
disclosed	disclose	vvn
to	to	ii
the	the	at
agency	agency	nn1
any	any	dd
material	material	nn1_jj@
information	information	nn1
in	in	ii
its	its	z'
possession	possession	nn1
,	,	y
or	or	cc
of	of	io
which	which	ddq
it	it	pph1
has	have	vhz
reason	reason	nn1
to	to	to
be	be	vbi
aware	aware	jj
,	,	y
concerning	concern	vvg_ii
the	the	at
products	product	nn2
'	'	ge
risks	risk	nn2
and	and	cc
means	mean	nn
of	of	io
controlling	control	vvg
them.		zz
(	(	y
n188	n188	fo
)	)	y
<p>	<p>	y
The	the	at
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
incorporates	incorporate	vvz
a	a	at1
similar	similar	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
considered	consider	vvn
defective	defective	jj
as	as	ii
a	a	at1
matter	matter	nn1
of	of	io
law	law	nn1
in	in	ii
the	the	at
following	following	jj
circumstances	circumstance	nn2
:	:	y
<p>	<p>	y
When	when	cs
the	the	at
safety	safety	nn1
statute	statute	nn1
or	or	cc
regulation	regulation	nn1
was	be	vbdz
promulgated	promulgate	vvn
recently	recently	rr
,	,	y
thus	thus	rr
supplying	supply	vvg
currency	currency	nn1
to	to	ii
the	the	at
standard	standard	nn1_jj
therein	therein	rr
established	establish	vvn_vvd
;	;	y
when	when	cs_rrq
the	the	at
specific	specific	jj
standard	standard	nn1
addresses	address	vvz
the	the	at
very	very	jj
issue	issue	nn1
of	of	io
product	product	nn1
design	design	nn1
or	or	cc
warning	warning	nn1
presented	present	vvn_vvd
in	in	ii
the	the	at
case	case	nn1
before	before	ii_cs
the	the	at
court	court	nn1
;	;	y
and	and	cc
when	when	cs_rrq
the	the	at
court	court	nn1
is	be	vbz
confident	confident	jj
that	that	cst
the	the	at
deliberative	deliberative	jj
process	process	nn1
by	by	ii
which	which	ddq
the	the	at
safety	safety	nn1
standard	standard	nn1
was	be	vbdz
established	establish	vvn
was	be	vbdz
full	full	jj
,	,	y
fair	fair	jj_rr@
,	,	y
and	and	cc
thorough	thorough	jj
and	and	cc
reflected	reflect	vvd_vvn_jj@
substantial	substantial	jj
expertise.	expertise	nnu
(	(	y
n189	n189	fo
)	)	y
<p>	<p>	y
The	the	at
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
also	also	rr
acknowledges	acknowledge	vvz
that	that	cst
this	this	dd1
liability	liability	nn1
protection	protection	nn1
would	would	vm
not	not	xx
apply	apply	vvi
"	"	y
when	when	rrq_cs
the	the	at
deliberative	deliberative	jj
process	process	nn1
that	that	cst
led	lead	vvd
to	to	ii
the	the	at
safety	safety	nn1
standard	standard	nn1
...	...	...
was	be	vbdz
tainted	taint	vvn
by	by	ii
the	the	at
supplying	supplying	nn1
of	of	io
false	false	jj
information	information	nn1
to	to	ii_to
,	,	y
or	or	cc
the	the	at
withholding	withholding	nn1
of	of	io
necessary	necessary	jj
and	and	cc
valid	valid	jj
information	information	nn1
from	from	ii
,	,	y
the	the	at
agency	agency	nn1
that	that	cst
promulgated	promulgate	vvd@
the	the	at
standard	standard	nn1_jj
or	or	cc
certified	certified	jj_vvn
or	or	cc
approved	approve	vvd_vvn
the	the	at
product	product	nn1
.	.	y
"	"	y
(	(	y
n190	n190	fo
)	)	y
<p>	<p>	y
The	the	at
Restatement	restatement	nn1
(	(	y
Third	third	md_np1%
)	)	y
recognizes	recognize	vvz
that	that	cst_dd1
courts	court	vvz@_nn2
frequently	frequently	rr
cite	cite	vv0
compliance	compliance	nn1
with	with	iw
safety	safety	nn1
regulations	regulation	nn2
as	as	ii_csa
a	a	at1
factor	factor	nn1
used	use	vmk
to	to	to
justify	justify	vvi
a	a	at1
directed	directed	jj@
verdict	verdict	nn1
for	for	if
a	a	at1
defendant.	defendant	nnu
n191	n191	fo
In	in	ii
some	some	dd
cases	case	nn2
,	,	y
courts	court	nn2
have	have	vh0
accorded	accord	vvn
weight	weight	nn1
to	to	ii
government	government	nn1
safety	safety	nn1
standards	standard	nn2
and	and	cc
approvals	approval	nn2
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
n192	n192	fo
Courts	court	nn2_vvz%
occasionally	occasionally	rr
find	find	vv0
that	that	cst_dd1
meeting	meet	vvg
a	a	at1
safety	safety	nn1
standard	standard	nn1_jj
set	set	vvn
by	by	ii
government	government	nn1
regulations	regulation	nn2
precludes	preclude	vvz
tort	tort	nn1_vv0
liability.	liability	nnu
n193	n193	fo
For	for	rex21
example	example	rex22
,	,	y
the	the	at
Maryland	maryland	np1
Court	court	nn1
of	of	io
Appeals	appeal	nn2
has	have	vhz
recognized	recognize	vvn
that	that	cst
"	"	y
where	where	cs
no	no	at
special	special	jj
circumstances	circumstance	nn2
require	require	vv0
extra	extra	jj
caution	caution	nn1
,	,	y
a	a	at1
court	court	nn1
may	may	vm
find	find	vvi
that	that	dd1_cst
conformity	conformity	nn1
to	to	ii
the	the	at
statutory	statutory	jj
standard	standard	jj_nn1
amounts	amount	nn2
to	to	ii
due	due	jj
care	care	nn1
as	as	ii
a	a	at1
matter	matter	nn1
of	of	io
law	law	nn1
.	.	y
"	"	y
(	(	y
n194	n194	fo
)	)	y
<p>	<p>	y
2	2	mc
.	.	y
Statutory	statutory	jj
Consideration	consideration	nn1
of	of	io
the	the	at
Effect	effect	nn1
of	of	io
Regulatory	regulatory	jj
Compliance	compliance	nn1
on	on	ii
Liability	liability	nn1
Aside	aside	ii21
from	from	ii22
these	these	dd2
common	common	jj
law	law	nn1
principles	principle	nn2
,	,	y
three	three	mc
types	type	nn2
of	of	io
state	state	nn1
statutes	statute	nn2
impact	impact	nn1_vv0%
liability	liability	nn1
related	relate	vvn_vvd
to	to	ii
the	the	at
marketing	marketing	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
products	product	nn2
.	.	y
The	the	at
first	first	md
comes	come	vvz
into	into	ii
play	play	nn1
in	in	ii
product	product	nn1
liability	liability	nn1
cases	case	nn2
and	and	cc
provides	provide	vvz
a	a	at1
presumption	presumption	nn1
that	that	cst
a	a	at1
product	product	nn1
approved	approve	vvn
by	by	ii
a	a	at1
government	government	nn1
agency	agency	nn1
is	be	vbz
not	not	xx
defective	defective	jj
.	.	y
The	the	at
second	second	md
type	type	nn1
of	of	io
these	these	dd2
laws	law	nn2
,	,	y
also	also	rr
applicable	applicable	jj
in	in	ii
product	product	nn1
liability	liability	nn1
actions	action	nn2
,	,	y
precludes	preclude	vvz
an	a	at1
award	award	nn1
of	of	io
punitive	punitive	jj
damages	damage	nn2
with	with	ii31
respect	respect	ii32
to	to	ii33
injuries	injury	nn2
from	from	ii
FDA-approved	fda-approved	jj_nn1
drugs	drug	nn2
,	,	y
with	with	iw
limited	limited	jj
exceptions	exception	nn2
.	.	y
The	the	at
third	third	md
includes	include	vvz
provisions	provision	nn2
which	which	ddq
place	place	vv0
conduct	conduct	vv0_nn1
that	that	dd1_cst
is	be	vbz
closely	closely	rr
regulated	regulate	vvn_vvd
or	or	cc
approved	approve	vvn
by	by	ii
government	government	nn1
agencies	agency	nn2
beyond	beyond	ii
the	the	at
scope	scope	nn1
of	of	io
more	more	rgr_dar
general	general	jj
state	state	nn1
statutes	statute	nn2
prohibiting	prohibit	vvg
deceptive	deceptive	jj
advertising	advertising	nn1
.	.	y
<p>	<p>	y
a	a	at1
.	.	y
Presumption	presumption	nn1
of	of	io
Nondefectiveness		np1_nn1
Seven	seven	mc
states	state	nn2
provide	provide	vv0
that	that	dd1_cst
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
rebuttable	rebuttable	jj
presumption	presumption	nn1
that	that	cst
a	a	at1
product	product	nn1
is	be	vbz
not	not	xx
defective.		nnu
n195	n195	fo
The	the	at
relevant	relevant	jj
statutes	statute	nn2
respect	respect	vv0@
the	the	at
decision	decision	nn1
making	making	nn1@_vvg
of	of	io
federal	federal	jj
and	and	cc
state	state	vv0
regulatory	regulatory	jj
agencies	agency	nn2
charged	charge	vvn_vvd
with	with	iw
protecting	protect	vvg_jj@
public	public	jj_nn1
safety	safety	nn1
in	in	ii
tort	tort	nn1
lawsuits	lawsuit	nn2
.	.	y
Such	such	da
laws	law	nn2
are	be	vbr
broadly	broadly	rr
applicable	applicable	jj
to	to	ii
any	any	dd
product	product	nn1
governed	govern	vvn
by	by	ii
government	government	nn1
safety	safety	nn1
regulations	regulation	nn2
and	and	cc
have	have	vh0
been	be	vbn
invoked	invoke	vvn
in	in	ii
cases	case	nn2
involving	involve	vvg
a	a	at1
wide	wide	jj
range	range	nn1
of	of	io
products	product	nn2
including	including	ii
ladders	ladder	nn2
,	,	y
n196	n196	fo
nail	nail	nn1_vv0@
guns	gun	nn2
,	,	y
n197	n197	fo
cleaning	cleaning	nn1_vvg
products	product	nn2
,	,	y
n198	n198	fo
clothing	clothing	nn1
,	,	y
n199	n199	fo
airplanes	airplane	nn2
,	,	y
n200	n200	fo
and	and	cc
automobiles.	automobile	nnu
n201	n201	fo
The	the	at
statutes	statute	nn2
generally	generally	rr
provide	provide	vv0
a	a	at1
presumption	presumption	nn1
that	that	cst
a	a	at1
product	product	nn1
is	be	vbz
not	not	xx
unreasonably	unreasonably	rr
dangerous	dangerous	jj
if	if	cs_csw@
it	it	pph1
meets	meet	vvz
safety	safety	nn1
requirements	requirement	nn2
,	,	y
thus	thus	rr
reducing	reduce	vvg
the	the	at
potential	potential	nn1_jj
for	for	if
a	a	at1
finding	finding	nn1
of	of	io
liability	liability	nn1
.	.	y
For	for	rex21
example	example	rex22
,	,	y
since	since	ii
1977	1977	mc
Colorado	colorado	np1
law	law	nn1
has	have	vhz
provided	provide	vvn
:	:	y
<p>	<p>	y
In	in	ii
any	any	dd
product	product	nn1
liability	liability	nn1
action	action	nn1
,	,	y
it	it	pph1
shall	shall	vm
be	be	vbi
rebuttably	rebuttably	rr
presumed	presume	vvn_vvd
that	that	cst
the	the	at
product	product	nn1
which	which	ddq
caused	cause	vvd
the	the	at
injury	injury	nn1
,	,	y
death	death	nn1
,	,	y
or	or	cc
property	property	nn1
damage	damage	nn1
was	be	vbdz
not	not	xx
defective	defective	jj
and	and	cc
that	that	cst
the	the	at
manufacturer	manufacturer	nn1
or	or	cc
seller	seller	nn1
thereof	thereof	rr
was	be	vbdz
not	not	xx
negligent	negligent	jj
if	if	cs_csw@
the	the	at
product	product	nn1
...	...	...
complied	comply	vvn_vvd
with	with	iw
,	,	y
at	at	ii
the	the	at
time	time	nnt1
of	of	io
sale	sale	nn1
by	by	ii
the	the	at
manufacturer	manufacturer	nn1
,	,	y
any	any	dd
applicable	applicable	jj
code	code	nn1
,	,	y
standard	standard	nn1_jj
,	,	y
or	or	cc
regulation	regulation	nn1
adopted	adopt	vvn_vvd
or	or	cc
promulgated	promulgate	vvn
by	by	ii
the	the	at
United	united	np1
States	state	np1
or	or	cc
by	by	ii
this	this	dd1
state.	state	nnu
(	(	y
n202	n202	fo
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Texas	texas	np1
,	,	y
and	and	cc
Utah	utah	np1
have	have	vh0
chosen	choose	vvn
similar	similar	jj
routes.	routes	nnu
n203	n203	fo
These	these	dd2
laws	law	nn2
assure	assure	vv0
that	that	cst
courts	court	nn2
allow	allow	vv0
juries	jury	nn2
to	to	to
hear	hear	vvi
and	and	cc
appropriately	appropriately	rr
consider	consider	vvi
a	a	at1
product	product	nn1
's	's	ge
compliance	compliance	nn1
with	with	iw
government	government	nn1
standards	standard	nn2
when	when	cs_rrq
they	they	pphs2
consider	consider	vv0
whether	whether	csw
the	the	at
product	product	nn1
is	be	vbz
defective	defective	jj
.	.	y
<p>	<p>	y
Such	such	da
laws	law	nn2
appear	appear	vv0
to	to	to
include	include	vvi
claims	claim	nn2
challenging	challenge	vvg
the	the	at
sufficiency	sufficiency	nn1
of	of	io
a	a	at1
pharmaceutical	pharmaceutical	jj
product	product	nn1
's	be	vbz_ge
labeling	label	vvg_nn1@_jj@
and	and	cc
warnings	warning	nn2
,	,	y
including	include	vvg@_ii
failure-to-warn	failure-to-warn	vv0
claims	claim	nn2
associated	associate	vvn
with	with	iw
DTC	dtc	np1
marketing	marketing	nn1
.	.	y
Curiously	curiously	rr
,	,	y
there	there	ex
is	be	vbz
very	very	rg
little	little	da1
case	case	nn1
law	law	nn1
applying	apply	vvg
the	the	at
statutory	statutory	jj
presumptions	presumption	nn2
of	of	io
nondefectiveness	nondefectiveness	nn1
to	to	ii
FDA-approved	fda-approved	jj_nn1
warnings.	warnings	nnu
(	(	y
n204	n204	fo
)	)	y
<p>	<p>	y
b	b	zz1
.	.	y
Preclusion	preclusion	nn1
of	of	io
Punitive	punitive	jj
Damages	damage	nn2
for	for	if
FDA-Approved	fda-approved	jj_nn1
Pharmaceuticals	pharmaceutical	nn2
Special	special	jj
considerations	consideration	nn2
come	come	vv0_vvn@
into	into	ii
play	play	nn1
when	when	rrq_cs
lawsuits	lawsuit	nn2
charge	charge	vv0@
that	that	cst
a	a	at1
prescription	prescription	nn1
drug	drug	nn1
manufacturer	manufacturer	nn1
acted	act	vvn_vvd
with	with	iw
such	such	da
malice	malice	nn1
in	in	ii
offering	offer	vvg
a	a	at1
product	product	nn1
to	to	ii
patients	patient	nn2
that	that	cst
it	it	pph1
should	should	vm
be	be	vbi
subject	subject	ii21
to	to	ii22
punitive	punitive	jj
damages	damage	nn2
even	even	cs21
though	though	cs22
the	the	at
FDA	fda	nn1_np1
approval	approval	nn1
process	process	nn1
includes	include	vvz
a	a	at1
rigorous	rigorous	jj
review	review	nn1
that	that	cst_dd1
can	can	vm
span	span	vvi
thousands	thousand	m
of	of	io
hours	hour	nnt2
over	over	ii_rp
more	more	dar_rrr
than	than	csn
a	a	at1
decade.	decade	nnu
(	(	y
n205	n205	fo
)	)	y
<p>	<p>	y
For	for	if
this	this	dd1
reason	reason	nn1
,	,	y
five	five	mc
states	state	nn2
have	have	vh0
enacted	enact	vvn
statutes	statute	nn2
that	that	cst
preclude	preclude	vv0
punitive	punitive	jj
damage	damage	nn1
liability	liability	nn1
when	when	cs_rrq
the	the	at
manufacturer	manufacturer	nn1
received	receive	vvd_vvn
FDA	fda	np1_nn1
approval	approval	nn1
for	for	if
the	the	at
product	product	nn1
at	at	ii
issue	issue	nn1
.	.	y
New	new	np1
Jersey	jersey	np1
,	,	y
Oregon	oregon	np1
,	,	y
and	and	cc
Ohio	ohio	np1
were	be	vbdr
the	the	at
first	first	md
states	state	vvz_nn2
to	to	to
adopt	adopt	vvi
such	such	da
laws.	laws	nnu
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
punitive	punitive	jj
damages	damage	nn2
in	in	ii
cases	case	nn2
involving	involve	vvg
FDA-approved	fda-approved	jj_nn1
or	or	cc
licensed	licensed	jj_vvd@_vvn
products.	products	nnu
n207	n207	fo
Additionally	additionally	rr
,	,	y
Michigan	michigan	np1
,	,	y
a	a	at1
state	state	nn1
that	that	cst_dd1
does	do	vdz
not	not	xx
recognize	recognize	vvi
punitive	punitive	jj
damages	damage	nn2
,	,	y
limits	limit	vvz_nn2
manufacturer	manufacturer	nn1
liability	liability	nn1
for	for	if
compensatory	compensatory	jj
damages	damage	nn2
in	in	ii
product	product	nn1
liability	liability	nn1
actions	action	nn2
involving	involve	vvg
FDA-approved	fda-approved	jj_nn1
drugs	drug	nn2
.	.	y
Michigan	michigan	np1
law	law	nn1
defers	defer	vvz
to	to	ii
the	the	at
federal	federal	jj
agency	agency	nn1
's	's	ge_vbz
comprehensive	comprehensive	jj
regulatory	regulatory	jj
process	process	nn1
by	by	ii
providing	provide	vvg
a	a	at1
rebuttable	rebuttable	jj
presumption	presumption	nn1
that	that	cst
a	a	at1
drug	drug	nn1
,	,	y
including	including	ii_vvg@
its	its	z'
labeling	labeling	nn1@_jj@
and	and	cc
packaging	packaging	nn1
,	,	y
is	be	vbz
not	not	xx
defective	defective	jj
or	or	cc
unreasonably	unreasonably	rr
dangerous	dangerous	jj
if	if	cs_csw@
the	the	at
drug	drug	nn1
is	be	vbz
approved	approve	vvn
for	for	if
safety	safety	nn1
and	and	cc
efficacy	efficacy	nn1
by	by	ii
the	the	at
FDA.	fda	np1
(	(	y
n208	n208	fo
)	)	y
<p>	<p>	y
There	there	ex
are	be	vbr
variations	variation	nn2
as	as	ii21
to	to	ii22
the	the	at
scope	scope	nn1
of	of	io
these	these	dd2
laws	law	nn2
,	,	y
such	such	ii21
as	as	ii22
whether	whether	csw
the	the	at
limitation	limitation	nn1
on	on	ii
liability	liability	nn1
applies	apply	vvz
solely	solely	rr
to	to	ii
prescription	prescription	nn1
drugs	drug	nn2
or	or	cc
to	to	ii
other	other	jj
FDA-approved	fda-approved	jj_nn1
products	product	nn2
as	as	rr21_rg
well	well	rr22_rr
.	.	y
Generally	generally	rr
,	,	y
each	each	dd1
law	law	nn1
includes	include	vvz
exceptions	exception	nn2
permitting	permit	vvg
full	full	jj
liability	liability	nn1
in	in	ii
three	three	mc
circumstances	circumstance	nn2
:	:	y
(	(	y
1	1	mc1
)	)	y
if	if	cs
the	the	at
drug	drug	nn1
was	be	vbdz
sold	sell	vvn
after	after	ii
an	a	at1
FDA	fda	nn1
product	product	nn1
recall	recall	nn1@_vv0
or	or	cc
withdrawal	withdrawal	nn1
of	of	io
approval	approval	nn1
;	;	y
(	(	y
2	2	mc
)	)	y
if	if	cs
the	the	at
defendant	defendant	nn1
knowingly	knowingly	rr
withheld	withhold	vvn_vvd
material	material	nn1_jj@
information	information	nn1
from	from	ii
or	or	cc
misrepresented	misrepresented	jj@_vvd
material	material	nn1_jj@
information	information	nn1
to	to	ii
the	the	at
FDA	fda	nn1_np1
;	;	y
or	or	cc
(	(	y
3	3	mc
)	)	y
if	if	cs
the	the	at
defendant	defendant	nn1
bribed	bribe	vvd_vvn
a	a	at1
public	public	jj_nn1
official	official	nn1_jj
.	.	y
Ohio	ohio	np1
law	law	nn1
further	far	rrr
permits	permit	vvz
punitive	punitive	jj
damages	damage	nn2
upon	upon	ii
a	a	at1
finding	finding	nn1
that	that	cst
the	the	at
manufacturer	manufacturer	nn1
acted	act	vvn_vvd
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
might	might	vm
be	be	vbi
harmed	harm	vvn
by	by	ii
the	the	at
product	product	nn1
"	"	y
and	and	cc
provides	provide	vvz
that	that	cst
the	the	at
court	court	nn1
is	be	vbz
to	to	to
decide	decide	vvi
the	the	at
amount	amount	nn1
of	of	io
punitive	punitive	jj
damages	damage	nn2
upon	upon	ii
a	a	at1
jury	jury	nn1
verdict	verdict	nn1
finding	find	vvg
punitive	punitive	jj
damages	damage	nn2
appropriate.	appropriate	nnu
n209	n209	fo
The	the	at
laws	law	nn2
also	also	rr
differ	differ	vv0
on	on	ii_rp@
the	the	at
burden	burden	nn1
of	of	io
proof	proof	nn1
required	require	vvn
to	to	to
overcome	overcome	vvi
the	the	at
limitation	limitation	nn1
on	on	ii
liability.	liability	nnu
(	(	y
n210	n210	fo
)	)	y
<p>	<p>	y
It	it	pph1
is	be	vbz
inaccurate	inaccurate	jj
,	,	y
however	however	rr
,	,	y
to	to	to
call	call	vvi
this	this	dd1
an	a	at1
"	"	y
FDA-approval	fda-approval	jj_nn1
"	"	y
defense	defense	nn1
.	.	y
The	the	at
defense	defense	nn1
neither	neither	rr_dd1
completely	completely	rr
eliminates	eliminate	vvz
liability	liability	nn1
(	(	y
except	except	cs_vv0%
in	in	ii
Michigan	michigan	np1
,	,	y
with	with	iw
limited	limited	jj
exceptions	exception	nn2
)	)	y
,	,	y
nor	nor	cc
results	result	nn2_vvz@
in	in	ii
the	the	at
elimination	elimination	nn1
of	of	io
punitive	punitive	jj
damages	damage	nn2
simply	simply	rr
based	base	vvn
on	on	ii
FDA	fda	np1_nn1
approval	approval	nn1
.	.	y
FDA	fda	np1_nn1
approval	approval	nn1
of	of	io
a	a	at1
prescription	prescription	nn1
drug	drug	nn1
is	be	vbz
insufficient	insufficient	jj
to	to	to
merit	merit	vvi
such	such	da
treatment	treatment	nn1
unless	unless	cs
the	the	at
manufacturer	manufacturer	nn1
follows	follow	vvz
FDA	fda	nn1_np1
rules	rule	nn2
and	and	cc
submits	submit	vvz
the	the	at
extensive	extensive	jj
test	test	nn1
results	result	nn2
required	require	vvn
by	by	ii
FDA	fda	np1_nn1
regulations	regulation	nn2
.	.	y
In	in	rr21
addition	addition	rr22
,	,	y
FDA	fda	np1_nn1
regulations	regulation	nn2
require	require	vv0
submission	submission	nn1
of	of	io
certain	certain	jj
information	information	nn1
after	after	ii_cs
approval	approval	nn1
of	of	io
the	the	at
drug	drug	nn1
,	,	y
such	such	ii21
as	as	ii22
adverse	adverse	jj
reaction	reaction	nn1
reports	report	nn2_vvz
and	and	cc
new	new	jj
developments	development	nn2
in	in	ii
scientific	scientific	jj
knowledge	knowledge	nn1
on	on	ii
the	the	at
drug	drug	nn1
,	,	y
which	which	ddq
allows	allow	vvz
the	the	at
agency	agency	nn1
to	to	to
determine	determine	vvi
whether	whether	csw
it	it	pph1
should	should	vm
withdraw	withdraw	vvi
its	its	z'
approval	approval	nn1
and	and	cc
require	require	vvi
the	the	at
manufacturer	manufacturer	nn1
to	to	to
withdraw	withdraw	vvi
the	the	at
product.	product	nnu
(	(	y
n211	n211	fo
)	)	y
<p>	<p>	y
Protection	protection	nn1
from	from	ii
punitive	punitive	jj
damages	damage	nn2
would	would	vm
only	only	rr
apply	apply	vvi
when	when	rrq_cs
the	the	at
manufacturer	manufacturer	nn1
has	have	vhz
met	meet	vvn
all	all	db
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
companies	company	nn2
to	to	to
disclose	disclose	vvi
fully	fully	rr
all	all	db
pre-	pre-	jj
and	and	cc
post-marketing	post-marketing	jj
data	data	nn
and	and	cc
to	to	to
meet	meet	vvi
or	or	cc
exceed	exceed	vvi
the	the	at
agency	agency	nn1
's	's	ge
requirements	requirement	nn2
in	in	bcl21
order	order	bcl22
to	to	to
qualify	qualify	vvi
for	for	if
protection	protection	nn1
from	from	ii
extensive	extensive	jj
punitive	punitive	jj
damages	damage	nn2
should	should	vm
it	it	pph1
later	later	rrr
be	be	vbi
found	find	vvn
that	that	cst
the	the	at
manufacturer	manufacturer	nn1
failed	fail	vvd_vvn
to	to	to
warn	warn	vvi
of	of	io
known	known	jj@
risk	risk	nn1
.	.	y
<p>	<p>	y
c	c	zz1
.	.	y
Placing	place	vvg_nn1
Regulated	regulated	jj@_vvd_vvn
Conduct	conduct	nn1
Beyond	beyond	ii
the	the	at
Scope	scope	nn1
of	of	io
Consumer	consumer	nn1
Protection	protection	nn1
Laws	law	nn2
Product	product	nn1
liability	liability	nn1
claims	claim	vvz_nn2
against	against	ii
pharmaceutical	pharmaceutical	jj
manufacturers	manufacturer	nn2
are	be	vbr
generally	generally	rr
brought	bring	vvn_vvd
on	on	ii31
behalf	behalf	ii32
of	of	ii33
plaintiffs	plaintiff	nn2
who	who	pnqs
have	have	vh0
experienced	experience	vvn
physical	physical	jj
injuries	injury	nn2
.	.	y
Increasingly	increasingly	rr
,	,	y
lawyers	lawyer	nn2
are	be	vbr
alleging	allege	vvg
claims	claim	nn2
under	under	ii
state	state	nn1
consumer	consumer	nn1
protection	protection	nn1
laws.	laws	nnu
n212	n212	fo
Although	although	cs
these	these	dd2
types	type	nn2
of	of	io
claims	claim	nn2
appear	appear	vv0
to	to	to
be	be	vbi
increasing	increase	vvg_jj
across	across	ii
the	the	at
board	board	nn1
,	,	y
pharmaceutical	pharmaceutical	jj
manufacturers	manufacturer	nn2
are	be	vbr
a	a	at1
principal	principal	jj_nn1
target.	target	nnu
(	(	y
n213	n213	fo
)	)	y
<p>	<p>	y
Typically	typically	rr
,	,	y
lawyers	lawyer	nn2
bring	bring	vv0
Consumer	consumer	nn1
Protection	protection	nn1
Act	act	nn1
(	(	y
CPA	cpa	np1
)	)	y
claims	claim	vvz_nn2
involving	involve	vvg
prescription	prescription	nn1
drugs	drug	nn2
as	as	csa_ii@
class	class	nn1_jj%
actions	action	nn2_vvz@
on	on	ii31
behalf	behalf	ii32
of	of	ii33
a	a	at1
group	group	nn1
of	of	io
individuals	individual	nn2
who	who	pnqs
purchased	purchase	vvd
the	the	at
drug	drug	nn1
but	but	ccb
did	do	vdd
not	not	xx
suffer	suffer	vvi
any	any	dd
ill	ill	z'
effects	effect	nn2
.	.	y
These	these	dd2
lawsuits	lawsuit	nn2
usually	usually	rr
allege	allege	vv0
that	that	cst
the	the	at
company	company	nn1
promoted	promote	vvn_vvd@
a	a	at1
drug	drug	nn1
as	as	csa_rg@_ii@
safe	safe	jj
and	and	cc
effective	effective	jj
,	,	y
when	when	cs_rrq
in	in	ii
fact	fact	nn1
either	either	rr
the	the	at
product	product	nn1
was	be	vbdz
not	not	xx
as	as	rg
effective	effective	jj
as	as	csa
consumers	consumer	nn2
believed	believe	vvn_vvd
or	or	cc
the	the	at
advertising	advertising	nn1
failed	fail	vvd_vvn
to	to	to
disclose	disclose	vvi
a	a	at1
known	known	jj@
risk	risk	nn1
associated	associate	vvn
with	with	iw
the	the	at
drug	drug	nn1
.	.	y
Claims	claim	nn2
may	may	vm
allege	allege	vvi
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
in	in	ii
artificial	artificial	jj
inflation	inflation	nn1
of	of	io
the	the	at
product	product	nn1
's	's	ge
price	price	nn1
beyond	beyond	ii
its	its	z'
actual	actual	jj
value	value	nn1
.	.	y
Damages	damage	nn2
sought	seek	vvn
are	be	vbr
usually	usually	rr
either	either	rr
a	a	at1
complete	complete	jj
refund	refund	nn1
of	of	io
the	the	at
purchase	purchase	nn1
price	price	nn1
(	(	y
on	on	ii31
behalf	behalf	ii32
of	of	ii33
thousands	thousand	m
of	of	io
consumers	consumer	nn2
)	)	y
or	or	cc
the	the	at
difference	difference	nn1
between	between	ii
the	the	at
sale	sale	nn1
price	price	nn1
and	and	cc
the	the	at
hypothetical	hypothetical	jj
actual	actual	jj
value	value	nn1
.	.	y
In	in	ii
recent	recent	jj
years	year	nnt2
,	,	y
such	such	da
claims	claim	nn2
have	have	vh0
been	be	vbn
made	make	vvn
involving	involve	vvg
Claritin	claritin	np1
,	,	y
n214	n214	fo
OxyContin	oxycontin	np1
,	,	y
n215	n215	fo
Prempro	prempro	np1_nn1
,	,	y
n216	n216	fo
Rezulin	rezulin	np1
,	,	y
n217	n217	fo
and	and	cc
Vioxx	vioxx	np1_nn1_vv0
,	,	y
n218	n218	fo
among	among	ii
other	other	jj
products	product	nn2
.	.	y
<p>	<p>	y
State	state	vv0_nn1
consumer	consumer	nn1
protection	protection	nn1
laws	law	nn2
were	be	vbdr
once	once	rr
primarily	primarily	rr
used	use	vvn
by	by	ii
government	government	nn1
regulators	regulator	nn2
to	to	to
attack	attack	vvi
truly	truly	rr
deceptive	deceptive	jj
practices	practice	nn2
and	and	cc
by	by	ii
consumers	consumer	nn2
to	to	to
bring	bring	vvi
small	small	jj
claims	claim	nn2
to	to	to
get	get	vvi
reimbursement	reimbursement	nn1
for	for	if
being	be	vbg
duped	dupe	vvn
at	at	ii
the	the	at
cash	cash	nn1
register	register	nn1_vv0
,	,	y
but	but	ccb
now	now	rt
they	they	pphs2
are	be	vbr
routinely	routinely	rr
tacked	tack	vvn_vvd
on	on	ii21_rp
to	to	ii22_ii
substantial	substantial	jj
lawsuits.	lawsuits	nnu
n219	n219	fo
These	these	dd2
laws	law	nn2
are	be	vbr
particularly	particularly	rr
attractive	attractive	jj
for	for	if
private	private	jj
claims	claim	nn2
because	because	cs
they	they	pphs2
often	often	rr
provide	provide	vv0
for	for	if
minimum	minimum	jj_nn1
awards	award	nn2
set	set	vvn
by	by	ii
statute	statute	nn1
in	in	ii
absence	absence	nn1
of	of	io
proof	proof	nn1
of	of	io
injury	injury	nn1
,	,	y
treble	treble	jj_vv0_nn1
damages	damage	nn2
,	,	y
and	and	cc
attorneys	attorney	nn2
'	'	ge
fees.	fees	nnu
(	(	y
n220	n220	fo
)	)	y
<p>	<p>	y
Some	some	dd
have	have	vh0
argued	argue	vvn
that	that	cst
the	the	at
scope	scope	nn1
of	of	io
CPAs	cpa	np2
was	be	vbdz
never	never	rr
meant	mean	vvn_vvd
to	to	to
include	include	vvi
FDA-approved	fda-approved	jj_nn1
drugs.	drug	nnu
n221	n221	fo
That	that	dd1
is	be	vbz
why	why	rrq
approximately	approximately	rr
two-thirds	two-thirds	mf
of	of	io
CPAs	cpa	np2_nn2
exclude	exclude	vv0
from	from	ii
their	their	appge
scope	scope	nn1
conduct	conduct	nn1
regulated	regulate	vvn
by	by	ii
state	state	nn1
or	or	cc
federal	federal	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
is	be	vbz
that	that	cst
CPAs	cpa	nn2
were	be	vbdr
meant	mean	vvn
to	to	to
fill	fill	vvi
a	a	at1
"	"	y
legal	legal	jj
gap	gap	nn1
"	"	y
by	by	ii
protecting	protect	vvg_jj@
consumers	consumer	nn2
where	where	rrq_cs
product	product	nn1
safety	safety	nn1
was	be	vbdz
not	not	xx
already	already	rr
closely	closely	rr
monitored	monitor	vvn_vvd
and	and	cc
regulated	regulate	vvn
by	by	ii
the	the	at
government.	government	nnu
n223	n223	fo
These	these	dd2
provisions	provision	nn2
are	be	vbr
only	only	rr
infrequently	infrequently	rr
applied	apply	vvn_vvd
in	in	ii
cases	case	nn2
involving	involve	vvg
pharmaceutical	pharmaceutical	jj
marketing	marketing	nn1
.	.	y
Instead	instead	rr
,	,	y
courts	court	nn2
appear	appear	vv0
more	more	rgr_rrr
frequently	frequently	rr
to	to	to
apply	apply	vvi
principles	principle	nn2
of	of	io
conflict	conflict	nn1
preemption	preemption	nn1
in	in	ii
claims	claim	nn2
challenging	challenge	vvg_jj
drug	drug	nn1
warnings.	warnings	nnu
(	(	y
n224	n224	fo
)	)	y
<p>	<p>	y
C.	c	np1
Conflicts	conflict	nn2
with	with	iw
Federal	federal	jj
Authority	authority	nn1
:	:	y
Preemption	preemption	nn1_np1@
The	the	at
constitutional	constitutional	jj
principle	principle	nn1
of	of	io
preemption	preemption	nn1
provides	provide	vvz
a	a	at1
final	final	jj
safeguard	safeguard	nn1
in	in	ii
the	the	at
development	development	nn1
and	and	cc
communication	communication	nn1
of	of	io
drug	drug	nn1
warnings	warning	nn2
.	.	y
Under	under	ii
the	the	at
Supremacy	supremacy	nn1
Clause	clause	nn1
of	of	io
the	the	at
United	united	np1
States	state	np1
Constitution	constitution	nn1
,	,	y
state	state	vv0_nn1
law	law	nn1
must	must	vm
yield	yield	vvi
to	to	ii
federal	federal	jj
law	law	nn1
when	when	cs_rrq
the	the	at
two	two	mc
conflict.	conflict	nnu
n225	n225	fo
Acts	act	nn2_vvz
of	of	io
Congress	congress	nn1
or	or	cc
agencies	agency	nn2
empowered	empower	vvd_vvn
to	to	to
act	act	vvi
on	on	ii
Congress	congress	nn1
's	's	ge
behalf	behalf	nn1
override	override	vv0_nn1
any	any	dd
state	state	nn1_vv0
law	law	nn1
that	that	cst_dd1
is	be	vbz
inconsistent	inconsistent	jj
with	with	iw
the	the	at
exercise	exercise	nn1
of	of	io
federal	federal	jj
power.	power	nnu
n226	n226	fo
In	in	ii
the	the	at
prescription	prescription	nn1
drug	drug	nn1
context	context	nn1
,	,	y
the	the	at
FDA	fda	nn1_np1
acting	act	vvg
pursuant	pursuant	ii21
to	to	ii22
the	the	at
FDCA	fdca	nn1_np1
is	be	vbz
such	such	da
an	a	at1
agency	agency	nn1
,	,	y
able	able	jk
to	to	to
exercise	exercise	vvi
federal	federal	jj
power.	power	nnu
n227	n227	fo
In	in	ii
some	some	dd
instances	instance	nn2
,	,	y
preemption	preemption	nn1
establishes	establish	vvz
an	a	at1
affirmative	affirmative	jj_nn1
defense	defense	nn1
for	for	if
drug	drug	nn1
manufacturers	manufacturer	nn2
,	,	y
in	in	ii
effect	effect	nn1
barring	barring	ii_vvg
state	state	nn1
tort	tort	nn1
actions	action	vvz@_nn2
that	that	cst
rely	rely	vv0
on	on	ii_rp@
court	court	nn1
decisions	decision	nn2
contrary	contrary	ii21
to	to	ii22
FDA	fda	np1_nn1
decisions	decision	nn2
.	.	y
<p>	<p>	y
1	1	mc1
.	.	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
The	the	at
most	most	rgt
straightforward	straightforward	jj
,	,	y
known	know	vvn
as	as	ii
"	"	y
express	express	jj@
preemption	preemption	nn1
,	,	y
"	"	y
occurs	occur	vvz
where	where	rrq_cs
a	a	at1
federal	federal	jj
law	law	nn1
preempts	preempts	nn2_vvz
state	state	vv0_nn1
statutes	statute	nn2
and	and	cc
common	common	jj
law	law	nn1
within	within	ii
the	the	at
text	text	nn1
of	of	io
the	the	at
statute	statute	nn1
.	.	y
For	for	rex21
example	example	rex22
,	,	y
the	the	at
Medical	medical	jj
Device	device	nn1
Amendments	amendment	nn2
to	to	ii
the	the	at
FDCA	fdca	nn1_np1
contain	contain	vv0
an	a	at1
express	express	jj@
preemption	preemption	nn1
provision	provision	nn1
barring	barring	ii_vvg
certain	certain	jj
state	state	nn1
actions	action	nn2_vvz@
where	where	rrq_cs
the	the	at
device	device	nn1
complies	comply	vvz
with	with	iw
FDA	fda	nn1_np1
regulations.	regulations	nnu
n228	n228	fo
This	this	dd1
practice	practice	nn1
has	have	vhz
the	the	at
benefit	benefit	nn1
of	of	io
reducing	reduce	vvg_jj@
uncertainty	uncertainty	nn1
over	over	ii
Congressional	congressional	jj
intent	intent	nn1_jj
;	;	y
it	it	pph1
may	may	vm
still	still	rr
,	,	y
however	however	rr
,	,	y
leave	leave	vv0_nn1
questions	question	nn2
over	over	ii
the	the	at
scope	scope	nn1
of	of	io
the	the	at
preemption.	preemption	nnu
(	(	y
n229	n229	fo
)	)	y
<p>	<p>	y
In	in	ii
other	other	jj
cases	case	nn2
,	,	y
preemption	preemption	nn1
can	can	vm
be	be	vbi
implied	imply	vvn
through	through	ii
the	the	at
purpose	purpose	nn1
or	or	cc
structure	structure	nn1
of	of	io
the	the	at
federal	federal	jj
law.	law	nnu
n230	n230	fo
Such	such	da
"	"	y
implied	implied	jj@
preemption	preemption	nn1
"	"	y
occurs	occur	vvz
in	in	ii
three	three	mc
situations	situation	nn2
:	:	y
(	(	y
1	1	mc1
)	)	y
"	"	y
field	field	nn1_vv0@
preemption	preemption	nn1
,	,	y
"	"	y
in	in	ii
which	which	ddq
Congress	congress	nn1
intends	intend	vvz
to	to	to
occupy	occupy	vvi
an	a	at1
entire	entire	jj
regulatory	regulatory	jj
field	field	nn1
,	,	y
leaving	leave	vvg
no	no	at
room	room	nn1
for	for	if
state	state	nn1
lawmaking	lawmaking	vvg_nn1@
;	;	y
n231	n231	fo
(	(	y
2	2	mc
)	)	y
"	"	y
conflict	conflict	nn1_vv0@
preemption	preemption	nn1
,	,	y
"	"	y
in	in	ii
which	which	ddq
"	"	y
compliance	compliance	nn1
with	with	iw
both	both	db2_rr
federal	federal	jj
and	and	cc
state	state	vv0_nn1
regulations	regulation	nn2
is	be	vbz
a	a	at1
physical	physical	jj
impossibility	impossibility	nn1
"	"	y
;	;	y
n232	n232	fo
and	and	cc
(	(	y
3	3	mc
)	)	y
"	"	y
obstacle	obstacle	nn1
preemption	preemption	nn1
,	,	y
"	"	y
in	in	ii
which	which	ddq
state	state	vv0_nn1
law	law	nn1
"	"	y
stands	stand	vvz_nn2
as	as	ii_csa
an	a	at1
obstacle	obstacle	nn1
to	to	ii
the	the	at
accomplishment	accomplishment	nn1
and	and	cc
execution	execution	nn1
of	of	io
the	the	at
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
practice	practice	nn1
,	,	y
only	only	rr
the	the	at
latter	latter	da
two	two	mc
forms	form	nn2
apply	apply	vv0
to	to	ii
prescription	prescription	nn1
drugs	drug	nn2
as	as	ii_csa
no	no	at
court	court	nn1
has	have	vhz
yet	yet	rr
found	find	vvn
implied	implied	jj@
field	field	nn1
preemption	preemption	nn1
for	for	if
the	the	at
FDA	fda	np1_nn1
's	's	ge
regulation	regulation	nn1
of	of	io
drugs	drug	nn2
and	and	cc
medical	medical	jj
devices.	devices	nnu
n234	n234	fo
These	these	dd2
two	two	mc
forms	form	nn2
are	be	vbr
generally	generally	rr
joined	join	vvn_vvd
together	together	rl
by	by	ii
courts	court	nn2
and	and	cc
commentators	commentator	nn2
under	under	ii
the	the	at
term	term	nn1
"	"	y
conflict	conflict	nn1
preemption	preemption	nn1
"	"	y
despite	despite	ii
distinct	distinct	jj
inquiries	inquiry	nn2
of	of	io
analysis.	analysis	nnu
n235	n235	fo
Because	because	cs
express	express	jj@
preemption	preemption	nn1
is	be	vbz
relatively	relatively	rr
clear	clear	rr
cut	cut	vvn
in	in	ii
most	most	dat
instances	instance	nn2
and	and	cc
field	field	nn1
preemption	preemption	nn1
is	be	vbz
not	not	xx
yet	yet	rr
recognized	recognize	vvn_vvd
for	for	if
the	the	at
FDA	fda	np1_nn1
's	's	ge
regulatory	regulatory	jj
coverage	coverage	nn1
,	,	y
implied	imply	vvd_jj@_vvn
conflict	conflict	nn1
preemption	preemption	nn1
principles	principle	nn2
represent	represent	vv0
the	the	at
common	common	jj
method	method	nn1
for	for	if
recognizing	recognize	vvg
preemption	preemption	nn1
in	in	ii
pharmaceutical	pharmaceutical	jj
regulations	regulation	nn2
.	.	y
<p>	<p>	y
2	2	mc
.	.	y
The	the	at
FDA	fda	np1_nn1
's	's	ge
Changing	changing	jj
Priorities	priority	nn2
in	in	ii
a	a	at1
DTC	dtc	np1
Environment	environment	nn1
In	in	ii
recent	recent	jj
years	year	nnt2
,	,	y
the	the	at
FDA	fda	nn1_np1
has	have	vhz
increasingly	increasingly	rr
recognized	recognize	vvn
implied	implied	jj@
conflict	conflict	nn1
preemption	preemption	nn1
of	of	io
state	state	nn1
tort	tort	nn1
claims	claim	vvz_nn2
as	as	ii
a	a	at1
result	result	nn1
of	of	io
its	its	z'
regulations	regulation	nn2
and	and	cc
decision	decision	nn1
making.	making	nnu
n236	n236	fo
Since	since	ii
2000	2000	mc
,	,	y
the	the	at
agency	agency	nn1
has	have	vhz
filed	file	vvn
a	a	at1
number	number	nn1
of	of	io
amicus	amicus	nn1
curiae	curia	nn2
briefs	brief	nn2_vvz@
arguing	argue	vvg
that	that	cst
its	its	z'
regulatory	regulatory	jj
interpretations	interpretation	nn2
support	support	vv0
a	a	at1
finding	finding	nn1
of	of	io
preemption.	preemption	nnu
n237	n237	fo
As	as	csa_ii@
amicus	amicus	nn1
,	,	y
the	the	at
FDA	fda	nn1_np1
takes	take	vvz
the	the	at
clear	clear	jj
position	position	nn1
that	that	cst_dd1
,	,	y
under	under	ii
the	the	at
agency	agency	nn1
's	's	ge_vbz
comprehensive	comprehensive	jj
regulatory	regulatory	jj
scheme	scheme	nn1
,	,	y
a	a	at1
drug	drug	nn1
manufacturer	manufacturer	nn1
can	can	vm
not	not	xx
unilaterally	unilaterally	rr
strengthen	strengthen	vvi
a	a	at1
drug	drug	nn1
warning	warning	nn1_vvg@
without	without	iw
FDA	fda	nn1_np1
approval.	approval	nnu
n238	n238	fo
This	this	dd1
view	view	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
"	"	y
its	its	z'
"	"	y
thorough	thorough	jj
understanding	understanding	nn1
of	of	io
its	its	z'
own	own	da
regulation	regulation	nn1
,	,	y
"	"	y
and	and	cc
its	its	z'
"	"	y
uniquely	uniquely	rr
qualified	qualified	jj_vvn
"	"	y
position	position	nn1
to	to	to
"	"	y
comprehend	comprehend	vvi
the	the	at
likely	likely	jj
impact	impact	nn1
of	of	io
state	state	nn1
requirements	requirement	nn2
.	.	y
"	"	y
(	(	y
n239	n239	fo
)	)	y
<p>	<p>	y
In	in	ii
2006	2006	mc
,	,	y
the	the	at
FDA	fda	np1_nn1
issued	issue	vvd_vvn
a	a	at1
Preamble	preamble	nn1
to	to	ii
a	a	at1
rule	rule	nn1
updating	update	vvg
and	and	cc
strengthening	strengthen	vvg_nn1
prescription	prescription	nn1
drug	drug	nn1
labeling	label	vvg_nn1@
requirements	requirement	nn2
,	,	y
which	which	ddq
expressed	express	vvd
its	its	z'
view	view	nn1
that	that	cst
several	several	da2
types	type	nn2
of	of	io
product	product	nn1
liability	liability	nn1
claims	claim	nn2
were	be	vbdr
preempted	preempt	vvn
by	by	ii
federal	federal	jj
regulation.	regulation	nnu
n240	n240	fo
The	the	at
agency	agency	nn1
explained	explain	vvd_vvn
that	that	cst
these	these	dd2
claims	claim	nn2
either	either	rr
stood	stand	vvd_vvn@
as	as	ii
an	a	at1
obstacle	obstacle	nn1
to	to	ii
carrying	carry	vvg
out	out	rp
its	its	z'
mission	mission	nn1
or	or	cc
conflicted	conflict	vvd_vvn@
with	with	iw
the	the	at
FDA	fda	np1_nn1
's	's	ge
decision-making	decision-making	jj_nn1
authority	authority	nn1
.	.	y
Specifically	specifically	rr
,	,	y
the	the	at
Preamble	preamble	nn1
states	state	vvz_nn2
that	that	cst_dd1
"	"	y
FDA	fda	np1_nn1
approval	approval	nn1
of	of	io
labeling	label	vvg
under	under	ii
the	the	at
new	new	jj
guidelines	guideline	nn2
...	...	...
preempts	preempt	vvz_nn2
conflicting	conflicting	jj
or	or	cc
contrary	contrary	jj_nn1
State	state	nn1
law	law	nn1
,	,	y
regulations	regulation	nn2
,	,	y
or	or	cc
decisions	decision	nn2
of	of	io
a	a	at1
court	court	nn1
of	of	io
law	law	nn1
for	for	if
purposes	purpose	nn2
of	of	io
product	product	nn1
liability	liability	nn1
litigation	litigation	nn1
.	.	y
"	"	y
n241	n241	fo
The	the	at
Preamble	preamble	nn1
emphasizes	emphasize	vvz
the	the	at
agency	agency	nn1
's	be	vbz
"	"	y
statutorily	statutorily	rr
prescribed	prescribed	jj_vvn
role	role	nn1
as	as	ii_csa
the	the	at
expert	expert	nn1_jj@
Federal	federal	jj
agency	agency	nn1
responsible	responsible	jj
for	for	if
evaluating	evaluate	vvg
and	and	cc
regulating	regulate	vvg
drugs	drug	nn2
,	,	y
"	"	y
n242	n242	fo
and	and	cc
cautions	caution	vvz_nn2
that	that	cst_dd1
state	state	vv0_nn1
tort	tort	nn1_vv0
actions	action	nn2
can	can	vm
"	"	y
encourage	encourage	vv0
,	,	y
and	and	cc
in	in	ii
fact	fact	nn1
require	require	vv0
,	,	y
lay	lay	vvd_vv0_jj@
judges	judge	nn2
and	and	cc
juries	jury	nn2
to	to	ii
second	second	nnt1_md
guess	guess	vv0
the	the	at
assessment	assessment	nn1
of	of	io
benefits	benefit	nn2
versus	versus	ii
risks	risk	nn2
of	of	io
a	a	at1
specific	specific	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	to
add	add	vvi
warnings	warning	nn2
...	...	...
and	and	cc
to	to	to
propose	propose	vvi
'	'	ge
defensive	defensive	jj
labeling	labeling	nn1@
'	'	ge
...	...	...
which	which	ddq
,	,	y
if	if	cs
implemented	implement	vvn
,	,	y
could	could	vm
result	result	vvi
in	in	ii
scientifically	scientifically	rr
unsubstantiated	unsubstantiated	jj
warnings	warning	nn2
and	and	cc
underutilization	underutilization	nn1
of	of	io
beneficial	beneficial	jj
treatments	treatment	nn2
.	.	y
"	"	y
n243	n243	fo
The	the	at
Preamble	preamble	nn1
cites	cite	vvz
six	six	mc
instances	instance	nn2
where	where	rrq_cs
preemption	preemption	nn1
should	should	vm
be	be	vbi
implied.	implied	nnu
n244	n244	fo
Hence	hence	rr
,	,	y
although	although	cs
still	still	rr
acknowledging	acknowledge	vvg
that	that	dd1_cst
"	"	y
FDA	fda	nn1_np1
labeling	label	vvg_jj@_nn1@
requirements	requirement	nn2
represent	represent	vv0
a	a	at1
minimum	minimum	jj_nn1
safety	safety	nn1
standard	standard	nn1
,	,	y
"	"	y
the	the	at
FDA	fda	np1_nn1
interpreted	interpret	vvd
its	its	z'
comprehensive	comprehensive	jj
regulatory	regulatory	jj
procedures	procedure	nn2
as	as	csa_ii@
creating	create	vvg
"	"	y
both	both	rr
a	a	at1
"	"	y
floor	floor	nn1
'	'	ge
and	and	cc
a	a	at1
'	'	ge
ceiling	ceiling	nn1
'	'	ge
"	"	y
for	for	if
the	the	at
imposition	imposition	nn1
of	of	io
liability.	liability	nnu
(	(	y
n245	n245	fo
)	)	y
<p>	<p>	y
The	the	at
Preamble	preamble	nn1
sparked	spark	vvd_vvn
debate	debate	nn1
over	over	ii
the	the	at
FDA	fda	np1_nn1
's	's	ge
role	role	nn1
in	in	ii
regulating	regulate	vvg
drugs	drug	nn2
n246	n246	fo
and	and	cc
the	the	at
relative	relative	jj_nn1
deference	deference	nn1
a	a	at1
court	court	nn1
should	should	vm
afford	afford	vvi
an	a	at1
agency	agency	nn1
's	's	ge
interpretation	interpretation	nn1
of	of	io
the	the	at
scope	scope	nn1
of	of	io
preemption	preemption	nn1
as	as	csa
expressed	express	vvn
in	in	ii
a	a	at1
preamble.		nnu
n247	n247	fo
Courts	court	nn2
have	have	vh0
varied	vary	vvn
in	in	ii
the	the	at
deference	deference	nn1
given	give	vvn
to	to	ii
the	the	at
FDA	fda	np1_nn1
's	's	ge
view.	view	nnu
n248	n248	fo
In	in	ii
past	past	jj_nn1
decisions	decision	nn2
,	,	y
the	the	at
Supreme	supreme	jj
Court	court	nn1
has	have	vhz
expressed	express	vvn
the	the	at
view	view	nn1
that	that	cst_dd1
agency	agency	nn1
statements	statement	nn2
warrant	warrant	vv0
some	some	dd
degree	degree	nn1
of	of	io
deference	deference	nn1
.	.	y
For	for	rex21
example	example	rex22
,	,	y
in	in	ii
Medtronic	medtronic	jj
,	,	y
Inc.	inc	jj
v.	xx_v	ii
Lohr	lohr	np1_nn1
,	,	y
a	a	at1
medical	medical	jj
device	device	nn1
case	case	nn1
,	,	y
Justice	justice	np1@_nn1
Breyer	breyer	np1
's	's	ge
concurrence	concurrence	nn1
noted	note	vvd_vvn
,	,	y
"	"	y
in	in	ii
the	the	at
absence	absence	nn1
of	of	io
a	a	at1
clear	clear	jj
congressional	congressional	jj
command	command	nn1
as	as	ii21
to	to	ii22
preemption	preemption	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
a	a	at1
degree	degree	nn1
of	of	io
leeway	leeway	nn1
to	to	to
determine	determine	vvi
which	which	ddq
rules	rule	vvz@_nn2
,	,	y
regulations	regulation	nn2
,	,	y
or	or	cc
other	other	jj
administrative	administrative	jj
actions	action	nn2
will	will	vm
have	have	vhi
pre-emptive	pre-emptive	jj
effect	effect	nn1
.	.	y
"	"	y
n249	n249	fo
Likewise	likewise	rr
,	,	y
in	in	ii
Hillsborough	hillsborough	np1
County	county	nn1
v.	xx_v	ii
Automated	automated	jj
Medical	medical	jj
Laboratories	laboratory	nn2
,	,	y
Inc.	inc	jj
,	,	y
the	the	at
Court	court	nn1
recognized	recognize	vvd_vvn
that	that	cst
"	"	y
because	because	cs
agencies	agency	nn2
normally	normally	rr
address	address	vv0@_nn1
problems	problem	nn2
in	in	ii
a	a	at1
detailed	detailed	jj
manner	manner	nn1
and	and	cc
can	can	vm
speak	speak	vvi
through	through	ii_rp@
a	a	at1
variety	variety	nn1
of	of	io
means	mean	nn
,	,	y
including	including	ii_vvg@
regulations	regulation	nn2
,	,	y
preambles	preamble	nn2
,	,	y
interpretative	interpretative	jj
statements	statement	nn2
,	,	y
and	and	cc
responses	response	nn2
to	to	ii
comments	comment	nn2
,	,	y
we	we	ppis2
can	can	vm
expect	expect	vvi
that	that	cst
they	they	pphs2
will	will	vm
make	make	vvi
their	their	appge
intentions	intention	nn2
clear	clear	vvi
if	if	csw@_cs
they	they	pphs2
intend	intend	vv0
for	for	if
their	their	appge
regulations	regulation	nn2
to	to	to
be	be	vbi
exclusive	exclusive	jj
.	.	y
"	"	y
(	(	y
n250	n250	fo
)	)	y
<p>	<p>	y
Although	although	cs
the	the	at
Court	court	nn1
has	have	vhz
not	not	xx
yet	yet	rr
directly	directly	rr
addressed	address	vvd_vvn
the	the	at
preemptive	pre-emptive	jj
effect	effect	nn1
of	of	io
the	the	at
FDA	fda	np1_nn1
's	's	ge
regulation	regulation	nn1
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
or	or	cc
the	the	at
level	level	nn1
of	of	io
deference	deference	nn1
to	to	to
be	be	vbi
accorded	accord	vvn
to	to	ii
the	the	at
FDA	fda	np1_nn1
's	's	ge
view	view	nn1
,	,	y
the	the	at
Court	court	nn1
's	's	ge
consideration	consideration	nn1
of	of	io
Levine	levine	np1_nn1@
v.	xx_v	ii
Wyeth	wyeth	np1
is	be	vbz
likely	likely	jj
to	to	to
shine	shine	vvi
significant	significant	jj
light	light	nn1
on	on	ii
these	these	dd2
issues	issue	nn2
as	as	ii31
well	well	ii32
as	as	ii33
the	the	at
modem	modem	nn1
role	role	nn1
of	of	io
the	the	at
FDA.	fda	np1
n251	n251	fo
In	in	ii
Levine	levine	np1
,	,	y
the	the	at
plaintiff	plaintiff	nn1
went	go	vvd
to	to	ii
the	the	at
hospital	hospital	nn1
for	for	if
treatment	treatment	nn1
of	of	io
a	a	at1
serious	serious	jj
migraine	migraine	nn1
headache	headache	nn1
and	and	cc
,	,	y
after	after	cs_ii
injection	injection	nn1
with	with	iw
the	the	at
drug	drug	nn1
Phenergan	phenergan	np1_nn1@
,	,	y
was	be	vbdz
left	leave	vvn
with	with	iw
injuries	injury	nn2
that	that	cst
led	lead	vvd
to	to	ii
the	the	at
amputation	amputation	nn1
of	of	io
her	her	appge_ppho1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
intravenous	intravenous	jj
(	(	y
IV	iv	mc
)	)	y
injection	injection	nn1
,	,	y
a	a	at1
risk	risk	nn1
the	the	at
FDA	fda	nn1_np1
had	have	vhd
closely	closely	rr
considered	consider	vvn
when	when	cs
deeming	deem	vvg
the	the	at
anti-nausea	anti-nausea	jj_nn1
medication	medication	nn1
safe	safe	nn1@_jj
for	for	if
use.	use	nnu
n253	n253	fo
The	the	at
agency	agency	nn1
approved	approve	vvd_vvn
a	a	at1
warning	warning	nn1
cautioning	caution	vvg
against	against	ii
inadvertent	inadvertent	jj_nn1
injection	injection	nn1
and	and	cc
providing	provide	vvg
instructions	instruction	nn2
to	to	to
minimize	minimize	vvi
the	the	at
risk	risk	nn1
but	but	ccb
chose	choose	vvd
not	not	xx
to	to	to
prohibit	prohibit	vvi
IV	iv	mc
push	push	vv0_nn1@
as	as	ii
a	a	at1
means	mean	nn
of	of	io
administration.	administration	nnu
n254	n254	fo
In	in	ii
fact	fact	nn1
,	,	y
Wyeth	wyeth	np1
asked	ask	vvd
the	the	at
FDA	fda	nn1_np1
in	in	ii
2000	2000	mc
to	to	to
alter	alter	vvi
the	the	at
warning	warning	nn1
to	to	to
place	place	vvi
greater	great	jjr
emphasis	emphasis	nn1
on	on	ii
the	the	at
risk	risk	nn1
at	at	ii
issue	issue	nn1
,	,	y
but	but	ccb
the	the	at
FDA	fda	np1_nn1
indicated	indicate	vvd
the	the	at
warning	warning	nn1
should	should	vm
remain	remain	vvi
unaltered.		nnu
n255	n255	fo
Wyeth	wyeth	np1_vvz
acquiesced	acquiesce	vvd_vvn
and	and	cc
the	the	at
warning	warning	nn1
was	be	vbdz
unchanged	unchanged	jj
leading	leading	jj_vvg
up	up	ii21
to	to	ii22
the	the	at
state	state	nn1
lawsuit	lawsuit	nn1
.	.	y
<p>	<p>	y
The	the	at
Vermont	vermont	np1
Supreme	supreme	jj
Court	court	nn1
found	find	vvd_vvn
that	that	cst_dd1
FDA	fda	np1_nn1
compliance	compliance	nn1
is	be	vbz
only	only	rr
a	a	at1
minimum	minimum	jj_nn1
standard	standard	nn1_jj
and	and	cc
referred	refer	vvn_vvd
to	to	ii
FDA	fda	np1_nn1
approval	approval	nn1
as	as	csa_rg@
simply	simply	rr
a	a	at1
"	"	y
first	first	md
step	step	nn1_vv0
"	"	y
in	in	ii
pharmaceutical	pharmaceutical	jj
labeling.	labeling	nnu
n256	n256	fo
The	the	at
court	court	nn1
rejected	reject	vvd_vvn
both	both	rr
conflict	conflict	vv0@_nn1
and	and	cc
obstacle	obstacle	nn1
preemption	preemption	nn1
,	,	y
concluding	conclude	vvg
that	that	cst
the	the	at
manufacturer	manufacturer	nn1
was	be	vbdz
"	"	y
free	free	jj
"	"	y
to	to	to
supplement	supplement	vvi
or	or	cc
strengthen	strengthen	vvi
warnings	warning	nn2
at	at	ii
any	any	dd
time.	time	nnu
n257	n257	fo
The	the	at
court	court	nn1
also	also	rr
acknowledged	acknowledge	vvd_vvn
the	the	at
FDA	fda	nn1_np1
Preamble	preamble	nn1
,	,	y
yet	yet	rr
held	hold	vvn_vvd
that	that	cst_dd1
"	"	y
irrespective	irrespective	ii21
of	of	ii22
the	the	at
level	level	nn1
of	of	io
deference	deference	nn1
it	it	pph1
might	might	vm
apply	apply	vvi
,	,	y
the	the	at
statement	statement	nn1
would	would	vm
not	not	xx
affect	affect	vvi
the	the	at
outcome	outcome	nn1
of	of	io
the	the	at
appeal	appeal	nn1
,	,	y
"	"	y
and	and	cc
further	far	rrr
stated	state	vvn_vvd
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
(	(	y
n258	n258	fo
)	)	y
<p>	<p>	y
The	the	at
Solicitor	solicitor	nn1
General	general	nn1
,	,	y
in	in	ii
a	a	at1
brief	brief	jj
as	as	csa_ii@
amicus	amicus	nn1
curiae	curia	nn2
filed	file	vvn_vvd
at	at	ii
the	the	at
invitation	invitation	nn1
of	of	io
the	the	at
U.S.	us	np1
Supreme	supreme	jj
Court	court	nn1
,	,	y
disagreed	disagree	vvd
with	with	iw
the	the	at
Vermont	vermont	np1
ruling.	ruling	nnu
n259	n259	fo
The	the	at
Solicitor	solicitor	nn1
recognized	recognize	vvd_vvn
that	that	dd1_cst
labeling	labeling	nn1@_vvg
is	be	vbz
an	a	at1
inextricable	inextricable	jj
component	component	nn1
of	of	io
the	the	at
approval	approval	nn1
process	process	nn1_vv0
,	,	y
noting	note	vvg
that	that	cst
the	the	at
FDA	fda	nn1_np1
may	may	vm
convey	convey	vvi
to	to	ii
physicians	physician	nn2
and	and	cc
their	their	appge
patients	patient	nn2
the	the	at
conditions	condition	nn2
under	under	ii
which	which	ddq
the	the	at
potential	potential	jj_nn1
benefits	benefit	nn2
of	of	io
the	the	at
product	product	nn1
exceed	exceed	vv0
its	its	z'
risks	risk	nn2
,	,	y
while	while	cs
not	not	xx
unnecessarily	unnecessarily	rr
deterring	deter	vvg
beneficial	beneficial	jj
uses.	use	nnu
n260	n260	fo
"	"	y
If	if	cs
manufacturers	manufacturer	nn2
were	be	vbdr
free	free	jj
to	to	to
make	make	vvi
unilateral	unilateral	jj
changes	change	nn2
to	to	ii
labeling	label	vvg
the	the	at
day	day	nnt1
after	after	ii_cs
FDA	fda	np1
's	's	ge
approval	approval	nn1
,	,	y
based	base	vvn
on	on	ii
information	information	nn1
that	that	cst_dd1
was	be	vbdz
previously	previously	rr
available	available	jj
to	to	ii
FDA	fda	np1_nn1
,	,	y
the	the	at
approval	approval	nn1
process	process	nn1
would	would	vm
be	be	vbi
greatly	greatly	rr
undermined	undermine	vvn_vvd
and	and	cc
the	the	at
agency	agency	nn1
's	's	ge
careful	careful	jj
balancing	balancing	nn1@
of	of	io
risks	risk	nn2
and	and	cc
benefits	benefit	nn2
thwarted	thwart	vvd_vvn
.	.	y
"	"	y
n261	n261	fo
Having	have	vhg
granted	grant	vvn
certiorari	certiorari	nn2
,	,	y
the	the	at
Court	court	nn1
will	will	vm
decide	decide	vvi
whether	whether	csw
FDA-approved	fda-approved	jj
warnings	warning	nn2
are	be	vbr
merely	merely	rr
a	a	at1
floor	floor	nn1
,	,	y
as	as	csa
suggested	suggest	vvn
by	by	ii
the	the	at
Vermont	vermont	np1
Supreme	supreme	jj
Court	court	nn1
,	,	y
or	or	cc
both	both	rr
floor	floor	nn1
and	and	cc
ceiling	ceiling	nn1
,	,	y
as	as	csa
argued	argue	vvn
by	by	ii
the	the	at
Solicitor	solicitor	nn1
General.	general	zz
(	(	y
n262	n262	fo
)	)	y
<p>	<p>	y
Other	other	jj
courts	court	nn2
have	have	vh0
found	find	vvn
that	that	cst_dd1
state	state	vv0_nn1
tort	tort	nn1_vv0
law	law	nn1
claims	claim	vvz_nn2
challenging	challenging	jj_vvg
conduct	conduct	nn1
in	in	ii
compliance	compliance	nn1
with	with	iw
FDA	fda	nn1_np1
requirements	requirement	nn2
are	be	vbr
preempted	preempt	vvn@_jj@
.	.	y
For	for	rex21
instance	instance	rex22
,	,	y
a	a	at1
federal	federal	jj
district	district	nn1
court	court	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	ii
an	a	at1
anti-depression	anti-depression	nn1_jj
and	and	cc
anti-anxiety	anti-anxiety	jj_nn1
drug	drug	nn1
's	's	ge
(	(	y
Paxil	paxil	np1
)	)	y
risk	risk	nn1
of	of	io
suicide	suicide	nn1
,	,	y
and	and	cc
found	find	vvd
them	them	ppho2
to	to	to
be	be	vbi
preempted.	preempted	nnu
n263	n263	fo
The	the	at
case	case	nn1
,	,	y
which	which	ddq
also	also	rr
involved	involve	vvd_vvn
the	the	at
drug	drug	nn1
's	's	ge
generic	generic	jj
versions	version	nn2
,	,	y
examined	examine	vvd_vvn
the	the	at
FDA	fda	np1_nn1
's	's	ge
position	position	nn1
on	on	ii
preemption	preemption	nn1
,	,	y
holding	hold	vvg
that	that	cst
it	it	pph1
is	be	vbz
"	"	y
abundantly	abundantly	rr
clear	clear	vv0@_jj
"	"	y
that	that	cst_dd1
such	such	da
evidence	evidence	nn1
of	of	io
intent	intent	nn1
is	be	vbz
entitled	entitle	vvn
to	to	ii
"	"	y
significant	significant	jj
deference	deference	nn1
.	.	y
"	"	y
n264	n264	fo
Similarly	similarly	rr
,	,	y
a	a	at1
federal	federal	jj
district	district	nn1
court	court	nn1
in	in	ii
California	california	np1
reached	reach	vvd
a	a	at1
similar	similar	jj
determination	determination	nn1
and	and	cc
preempted	preempted	jj@_vvd
state	state	nn1
claims	claim	nn2_vvz
for	for	if
failure	failure	nn1
to	to	to
warn	warn	vvi
of	of	io
the	the	at
drug	drug	nn1
Celebrex	celebrex	np1_nn1
's	's	ge_vbz
cardiovascular	cardiovascular	jj
risks.	risk	nnu
(	(	y
n265	n265	fo
)	)	y
<p>	<p>	y
Armed	arm	vvn_jj
with	with	iw
evidence	evidence	nn1
of	of	io
the	the	at
FDA	fda	np1_nn1
's	's	ge
understanding	understanding	nn1
of	of	io
the	the	at
scope	scope	nn1
of	of	io
preemption	preemption	nn1
,	,	y
a	a	at1
growing	growing	jj
number	number	nn1
of	of	io
courts	court	nn2
acknowledge	acknowledge	vv0
implied	implied	jj@
conflict	conflict	nn1
preemption	preemption	nn1
in	in	ii
drug	drug	nn1
warnings	warning	nn2
.	.	y
Although	although	cs
this	this	dd1
development	development	nn1
is	be	vbz
gradual	gradual	jj
and	and	cc
uneven	uneven	jj
,	,	y
it	it	pph1
signals	signal	vvz@
a	a	at1
renewed	renewed	jj
viability	viability	nn1
of	of	io
implied	implied	jj@
preemption	preemption	nn1
as	as	ii_csa
a	a	at1
final	final	jj_nn1
,	,	y
constitutional	constitutional	jj
check	check	nn1
on	on	ii
the	the	at
sufficiency	sufficiency	nn1
of	of	io
drug	drug	nn1
warnings	warning	nn2
.	.	y
<p>	<p>	y
Federal	federal	jj
law	law	nn1
may	may	vm
not	not	xx
only	only	rr
preclude	preclude	vvi
state	state	nn1
product	product	nn1
liability	liability	nn1
claims	claim	nn2_vvz
,	,	y
but	but	ccb
it	it	pph1
may	may	vm
also	also	rr
preempt	preempt	vvi
CPA	cpa	nn1_np1
claims	claim	nn2_vvz
.	.	y
For	for	rex21
example	example	rex22
,	,	y
in	in	ii
Pennsylvania	pennsylvania	np1
Employees	employee	nn2
Benefit	benefit	vv0
Trust	trust	nn1_vv0
Fund	fund	nn1
v.	xx_v	ii
Zeneca	zeneca	np1
,	,	y
Inc.	inc	jj
,	,	y
the	the	at
plaintiffs	plaintiff	nn2
claimed	claim	vvd_vvn
that	that	cst
the	the	at
manufacturer	manufacturer	nn1
of	of	io
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Nexium	nexium	np1_nn1
was	be	vbdz
superior	superior	jj
to	to	ii
Prilosec.		np1
n266	n266	fo
Both	both	db2
drugs	drug	nn2
treat	treat	vv0
acid	acid	nn1
reflux	reflux	nn1
disease	disease	nn1
and	and	cc
frequent	frequent	jj
heartburn	heartburn	nn1
.	.	y
Delaware	delaware	np1
's	's	ge
consumer	consumer	nn1
protection	protection	nn1
law	law	nn1
exempts	exempt	vvz
advertising	advertising	nn1
or	or	cc
mechanizing	mechanize	vvg_jj@
practices	practice	nn2
that	that	cst
comply	comply	vv0
with	with	iw
the	the	at
rules	rule	nn2
and	and	cc
regulations	regulation	nn2
of	of	io
the	the	at
FTC	ftc	np1
,	,	y
but	but	ccb
does	do	vdz
not	not	xx
contain	contain	vvi
a	a	at1
general	general	jj
regulatory	regulatory	jj
compliance	compliance	nn1
exemption	exemption	nn1
for	for	if
conduct	conduct	nn1
in	in	ii
compliance	compliance	nn1
with	with	iw
the	the	at
rules	rule	nn2
of	of	io
other	other	jj
government	government	nn1
agencies.	agencies	nnu
n267	n267	fo
The	the	at
Third	third	md
Circuit	circuit	nn1
,	,	y
although	although	cs
noting	note	vvg
that	that	cst
the	the	at
FTC	ftc	np1
and	and	cc
FDA	fda	np1_nn1
initially	initially	rr
had	have	vhn@_vhd
concurrent	concurrent	jj
jurisdiction	jurisdiction	nn1
over	over	ii
prescription	prescription	nn1
drug	drug	nn1
advertising	advertising	nn1
,	,	y
declined	decline	vvd_vvn
to	to	to
extend	extend	vvi
the	the	at
clear	clear	jj
statutory	statutory	jj
language	language	nn1
to	to	to
conduct	conduct	vvi
that	that	cst_dd1
now	now	rt
falls	fall	vvz
exclusively	exclusively	rr
within	within	ii
the	the	at
FDA	fda	np1_nn1
's	's	ge
jurisdiction.	jurisdiction	nnu
n268	n268	fo
The	the	at
court	court	nn1
found	find	vvd_vvn
,	,	y
however	however	rr
,	,	y
that	that	cst
the	the	at
purpose	purpose	nn1
of	of	io
the	the	at
Food	food	nn1
,	,	y
Drug	drug	nn1
,	,	y
and	and	cc
Cosmetic	cosmetic	jj
Act	act	nn1
"	"	y
would	would	vm
be	be	vbi
frustrated	frustrate	vvn
if	if	cs_csw@
states	state	nn2
were	be	vbdr
allowed	allow	vvn
to	to	to
interpose	interpose	vvi
consumer	consumer	nn1
fraud	fraud	nn1
laws	law	nn2
that	that	cst
permitted	permit	vvd_jj@
plaintiffs	plaintiff	nn2
to	to	to
question	question	vvi
the	the	at
veracity	veracity	nn1
of	of	io
statements	statement	nn2
approved	approve	vvn
by	by	ii
the	the	at
FDA.	fda	np1
"	"	y
n269	n269	fo
Thus	thus	rr
,	,	y
the	the	at
court	court	nn1
found	find	vvd_vvn
claims	claim	nn2
under	under	ii
Delaware	delaware	np1
's	's	ge
consumer	consumer	nn1
protection	protection	nn1
law	law	nn1
challenging	challenging	jj_vvg
labeling	labeling	nn1@_jj@_vvg
or	or	cc
advertising	advertising	nn1
of	of	io
FDA-approved	fda-approved	jj_nn1
prescription	prescription	nn1
drugs	drug	nn2
implicitly	implicitly	rr
preempted.	preempted	nnu
(	(	y
n270	n270	fo
)	)	y
<p>	<p>	y
3	3	mc
.	.	y
Public	public	jj_nn1
Policy	policy	nn1
Supports	support	vvz_nn2
Expanding	expanding	jj_vvg
Scope	scope	nn1
of	of	io
Preemption	preemption	nn1_np1@
The	the	at
FDA	fda	np1_nn1
's	's	ge
interpretation	interpretation	nn1
of	of	io
the	the	at
scope	scope	nn1
of	of	io
implied	implied	jj@
preemption	preemption	nn1
appears	appear	vvz
cognizant	cognizant	nn1_jj
of	of	io
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
scale	scale	nn1
and	and	cc
complexity	complexity	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
production	production	nn1
reaches	reach	vvz
new	new	jj
heights	height	nn2
,	,	y
the	the	at
need	need	nn1
for	for	if
comprehensive	comprehensive	jj
federal	federal	jj
regulation	regulation	nn1
becomes	become	vvz
increasingly	increasingly	rr
imperative.	imperative	nnu
n271	n271	fo
Greater	greater	np1
recognition	recognition	nn1
of	of	io
federal	federal	jj
preemption	preemption	nn1
helps	help	vvz
to	to	to
achieve	achieve	vvi
the	the	at
objectives	objective	nn2
of	of	io
such	such	da
regulation	regulation	nn1
by	by	ii
assuring	assure	vvg
definitive	definitive	jj
and	and	cc
uniform	uniform	jj_nn1
application	application	nn1
.	.	y
Further	far	rrr_jjr
,	,	y
preemption	preemption	nn1
serves	serve	vvz
public	public	jj
policy	policy	nn1
goals	goal	nn2
of	of	io
predictability	predictability	nn1
and	and	cc
fundamental	fundamental	jj
fairness	fairness	nn1
by	by	ii
informing	inform	vvg
pharmaceutical	pharmaceutical	jj
participants	participant	nn2
of	of	io
their	their	appge
complete	complete	jj
set	set	nn1
of	of	io
legal	legal	jj
obligations	obligation	nn2
rather	rather	ii21_cs21@
than	than	ii22_cs22@
simply	simply	rr
setting	set	vvg
a	a	at1
floor	floor	nn1
and	and	cc
forcing	force	vvg
manufacturers	manufacturer	nn2
to	to	to
abide	abide	vvi
by	by	ii
fifty	fifty	mc
different	different	jj
state	state	nn1
law	law	nn1
interpretations.	interpretation	nnu
(	(	y
n272	n272	fo
)	)	y
<p>	<p>	y
From	from	ii
a	a	at1
practical	practical	jj
standpoint	standpoint	nn1
,	,	y
the	the	at
FDA	fda	np1_nn1
's	's	ge
interpretation	interpretation	nn1
is	be	vbz
a	a	at1
logical	logical	jj
,	,	y
perhaps	perhaps	rr
inevitable	inevitable	jj
,	,	y
step	step	vv0_nn1
toward	toward	ii
meeting	meet	vvg
its	its	z'
congressional	congressional	jj
mandate	mandate	nn1
as	as	ii_csa
the	the	at
federal	federal	jj
agency	agency	nn1
responsible	responsible	jj
for	for	if
regulating	regulate	vvg
drugs.	drug	nnu
n273	n273	fo
The	the	at
FDCA	fdca	nn1_np1
,	,	y
originally	originally	rr
enacted	enact	vvn_vvd
in	in	ii
1938	1938	mc
,	,	y
does	do	vdz
not	not	xx
contain	contain	vvi
express	express	jj@
preemption	preemption	nn1
language	language	nn1
with	with	ii31
regard	regard	ii32
to	to	ii33
drug	drug	nn1
regulation.	regulation	nnu
n274	n274	fo
Hence	hence	rr
,	,	y
implied	imply	vvd_jj@_vvn
conflict	conflict	nn1
preemption	preemption	nn1
is	be	vbz
necessary	necessary	jj
for	for	if
the	the	at
FDA	fda	nn1_np1
to	to	to
assert	assert	vvi
its	its	z'
regulatory	regulatory	jj
authority	authority	nn1
,	,	y
provide	provide	vv0
definitive	definitive	jj
standards	standard	nn2
,	,	y
and	and	cc
safeguard	safeguard	vv0_nn1
drug	drug	nn1
manufacturers	manufacturer	nn2
when	when	cs_rrq
they	they	pphs2
comply	comply	vv0
with	with	iw
existing	existing	jj
regulations	regulation	nn2
.	.	y
<p>	<p>	y
In	in	ii
comparison	comparison	nn1
,	,	y
the	the	at
MDA	mda	nn1_np1
,	,	y
enacted	enact	vvd_vvn
over	over	rp_ii
a	a	at1
half	half	db
century	century	nnt1
after	after	ii_cs
the	the	at
FDCA	fdca	nn1_np1
,	,	y
does	do	vdz
contain	contain	vvi
an	a	at1
express	express	jj@
preemption	preemption	nn1
provision	provision	nn1
for	for	if
medical	medical	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
such	such	ii21
as	as	ii22
application	application	nn1
of	of	io
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
,	,	y
between	between	ii
prescription	prescription	nn1
drugs	drug	nn2
and	and	cc
prescription	prescription	nn1
medical	medical	jj
devices	device	nn2
,	,	y
n276	n276	fo
there	there	ex
appears	appear	vvz
to	to	to
be	be	vbi
little	little	jj_da1
justification	justification	nn1
for	for	if
such	such	da
a	a	at1
discrepancy	discrepancy	nn1
if	if	cs
the	the	at
FDA	fda	nn1_np1
was	be	vbdz
not	not	xx
supposed	supposed	jj
to	to	to
preempt	preempt	vvi
implicitly	implicitly	rr
state	state	vv0
laws	law	nn2
regarding	regarding	ii_vvg
drug	drug	nn1
warnings	warning	nn2
.	.	y
Rather	rather	rr@_rg
,	,	y
the	the	at
FDA	fda	nn1_np1
's	's	ge
stronger	strong	jjr
endorsement	endorsement	nn1
of	of	io
implied	implied	jj@
preemption	preemption	nn1
seems	seem	vvz
to	to	to
align	align	vvi
preemption	preemption	nn1
principles	principle	nn2
between	between	ii
these	these	dd2
Acts	act	nn2
,	,	y
promoting	promote	vvg
the	the	at
policy	policy	nn1
goal	goal	nn1
of	of	io
consistency	consistency	nn1
among	among	ii
laws	law	nn2
.	.	y
<p>	<p>	y
Growth	growth	nn1
in	in	ii
DTC	dtc	np1
marketing	marketing	nn1
plays	play	vvz
an	a	at1
important	important	jj
part	part	nn1
in	in	ii
the	the	at
changing	changing	jj
landscape	landscape	nn1
of	of	io
drug	drug	nn1
regulation	regulation	nn1
and	and	cc
the	the	at
modem	modem	nn1
role	role	nn1
of	of	io
the	the	at
FDA	fda	nn1_np1
.	.	y
Although	although	cs
the	the	at
dynamics	dynamics	nn
of	of	io
the	the	at
physician-patient	physician-patient	jj_nn1
relationship	relationship	nn1
remain	remain	vv0
unaffected	unaffected	jj
by	by	ii
DTC	dtc	np1
marketing	marketing	nn1
,	,	y
the	the	at
scale	scale	nn1
of	of	io
the	the	at
marketing	marketing	nn1
efforts	effort	nn2
is	be	vbz
national	national	jj
and	and	cc
warrants	warrant	vvz_nn2
comprehensive	comprehensive	jj
federal	federal	jj
regulation	regulation	nn1
.	.	y
Many	many	da2
states	state	nn2
have	have	vh0
long	long	rr
recognized	recognize	vvn
the	the	at
policy	policy	nn1
benefits	benefit	nn2
of	of	io
a	a	at1
uniform	uniform	jj
federal	federal	jj
system	system	nn1
of	of	io
regulation	regulation	nn1
and	and	cc
apply	apply	vv0
state	state	nn1_vv0
law	law	nn1
regulatory	regulatory	jj
compliance	compliance	nn1
exceptions	exception	nn2
to	to	ii_to
further	far	rrr
this	this	dd1
result.	result	nnu
n277	n277	fo
Where	where	rrq_cs
the	the	at
scope	scope	nn1
of	of	io
these	these	dd2
regulatory	regulatory	jj
exemptions	exemption	nn2
is	be	vbz
limited	limit	vvn_jj
,	,	y
constitutional	constitutional	jj
principles	principle	nn2
of	of	io
preemption	preemption	nn1
should	should	vm
apply	apply	vvi
to	to	to
preclude	preclude	vvi
most	most	dat_rrt@
state	state	nn1_vv0
tort	tort	nn1_vv0
claims	claim	nn2
based	base	vvn
on	on	ii
design	design	nn1
,	,	y
failure	failure	nn1
to	to	to
warn	warn	vvi
,	,	y
and	and	cc
consumer	consumer	nn1
protection	protection	nn1
acts	act	vvz_nn2
if	if	cs_csw@
the	the	at
drug	drug	nn1
manufacturer	manufacturer	nn1
strictly	strictly	rr
complies	comply	vvz
with	with	iw
federal	federal	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
encourages	encourage	vvz
individuals	individual	nn2
to	to	to
seek	seek	vvi
effective	effective	jj
treatment	treatment	nn1
for	for	if
health	health	nn1
conditions	condition	nn2
or	or	cc
pushes	push	vvz
them	them	ppho2
to	to	ii
pressure	pressure	nn1
their	their	appge
doctors	doctor	nn2
for	for	if
unnecessary	unnecessary	jj
designer	designer	nn1
medications	medication	nn2
is	be	vbz
likely	likely	jj
to	to	to
rage	rage	vvi
on	on	rp@_ii
far	far	rr_jj
into	into	ii
the	the	at
future	future	nn1_jj
.	.	y
The	the	at
answer	answer	nn1
to	to	ii
that	that	dd1
question	question	nn1
is	be	vbz
beyond	beyond	ii
the	the	at
scope	scope	nn1
of	of	io
this	this	dd1
Article	article	nn1
.	.	y
What	what	ddq
is	be	vbz
clear	clear	jj
,	,	y
however	however	rr
,	,	y
is	be	vbz
that	that	cst_dd1
despite	despite	ii
increasing	increase	vvg_jj
DTC	dtc	np1
advertising	advertising	nn1
,	,	y
the	the	at
basic	basic	jj
relationship	relationship	nn1
between	between	ii
pharmaceutical	pharmaceutical	jj
manufacturers	manufacturer	nn2
and	and	cc
the	the	at
medical	medical	jj
community	community	nn1
with	with	ii31
regard	regard	ii32
to	to	ii33
drug	drug	nn1
warnings	warning	nn2
remains	remain	vvz
virtually	virtually	rr
unchanged	unchanged	jj
.	.	y
After	after	cs_ii
the	the	at
FDA	fda	nn1_np1
approves	approve	vvz
a	a	at1
prescription	prescription	nn1
drug	drug	nn1
as	as	csa_rg@_ii@
safe	safe	jj
and	and	cc
effective	effective	jj
,	,	y
patients	patient	nn2
must	must	vm
still	still	rr
consult	consult	vvi
with	with	iw
a	a	at1
physician	physician	nn1
before	before	ii
obtaining	obtain	vvg
the	the	at
medication	medication	nn1
.	.	y
Physicians	physician	nn2
,	,	y
based	base	vvn
on	on	ii
the	the	at
specific	specific	jj
medical	medical	jj
history	history	nn1
and	and	cc
individual	individual	jj
characteristics	characteristic	nn2
of	of	io
each	each	dd1
patient	patient	nn1_jj
,	,	y
must	must	vm
adequately	adequately	rr
inform	inform	vvi
their	their	appge
patients	patient	nn2
of	of	io
potential	potential	jj_nn1
side	side	nn1
effects	effect	nn2
and	and	cc
evaluate	evaluate	vv0
other	other	jj
relevant	relevant	jj
risks	risk	nn2
before	before	ii
pursuing	pursue	vvg
a	a	at1
treatment	treatment	nn1
course	course	nn1
.	.	y
The	the	at
role	role	nn1
,	,	y
and	and	cc
indeed	indeed	rr
the	the	at
objective	objective	nn1_jj
,	,	y
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
in	in	ii
this	this	dd1
doctor-patient	doctor-patient	jj_nn1
relationship	relationship	nn1
is	be	vbz
to	to	to
prompt	prompt	vvi
the	the	at
patient	patient	jj_nn1
to	to	to
question	question	vvi
his	his	appge
doctor	doctor	nn1
about	about	ii
potential	potential	jj_nn1
drug	drug	nn1
treatments	treatment	nn2
.	.	y
Even	even	cs21
though	though	cs22
all	all	db
advertisements	advertisement	nn2
direct	direct	jj_vv0@
patients	patient	nn2
to	to	ii_to
,	,	y
"	"	y
ask	ask	vv0
their	their	appge
doctor	doctor	nn1
about	about	ii
"	"	y
the	the	at
drug	drug	nn1
in	in	ii
question	question	nn1
,	,	y
it	it	pph1
remains	remain	vvz
the	the	at
physician	physician	nn1
's	's	ge
ultimate	ultimate	jj
responsibility	responsibility	nn1
to	to	to
evaluate	evaluate	vvi
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
a	a	at1
beneficial	beneficial	jj
,	,	y
treatment	treatment	nn1
.	.	y
DTC	dtc	np1
advertising	advertising	nn1
can	can	vm
never	never	rr
replace	replace	vvi
or	or	cc
undermine	undermine	vvi
the	the	at
personal	personal	jj
relationship	relationship	nn1
between	between	ii
a	a	at1
physician	physician	nn1
and	and	cc
a	a	at1
patient	patient	nn1_jj
and	and	cc
the	the	at
communication	communication	nn1
of	of	io
the	the	at
risks	risk	nn2
and	and	cc
benefits	benefit	nn2
of	of	io
a	a	at1
drug	drug	nn1
discussed	discuss	vvn_vvd
in	in	ii
the	the	at
doctor	doctor	nn1
's	's	ge
office	office	nn1
.	.	y
That	that	cst_dd1_rg%
many	many	da2
patients	patient	nn2
are	be	vbr
able	able	jk
to	to	to
become	become	vvi
more	more	rrr_dar
informed	inform	vvn_vvd
about	about	ii
possible	possible	jj
treatments	treatment	nn2
through	through	ii
DTC	dtc	np1
advertising	advertising	nn1
and	and	cc
take	take	vv0
a	a	at1
more	more	rgr
active	active	jj
role	role	nn1
in	in	ii
improving	improve	vvg
their	their	appge
health	health	nn1
should	should	vm
be	be	vbi
viewed	view	vvn
as	as	ii
a	a	at1
considerable	considerable	jj
benefit	benefit	nn1
to	to	ii
the	the	at
healthcare	health-care	nn1
system--one	system--one	mc
that	that	cst_dd1
in	in	ii
no	no	at
way	way	nn1
undercuts	undercut	vvz
the	the	at
traditional	traditional	jj
rules	rule	nn2
of	of	io
law	law	nn1
related	relate	vvn_vvd
to	to	ii
drug	drug	nn1
warnings.	warnings	nnu
(	(	y
n278	n278	fo
)	)	y
<p>	<p>	y
All	all	db
this	this	dd1
is	be	vbz
not	not	xx
to	to	to
say	say	vvi
,	,	y
however	however	rr
,	,	y
that	that	cst
the	the	at
regulation	regulation	nn1
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
is	be	vbz
without	without	iw
any	any	dd
gaps	gap	nn2
or	or	cc
weaknesses	weakness	nn2
.	.	y
Regulation	regulation	nn1
could	could	vm
potentially	potentially	rr
be	be	vbi
improved	improve	vvn
if	if	cs_csw@
the	the	at
FDA	fda	np1_nn1
considered	consider	vvd_vvn
making	make	vvg
predissemination	predissemination	nn1
submission	submission	nn1
of	of	io
DTC	dtc	np1
advertisements	advertisement	nn2
for	for	if
the	the	at
agency	agency	nn1
's	's	ge
review	review	nn1
mandatory	mandatory	jj
,	,	y
rather	rather	ii21_cs21@
than	than	ii22_cs22@
voluntary	voluntary	jj
,	,	y
and	and	cc
requiring	require	vvg
affirmative	affirmative	jj_nn1
FDA	fda	nn1
approval	approval	nn1
before	before	ii
permitting	permit	vvg
advertisements	advertisement	nn2
to	to	ii
air	air	nn1
.	.	y
The	the	at
practicality	practicality	nn1
,	,	y
effectiveness	effectiveness	nn1
,	,	y
and	and	cc
fairness	fairness	nn1
of	of	io
such	such	da
a	a	at1
requirement	requirement	nn1
,	,	y
however	however	rr
,	,	y
would	would	vm
largely	largely	rr
depend	depend	vvi
on	on	ii
whether	whether	csw
Congress	congress	nn1
provided	provided	cs_vvd
the	the	at
FDA	fda	nn1
with	with	iw
sufficient	sufficient	jj
resources	resource	nn2
to	to	to
review	review	vvi
promptly	promptly	rr
a	a	at1
surge	surge	nn1
in	in	ii
submissions	submission	nn2
,	,	y
because	because	cs
,	,	y
according	according	ii21
to	to	ii22
the	the	at
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
.	.	y
<p>	<p>	y
Despite	despite	ii
the	the	at
potential	potential	jj_nn1
benefit	benefit	nn1
of	of	io
the	the	at
aforementioned	aforementioned	jj
changes	change	nn2
,	,	y
this	this	dd1
Article	article	nn1
has	have	vhz
shown	show	vvn
that	that	cst
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
retains	retain	vvz
its	its	z'
viability	viability	nn1
in	in	ii
our	our	appge
current	current	jj
post-DTC	post-dtc	jj
world	world	nn1
.	.	y
Most	most	dat
state	state	vv0_nn1
courts	court	nn2
continue	continue	vv0
to	to	to
apply	apply	vvi
the	the	at
doctrine	doctrine	nn1
fully	fully	rr
,	,	y
despite	despite	ii
aberrations	aberration	nn2
such	such	ii21
as	as	ii22
the	the	at
recent	recent	jj
West	west	np1
Virginia	virginia	np1
Supreme	supreme	jj
Court	court	nn1
of	of	io
Appeals	appeal	nn2
decision	decision	nn1
or	or	cc
more	more	rgr_dar
limited	limited	jj
exclusions	exclusion	nn2
for	for	if
common	common	jj
oral	oral	jj_nn1
contraceptives	contraceptive	nn2
.	.	y
Moreover	moreover	rr
,	,	y
this	this	dd1
Article	article	nn1
has	have	vhz
also	also	rr
shown	show	vvn
that	that	cst_dd1
extensive	extensive	jj
federal	federal	jj
regulation	regulation	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
products	product	nn2
,	,	y
including	including	ii
DTC	dtc	np1
advertising	advertising	nn1
,	,	y
should	should	vm
preclude	preclude	vvi
state	state	nn1
product	product	nn1
liability	liability	nn1
and	and	cc
consumer	consumer	nn1
protection	protection	nn1
claims	claim	nn2_vvz
,	,	y
whether	whether	csw
on	on	ii
the	the	at
basis	basis	nn1
of	of	io
common-law	common-law	nn1
compliance	compliance	nn1
with	with	iw
standards	standard	nn2
defenses	defense	nn2
,	,	y
statutory	statutory	jj
exemption	exemption	nn1
,	,	y
or	or	cc
federal	federal	jj
preemption	preemption	nn1
.	.	y
These	these	dd2
measures	measure	nn2
are	be	vbr
all	all	db_rr@
supported	support	vvn
by	by	ii
sound	sound	nn1_jj@
public	public	nn1_jj
policy	policy	nn1
,	,	y
particularly	particularly	rr
where	where	cs_rrq
there	there	ex
is	be	vbz
tension	tension	nn1
between	between	ii
the	the	at
FDA	fda	np1_nn1
's	's	ge
reasoned	reasoned	jj
decision	decision	nn1
making	make	vvg_nn1@
and	and	cc
the	the	at
theory	theory	nn1
of	of	io
the	the	at
lawsuit	lawsuit	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
Footnotes	footnote	nn2
--		nn1_jj
(	(	y
n1	n1	fo
.	.	y
)	)	y
Julie	julie	np1
M.	m	nn1
Donohue	donohue	np1
et	et	ra21
al.	al	ra22
,	,	y
A	a	zz1_at1@
Decade	decade	nnt1
of	of	io
Direct-to-Consumer		np1
Advertising	advertising	nn1
of	of	io
Prescription	prescription	nn1
Drugs	drug	nn2
,	,	y
357	357	mc
NEW	new	jj
ENG	eng	np1
.	.	y
J.	xx_j	np1
MED.	med	np1
673	673	mc
,	,	y
673	673	mc
,	,	y
676	676	mc
(	(	y
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n2	n2	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n3	n3	fo
.	.	y
)	)	y
See	see	vv0
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
total	total	jj_nn1
industry	industry	nn1
expenditures	expenditure	nn2
on	on	ii
pharmaceutical	pharmaceutical	jj
promotion	promotion	nn1
were	be	vbdr
devoted	devoted	jj_vvn%
to	to	ii
DTC	dtc	np1
advertising	advertising	nn1
in	in	ii
2005	2005	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n4	n4	fo
.	.	y
)	)	y
U.S.	us	np1
GEN	gen	nn1
.	.	y
ACCOUNTING	account	vvg_nn1_jj@
OFFICE	office	nn1
,	,	y
GAO-07-54		np1
,	,	y
PRESCRIPTION	prescription	nn1
DRUGS	drug	nn2
:	:	y
IMPROVEMENTS	improvement	nn2
NEEDED	need	vvn_vvd
IN	in	ii
FDA	fda	np1
'S	's	ge
OVERSIGHT	oversight	nn1
OF	of	io
DIRECT-TO-CONSUMER	direct-to-consumer	jj_nn1
ADVERTISING	advertising	nn1
13	13	mc
(	(	y
2006	2006	mc
)	)	y
hereinafter	hereinafter	rr
2006	2006	mc
GAO	gao	np1
REPORT	report	nn1
.	.	y
Manufacturer	manufacturer	nn1
spending	spend	vvg_nn1
on	on	ii
DTC	dtc	np1
advertising	advertising	nn1_vvg@
also	also	rr
pales	pale	vvz
in	in	ii
comparison	comparison	nn1
to	to	ii
industry	industry	nn1
spending	spend	vvg_nn1
on	on	ii
research	research	nn1
and	and	cc
development	development	nn1
,	,	y
with	with	iw
$31.4	$31.4	nnu
billion	billion	m
spent	spend	vvn_vvd
in	in	ii
2005	2005	mc
.	.	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n5	n5	fo
.	.	y
)	)	y
Donohue	donohue	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
1	1	mc1
,	,	y
at	at	ii
676	676	mc
(	(	y
finding	find	vvg_nn1
that	that	cst
the	the	at
twenty	twenty	mc
drugs	drug	nn2
with	with	iw
the	the	at
highest	high	jjt
DTC	dtc	np1
spending	spending	nn1
made	make	vvd_vvn
up	up	rp_ii@
54.4%	54.4%	fo
of	of	io
total	total	jj_nn1
industry	industry	nn1
spending	spend	vvg_nn1
on	on	ii
DTC	dtc	np1
advertising	advertising	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n6	n6	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
infra	infra	rr
Part	part	nn1
III.C	iii.c	np1
(	(	y
discussing	discuss	vvg
the	the	at
preemption	preemption	nn1
debate	debate	nn1
for	for	if
DTC-advertised	dtc-advertised	jj_nn1
drugs	drug	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n7	n7	fo
.	.	y
)	)	y
See	see	vv0
Michael	michael	np1
S.	s	np1
Wilkes	wilkes	np1
et	et	ra21
al.	al	ra22
,	,	y
Direct-To-Consumer		np1
Prescription	prescription	nn1
Drug	drug	nn1
Advertising	advertising	nn1
:	:	y
Trends	trend	nn2
,	,	y
Impact	impact	nn1
,	,	y
and	and	cc
Implications	implication	nn2
,	,	y
19	19	mc
HEALTH	health	nn1
AFF.	aff	np1
110	110	mc
,	,	y
112	112	mc
(	(	y
2000	2000	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n8	n8	fo
.	.	y
)	)	y
See	see	vv0
UPTON	upton	np1
SINCLAIR	sinclair	np1
,	,	y
THE	the	at
JUNGLE	jungle	nn1
(	(	y
n1906		fo
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n9	n9	fo
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Pub	pub	nn1
.	.	y
L.	l	np1
No.	no	xx
59-384		mcmc
,	,	y
34	34	mc
Stat.	stat	np1
768	768	mc
,	,	y
repealed	repeal	vvn
by	by	ii
the	the	at
Federal	federal	jj
Food	food	nn1
,	,	y
Drug	drug	nn1
,	,	y
and	and	cc
Cosmetic	cosmetic	jj
Act	act	nn1
of	of	io
1938	1938	mc
,	,	y
Pub	pub	nn1
.	.	y
L.	l	np1
No.	no	xx
75-717	75-717	mcmc
,	,	y
52	52	mc
Stat.	stat	np1
1040	1040	mc
(	(	y
codified	codify	vvn@_jj@_vvd
as	as	csa
amended	amend	vvn
at	at	ii
21	21	mc
U.S.C.	usc	np1
Subsection	subsection	np1@_nn1
301-399		mcmc
(	(	y
2000	2000	mc
)	)	y
)	)	y
;	;	y
see	see	vv0
also	also	rr
U.S.	us	np1
Food	food	nn1
&;		null
Drug	drug	nn1
Admin.	admin	np1
,	,	y
Milestones	milestone	np2_nn2@
in	in	ii
U.S.	us	np1
Food	food	nn1
and	and	cc
Drug	drug	nn1
Law	law	nn1
History	history	nn1
,	,	y
FDA	fda	np1_nn1
BACKGROUNDER	backgrounder	nn1
,	,	y
May	may	npm1
3	3	mc
,	,	y
1999	1999	mc
,	,	y
http		nnu
:	:	y
**45;1347;TOOLONG		fu
(	(	y
citing	cite	vvg
,	,	y
in	in	ii31
addition	addition	ii32
to	to	ii33
reaction	reaction	nn1
to	to	ii
The	the	at
Jungle	jungle	nn1
,	,	y
public	public	jj_nn1
unrest	unrest	nn1
over	over	ii
"	"	y
the	the	at
use	use	nn1
of	of	io
poisonous	poisonous	jj
preservatives	preservative	nn2
and	and	cc
dyes	dye	nn2
in	in	ii
foods	food	nn2
,	,	y
and	and	cc
cure-all	cure-all	db
claims	claim	nn2
for	for	if
worthless	worthless	jj
and	and	cc
dangerous	dangerous	jj
patent	patent	nn1_jj@
medicines	medicine	nn2
"	"	y
as	as	ii_csa
the	the	at
"	"	y
major	major	jj
problems	problem	nn2
leading	lead	vvg
to	to	ii
the	the	at
enactment	enactment	nn1
of	of	io
"	"	y
the	the	at
1906	1906	mc
Act	act	nn1
and	and	cc
the	the	at
Meat	meat	nn1
Inspection	inspection	nn1
Act	act	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n10	n10	fo
.	.	y
)	)	y
See	see	vv0
Francis	francis	np1
B.	b	np1
Palumbo	palumbo	np1
&;		null
C.	c	np1
Daniel	daniel	np1
Mullins	mullins	np1
,	,	y
The	the	at
Development	development	nn1
of	of	io
Direct-to-Consumer		np1
Prescription	prescription	nn1
Drug	drug	nn1
Advertising	advertising	nn1
Regulation	regulation	nn1
,	,	y
57	57	mc
FOOD	food	nn1
&;		null
DRUG	drug	nn1
L.J	lj	np1
.	.	y
423	423	mc
,	,	y
424-25	424-25	mcmc
&;		null
n.12	n.12	fo
(	(	y
2002	2002	mc
)	)	y
(	(	y
noting	note	vvg
the	the	at
portion	portion	nn1
of	of	io
the	the	at
1906	1906	mc
Act	act	nn1_vv0@
stating	state	vvg
that	that	cst
a	a	at1
drug	drug	nn1
would	would	vm
be	be	vbi
deemed	deem	vvn
misbranded	misbranded	vvd_jj@_vvn@
if	if	cs_csw@
"	"	y
'	'	"@_ge
its	its	z'
package	package	nn1
or	or	cc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
or	or	cc
device	device	nn1
regarding	regarding	ii_vvg
the	the	at
curative	curative	nn1_jj
or	or	cc
therapeutic	therapeutic	jj
effect	effect	nn1
of	of	io
such	such	da
article	article	nn1
...	...	...
which	which	ddq
is	be	vbz
false	false	jj
or	or	cc
fraudulent	fraudulent	jj
'	'	ge
"	"	y
(	(	y
quoting	quote	vvg
the	the	at
Pure	pure	jj
Food	food	nn1
and	and	cc
Drugs	drug	nn2
Act	act	vv0@_nn1
8	8	mc
,	,	y
34	34	mc
Stat.	stat	np1
at	at	ii
770	770	mc
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n11	n11	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
425	425	mc
&;		null
n.12	n.12	fo
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n12	n12	fo
.	.	y
)	)	y
See	see	vv0
Carol	carol	np1
Ballentine	ballentine	np1
,	,	y
Taste	taste	nn1
of	of	io
Raspberries	raspberry	nn2
,	,	y
Taste	taste	nn1
of	of	io
Death	death	nn1
:	:	y
The	the	at
1937	1937	mc
Elixir	elixir	np1_nn1
Sulfanilamide	sulfanilamide	np1_nn1
Incident	incident	nn1
,	,	y
FDA	fda	np1_nn1
CONSUMER	consumer	nn1
,	,	y
June	june	npm1
1981	1981	mc
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**36;1394;TOOLONG		fu
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n13	n13	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n14	n14	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n15	n15	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Pankaj	pankaj	np1
Hari	hari	np1
et	et	ra21
al.	al	ra22
,	,	y
Fatal	fatal	jj
Encephalopathy	encephalopathy	nn1
and	and	cc
Renal	renal	jj_np1
Failure	failure	nn1
Caused	cause	vvn
by	by	ii
Diethylene	diethylene	np1
Glycol	glycol	np1_nn1
Poisoning	poisoning	nn1_vvg
,	,	y
56	56	mc
J.	xx_j	np1
TROPICAL	tropical	jj
PEDIATRICS	pediatrics	nn1
442	442	mc
(	(	y
2006	2006	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n16	n16	fo
.	.	y
)	)	y
See	see	vv0
Ballentine	ballentine	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
12	12	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n17	n17	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n18	n18	fo
.	.	y
)	)	y
See	see	vv0
David	david	np1
F.	f	np1
Cavers	cavers	np1
,	,	y
The	the	at
Food	food	nn1
,	,	y
Drug	drug	nn1
,	,	y
and	and	cc
Cosmetic	cosmetic	jj
Act	act	nn1
of	of	io
1938	1938	mc
:	:	y
Its	its	z'
Legislative	legislative	jj
History	history	nn1
and	and	cc
Its	its	z'
Substantive	substantive	jj
Provisions	provision	nn2
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
n1939		fo
)	)	y
,	,	y
reprinted	reprint	vvn
in	in	ii
PETER	peter	np1
BARTON	barton	np1
HUTT	hutt	np1
ET	et	ra21
AL.	al	ra22
,	,	y
FOOD	food	nn1
AND	and	cc
DRUG	drug	nn1
LAW	law	nn1
,	,	y
CASES	case	nn2
AND	and	cc
MATERIALS	material	nn2
577	577	mc
,	,	y
577-78	577-78	mcmc
(	(	y
3d	3d	nnu
ed.	ed	nn1
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n19	n19	fo
.	.	y
)	)	y
See	see	vv0
Ballentine	ballentine	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
12	12	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n20	n20	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n21	n21	fo
.	.	y
)	)	y
Federal	federal	jj
Food	food	nn1
,	,	y
Drug	drug	nn1
,	,	y
and	and	cc
Cosmetic	cosmetic	jj
Act	act	nn1
of	of	io
1938	1938	mc
,	,	y
Pub	pub	nn1
.	.	y
L.	l	np1
No.	no	xx
75-717	75-717	mcmc
,	,	y
52	52	mc
Stat.	stat	np1
1040	1040	mc
(	(	y
codified	codify	vvn@_jj@_vvd
as	as	csa
amended	amend	vvn
at	at	ii
21	21	mc
U.S.C.	usc	np1
Subsection	subsection	np1@_nn1
301-399		mcmc
(	(	y
2000	2000	mc
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n22	n22	fo
.	.	y
)	)	y
HUTT	hutt	np1_vv0
ET	et	ra21
AL.	al	ra22
,	,	y
supra	supra	nn1
note	note	nn1_vv0
18	18	mc
,	,	y
at	at	ii
577	577	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n23	n23	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n24	n24	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
578	578	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n25	n25	fo
.	.	y
)	)	y
See	see	vv0
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
426	426	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n26	n26	fo
.	.	y
)	)	y
Federal	federal	jj
Trade	trade	nn1
Commission	commission	nn1
Act	act	nn1
,	,	y
Pub	pub	nn1
.	.	y
L.	l	np1
No.	no	xx
63-203		mcmc
,	,	y
38	38	mc
Stat.	stat	np1
717	717	mc
(	(	y
n1914		fo
)	)	y
(	(	y
codified	codify	vvn@_jj@_vvd
as	as	csa
amended	amend	vvn
at	at	ii
15	15	mc
U.S.C.	usc	np1
Subsection	subsection	np1@_nn1
41-58	41-58	mcmc
(	(	y
2000	2000	mc
)	)	y
)	)	y
(	(	y
establishing	establish	vvg
the	the	at
FTC	ftc	np1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
10	10	mc
,	,	y
at	at	ii
425	425	mc
&;		null
n.14	n.14	fo
(	(	y
citing	cite	vvg
FTC	ftc	np1
v.	xx_v	ii
Raladam		np1
Co.	co	np1
,	,	y
283	283	mc
U.S.	us	np1
643	643	mc
(	(	y
n1931		fo
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n28	n28	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
425	425	mc
n.18	n.18	fo
(	(	y
quoting	quote	vvg
S.	s	np1_nn1@
1944	1944	mc
,	,	y
73d	73d	nnu
Cong	cong	np1
.	.	y
9(c)	9(c)	fo
(	(	y
n1933		fo
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n29	n29	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n30	n30	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
426	426	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n31.		fo
)	)	y
1962	1962	mc
Kefauver-Harris	kefauver-harris	np1
Drug	drug	nn1
Amendments	amendment	nn2
,	,	y
Pub	pub	nn1
.	.	y
L.	l	np1
No.	no	xx
87-781		mcmc
,	,	y
76	76	mc
Stat.	stat	np1
780	780	mc
(	(	y
n1962		fo
)	)	y
(	(	y
codified	codify	vvn@_jj@_vvd
as	as	csa
amended	amend	vvn
at	at	ii
21	21	mc
U.S.C.	usc	np1
352(n)		fo
(	(	y
2000	2000	mc
)	)	y
)	)	y
;	;	y
see	see	vv0
also	also	rr
15	15	mc
U.S.C.	usc	np1
Subsection	subsection	nn1_np1@
45	45	mc
,	,	y
52	52	mc
(	(	y
2000	2000	mc
)	)	y
;	;	y
21	21	mc
U.S.C.	usc	np1
352(n)		fo
(	(	y
2000	2000	mc
)	)	y
(	(	y
removing	remove	vvg
any	any	dd
"	"	y
advertisement	advertisement	nn1
of	of	io
a	a	at1
prescription	prescription	nn1
drug	drug	nn1
,	,	y
published	publish	vvn_vvd
after	after	ii_cs
the	the	at
effective	effective	jj
date	date	nn1
of	of	io
regulations	regulation	nn2
issued	issue	vvn_vvd
under	under	ii
this	this	dd1
paragraph	paragraph	nn1
applicable	applicable	jj
to	to	ii
advertisements	advertisement	nn2
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
,	,	y
"	"	y
from	from	ii
the	the	at
purview	purview	nn1
of	of	io
the	the	at
provisions	provision	nn2
of	of	io
15	15	mc
U.S.C.	usc	np1
Subsection	subsection	np1@_nn1
52-57	52-57	mcmc
)	)	y
;	;	y
21	21	mc
U.S.C.	usc	np1
393(b)		fo
(	(	y
n1	n1	fo
)	)	y
(	(	y
2000	2000	mc
)	)	y
(	(	y
"	"	y
The	the	at
FDA	fda	nn1_np1
shall	shall	vm
...	...	...
promote	promote	vv0
the	the	at
public	public	jj_nn1
health	health	nn1
by	by	ii
...	...	...
taking	take	vvg
appropriate	appropriate	jj
action	action	nn1
on	on	ii
the	the	at
marketing	marketing	nn1
of	of	io
regulated	regulated	jj@
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
--		nn1_jj
(	(	y
n32	n32	fo
.	.	y
)	)	y
See	see	vv0
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
427	427	mc
n.29	n.29	fo
(	(	y
"	"	y
There	there	ex_rl
is	be	vbz
a	a	at1
marked	marked	jj
difference	difference	nn1
in	in	ii
the	the	at
advertising	advertising	nn1
and	and	cc
promotion	promotion	nn1
of	of	io
proprietary	proprietary	jj
and	and	cc
ethical	ethical	jj
drugs	drug	nn2
.	.	y
Proprietary	proprietary	jj
drugs--those		nn2
sold	sell	vvn_vvd
over	over	ii_rp
the	the	at
drugstore	drugstore	nn1
counter--are		nn1_vv0
like	like	ii
most	most	dat
other	other	jj
products	product	nn2
in	in	ii
that	that	dd1
sales	sales	nn
pressures	pressure	nn2
are	be	vbr
exerted	exert	vvn
upon	upon	ii
the	the	at
final	final	jj_nn1
consumer	consumer	nn1
who	who	pnqs
is	be	vbz
subjected	subject	vvn
to	to	ii
an	a	at1
intensive	intensive	jj
barrage	barrage	nn1
of	of	io
advertisements	advertisement	nn2
for	for	if
brand	brand	nn1
name	name	nn1
products	product	nn2
in	in	ii
newspapers	newspaper	nn2
,	,	y
magazines	magazine	nn2
,	,	y
radio	radio	nn1
,	,	y
and	and	cc
television	television	nn1
.	.	y
In	in	ii
the	the	at
case	case	nn1
of	of	io
ethical	ethical	jj
drugs--those		nn2
sold	sell	vvn_vvd
under	under	ii
prescription-the		at
brunt	brunt	nn1
of	of	io
promotion	promotion	nn1
effort	effort	nn1
is	be	vbz
directed	direct	vvn
to	to	ii
the	the	at
prescribing	prescribing	nn1@
physician	physician	nn1
.	.	y
Since	since	cs
his	his	appge
prescription	prescription	nn1
dictates	dictate	vvz
the	the	at
particular	particular	jj
drug	drug	nn1
to	to	to
be	be	vbi
used	use	vvn
,	,	y
usually	usually	rr
the	the	at
brand	brand	nn1
name	name	nn1
,	,	y
the	the	at
physician	physician	nn1
is	be	vbz
the	the	at
focal	focal	jj
center	center	nn1
of	of	io
advertising	advertising	nn1
and	and	cc
promotional	promotional	jj
pressures	pressure	nn2
.	.	y
"	"	y
(	(	y
citing	cite	vvg
S.	s	np1_nn1@
Rep.	rep	nn1@
No.	no	xx
87-448		mcmc
,	,	y
at	at	ii
115	115	mc
et	et	fw
seq	seq	fw
.	.	y
(	(	y
n1961		fo
)	)	y
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n33	n33	fo
.	.	y
)	)	y
See	see	vv0
Memorandum	memorandum	nn1
of	of	io
Understanding	understand	vvg_nn1
Between	between	ii
FTC	ftc	np1
and	and	cc
the	the	at
FDA	fda	nn1_np1
,	,	y
36	36	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
18,539	18,539	mc
(	(	y
Sept.	sept	npm1
15	15	mc
,	,	y
1971	1971	mc
)	)	y
(	(	y
providing	provide	vvg_cs@
most	most	rgt_dat
recent	recent	jj
agreement	agreement	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n34	n34	fo
.	.	y
)	)	y
The	the	at
FDCA	fdca	np1_nn1
's	's	ge
treatment	treatment	nn1
of	of	io
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
that	that	cst
the	the	at
advertisement	advertisement	nn1
include	include	vv0
the	the	at
drug	drug	nn1
's	's	ge
name	name	nn1
and	and	cc
formula	formula	nn1
,	,	y
and	and	cc
a	a	at1
brief	brief	jj
summary	summary	nn1
describing	describe	vvg
the	the	at
drug	drug	nn1
's	's	ge
effectiveness	effectiveness	nn1
and	and	cc
its	its	z'
safety	safety	nn1
risks	risk	nn2
.	.	y
See	see	vv0
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
428	428	mc
(	(	y
citing	cite	vvg
21	21	mc
U.S.C.	usc	np1
352(n)		fo
(	(	y
2002	2002	mc
)	)	y
)	)	y
.	.	y
Shortly	shortly	rr
after	after	ii_cs
the	the	at
1962	1962	mc
Drug	drug	nn1
Amendments	amendment	nn2
'	'	ge
passage	passage	nn1
,	,	y
the	the	at
FDA	fda	nn1_np1
implemented	implement	vvn_vvd@
its	its	z'
original	original	jj
drug-advertising	drug-advertising	jj_nn1
regulations	regulation	nn2
.	.	y
See	see	vv0
HUTT	hutt	np1
ET	et	ra21
AL.	al	ra22
,	,	y
supra	supra	nn1
note	note	nn1_vv0
18	18	mc
,	,	y
at	at	ii
535	535	mc
(	(	y
citing	cite	vvg
28	28	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
1448	1448	mc
(	(	y
Feb.	feb	npm1
14	14	mc
,	,	y
1963	1963	mc
)	)	y
,	,	y
28	28	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
6375	6375	mc
(	(	y
June	june	npm1
20	20	mc
,	,	y
1963	1963	mc
)	)	y
,	,	y
28	28	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
9837	9837	mc
(	(	y
Sept.	sept	npm1
10	10	mc
,	,	y
1963	1963	mc
)	)	y
,	,	y
28	28	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
10993	10993	mc
(	(	y
Oct.	oct	npm1
15	15	mc
,	,	y
1963	1963	mc
)	)	y
,	,	y
29	29	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
257	257	mc
(	(	y
Jan.	jan	npm1
10	10	mc
,	,	y
1964	1964	mc
)	)	y
)	)	y
.	.	y
The	the	at
FDA	fda	nn1_np1
further	far	rrr
revised	revise	vvd_vvn
those	those	dd2
regulations	regulation	nn2
later	later	rrr
that	that	dd1
same	same	da
decade	decade	nnt1
.	.	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n35.		fo
)	)	y
21	21	mc
C.F.R.	c.f.r	np1
202.1(e)		fo
(	(	y
n1979		fo
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n36.		fo
)	)	y
21	21	mc
C.F.R.	c.f.r	np1
202.1(e)		fo
(	(	y
5	5	mc
)	)	y
(	(	y
ii	ii	mc
)	)	y
(	(	y
n1979		fo
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n37	n37	fo
.	.	y
)	)	y
See	see	vv0
HUTT	hutt	np1
ET	et	ra21
AL.	al	ra22
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
(	(	y
n38	n38	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
579	579	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n39	n39	fo
.	.	y
)	)	y
Section	section	nn1
505(d)		fo
of	of	io
the	the	at
FDCA	fdca	nn1_np1
requires	require	vvz
"	"	y
the	the	at
FDA	fda	nn1_np1
to	to	to
withhold	withhold	vvi
approval	approval	nn1
unless	unless	cs
the	the	at
sponsor	sponsor	nn1
's	's	ge
NDA	nda	nn1_np1
shows	show	vvz
the	the	at
drug	drug	nn1
to	to	to
be	be	vbi
safe	safe	jj_nn1@
'	'	ge
by	by	ii
all	all	db
methods	method	nn2
reasonably	reasonably	rr
applicable	applicable	jj
to	to	to
show	show	vvi
whether	whether	csw31
or	or	csw32
not	not	csw33
such	such	da
drug	drug	nn1
is	be	vbz
safe	safe	jj
for	for	if
use	use	nn1
under	under	ii
the	the	at
conditions	condition	nn2
of	of	io
use	use	nn1
prescribed	prescribe	vvn_jj_vvd@
,	,	y
recommended	recommend	vvd_vvn
,	,	y
or	or	cc
suggested	suggested	jj@
'	'	ge
in	in	ii
the	the	at
proposed	proposed	jj
labeling	labeling	nn1@
.	.	y
"	"	y
Id	id	z'
.	.	y
at	at	ii
685	685	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n40	n40	fo
.	.	y
)	)	y
Section	section	nn1
505(d)		fo
of	of	io
the	the	at
FDCA	fdca	nn1_np1
requires	require	vvz
the	the	at
FDA	fda	nn1_np1
to	to	to
withhold	withhold	vvi
approval	approval	nn1
unless	unless	cs
the	the	at
sponsor	sponsor	nn1
's	's	ge
NDA	nda	nn1_np1
provides	provide	vvz
"	"	y
'	'	ge
substantial	substantial	jj
evidence	evidence	nn1
that	that	cst
the	the	at
drug	drug	nn1
will	will	vm
have	have	vhi
the	the	at
effect	effect	nn1
it	it	pph1
purports	purport	vvz
or	or	cc
is	be	vbz
represented	represent	vvn
to	to	to
have	have	vhi
under	under	ii
the	the	at
conditions	condition	nn2
of	of	io
use	use	nn1
prescribed	prescribe	vvn_jj_vvd@
,	,	y
recommended	recommend	vvd_vvn
,	,	y
or	or	cc
suggested	suggest	vvn_vvd
in	in	ii
the	the	at
proposed	proposed	jj
labeling	labeling	nn1@
.	.	y
'	'	"@_ge
"	"	y
Id	id	z'
.	.	y
at	at	ii
579	579	mc
.	.	y
Section	section	nn1
505(e)		fo
requires	require	vvz
the	the	at
FDA	fda	nn1_np1
to	to	to
"	"	y
withdraw	withdraw	vvi
approval	approval	nn1
of	of	io
any	any	dd
drug	drug	nn1
after	after	ii_cs
notice	notice	nn1
and	and	cc
opportunity	opportunity	nn1
for	for	if
hearing	hear	vvg_nn1
if	if	csw@_cs
he	he	pphs1
finds	find	vvz
that	that	dd1
'		vbz
on	on	ii
the	the	at
basis	basis	nn1
of	of	io
new	new	jj
information	information	nn1
before	before	ii
him	him	ppho1
'	'	ge
substantial	substantial	jj
evidence	evidence	nn1
of	of	io
efficacy	efficacy	nn1
is	be	vbz
lacking	lack	vvg
.	.	y
"	"	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n41	n41	fo
.	.	y
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
an	a	at1
NDA	nda	nn1
must	must	vm
summarize	summarize	vvi
the	the	at
general	general	jj_nn1
understanding	understanding	nn1
of	of	io
the	the	at
application	application	nn1
,	,	y
the	the	at
drug	drug	nn1
type	type	nn1
,	,	y
and	and	cc
the	the	at
rationale	rationale	nn1
for	for	if
approval	approval	nn1
,	,	y
as	as	ii31
well	well	ii32
as	as	ii33
a	a	at1
description	description	nn1
of	of	io
the	the	at
drug	drug	nn1
's	's	ge
chemistry	chemistry	nn1
,	,	y
its	its	z'
manufacturing	manufacturing	nn1
practices	practice	nn2
,	,	y
and	and	cc
its	its	z'
quality	quality	nn1
controls	control	nn2_vvz
.	.	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
314.50(c)-(d)		zz1
(	(	y
2000	2000	mc
)	)	y
.	.	y
It	it	pph1
must	must	vm
contain	contain	vvi
pre-clinical	pre-clinical	jj
data	data	nn
(	(	y
that	that	rex21
is	is	rex22
,	,	y
the	the	at
results	result	nn2
of	of	io
animal	animal	nn1
and	and	cc
in	in	jj21_rr21
vitro	vitro	jj22_rr22
studies	study	nn2
)	)	y
regarding	regarding	ii_vvg
the	the	at
product	product	nn1
's	's	ge
pharmacology	pharmacology	nn1
and	and	cc
toxicology	toxicology	nn1
,	,	y
and	and	cc
that	that	dd1_cst
data	data	nn
must	must	vm
be	be	vbi
accompanied	accompany	vvn
by	by	ii
a	a	at1
statement	statement	nn1
of	of	io
compliance	compliance	nn1
with	with	iw
good	good	jj
laboratory	laboratory	nn1
practices	practice	nn2
.	.	y
See	see	vv0
id	id	z'
.	.	y
The	the	at
NDA	nda	nn1_np1
must	must	vm
describe	describe	vvi
the	the	at
drug	drug	nn1
's	's	ge
pharmacokinetics	pharmacokinetics	nn1_nn2
and	and	cc
bioavailability	bioavailability	nn1
(	(	y
that	that	rex21
is	is	rex22
,	,	y
how	how	rrq
the	the	at
drug	drug	nn1
is	be	vbz
expected	expect	vvn_jj
to	to	to
react	react	vvi
in	in	ii
the	the	at
human	human	jj_nn1
system	system	nn1
)	)	y
.	.	y
See	see	vv0
id	id	z'
.	.	y
It	it	pph1
must	must	vm
contain	contain	vvi
a	a	at1
wealth	wealth	nn1
of	of	io
clinical	clinical	jj
data	data	nn
from	from	ii
Phase	phase	nn1
I	i	zz1%_ppis1_mc1%
,	,	y
II	ii	mc
,	,	y
and	and	cc
IN	in	ii
clinical	clinical	jj
trials	trial	nn2
on	on	ii
humans	human	nn2
.	.	y
That	that	dd1
data	data	nn
must	must	vm
also	also	rr
be	be	vbi
accompanied	accompany	vvn
by	by	ii
an	a	at1
integrated	integrated	jj
summary	summary	nn1
of	of	io
the	the	at
product	product	nn1
's	's	ge
effectiveness	effectiveness	nn1
and	and	cc
safety	safety	nn1
profile	profile	nn1
,	,	y
along	along	ii21
with	with	ii22
hill	hill	nn1
disclosure	disclosure	nn1
of	of	io
the	the	at
study	study	nn1
results	result	nn2
.	.	y
Finally	finally	rr
,	,	y
the	the	at
NDA	nda	nn1_np1
must	must	vm
include	include	vvi
both	both	rr
a	a	at1
sample	sample	nn1
of	of	io
the	the	at
product	product	nn1
and	and	cc
the	the	at
product	product	nn1
's	be	vbz_ge
labeling	label	vvg_nn1@_jj@
.	.	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
(	(	y
n42	n42	fo
.	.	y
)	)	y
See	see	vv0
HUTT	hutt	np1
ET	et	ra21
AL.	al	ra22
,	,	y
supra	supra	nn1
note	note	nn1_vv0
18	18	mc
,	,	y
at	at	ii
688	688	mc
.	.	y
The	the	at
process	process	nn1
from	from	ii
the	the	at
discovery	discovery	nn1
of	of	io
a	a	at1
molecule	molecule	nn1
's	's	ge
treatment	treatment	nn1
potential	potential	nn1
to	to	ii
its	its	z'
submission	submission	nn1
in	in	ii
an	a	at1
NDA	nda	nn1
is	be	vbz
laborious	laborious	jj
,	,	y
long	long	rr_jj
,	,	y
and	and	cc
expensive	expensive	jj
.	.	y
On	on	ii
average	average	nn1_jj
,	,	y
for	for	if
10,000	10,000	mc
drugs	drug	nn2
identified	identify	vvn
as	as	csa
having	have	vhg
treatment	treatment	nn1
potential	potential	nn1_jj
and	and	cc
therefore	therefore	rr
submitted	submit	vvn_vvd
to	to	ii
laboratory	laboratory	nn1
and	and	cc
animal	animal	nn1
testing	testing	nn1_vvg
,	,	y
only	only	rr
one	one	pn1_mc1
might	might	vm
make	make	vvi
it	it	pph1
through	through	ii
Phase	phase	nn1
I	i	zz1%_ppis1_mc1%
,	,	y
II	ii	mc
,	,	y
and	and	cc
III	iii	mc
clinical	clinical	jj
testing	testing	nn1
on	on	ii
humans	human	nn2
and	and	cc
become	become	vv0
the	the	at
subject	subject	nn1
of	of	io
an	a	at1
NDA	nda	nn1
.	.	y
See	see	vv0
PhRMA	phrma	np1
,	,	y
Innovation	innovation	nn1
(	(	y
2008	2008	mc
)	)	y
,	,	y
http		nnu
:	:	y
**26;1432;TOOLONG		nn1
.	.	y
The	the	at
Tufts	tuft	nn2
Center	center	nn1
for	for	if
the	the	at
Study	study	nn1
of	of	io
Drug	drug	nn1
Development	development	nn1
,	,	y
for	for	rex21
example	example	rex22
,	,	y
calculated	calculate	vvd_vvn
that	that	cst
the	the	at
average	average	jj_nn1
cost	cost	nn1
of	of	io
bringing	bring	vvg
a	a	at1
new	new	jj
drug	drug	nn1
to	to	to
market	market	vvi
in	in	ii
2001	2001	mc
was	be	vbdz
$802,000,000		nnu
.	.	y
See	see	vv0
Joseph	joseph	np1
A.	a	zz
DiMasi	dimasi	np1
et	et	ra21
al.	al	ra22
,	,	y
The	the	at
Price	price	nn1
of	of	io
Innovation	innovation	nn1
:	:	y
New	new	jj
Estimates	estimate	nn2
of	of	io
Drug	drug	nn1
Development	development	nn1
Costs	cost	nn2_vvz
,	,	y
22	22	mc
J.	xx_j	np1
HEALTH	health	nn1
ECON.	econ	np1
151	151	mc
,	,	y
166	166	mc
(	(	y
2003	2003	mc
)	)	y
(	(	y
presenting	present	vvg
study	study	nn1
by	by	ii
Tufts	tuft	nn2
Center	center	nn1
for	for	if
the	the	at
Study	study	nn1
of	of	io
Drug	drug	nn1
Development	development	nn1
)	)	y
.	.	y
In	in	ii
a	a	at1
2006	2006	mc
study	study	nn1
,	,	y
the	the	at
Center	center	nn1
for	for	if
the	the	at
Study	study	nn1
of	of	io
Drug	drug	nn1
Development	development	nn1
pegged	peg	vvn_vvd@
the	the	at
average	average	jj_nn1
cost	cost	nn1
of	of	io
developing	develop	vvg
a	a	at1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
THE	the	at
STUDY	study	nn1
OF	of	io
DRUG	drug	nn1
DEVELOPMENT	development	nn1
,	,	y
OUTLOOK	outlook	nn1
2008	2008	mc
,	,	y
at	at	ii
2	2	mc
(	(	y
2008	2008	mc
)	)	y
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**48;1460;TOOLONG		fu
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n43.		fo
)	)	y
21	21	mc
U.S.C.	usc	np1
355(b)		fo
(	(	y
2000	2000	mc
)	)	y
.	.	y
CDER	cder	np1_nn1
examines	examine	vvz
six	six	mc
components	component	nn2
of	of	io
the	the	at
NDA	nda	np1_nn1
:	:	y
medical	medical	jj
,	,	y
biopharmaceutical	biopharmaceutical	jj
,	,	y
pharmacological	pharmacological	jj
,	,	y
statistical	statistical	jj
,	,	y
chemical	chemical	nn1_jj
,	,	y
and	and	cc
microbiological	microbiological	jj
.	.	y
Medical	medical	jj
reviewers	reviewer	nn2
are	be	vbr
responsible	responsible	jj
for	for	if
evaluating	evaluate	vvg
the	the	at
clinical	clinical	jj
sections	section	nn2
of	of	io
submissions	submission	nn2
and	and	cc
therefore	therefore	rr
take	take	vv0
the	the	at
lead	lead	nn1
role	role	nn1
in	in	ii
NDA	nda	np1_nn1
review	review	nn1
.	.	y
See	see	vv0
CTR	ctr	np1
.	.	y
FOR	for	if
DRUG	drug	nn1
EVALUATION	evaluation	nn1
&;		null
RESEARCH	research	nn1
,	,	y
FOOD	food	nn1
&;		null
DRUG	drug	nn1
ADMIN.	admin	np1
,	,	y
CDER		jjr_np1_vv0
HANDBOOK	handbook	nn1
15-19	15-19	mcmc
(	(	y
n1998		fo
)	)	y
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**37;1510;TOOLONG		fu
hereinafter	hereinafter	rr
CDER		jjr
HANDBOOK	handbook	nn1
.	.	y
CDER	cder	np1_nn1_vv0
may	may	vm
also	also	rr
host	host	vvi
Advisory	advisory	jj
Committee	committee	nn1
meetings	meeting	nn2
at	at	ii
this	this	dd1
stage	stage	nn1
to	to	to
obtain	obtain	vvi
outside	outside	jj_ii
advice	advice	nn1
and	and	cc
opinions	opinion	nn2
from	from	ii
experts	expert	nn2
.	.	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
11	11	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n44	n44	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
U.S.C.	usc	np1
352	352	mc
(	(	y
2000	2000	mc
)	)	y
;	;	y
21	21	mc
C.F.R.	c.f.r	np1
201.56	201.56	mc
(	(	y
2008	2008	mc
)	)	y
(	(	y
general	general	jj_nn1
requirements	requirement	nn2
for	for	if
prescription	prescription	nn1
drug	drug	nn1
labeling	label	vvg_nn1@
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n45	n45	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
201.56	201.56	mc
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n46	n46	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
201.57(a)		fo
(	(	y
6	6	mc
)	)	y
-(8)		nn1_jj
,	,	y
(	(	y
c	c	zz1
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
n47	n47	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
201.57(a)		fo
(	(	y
9	9	mc
)	)	y
,	,	y
(	(	y
c	c	zz1
)	)	y
(	(	y
5	5	mc
)	)	y
(	(	y
2008	2008	mc
)	)	y
(	(	y
requiring	require	vvg
a	a	at1
description	description	nn1
of	of	io
situations	situation	nn2
in	in	ii
which	which	ddq
the	the	at
drug	drug	nn1
should	should	vm
not	not	xx
be	be	vbi
used	use	vvn
because	because	cs
the	the	at
risk	risk	nn1
of	of	io
use	use	nn1
clearly	clearly	rr
outweighs	outweigh	vvz
any	any	dd
possible	possible	jj
benefit	benefit	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n48	n48	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
201.57(a)		fo
(	(	y
n10	n10	fo
)	)	y
,	,	y
(	(	y
c	c	zz1
)	)	y
(	(	y
6	6	mc
)	)	y
(	(	y
2008	2008	mc
)	)	y
(	(	y
requiring	require	vvg
a	a	at1
description	description	nn1
of	of	io
any	any	dd
serious	serious	jj
adverse	adverse	jj
reactions	reaction	nn2
and	and	cc
potential	potential	jj
safety	safety	nn1
hazards	hazard	nn2
,	,	y
subsequent	subsequent	jj
limitation	limitation	nn1
in	in	ii
use	use	nn1
,	,	y
and	and	cc
steps	step	nn2_vvz@
that	that	cst_dd1
should	should	vm
be	be	vbi
taken	take	vvn
if	if	cs_csw@
they	they	pphs2
occur	occur	vv0
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n49	n49	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
201.57(a)		fo
(	(	y
n10	n10	fo
)	)	y
,	,	y
(	(	y
c	c	zz1
)	)	y
(	(	y
6	6	mc
)	)	y
,	,	y
(	(	y
c	c	zz1
)	)	y
(	(	y
8	8	mc
)	)	y
(	(	y
2008	2008	mc
)	)	y
(	(	y
requiring	require	vvg
a	a	at1
description	description	nn1
of	of	io
any	any	dd
special	special	jj
care	care	nn1
to	to	to
be	be	vbi
exercised	exercise	vvn
for	for	if
the	the	at
safe	safe	jj_nn1@
and	and	cc
effective	effective	jj
use	use	nn1
of	of	io
the	the	at
drug	drug	nn1
,	,	y
including	including	ii_vvg@
general	general	jj_nn1
precautions	precaution	nn2
and	and	cc
information	information	nn1
for	for	if
patients	patient	nn2
on	on	ii
drug	drug	nn1
interactions	interaction	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n50	n50	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
201.57(a)		fo
(	(	y
n11	n11	fo
)	)	y
,	,	y
(	(	y
c	c	zz1
)	)	y
(	(	y
7	7	mc
)	)	y
(	(	y
2008	2008	mc
)	)	y
(	(	y
requiring	require	vvg
a	a	at1
description	description	nn1
of	of	io
any	any	dd
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
drug	drug	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n51	n51	fo
.	.	y
)	)	y
See	see	vv0
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
429	429	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n52.		fo
)	)	y
21	21	mc
C.F.R.	c.f.r	np1
202.1(e)		fo
(	(	y
2	2	mc
)	)	y
(	(	y
i	i	zz1
)	)	y
(	(	y
2008	2008	mc
)	)	y
.	.	y
PhRMA	phrma	np1@_nn1
's	's	ge
Guiding	guiding	jj
Principles	principle	nn2
urge	urge	vv0
its	its	z'
members	member	nn2
not	not	xx
to	to	to
engage	engage	vvi
in	in	ii_rp@
this	this	dd1
practice	practice	nn1
.	.	y
See	see	vv0
PHRMA	phrma	np1_nn1
,	,	y
PHRMA	phrma	np1_nn1
GUIDING	guide	vvg_jj@
PRINCIPLES	principle	nn2
:	:	y
DIRECT	direct	jj_vv0@_rr@
TO	to	ii
CONSUMER	consumer	nn1
ADVERTISEMENTS	advertisement	nn2
ABOUT	about	ii
PRESCRIPTION	prescription	nn1
MEDICINES	medicine	nn2
4	4	mc
(	(	y
2005	2005	mc
)	)	y
,	,	y
http		nnu
:	:	y
**46;1549;TOOLONG		fu
(	(	y
Principle	principle	nn1
10	10	mc
:	:	y
"	"	y
DTC	dtc	np1
television	television	nn1
advertising	advertising	nn1_vvg@
that	that	cst_dd1
identifies	identify	vvz
a	a	at1
product	product	nn1
by	by	ii
name	name	nn1
should	should	vm
clearly	clearly	rr
state	state	vvi
the	the	at
health	health	nn1
conditions	condition	nn2
for	for	if
which	which	ddq
the	the	at
medicine	medicine	nn1
is	be	vbz
approved	approve	vvn_jj
and	and	cc
the	the	at
major	major	jj
risks	risk	nn2
associated	associate	vvn
with	with	iw
the	the	at
medicine	medicine	nn1
being	be	vbg
advertised	advertise	vvn
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n53	n53	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
202.1(e)		fo
(	(	y
2	2	mc
)	)	y
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n54	n54	fo
.	.	y
)	)	y
Direct-to-Consumer	direct-to-consumer	jj_nn1
Promotion	promotion	nn1
;	;	y
Public	public	jj_nn1
Hearing	hearing	nn1
,	,	y
60	60	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
42,581	42,581	mc
,	,	y
42,582	42,582	mc
(	(	y
Aug.	aug	npm1
16	16	mc
,	,	y
1995	1995	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n55	n55	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
202.1(e)		fo
(	(	y
n1	n1	fo
)	)	y
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n56	n56	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
202.1(e)		fo
(	(	y
5	5	mc
)	)	y
-(6)	-(6)	nn1_jj
(	(	y
2008	2008	mc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
satisfy	satisfy	vvi
fair	fair	jj
balance	balance	nn1
requirements	requirement	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n57	n57	fo
.	.	y
)	)	y
See	see	vv0
KIM	kim	np1
SHEEHAN	sheehan	np1
,	,	y
CONTROVERSIES	controversy	nn2
IN	in	ii
CONTEMPORARY	contemporary	jj
ADVERTISING	advertising	nn1
209	209	mc
(	(	y
2004	2004	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n58	n58	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
210	210	mc
;	;	y
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
424	424	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n59	n59	fo
.	.	y
)	)	y
See	see	vv0
SHEEHAN	sheehan	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
57	57	mc
,	,	y
at	at	ii
210	210	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n60	n60	fo
.	.	y
)	)	y
Direct-to-Consumer	direct-to-consumer	jj_nn1
Advertising	advertising	nn1
of	of	io
Prescription	prescription	nn1
Drugs	drug	nn2
;	;	y
Withdrawal	withdrawal	nn1
of	of	io
Moratorium	moratorium	nn1
,	,	y
50	50	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
36,677	36,677	mc
(	(	y
Sept.	sept	npm1
9	9	mc
,	,	y
1985	1985	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n61	n61	fo
.	.	y
)	)	y
See	see	vv0
SHEEHAN	sheehan	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
57	57	mc
,	,	y
at	at	ii
210-11	210-11	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n62	n62	fo
.	.	y
)	)	y
FOOD	food	nn1
&;		null
DRUG	drug	nn1
ADMIN.	admin	np1
,	,	y
GUIDANCE	guidance	nn1
FOR	for	if
INDUSTRY	industry	nn1
:	:	y
CONSUMER-DIRECTED	consumer-directed	jj_nn1
BROADCAST	broadcast	nn1_jj@
ADVERTISEMENTS	advertisement	nn2
(	(	y
August	august	npm1
1999	1999	mc
)	)	y
hereinafter	hereinafter	rr
GUIDANCE	guidance	nn1
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**37;1597;TOOLONG		fu
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n63	n63	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
1	1	mc1
;	;	y
SHEEHAN	sheehan	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
57	57	mc
,	,	y
at	at	ii
211	211	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n64	n64	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
202.1(e)		fo
(	(	y
n1	n1	fo
)	)	y
(	(	y
2008	2008	mc
)	)	y
.	.	y
On	on	ii
September	september	npm1
27	27	mc
,	,	y
2007	2007	mc
,	,	y
the	the	at
President	president	nn1
signed	sign	vvd_vvn
the	the	at
Food	food	nn1
and	and	cc
Drug	drug	nn1
Administration	administration	nn1
Amendment	amendment	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
statement	statement	nn1
be	be	vbi
presented	present	vvn
in	in	ii
a	a	at1
"	"	y
clear	clear	jj
,	,	y
conspicuous	conspicuous	jj
and	and	cc
neutral	neutral	jj
manner	manner	nn1
.	.	y
"	"	y
FDA	fda	np1_nn1
Amendment	amendment	nn1
Act	act	nn1
of	of	io
2007	2007	mc
,	,	y
Pub	pub	nn1
.	.	y
L.	l	np1
No.	no	xx
110-85	110-85	mcmc
,	,	y
503(B)		fo
,	,	y
121	121	mc
Star	star	nn1_jj@
.	.	y
823	823	mc
,	,	y
940	940	mc
(	(	y
to	to	to
be	be	vbi
codified	codify	vvn@
at	at	ii
21	21	mc
U.S.C.	usc	np1
353(b)		fo
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n65	n65	fo
.	.	y
)	)	y
GUIDANCE	guidance	nn1
supra	supra	nn1
note	note	nn1_vv0
62	62	mc
,	,	y
at	at	ii
2-3	2-3	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n66	n66	fo
.	.	y
)	)	y
See	see	vv0
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
430	430	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n67	n67	fo
.	.	y
)	)	y
On	on	ii
May	may	npm1
8	8	mc
,	,	y
2008	2008	mc
,	,	y
Ruth	ruth	np1
S.	s	np1
Day	day	np1
,	,	y
Ph.D	ph.d	nna
,	,	y
testified	testify	vvd_vvn@
before	before	ii_cs
the	the	at
House	house	nn1
Committee	committee	nn1
on	on	ii
Energy	energy	nn1
and	and	cc
Commerce	commerce	nn1
,	,	y
Subcommittee	subcommittee	nn1
on	on	ii
Oversight	oversight	np1_nn1
and	and	cc
Investigations	investigation	nn2
,	,	y
on	on	ii
the	the	at
field	field	nn1
of	of	io
"	"	y
cognitive	cognitive	jj
accessibility	accessibility	nn1
,	,	y
"	"	y
which	which	ddq
is	be	vbz
the	the	at
study	study	nn1
of	of	io
what	what	ddq
people	people	nn
understand	understand	vv0
and	and	cc
remember	remember	vv0
after	after	ii
viewing	view	vvg
DTC	dtc	np1
advertising	advertising	nn1
.	.	y
Dr.	dr	nnb
Day	day	np1
recommended	recommend	vvd
that	that	cst
the	the	at
FDA	fda	nn1_np1
adopt	adopt	vv0
a	a	at1
formal	formal	jj
"	"	y
evidence-based	evidence-based	jj_nn1
approach	approach	nn1
"	"	y
for	for	if
analyzing	analyze	vvg
the	the	at
cognitive	cognitive	jj
accessibility	accessibility	nn1
of	of	io
broadcast	broadcast	nn1_jj@
DTC	dtc	np1
advertising	advertising	nn1
.	.	y
See	see	vv0
Direct-to-Consumer		np1
Drug	drug	nn1
Ads	ad	nn2
:	:	y
What	what	ddq
do	do	vd0
People	people	nn
Understand	understand	vv0
and	and	cc
Remember	remember	vv0
:	:	y
Hearing	hear	vvg_nn1
Before	before	ii_cs
Subcomm.	subcomm	np1
on	on	ii
Oversight	oversight	np1_nn1
&;		null
Investigations	investigation	nn2
of	of	io
the	the	at
H.	h	np1
Comm.	comm	np1
on	on	ii
Energy	energy	nn1
&;		null
Commerce	commerce	nn1
,	,	y
110th	110th	md
Cong	cong	np1
.	.	y
(	(	y
2008	2008	mc
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
http		nnu
:	:	y
**95;1636;TOOLONG		fu
.	.	y
Day-testimony.pdf	day-testimony.pdf	jj_nnu
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n68	n68	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
312.84(c)		fo
(	(	y
2008	2008	mc
)	)	y
(	(	y
FDA	fda	np1_nn1
not	not	xx
approvable	approvable	jj
for	for	if
marketing	marketing	nn1_vvg@
letter	letter	nn1
)	)	y
;	;	y
see	see	vv0
also	also	rr
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
429	429	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n69	n69	fo
.	.	y
)	)	y
See	see	vv0
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
429	429	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n70	n70	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
314.120(a)		fo
(	(	y
FDA	fda	np1_nn1
"	"	y
not	not	xx
approvable	approvable	jj
letter	letter	nn1
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n71	n71	fo
.	.	y
)	)	y
See	see	vv0
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
429	429	mc
.	.	y
A	a	at1
study	study	nn1
by	by	ii
the	the	at
General	general	jj_nn1
Accounting	accounting	nn1_vvg_jj@
Office	office	nn1
(	(	y
GAO	gao	np1
)	)	y
found	find	vvd
that	that	cst_dd1
,	,	y
in	in	ii
a	a	at1
five-year	five-year	jj
period	period	nn1
between	between	ii
August	august	npm1
1997	1997	mc
and	and	cc
August	august	npm1
2002	2002	mc
,	,	y
the	the	at
FDA	fda	np1_nn1
issued	issue	vvd
eighty-eight	eighty-eight	mc
NOV	nov	npm1
and	and	cc
warning	warning	nn1_vvg@
letters	letter	nn2
for	for	if
violative	violative	jj
DTC	dtc	np1
advertising	advertising	nn1
.	.	y
See	see	vv0
U.S.	us	np1
GEN	gen	nn1
.	.	y
ACCOUNTING	account	vvg_nn1_jj@
OFFICE	office	nn1
,	,	y
GAO-03-177		np1
,	,	y
PRESCRIPTION	prescription	nn1
DRUGS	drug	nn2
:	:	y
FDA	fda	np1_nn1
OVERSIGHT	oversight	nn1_np1
OF	of	io
DIRECT-TO-CONSUMER	direct-to-consumer	jj_nn1
ADVERTISING	advertising	nn1
HAS	have	vhz
LIMITATIONS	limitation	nn2
18	18	mc
(	(	y
2002	2002	mc
)	)	y
hereinafter	hereinafter	rr
2002	2002	mc
GAO	gao	np1
REPORT	report	nn1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n72	n72	fo
.	.	y
)	)	y
See	see	vv0
2002	2002	mc
GAO	gao	np1
REPORT	report	nn1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
71	71	mc
,	,	y
at	at	ii
21	21	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n73	n73	fo
.	.	y
)	)	y
FDA	fda	np1_nn1
Amendments	amendment	nn2
Act	act	nn1
of	of	io
2007	2007	mc
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
823	823	mc
,	,	y
939-42		mcmc
(	(	y
to	to	to
be	be	vbi
codified	codify	vvn@
at	at	ii
21	21	mc
U.S.C.	usc	np1
353b		fo
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n74	n74	fo
.	.	y
)	)	y
The	the	at
FDAAA	fdaaa	nn1_np1
provides	provide	vvz
the	the	at
FDA	fda	nn1
with	with	iw
authority	authority	nn1
to	to	ii
mandate	mandate	nn1
submission	submission	nn1
of	of	io
television	television	nn1
advertisements	advertisement	nn2
not	not	xx
later	later	rrr_jjr
than	than	csn
forty-five	forty-five	mc
days	day	nnt2
prior	prior	ii21
to	to	ii22
broadcast	broadcast	nn1
.	.	y
Id	id	z'
.	.	y
at	at	ii
939-43		mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n75	n75	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
202.1(j)		fo
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n76	n76	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
202.1(j)		fo
(	(	y
4	4	mc
)	)	y
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n77	n77	fo
.	.	y
)	)	y
User	user	nn1
Fee	fee	nn1
Program	program	nn1
for	for	if
Advisory	advisory	jj
Review	review	nn1
of	of	io
Direct-to-Consumer		np1
Television	television	nn1
Advertisements	advertisement	nn2
for	for	if
Prescription	prescription	nn1
Drug	drug	nn1
and	and	cc
Biological	biological	jj
Products	product	nn2
;	;	y
Request	request	vv0_nn1
for	for	if
Notification	notification	nn1
of	of	io
Participation	participation	nn1
and	and	cc
Number	number	nn1
of	of	io
Advertisements	advertisement	nn2
for	for	if
Review	review	nn1_np1@
,	,	y
72	72	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
60,677	60,677	mc
,	,	y
60,678	60,678	mc
(	(	y
Oct.	oct	npm1
25	25	mc
,	,	y
2007	2007	mc
)	)	y
hereinafter	hereinafter	rr
User	user	nn1
Fee	fee	nn1
Notice	notice	nn1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n78	n78	fo
.	.	y
)	)	y
PHRMA	phrma	np1_nn1
,	,	y
PHRMA	phrma	np1_nn1
GUIDING	guide	vvg_jj@
PRINCIPLES	principle	nn2
:	:	y
DIRECT	direct	jj_vv0@_rr@
TO	to	ii
CONSUMER	consumer	nn1
ADVERTISEMENTS	advertisement	nn2
ABOUT	about	ii
PRESCRIPTION	prescription	nn1
MEDICINES	medicine	nn2
5	5	mc
(	(	y
2005	2005	mc
)	)	y
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**46;1733;TOOLONG		fu
(	(	y
Principle	principle	nn1
8	8	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n79	n79	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
ELI	eli	np1
LILLY	lilly	np1
&;		null
CO.	co	np1_fo
,	,	y
PROVIDING	provide	vvg
VALUE	value	nn1
TO	to	ii
PATIENTS	patient	nn2
AND	and	cc
SOCIETY	society	nn1
:	:	y
LILLY	lilly	np1
CORPORATE	corporate	jj
CITIZENSHIP	citizenship	nn1
REPORT	report	nn1
2006-07	2006-07	mcmc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
GLAXOSMITHKLINE	glaxosmithkline	np1_vv0
,	,	y
ANSWERING	answer	vvg
THE	the	at
QUESTIONS	question	nn2
THAT	that	cst_dd1
MATTER	matter	vv0_nn1
:	:	y
CORPORATE	corporate	jj
RESPONSIBILITY	responsibility	nn1
REPORT	report	nn1
2007	2007	mc
,	,	y
at	at	ii
64	64	mc
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**72;1834;TOOLONG		fu
;	;	y
MERCK	merck	np1_vv0
,	,	y
MERCK	merck	np1
'S	's	ge
ALIGNMENT	alignment	nn1
WITH	with	iw
THE	the	at
"	"	y
PHRMA	phrma	nn1_np1
GUIDING	guide	vvg_jj@
PRINCIPLES--DIRECT		nn2
TO	to	ii
CONSUMER	consumer	nn1
ADVERTISEMENTS	advertisement	nn2
ABOUT	about	ii
PRESCRIPTION	prescription	nn1
MEDICINE	medicine	nn1
"	"	y
3	3	mc
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**83;1908;TOOLONG		fu
ingprinciplesfinal.pdf		nnu
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n80	n80	fo
.	.	y
)	)	y
See	see	vv0
2002	2002	mc
GAO	gao	np1
REPORT	report	nn1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
71	71	mc
,	,	y
at	at	ii
21-23	21-23	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n81	n81	fo
.	.	y
)	)	y
See	see	vv0
2006	2006	mc
GAO	gao	np1
REPORT	report	nn1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
4	4	mc
,	,	y
at	at	ii
21-27	21-27	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n82	n82	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
17-19	17-19	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n83	n83	fo
.	.	y
)	)	y
User	user	nn1
Fee	fee	nn1
Notice	notice	nn1_vv0
,	,	y
supra	supra	nn1
note	note	nn1_vv0
77	77	mc
,	,	y
at	at	ii
60,678	60,678	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n84	n84	fo
.	.	y
)	)	y
See	see	vv0
FDA	fda	nn1_np1
Amendments	amendment	nn2
Act	act	nn1
of	of	io
2007	2007	mc
,	,	y
Pub	pub	nn1
.	.	y
L.	l	np1
No.	no	xx
110-85	110-85	mcmc
,	,	y
Subsection	subsection	nn1_np1@
101-109		mcmc
,	,	y
121	121	mc
Star	star	nn1_jj@
.	.	y
823	823	mc
,	,	y
825-42		mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n85	n85	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n86	n86	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
104	104	mc
,	,	y
121	121	mc
Stat.	stat	np1
at	at	ii
837-38	837-38	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n87	n87	fo
.	.	y
)	)	y
User	user	nn1
Fee	fee	nn1
Program	program	nn1
for	for	if
Advisory	advisory	jj
Review	review	nn1
of	of	io
Direct-to-Consumer		np1
Television	television	nn1
Advertisements	advertisement	nn2
for	for	if
Prescription	prescription	nn1
Drugs	drug	nn2
and	and	cc
Biological	biological	jj
Products	product	nn2
;	;	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
2924	2924	mc
(	(	y
Jan.	jan	npm1
16	16	mc
,	,	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n88	n88	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
The	the	at
FDA	fda	nn1_np1
responded	respond	vvn_vvd
in	in	ii
May	may	npm1
2008	2008	mc
to	to	ii
a	a	at1
GAO	gao	np1
recommendation	recommendation	nn1
and	and	cc
developed	developed	jj_vvd
criteria	criteria	nn2
to	to	to
prioritize	prioritize	vvi
its	its	z'
review	review	nn1
of	of	io
promotional	promotional	jj
material	material	nn1
for	for	if
those	those	dd2
products	product	nn2
that	that	cst
have	have	vh0
the	the	at
greatest	greatest	jjt
potential	potential	nn1_jj
to	to	to
negatively	negatively	rr
affect	affect	vvi
the	the	at
public	public	jj_nn1
health	health	nn1
.	.	y
But	but	ccb
a	a	at1
GAO	gao	np1
representative	representative	nn1
testified	testify	vvd_vvn@
before	before	ii
a	a	at1
congressional	congressional	jj
subcommittee	subcommittee	nn1
that	that	cst
the	the	at
FDA	fda	nn1_np1
still	still	rr
needed	need	vvn_vvd
to	to	to
document	document	vvi
its	its	z'
application	application	nn1
of	of	io
that	that	dd1
criteria	criteria	nn2
and	and	cc
systematically	systematically	rr
track	track	vv0@
its	its	z'
review	review	nn1
of	of	io
voluntarily	voluntarily	rr
submitted	submit	vvn_vvd
materials	material	nn2
in	in	bcl21
order	order	bcl22
to	to	to
improve	improve	vvi
oversight	oversight	nn1
.	.	y
U.S.	us	np1
GEN	gen	nn1
.	.	y
ACCOUNTING	account	vvg_nn1_jj@
OFFICE	office	nn1
,	,	y
GAO-08-758T		np1
,	,	y
PRESCRIPTION	prescription	nn1
DRUGS	drug	nn2
:	:	y
TRENDS	trend	nn2
IN	in	ii
FDA	fda	np1
'S	's	ge
OVERSIGHT	oversight	nn1
OF	of	io
DIRECT-TO-CONSUMER	direct-to-consumer	jj_nn1
ADVERTISING	advertising	nn1
3	3	mc
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n89	n89	fo
.	.	y
)	)	y
See	see	vv0
supra	supra	nn1
Part	part	nn1
I.A.	ia	np1
<p>	<p>	y
--		nn1_jj
(	(	y
n90	n90	fo
.	.	y
)	)	y
See	see	vv0
supra	supra	nn1
Part	part	nn1
I.A.	ia	np1
<p>	<p>	y
--		nn1_jj
(	(	y
n91	n91	fo
.	.	y
)	)	y
Palumbo	palumbo	np1@
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
425	425	mc
n.18	n.18	fo
(	(	y
quoting	quote	vvg
S.	s	np1_nn1@
1944	1944	mc
,	,	y
73d	73d	nnu
Cong	cong	np1
.	.	y
9(c)	9(c)	fo
(	(	y
n1933		fo
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n92	n92	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
425-26	425-26	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n93	n93	fo
.	.	y
)	)	y
See	see	vv0
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
429	429	mc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
supra	supra	nn1
note	note	nn1_vv0
57	57	mc
,	,	y
at	at	ii
210	210	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n95	n95	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
216	216	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n96	n96	fo
.	.	y
)	)	y
A	a	zz1_at1
2007	2007	mc
study	study	nn1_vv0@
in	in	ii
the	the	at
Journal	journal	nn1
of	of	io
Health	health	nn1
Communication	communication	nn1
took	take	vvd
issue	issue	nn1
with	with	iw
the	the	at
FDA	fda	np1_nn1
's	's	ge
effectiveness	effectiveness	nn1
in	in	ii
policing	police	vvg
the	the	at
"	"	y
fair	fair	jj
balance	balance	nn1
"	"	y
requirement	requirement	nn1
,	,	y
finding	find	vvg
that	that	cst
the	the	at
average	average	nn1_jj
sixty-second	sixty-second	md_nnu
commercial	commercial	nn1@_jj
contained	contain	vvd_vvn
less	less	dar
than	than	csn
eight	eight	mc
seconds	second	nnt2
of	of	io
side-effect	side-effect	jj_nn1
information	information	nn1
.	.	y
See	see	vv0
Wendy	wendy	np1
Macias	macias	np1
et	et	ra21
al.	al	ra22
,	,	y
A	a	zz1_at1@
Wonderful	wonderful	jj
Life	life	nn1
or	or	cc
Diarrhea	diarrhea	np1
and	and	cc
Dry	dry	jj
Mouth	mouth	nn1
?	?	y
Policy	policy	nn1
Issues	issue	nn2
of	of	io
Direct-to-Consumer		np1
Drug	drug	nn1
Advertising	advertising	nn1_vvg@
on	on	ii
Television	television	nn1
,	,	y
22	22	mc
HEALTH	health	nn1
COMM.	comm	np1
241	241	mc
,	,	y
247	247	mc
(	(	y
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n97	n97	fo
.	.	y
)	)	y
See	see	vv0
Public	public	jj_nn1
Views	view	nn2
of	of	io
Direct-to-Consumer		np1
Prescription	prescription	nn1
Drug	drug	nn1
Advertising	advertising	nn1
:	:	y
Hearing	hear	vvg_nn1
Before	before	ii_cs
the	the	at
H.	h	np1
Subcomm.	subcomm	np1
on	on	ii
Oversight	oversight	np1_nn1
&;		null
Investigations	investigation	nn2
,	,	y
Comm.	comm	np1
on	on	ii
Energy	energy	nn1
&;		null
Commerce	commerce	nn1
,	,	y
110th	110th	md
Cong	cong	np1
.	.	y
1-7	1-7	mcmc
(	(	y
2008	2008	mc
)	)	y
(	(	y
statement	statement	nn1
of	of	io
Mollyann	mollyann	np1
Brodie	brodie	np1
,	,	y
Vice	vice	jj_ii
President	president	nn1
and	and	cc
Director	director	nn1
,	,	y
Public	public	nn1
Opinion	opinion	nn1
and	and	cc
Media	media	nn
Research	research	nn1_vv0@
,	,	y
Henry	henry	np1
J.	xx_j	np1
Kaiser	kaiser	nnb
Family	family	np1
Foundation	foundation	nn1
)	)	y
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**66;1993;TOOLONG		fu
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n98	n98	fo
.	.	y
)	)	y
See	see	vv0
Donohue	donohue	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
1	1	mc1
,	,	y
at	at	ii
676	676	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n99	n99	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
that	that	dd1_cst
violation	violation	nn1
letters	letter	nn2
sent	send	vvn
by	by	ii
the	the	at
FDA	fda	nn1_np1
to	to	ii
manufacturers	manufacturer	nn2
had	have	vhd
fallen	fall	vvn
from	from	ii
142	142	mc
in	in	ii
1997	1997	mc
to	to	ii_to
only	only	rr
21	21	mc
in	in	ii
2006	2006	mc
,	,	y
and	and	cc
attributing	attribute	vvg
the	the	at
decrease	decrease	nn1
to	to	ii
policies	policy	nn2
and	and	cc
understaffing	understaffing	vvg
at	at	ii
the	the	at
FDA	fda	nn1
that	that	cst
have	have	vh0
weakened	weaken	vvn
the	the	at
FDA	fda	np1_nn1
's	's	ge
capacity	capacity	nn1
to	to	to
enforce	enforce	vvi
these	these	dd2
regulations	regulation	nn2
)	)	y
;	;	y
2006	2006	mc
GAO	gao	np1
REPORT	report	nn1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
4	4	mc
,	,	y
at	at	ii
21-27	21-27	mcmc
.	.	y
Reconciling	reconcile	vvg
the	the	at
debate	debate	nn1
is	be	vbz
beyond	beyond	ii
the	the	at
scope	scope	nn1
of	of	io
this	this	dd1
Article	article	nn1
,	,	y
but	but	ccb
it	it	pph1
deserves	deserve	vvz
mention	mention	nn1_vv0
that	that	cst_dd1
such	such	da
a	a	at1
theory	theory	nn1
presupposes	presuppose	vvz
that	that	cst
transgressions	transgression	nn2
of	of	io
advertising	advertising	nn1_vvg@
regulations	regulation	nn2
remain	remain	vv0
constant	constant	jj_nn1@
in	in	ii31
proportion	proportion	ii32
to	to	ii33
spending	spending	nn1_vvg
(	(	y
that	that	rex21
is	is	rex22
,	,	y
violations	violation	nn2
are	be	vbr
occurring	occur	vvg
at	at	ii
the	the	at
same	same	da
rate	rate	nn1
,	,	y
but	but	ccb
are	be	vbr
going	go	vvg
undetected	undetected	jj
)	)	y
,	,	y
which	which	ddq
rejects	reject	vvz
the	the	at
notion	notion	nn1
of	of	io
applied	applied	jj
learning	learning	nn1
from	from	ii
previous	previous	jj
experience	experience	nn1
or	or	cc
the	the	at
use	use	nn1
of	of	io
DDMAC		np1_nn1
's	's	ge_vbz
voluntary	voluntary	jj
pre-market	pre-market	jj_nn1
advertising	advertising	nn1
review	review	nn1
.	.	y
It	it	pph1
should	should	vm
be	be	vbi
noted	note	vvn
that	that	cst_dd1
,	,	y
after	after	cs_ii
an	a	at1
initial	initial	jj_nn1
uptick	uptick	nn1
in	in	ii
1999	1999	mc
in	in	ii
companies	company	nn2
seeking	seek	vvg
FDA	fda	nn1_np1
input	input	nn1_vvn@
through	through	ii
launch-campaign	launch-campaign	jj
advisory	advisory	jj
letters	letter	nn2
pursuant	pursuant	ii21
to	to	ii22
the	the	at
FDA	fda	np1_nn1
's	's	ge_vbz
pre-market	pre-market	jj_nn1
voluntary	voluntary	jj
submission	submission	nn1
process	process	nn1_vv0
,	,	y
FDA	fda	np1_nn1
advisory	advisory	jj
letters	letter	nn2
have	have	vh0
remained	remain	vvn
relatively	relatively	rr
stable	stable	jj
from	from	ii
2000	2000	mc
to	to	ii
2005	2005	mc
.	.	y
This	this	dd1
fact	fact	nn1
suggests	suggest	vvz
that	that	cst
the	the	at
industry	industry	nn1
continues	continue	vvz
to	to	to
seek	seek	vvi
out	out	rp
the	the	at
FDA	fda	np1_nn1
's	's	ge
insight	insight	nn1
and	and	cc
approval	approval	nn1
before	before	ii
releasing	release	vvg
campaigns	campaign	nn2
to	to	ii
the	the	at
public	public	nn1_jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
CDER	cder	np1_vv0_nn1_jjr
2005	2005	mc
REPORT	report	nn1_vv0@
TO	to	ii
THE	the	at
NATION	nation	nn1
:	:	y
IMPROVING	improving	jj_vvg
PUBLIC	public	jj_nn1
HEALTH	health	nn1
THROUGH	through	ii
HUMAN	human	jj_nn1
DRUGS	drug	nn2
45	45	mc
(	(	y
2005	2005	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n100	n100	fo
.	.	y
)	)	y
See	see	vv0
SHEEHAN	sheehan	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
57	57	mc
,	,	y
at	at	ii
210	210	mc
;	;	y
see	see	vv0
also	also	rr
Louis	louis	np1
A.	a	zz
Morris	morris	np1
et	et	ra21
al.	al	ra22
,	,	y
The	the	at
Attitudes	attitude	nn2
of	of	io
Consumers	consumer	nn2
toward	toward	ii
Direct	direct	jj
Advertising	advertising	nn1
of	of	io
Prescription	prescription	nn1
Drugs	drug	nn2
,	,	y
101	101	mc
PUB	pub	nn1
.	.	y
HEALTH	health	nn1
REP.	rep	nn1
82	82	mc
,	,	y
87	87	mc
(	(	y
n1986		fo
)	)	y
,	,	y
cited	cite	vvn_vvd
in	in	ii
Palumbo	palumbo	np1
&;		null
Mullins	mullins	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
10	10	mc
,	,	y
at	at	ii
424	424	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n101	n101	fo
.	.	y
)	)	y
See	see	vv0
SHEEHAN	sheehan	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
57	57	mc
,	,	y
at	at	ii
215	215	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n102	n102	fo
.	.	y
)	)	y
Public	public	jj_nn1
Views	view	nn2
of	of	io
Direct-to-Consumer		np1
Advertising	advertising	nn1
of	of	io
Prescription	prescription	nn1
Drugs	drug	nn2
,	,	y
supra	supra	nn1
note	note	nn1_vv0
97	97	mc
,	,	y
at	at	ii
5	5	mc
,	,	y
12	12	mc
fig.7	fig.7	fo
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n103	n103	fo
.	.	y
)	)	y
See	see	vv0
SHEEHAN	sheehan	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
57	57	mc
,	,	y
at	at	ii
210	210	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n104	n104	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
Although	although	cs
it	it	pph1
continues	continue	vvz
to	to	to
support	support	vvi
a	a	at1
case-by-case	case-by-case	jj_nn1
approach	approach	nn1
,	,	y
the	the	at
AMA	ama	nn1_np1
remains	remain	vvz
generally	generally	rr
skeptical	skeptical	jj
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
.	.	y
In	in	ii
testimony	testimony	nn1
before	before	ii_cs
Congress	congress	nn1
in	in	ii
May	may	npm1
2008	2008	mc
,	,	y
it	it	pph1
recommended	recommend	vvd
additional	additional	jj
research	research	nn1
into	into	ii
the	the	at
effect	effect	nn1
,	,	y
if	if	cs
any	any	dd
,	,	y
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
on	on	ii
the	the	at
doctor-patient	doctor-patient	jj_nn1
relationship	relationship	nn1
.	.	y
Direct-to-Consumer	direct-to-consumer	jj_nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Before	before	ii_cs
the	the	at
H.	h	np1
Subcomm.	subcomm	np1
on	on	ii
Oversight	oversight	np1_nn1
&;		null
Investigation	investigation	nn1
of	of	io
the	the	at
H.	h	np1
Comm.	comm	np1
on	on	ii
Energy	energy	nn1
&;		null
Commerce	commerce	nn1
,	,	y
110th	110th	md
Cong	cong	np1
.	.	y
12	12	mc
(	(	y
2008	2008	mc
)	)	y
(	(	y
statement	statement	nn1
of	of	io
Nancy	nancy	np1
H.	h	np1
Nielson	nielson	np1
,	,	y
President	president	nnb
Elect	elect	np1
,	,	y
American	american	jj
Medical	medical	jj
Association	association	nn1
)	)	y
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**82;2061;TOOLONG		fu
AMA	ama	nn1_np1
additionally	additionally	rr
recommended	recommend	vvn_vvd
a	a	at1
set	set	nn1
of	of	io
guidelines	guideline	nn2
for	for	if
DTC	dtc	np1
advertising	advertising	nn1
,	,	y
including	including	ii_vvg@
a	a	at1
moratorium	moratorium	nn1
on	on	ii
DTC	dtc	np1
advertising	advertising	nn1
of	of	io
all	all	db
newly	newly	rr
approved	approved	jj_vvn
drugs	drug	nn2
until	until	cs_ii@
physicians	physician	nn2
"	"	y
have	have	vh0
been	be	vbn
appropriately	appropriately	rr
educated	educate	vvn
about	about	ii
the	the	at
drug	drug	nn1
.	.	y
"	"	y
Id	id	z'
.	.	y
at	at	ii
6-7	6-7	mcmc
.	.	y
The	the	at
AMA	ama	nn1_np1
recommends	recommend	vvz
that	that	cst
the	the	at
length	length	nn1
of	of	io
the	the	at
moratorium	moratorium	nn1
be	be	vbi
determined	determine	vvn
by	by	ii
the	the	at
FDA	fda	nn1_np1
in	in	ii31
consultation	consultation	ii32
with	with	ii33
the	the	at
manufacturer	manufacturer	nn1
and	and	cc
be	be	vbi
dependent	dependent	jj
upon	upon	ii
numerous	numerous	jj
factors	factor	nn2
,	,	y
including	including	ii_vvg@
the	the	at
innovative	innovative	jj
nature	nature	nn1
of	of	io
the	the	at
drug	drug	nn1
,	,	y
the	the	at
severity	severity	nn1
of	of	io
the	the	at
disease	disease	nn1
the	the	at
drug	drug	nn1
is	be	vbz
intended	intend	vvn
to	to	to
treat	treat	vvi
,	,	y
the	the	at
availability	availability	nn1
of	of	io
alternative	alternative	jj_nn1
therapies	therapy	nn2
,	,	y
and	and	cc
the	the	at
intensity	intensity	nn1
and	and	cc
the	the	at
timeliness	timeliness	nn1
of	of	io
education	education	nn1
about	about	ii
the	the	at
drug	drug	nn1
for	for	if
physicians	physician	nn2
who	who	pnqs
are	be	vbr
likely	likely	jj
to	to	to
prescribe	prescribe	vvi
it	it	pph1
.	.	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n105	n105	fo
.	.	y
)	)	y
SHEEHAN	sheehan	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
57	57	mc
,	,	y
at	at	ii
216	216	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n106	n106	fo
.	.	y
)	)	y
KATHRYN	kathryn	np1
J.	xx_j	np1
AIKIN	aikin	np1
,	,	y
DIRECT-TO-CONSUMER	direct-to-consumer	jj_nn1
ADVERTISING	advertising	nn1
OF	of	io
PRESCRIPTION	prescription	nn1
DRUGS	drug	nn2
:	:	y
PHYSICIAN	physician	nn1
SURVEY	survey	nn1_vv0@
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
<p>	<p>	y
--		nn1_jj
(	(	y
n107	n107	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
3	3	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n108	n108	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
32	32	mc
,	,	y
38	38	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n109	n109	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
34	34	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n110	n110	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
12	12	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n111	n111	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
12-13	12-13	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n112	n112	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
21	21	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n113	n113	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
22	22	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n114	n114	fo
.	.	y
)	)	y
See	see	vv0
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
OF	of	io
TORTS	tort	nn2
:	:	y
PRODUCTS	product	nn2
LIABILITY	liability	nn1
6	6	mc
(	(	y
n1998		fo
)	)	y
hereinafter	hereinafter	rr
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n115	n115	fo
.	.	y
)	)	y
See	see	vv0
Reyes		nn2_np1
v.	xx_v	ii
Wyeth	wyeth	np1
Labs.	lab	zz
,	,	y
498	498	mc
F.2d	f.2d	fo
1264	1264	mc
,	,	y
1276	1276	mc
(	(	y
5th	5th	md
Cir.	cir	np1
1974	1974	mc
)	)	y
(	(	y
"	"	y
Prescription	prescription	nn1
drugs	drug	nn2
are	be	vbr
likely	likely	jj
to	to	to
be	be	vbi
complex	complex	jj
medicines	medicine	nn2
,	,	y
esoteric	esoteric	jj
in	in	ii
formula	formula	nn1
and	and	cc
varied	vary	vvn_vvd
in	in	ii
effect	effect	nn1
.	.	y
As	as	ii_csa
a	a	at1
medical	medical	jj
expert	expert	nn1
,	,	y
the	the	at
prescribing	prescribing	nn1@
physician	physician	nn1
can	can	vm
take	take	vvi
into	into	ii
account	account	nn1_vv0
the	the	at
propensities	propensity	nn2
of	of	io
the	the	at
drug	drug	nn1
,	,	y
as	as	ii31
well	well	ii32
as	as	ii33
the	the	at
susceptibilities	susceptibility	nn2
of	of	io
his	his	appge
patient	patient	nn1_jj
.	.	y
His	his	ppge@
is	be	vbz
the	the	at
task	task	nn1
of	of	io
weighing	weigh	vvg
the	the	at
benefits	benefit	nn2
of	of	io
any	any	dd
medication	medication	nn1
against	against	ii
its	its	z'
potential	potential	jj_nn1
dangers	danger	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
an	a	at1
individualized	individualized	jj@
medical	medical	jj
judgment	judgment	nn1
bottomed	bottome	vvn_vvd
on	on	ii_rp@
a	a	at1
knowledge	knowledge	nn1
of	of	io
both	both	rr
patient	patient	jj
and	and	cc
palliative.		nnu
"	"	y
)	)	y
;	;	y
see	see	vv0
also	also	rr
In	in	rp@_ii
re	re	ii
Zyprexa	zyprexa	np1
Prods	prod	nn2
.	.	y
Liab	liab	vv0_nn1_np1@
.	.	y
Litig.	litig	np1
,	,	y
489	489	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
230	230	mc
,	,	y
266	266	mc
(	(	y
E.D.N.Y.	e.d.n.y	np1
2007	2007	mc
)	)	y
(	(	y
stating	state	vvg
that	that	dd1_cst
"	"	y
'	'	ge_"@
whether	whether	csw
the	the	at
physician	physician	nn1
in	in	ii
fact	fact	nn1
reads	read	vvz
the	the	at
drug	drug	nn1
manufacturer	manufacturer	nn1
's	's	ge
warning	warning	nn1
or	or	cc
passes	pass	vvz
its	its	z'
contents	content	nn2
along	along	rp
to	to	ii
the	the	at
recipient	recipient	nn1
of	of	io
the	the	at
drug	drug	nn1
is	be	vbz
irrelevant	irrelevant	jj
'	'	ge
"	"	y
for	for	if
purposes	purpose	nn2
of	of	io
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
(	(	y
quoting	quote	vvg
E.R.	er	np1
Squibb	squibb	np1
&;		null
Sons	son	nn2
,	,	y
Inc.	inc	jj
v.	xx_v	ii_nnu
Fames	fames	nn2
,	,	y
697	697	mc
So	so	rr
.	.	y
2d	2d	nnu
825	825	mc
,	,	y
827	827	mc
(	(	y
Fla.	fla	np1
1997	1997	mc
)	)	y
)	)	y
)	)	y
;	;	y
West	west	nd1
v.	xx_v	ii
Searle	searle	np1
&;		null
Co.	co	np1
,	,	y
806	806	mc
S.W.2d	s.w.2d	fo
608	608	mc
,	,	y
613-14		mcmc
(	(	y
Ark.	ark	np1
1991	1991	mc
)	)	y
(	(	y
stating	state	vvg
that	that	cst
physicians	physician	nn2
must	must	vm
make	make	vvi
independent	independent	jj
judgments	judgment	nn2
as	as	ii21
to	to	ii22
whether	whether	csw
drugs	drug	nn2
are	be	vbr
beneficial	beneficial	jj
for	for	if
their	their	appge
patients	patient	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n116	n116	fo
.	.	y
)	)	y
See	see	vv0
Diane	diane	np1
Schmauder		np1
Kane	kane	np1
,	,	y
Annotation	annotation	nn1
,	,	y
Construction	construction	nn1
and	and	cc
Application	application	nn1
of	of	io
the	the	at
Learned-Intermediary		np1
Doctrine	doctrine	nn1
,	,	y
57	57	mc
A.L.R.5th		fo
1	1	mc1
(	(	y
n1998		fo
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n117	n117	fo
.	.	y
)	)	y
See	see	vv0
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
,	,	y
supra	supra	nn1
note	note	nn1_vv0
114	114	mc
,	,	y
6	6	mc
cmt.	cmt	nnu
b	b	zz1
(	(	y
"	"	y
Only-health	only-health	jj_nn1
care	care	nn1
professionals	professional	nn2
are	be	vbr
in	in	ii
a	a	at1
position	position	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
assess	assess	vvi
the	the	at
relative	relative	jj_nn1
advantages	advantage	nn2
and	and	cc
disadvantages	disadvantage	nn2
of	of	io
a	a	at1
given	given	jj@
form	form	nn1
of	of	io
prescription-based	prescription-based	jj_nn1
therapy	therapy	nn1
.	.	y
"	"	y
)	)	y
;	;	y
see	see	vv0
also	also	rr
Barbara	barbara	np1
Pope	pope	nnb
Flannagan	flannagan	np1
,	,	y
Products	product	nn2
Liability	liability	nn1
:	:	y
The	the	at
Continued	continued	jj
Viability	viability	nn1
of	of	io
the	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Rule	rule	nn1
as	as	csa
it	it	pph1
Applies	apply	vvz
to	to	ii
Product	product	nn1
Warnings	warning	nn2
for	for	if
Prescription	prescription	nn1
Drugs	drug	nn2
,	,	y
20	20	mc
U.	u	np1
RICH	rich	np1@_jj
.	.	y
L.	l	np1_nnu@
REV.	rev	nnu
405	405	mc
,	,	y
412	412	mc
(	(	y
n1986		fo
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n118	n118	fo
.	.	y
)	)	y
See	see	vv0
Vitanza	vitanza	np1_nn1@
v.	xx_v	ii
Upjohn	upjohn	np1
Co.	co	np1
,	,	y
778	778	mc
A.2d	a.2d	fo
829	829	mc
,	,	y
846	846	mc
(	(	y
Conn.	conn	np1
2001	2001	mc
)	)	y
(	(	y
acknowledging	acknowledge	vvg
that	that	cst
a	a	at1
physician	physician	nn1
"	"	y
is	be	vbz
in	in	ii
the	the	at
best	best	jjt
position	position	nn1_vv0@
to	to	to
convey	convey	vvi
adequate	adequate	jj
warnings	warning	nn2
based	base	vvn
upon	upon	ii
the	the	at
highly	highly	rr
personal	personal	jj
doctor-patient	doctor-patient	jj_nn1
relationship	relationship	nn1
"	"	y
)	)	y
;	;	y
see	see	vv0
also	also	rr
West	west	nd1
,	,	y
806	806	mc
S.W.2d	s.w.2d	fo
at	at	ii
613	613	mc
(	(	y
listing	list	vvg
common	common	jj
rationales	rationale	nn2
supporting	support	vvg
the	the	at
doctrine	doctrine	nn1
)	)	y
;	;	y
Terhune	terhune	np1
v.	xx_v	ii
A.H	ah	np1
.	.	y
Robins	robins	np
Co.	co	np1_nn1
,	,	y
577	577	mc
P.2d	p.2d	fo
975	975	mc
,	,	y
978	978	mc
(	(	y
Wash	wash	nn1_vv0
.	.	y
1978	1978	mc
)	)	y
(	(	y
"	"	y
The	the	at
reasons	reason	nn2
for	for	if
this	this	dd1
rule	rule	nn1
should	should	vm
be	be	vbi
obvious	obvious	jj
.	.	y
"	"	y
)	)	y
;	;	y
David	david	np1
P.	xx_p	np1
Graham	graham	np1
&;		null
Jeremy	jeremy	np1
C.	c	np1
Vest	vest	nn1
,	,	y
Doctors	doctor	nn2
,	,	y
Drugs	drug	nn2
,	,	y
and	and	cc
Duties	duty	nn2
to	to	to_ii
Warn	warn	vv0
,	,	y
72	72	mc
DEF	def	np1_nn1_vv0
.	.	y
COUNS		nn2
.	.	y
J.	xx_j	np1
380	380	mc
,	,	y
381	381	mc
(	(	y
2005	2005	mc
)	)	y
(	(	y
"	"	y
The	the	at
assumptions	assumption	nn2
that	that	cst
underlie	underlie	vv0
the	the	at
doctrine	doctrine	nn1
are	be	vbr
that	that	cst
patients	patient	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
in	in	ii31
light	light	ii32
of	of	ii33
their	their	appge
experience	experience	nn1
and	and	cc
expertise	expertise	nn1
,	,	y
are	be	vbr
in	in	ii
a	a	at1
better	better	jjr
position	position	nn1
than	than	csn
their	their	appge
patients	patient	nn2
to	to	to
evaluate	evaluate	vvi
and	and	cc
communicate	communicate	vvi
the	the	at
manufacturers	manufacturer	nn2
'	'	ge
warnings	warning	nn2
directly	directly	rr
to	to	ii
the	the	at
patients	patient	nn2
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n119	n119	fo
.	.	y
)	)	y
See	see	vv0
Monica	monica	np1
Renee	renee	np1_nn1
Matter	matter	nn1_vv0
,	,	y
Emerging	emerge	vvg_jj
DTC	dtc	np1
Advertising	advertising	nn1
of	of	io
Prescription	prescription	nn1
Drugs	drug	nn2
and	and	cc
the	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Doctrine	doctrine	nn1
,	,	y
69	69	mc
DEF	def	np1_nn1_vv0
.	.	y
COUNS		nn2
.	.	y
J.	xx_j	np1
79	79	mc
,	,	y
81	81	mc
(	(	y
2002	2002	mc
)	)	y
(	(	y
discussing	discuss	vvg
common	common	jj
rationales	rationale	nn2
favoring	favor	vvg
the	the	at
rule	rule	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n120	n120	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Gravis	gravis	np1
v.	xx_v	ii
Parke-Davis	parke-davis	np1
&;		null
Co.	co	np1
,	,	y
502	502	mc
S.W.2d	s.w.2d	fo
863	863	mc
,	,	y
870	870	mc
(	(	y
Tex	tex	np1
.	.	y
Civ	civ	mc
.	.	y
App.	app	np1
1973	1973	mc
)	)	y
(	(	y
"	"	y
The	the	at
entire	entire	jj
system	system	nn1
of	of	io
drug	drug	nn1
distribution	distribution	nn1
in	in	ii
America	america	np1
is	be	vbz
set	set	vvn
up	up	rp
so	so	bcl21
as	as	bcl22
to	to	to
place	place	vvi
the	the	at
responsibility	responsibility	nn1
of	of	io
distribution	distribution	nn1
and	and	cc
use	use	vvi
upon	upon	ii
professional	professional	jj
people	people	nn
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n121	n121	fo
.	.	y
)	)	y
See	see	vv0
In	in	rp@
re	re	ii
Norplant	norplant	np1_nn1
Contraceptive	contraceptive	jj_nn1
Prods	prod	nn2
.	.	y
Liab	liab	vv0_nn1_np1@
.	.	y
Litig.	litig	np1
,	,	y
215	215	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
795	795	mc
,	,	y
806-09		mcmc
(	(	y
E.D.	ed	nn1
Tex	tex	np1
.	.	y
2002	2002	mc
)	)	y
(	(	y
concluding	conclude	vvg_jj
that	that	cst_dd1_rg%
forty-eight	forty-eight	mc
states	state	nn2
,	,	y
the	the	at
District	district	nn1
of	of	io
Columbia	columbia	np1
,	,	y
and	and	cc
Puerto	puerto	np1
Rico	rico	np1
have	have	vh0
either	either	rr
applied	apply	vvn
or	or	cc
recognized	recognize	vvd
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
,	,	y
and	and	cc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
A.2d	a.2d	fo
at	at	ii
838	838	mc
n.11	n.11	fo
(	(	y
finding	find	vvg_nn1
that	that	cst_dd1_rg%
forty-four	forty-four	mc
other	other	jj
jurisdictions	jurisdiction	nn2
have	have	vh0
adopted	adopt	vvn
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
,	,	y
including	including	ii_vvg@
lower	low	jjr
state	state	nn1
courts	court	nn2
and	and	cc
federal	federal	jj
courts	court	nn2
applying	apply	vvg
state	state	nn1
law	law	nn1
)	)	y
;	;	y
Larkin	larkin	np1
v.	xx_v	ii
Pfizer	pfizer	np1_nn1
,	,	y
Inc.	inc	jj
,	,	y
153	153	mc
S.W.3d	s.w.3d	fo
758	758	mc
,	,	y
767	767	mc
&;		null
n.3	n.3	fo
(	(	y
Ky.	ky	np1
2004	2004	mc
)	)	y
(	(	y
observing	observe	vvg
that	that	cst_dd1_rg%
thirty-four	thirty-four	mc
states	state	nn2
have	have	vh0
specifically	specifically	rr
adopted	adopt	vvn
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
)	)	y
.	.	y
West	west	np1
Virginia	virginia	np1
appears	appear	vvz
to	to	to
be	be	vbi
the	the	at
only	only	jj
state	state	nn1
expressly	expressly	rr
declining	decline	vvg_jj
to	to	to
adopt	adopt	vvi
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
.	.	y
See	see	vv0
State	state	nn1
ex	ex	ii
rel	rel	nn1
.	.	y
Johnson	johnson	np1
&;		null
Johnson	johnson	np1
Corp	corp	npx
.	.	y
v.	xx_v	ii
Karl	karl	np1
,	,	y
647	647	mc
S.E.2d	s.e.2d	fo
899	899	mc
,	,	y
914	914	mc
(	(	y
W.	w	np1
Va	va	fw
.	.	y
2007	2007	mc
)	)	y
.	.	y
New	new	np1
Jersey	jersey	np1
does	do	vdz
not	not	xx
apply	apply	vvi
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
where	where	cs_rrq
the	the	at
prescription	prescription	nn1
drug	drug	nn1
manufacturer	manufacturer	nn1
attempts	attempt	nn2_vvz@
to	to	to
advertise	advertise	vvi
directly	directly	rr
to	to	ii
consumers	consumer	nn2
and	and	cc
the	the	at
consumer	consumer	nn1
relies	rely	vvz
on	on	ii
that	that	dd1
advertisement	advertisement	nn1
.	.	y
See	see	vv0
Perez	perez	np1
v.	xx_v	ii
Wyeth	wyeth	np1
Labs.	lab	zz
,	,	y
734	734	mc
A.2d	a.2d	fo
1245	1245	mc
,	,	y
1257-58		mcmc
(	(	y
N.J.	nj	np1
1999	1999	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
MacDonald	macdonald	np1
v.	xx_v	ii
Ortho	ortho	np1
Pharm	pharm	np1_nn1
.	.	y
Corp.	corp	np1
,	,	y
475	475	mc
N.E.2d	n.e.2d	fo
65	65	mc
,	,	y
69	69	mc
(	(	y
Mass.	mass	np1
1985	1985	mc
)	)	y
(	(	y
recognizing	recognize	vvg
an	a	at1
exception	exception	nn1
to	to	ii
the	the	at
general	general	jj_nn1
application	application	nn1
of	of	io
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
for	for	if
oral	oral	jj_nn1
contraceptives	contraceptive	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n122	n122	fo
.	.	y
)	)	y
Sterling	sterling	nn1_jj@
Drug	drug	nn1
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
8th	8th	md
Cir.	cir	np1
1966	1966	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Hruska	hruska	np1_nn1@
v.	xx_v	ii
Parke	parke	np1
,	,	y
Davis	davis	np1
&;		null
Co.	co	np1
,	,	y
6	6	mc
F.2d	f.2d	fo
536	536	mc
,	,	y
538	538	mc
(	(	y
8th	8th	md
Cir.	cir	np1
1925	1925	mc
)	)	y
(	(	y
acknowledging	acknowledge	vvg
public	public	nn1
is	be	vbz
"	"	y
not	not	xx
on	on	ii
an	a	at1
equal	equal	jj
footing	footing	nn1
"	"	y
with	with	iw
prescription	prescription	nn1
drug	drug	nn1
manufacturers	manufacturer	nn2
in	in	ii31
terms	terms	ii32
of	of	ii33
knowledge	knowledge	nn1
)	)	y
;	;	y
Marcus	marcus	np1
v.	xx_v	ii
Specific	specific	jj
Pharms.		np1
,	,	y
77	77	mc
N.Y.S.2d	n.y.s.2d	fo
508	508	mc
,	,	y
508-10	508-10	mcmc
(	(	y
Sup	sup	vv0
.	.	y
Ct	ct	np1_nn1
.	.	y
1948	1948	mc
)	)	y
(	(	y
first	first	md
holding	holding	nn1@_vvg
that	that	cst
a	a	at1
manufacturer	manufacturer	nn1
's	's	ge
duty	duty	nn1
to	to	to
warn	warn	vvi
was	be	vbdz
fulfilled	fulfil	vvn
by	by	ii
Informing	inform	vvg
the	the	at
physician	physician	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n123	n123	fo
.	.	y
)	)	y
See	see	vv0
Kane	kane	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
116	116	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n124	n124	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Beyette		np1_nn1
v.	xx_v	ii
Ortho	ortho	np1
Pharm	pharm	np1_nn1
.	.	y
Corp.	corp	np1
,	,	y
823	823	mc
F.2d	f.2d	fo
990	990	mc
,	,	y
992	992	mc
(	(	y
6th	6th	md
Cir.	cir	np1
1987	1987	mc
)	)	y
;	;	y
Tetuan	tetuan	np1_nn1_jj
v.	xx_v	ii
A.H	ah	np1
.	.	y
Robins	robins	np
Co.	co	np1_nn1
,	,	y
738	738	mc
P.2d	p.2d	fo
1210	1210	mc
,	,	y
1227-28		mcmc
(	(	y
Karl	karl	np1
.	.	y
1987	1987	mc
)	)	y
;	;	y
Terhune	terhune	np1
v.	xx_v	ii
A.	a	zz
H.	h	np1
Robins	robins	np
Co.	co	np1_nn1
,	,	y
577	577	mc
P.2d	p.2d	fo
975	975	mc
,	,	y
978	978	mc
(	(	y
Wash	wash	nn1_vv0
.	.	y
1978	1978	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n125	n125	fo
.	.	y
)	)	y
See	see	vv0
RESTATEMENT	restatement	nn1
(	(	y
SECOND	second	md_nnt1
)	)	y
OF	of	io
TORTS	tort	nn2
388	388	mc
cmt.	cmt	nnu
n	xx_n	zz1
(	(	y
n1965		fo
)	)	y
(	(	y
"	"	y
Modern	modern	jj
life	life	nn1
would	would	vm
be	be	vbi
intolerable	intolerable	jj
unless	unless	cs
one	one	pn1
were	be	vbdr
permitted	permit	vvn
to	to	to
rely	rely	vvi
to	to	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
do	do	vd0
,	,	y
particularly	particularly	rr
if	if	cs
it	it	pph1
is	be	vbz
their	their	appge
duty	duty	nn1
to	to	to
do	do	vdi
so	so	rr
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n126	n126	fo
.	.	y
)	)	y
See	see	vv0
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
,	,	y
supra	supra	nn1
note	note	nn1_vv0
114	114	mc
,	,	y
6	6	mc
(	(	y
n1998		fo
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n127	n127	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
6	6	mc
cmt.	cmt	nnu
e	e	zz1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n128	n128	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
MISS	miss	nn1
.	.	y
CODE	code	nn1_vv0@
11-1-63(c)		nn1_jj
(	(	y
2008	2008	mc
)	)	y
;	;	y
N.C.	nc	np1
GEN	gen	nn1
.	.	y
STAT.	stat	np1
99B-5(c)		nn1_jj
(	(	y
2007	2007	mc
)	)	y
;	;	y
N.J.	nj	np1
STAT.	stat	np1
2A:58C-4		fo
(	(	y
2008	2008	mc
)	)	y
;	;	y
OHIO	ohio	np1
REV	rev	nnu
.	.	y
CODE	code	nn1_vv0@
2307.76	2307.76	mc
(	(	y
2008	2008	mc
)	)	y
(	(	y
codifying	codify	vvg
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n129	n129	fo
.	.	y
)	)	y
See	see	vv0
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
,	,	y
supra	supra	nn1
note	note	nn1_vv0
114	114	mc
,	,	y
6	6	mc
cmt.	cmt	nnu
e	e	zz1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n130	n130	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n131	n131	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Mazur	mazur	vv0_np1_nn1
v.	xx_v	ii
Merck	merck	np1
&;		null
Co.	co	np1_nn1
,	,	y
964	964	mc
F.2d	f.2d	fo
1348	1348	mc
,	,	y
1355	1355	mc
(	(	y
3d	3d	nnu
Cir.	cir	np1
1992	1992	mc
)	)	y
(	(	y
applying	apply	vvg
the	the	at
"	"	y
mass	mass	jj_nn1
immunization	immunization	nn1
exception	exception	nn1
"	"	y
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
in	in	ii
an	a	at1
action	action	nn1
brought	bring	vvn_vvd
against	against	ii
the	the	at
manufacturer	manufacturer	nn1
of	of	io
a	a	at1
measles	measles	nn
,	,	y
mumps	mumps	nn2_vvz
,	,	y
and	and	cc
rubella	rubella	nn1
vaccine	vaccine	nn1
(	(	y
MMR	mmr	np1
II	ii	mc
)	)	y
by	by	ii
the	the	at
parents	parent	nn2
of	of	io
a	a	at1
child	child	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
;	;	y
Brazzell	brazzell	np1_vv0@
v.	xx_v	ii
United	united	np1
States	state	np1
,	,	y
788	788	mc
F.2d	f.2d	fo
1352	1352	mc
,	,	y
1357-58	1357-58	mcmc
(	(	y
8th	8th	md
Cir.	cir	np1
1986	1986	mc
)	)	y
(	(	y
swine	swine	nn
flu	flu	nn1
vaccine	vaccine	nn1
)	)	y
;	;	y
Petty	petty	jj
v.	xx_v	ii
United	united	np1
States	state	np1
,	,	y
740	740	mc
F.2d	f.2d	fo
1428	1428	mc
,	,	y
1438-39	1438-39	mcmc
(	(	y
8th	8th	md
Cir.	cir	np1
1984	1984	mc
)	)	y
(	(	y
same	same	da
)	)	y
.	.	y
The	the	at
most	most	rgt
common	common	jj
example	example	nn1
of	of	io
the	the	at
mass	mass	jj_nn1
immunization	immunization	nn1
exception	exception	nn1
has	have	vhz
occurred	occur	vvn
with	with	iw
polio	polio	nn1
vaccines	vaccine	nn2
.	.	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Plummer	plummer	np1_nn1
v.	xx_v	ii
Lederle	lederle	np1
Labs.	lab	zz
,	,	y
819	819	mc
F.2d	f.2d	fo
349	349	mc
,	,	y
356	356	mc
(	(	y
2d	2d	nnu
Cir.	cir	np1
1987	1987	mc
)	)	y
;	;	y
Givens	given	np1
v.	xx_v	ii
Merle	merle	np1
,	,	y
556	556	mc
F.2d	f.2d	fo
1341	1341	mc
,	,	y
1345	1345	mc
(	(	y
5th	5th	md
Cir.	cir	np1
1977	1977	mc
)	)	y
;	;	y
Reyes	reyes	np1_nn2_vvz
v.	xx_v	ii
Wyeth	wyeth	np1
Labs.	lab	zz
,	,	y
498	498	mc
F.2d	f.2d	fo
1264	1264	mc
,	,	y
1276	1276	mc
(	(	y
5th	5th	md
Cir.	cir	np1
1974	1974	mc
)	)	y
;	;	y
Davis	davis	np1
v.	xx_v	ii
Wyeth	wyeth	np1
Labs.	lab	zz
,	,	y
399	399	mc
F.2d	f.2d	fo
121	121	mc
,	,	y
131	131	mc
(	(	y
9th	9th	md
Cir.	cir	np1
1968	1968	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Cunningham	cunningham	np1
v.	xx_v	ii
Charles	charles	np1
Pfizer	pfizer	np1
&;		null
Co.	co	np1
,	,	y
532	532	mc
P.2d	p.2d	fo
1377	1377	mc
,	,	y
1380	1380	mc
(	(	y
Okla.	okla	np1
1974	1974	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n132	n132	fo
.	.	y
)	)	y
See	see	vv0
Brooks	brooks	np1_nn2@
v.	xx_v	ii
Medtronic	medtronic	jj
,	,	y
750	750	mc
F.2d	f.2d	fo
1227	1227	mc
,	,	y
1232	1232	mc
(	(	y
4th	4th	md
Cir.	cir	np1
1984	1984	mc
)	)	y
(	(	y
"	"	y
'	'	ge_"@
The	the	at
exception	exception	nn1
established	establish	vvn_vvd
for	for	if
the	the	at
vaccine	vaccine	nn1
cases	case	nn2
is	be	vbz
quite	quite	rg
narrow	narrow	jj
and	and	cc
highly	highly	rr
fact	fact	nn1
specific	specific	jj_nn1%
.	.	y
'	'	"@_ge
"	"	y
(	(	y
quoting	quote	vvg
Stanback	stanback	nn1_np1
v.	xx_v	ii
Parke	parke	np1
,	,	y
Davis	davis	np1
&;		null
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
1981	1981	mc
)	)	y
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n133	n133	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Mazur	mazur	np1_vv0_nn1
,	,	y
964	964	mc
F.2d	f.2d	fo
at	at	ii
1363	1363	mc
(	(	y
stating	state	vvg
that	that	cst
it	it	pph1
is	be	vbz
not	not	xx
the	the	at
size	size	nn1
of	of	io
the	the	at
immunization	immunization	nn1
program	program	nn1_vv0@
that	that	cst
matters	matter	nn2
but	but	ccb
whether	whether	csw
the	the	at
vaccine	vaccine	nn1
is	be	vbz
administered	administer	vvn
"	"	y
without	without	iw
an	a	at1
individualized	individualized	jj@
medical	medical	jj
balancing	balancing	nn1@
of	of	io
the	the	at
risks	risk	nn2
and	and	cc
benefits	benefit	nn2
of	of	io
inoculation	inoculation	nn1
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n134	n134	fo
.	.	y
)	)	y
Walker	walker	np1_nn1
v.	xx_v	ii
Merck	merck	np1
&;		null
Co.	co	np1_nn1
,	,	y
648	648	mc
F.	f	np1_ra@
Supp.	supp	np1
931	931	mc
,	,	y
934-35		mcmc
(	(	y
M.D.	m.d	np1
Ga	ga	np1
.	.	y
1986	1986	mc
)	)	y
,	,	y
aff	aff	nn1_vv0
'd	have	vm_vhd
,	,	y
831	831	mc
F.2d	f.2d	fo
1069	1069	mc
(	(	y
11th	11th	md
Cir.	cir	np1
1987	1987	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n135	n135	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
932	932	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n136	n136	fo
.	.	y
)	)	y
Percival	percival	np1
v.	xx_v	ii
Cyanamid	cyanamid	np1_jj
Co.	co	np1_nn1
,	,	y
689	689	mc
F.	f	np1_ra@
Supp.	supp	np1
1060	1060	mc
,	,	y
1061-63		mcmc
(	(	y
W.D	w.d	np1
.	.	y
Okla.	okla	np1
1987	1987	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n137	n137	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
1062	1062	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n138	n138	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Mazur	mazur	np1_vv0_nn1
,	,	y
964	964	mc
F.2d	f.2d	fo
at	at	ii
1363	1363	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n139	n139	fo
.	.	y
)	)	y
See	see	vv0
Victor	victor	np1
E.	e	np1
Schwartz	schwartz	np1
&;		null
Liberty	liberty	nn1
Mahshigian	mahshigian	nn1@_jj
,	,	y
National	national	jj
Childhood	childhood	nn1
Vaccine	vaccine	nn1
Injury	injury	nn1
Act	act	nn1
of	of	io
1986	1986	mc
:	:	y
An	a	at1
Ad	ad	jj21
Hoc	hoc	jj22
Remedy	remedy	nn1
or	or	cc
a	a	at1
Window	window	nn1
for	for	if
the	the	at
Future	future	nn1_jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
394	394	mc
(	(	y
n1987		fo
)	)	y
(	(	y
discussing	discuss	vvg
the	the	at
availability	availability	nn1
of	of	io
vaccines	vaccine	nn2
as	as	csa_ii@
one	one	mc1
of	of	io
the	the	at
public	public	jj_nn1
policy	policy	nn1
reasons	reason	nn2
underlying	underlie	vvg_jj
Congress	congress	nn1
's	's	ge
enactment	enactment	nn1
of	of	io
a	a	at1
no-fault	no-fault	jj
system	system	nn1
for	for	if
compensation	compensation	nn1
of	of	io
childhood	childhood	nn1
vaccine-related	vaccine-related	nn1_jj
injuries	injury	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n140	n140	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Odgers	odgers	vvz_np1_nn2
v.	xx_v	ii
Ortho	ortho	np1_nn1
Pharm	pharm	np1_nn1
.	.	y
Corp.	corp	np1
,	,	y
609	609	mc
F.	f	np1_ra@
Supp.	supp	np1
867	867	mc
,	,	y
873-75		mcmc
(	(	y
E.D.	ed	nn1
Mich.	mich	np1
1985	1985	mc
)	)	y
;	;	y
Stephens	stephens	np1
v.	xx_v	ii
G.D	g.d	np1
.	.	y
Searle	searle	np1
&;		null
Co.	co	np1
,	,	y
602	602	mc
F.	f	np1_ra@
Supp.	supp	np1
379	379	mc
,	,	y
380-81	380-81	mcmc
(	(	y
E.D.	ed	nn1
Mich.	mich	np1
1985	1985	mc
)	)	y
;	;	y
Lukaszewicz		np1_vv0@
v.	xx_v	ii
Ortho	ortho	np1
Pharm	pharm	np1_nn1
.	.	y
Corp.	corp	np1
,	,	y
510	510	mc
F.	f	np1_ra@
Supp.	supp	np1
961	961	mc
,	,	y
964-65		mcmc
(	(	y
E.D.	ed	nn1
Wis.	wis	np1
1981	1981	mc
)	)	y
,	,	y
amended	amend	vvn_vvd
on	on	ii
other	other	jj
grounds	ground	nn2
,	,	y
532	532	mc
F.	f	np1_ra@
Supp.	supp	np1
211	211	mc
(	(	y
E.D.	ed	nn1
Wis.	wis	np1
1981	1981	mc
)	)	y
;	;	y
MacDonald	macdonald	np1
v.	xx_v	ii
Ortho	ortho	np1
Pharm	pharm	np1_nn1
.	.	y
Corp.	corp	np1
,	,	y
475	475	mc
N.E.2d	n.e.2d	fo
65	65	mc
,	,	y
69-70	69-70	mcmc
(	(	y
Mass.	mass	np1
1985	1985	mc
)	)	y
.	.	y
But	but	ccb
see	see	vv0
Reaves	reaves	nn2_np1
v.	xx_v	ii
Ortho	ortho	np1
Pharm	pharm	np1_nn1
.	.	y
Corp.	corp	np1
,	,	y
765	765	mc
F.	f	np1_ra@
Supp.	supp	np1
1287	1287	mc
,	,	y
1291	1291	mc
(	(	y
E.D.	ed	nn1
Mich.	mich	np1
1991	1991	mc
)	)	y
(	(	y
holding	hold	vvg
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
applicable	applicable	jj
in	in	ii
cases	case	nn2
involving	involve	vvg
oral	oral	jj_nn1
contraceptives	contraceptive	nn2
because	because	cs
oral	oral	jj
contraceptives	contraceptive	nn2
do	do	vd0
not	not	xx
significantly	significantly	rr
differ	differ	vvi
from	from	ii
other	other	jj
prescription	prescription	nn1
drugs	drug	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n141	n141	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
MacDonald	macdonald	np1
,	,	y
475	475	mc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n143	n143	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
70	70	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n144	n144	fo
.	.	y
)	)	y
See	see	vv0
Martin	martin	np1
v.	xx_v	ii
Ortho	ortho	np1
Pharm	pharm	np1_nn1
.	.	y
Corp.	corp	np1
,	,	y
661	661	mc
N.E.2d	n.e.2d	fo
352	352	mc
,	,	y
357	357	mc
(	(	y
Ill.	ill	z'
1996	1996	mc
)	)	y
(	(	y
concluding	conclude	vvg_jj
that	that	cst
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
relieved	relieved	jj_vvd_vvn
manufacturer	manufacturer	nn1
of	of	io
duty	duty	nn1
to	to	to
warn	warn	vvi
consumers	consumer	nn2
that	that	cst
its	its	z'
contraceptives	contraceptive	nn2
could	could	vm
cause	cause	vvi
physical	physical	jj
deformities	deformity	nn2
in	in	ii
children	child	nn2
whose	whose	ddqge
mothers	mother	nn2
ingested	ingest	vvd_vvn
it	it	pph1
during	during	ii
pregnancy	pregnancy	nn1
)	)	y
;	;	y
McEwen	mcewen	np1
v.	xx_v	ii
Ortho	ortho	np1
Pharm	pharm	np1_nn1
.	.	y
Corp.	corp	np1
,	,	y
528	528	mc
P.2d	p.2d	fo
522	522	mc
(	(	y
Or	or	cc
.	.	y
1974	1974	mc
)	)	y
(	(	y
finding	find	vvg
the	the	at
same	same	da
for	for	if
contraceptive	contraceptive	jj_nn1
warnings	warning	nn2
related	relate	vvn_vvd
to	to	ii
circulatory	circulatory	jj
and	and	cc
visual	visual	jj
damage	damage	nn1
)	)	y
;	;	y
see	see	vv0
also	also	rr
In	in	rp@_ii
re	re	ii
Norplant	norplant	np1_nn1
Contraceptive	contraceptive	jj_nn1
Prods	prod	nn2
.	.	y
Liab	liab	vv0_nn1_np1@
.	.	y
Litig.	litig	np1
,	,	y
955	955	mc
F.	f	np1_ra@
Supp.	supp	np1
700	700	mc
,	,	y
709	709	mc
(	(	y
E.D.	ed	nn1
Tex	tex	np1
.	.	y
1997	1997	mc
)	)	y
(	(	y
applying	apply	vvg
Texas	texas	np1
law	law	nn1
)	)	y
;	;	y
MacPherson	macpherson	np1
v.	xx_v	ii
Searle	searle	np1
&;		null
Co.	co	np1
,	,	y
775	775	mc
F.	f	np1_ra@
Supp.	supp	np1
417	417	mc
,	,	y
425-26	425-26	mcmc
(	(	y
D.D.C	d.d.c	np1
.	.	y
1991	1991	mc
)	)	y
(	(	y
applying	apply	vvg
District	district	nn1
of	of	io
Columbia	columbia	np1
law	law	nn1
)	)	y
;	;	y
Zanzuri		np1_nn1_jj
v.	xx_v	ii
G.D	g.d	np1
.	.	y
Searle	searle	np1
&;		null
Co.	co	np1
,	,	y
748	748	mc
F.	f	np1_ra@
Supp.	supp	np1
1511	1511	mc
,	,	y
1514-15		mcmc
(	(	y
S.D.	sd	np1
Fla.	fla	np1
1990	1990	mc
)	)	y
(	(	y
applying	apply	vvg
Florida	florida	np1
law	law	nn1
)	)	y
;	;	y
Goodson	goodson	np1
v.	xx_v	ii
Searle	searle	np1
Labs.	lab	zz
,	,	y
471	471	mc
F.	f	np1_ra@
Supp.	supp	np1
546	546	mc
,	,	y
549	549	mc
(	(	y
D.	d	np1
Conn.	conn	np1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
G.D	g.d	np1
.	.	y
Searle	searle	np1
,	,	y
441	441	mc
F.	f	np1_ra@
Supp.	supp	np1
377	377	mc
,	,	y
381	381	mc
(	(	y
D.	d	np1
Md.	md	nna
1975	1975	mc
)	)	y
,	,	y
aff	aff	nn1_vv0
'd	have	vm_vhd
,	,	y
567	567	mc
F.2d	f.2d	fo
269	269	mc
(	(	y
4th	4th	md
Cir.	cir	np1
1977	1977	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n145	n145	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Hill	hill	np1_nn1
v.	xx_v	ii
Searle	searle	np1
Labs.	lab	zz
,	,	y
Inc.	inc	jj
,	,	y
884	884	mc
F.2d	f.2d	fo
1064	1064	mc
,	,	y
1070	1070	mc
(	(	y
8th	8th	md
Cir.	cir	np1
1989	1989	mc
)	)	y
(	(	y
"	"	y
We	we	ppis2
believe	believe	vv0
that	that	cst
IUDs	iud	nn2
,	,	y
like	like	ii
other	other	jj
forms	form	nn2
of	of	io
birth	birth	nn1
control	control	nn1
,	,	y
are	be	vbr
atypical	atypical	jj
from	from	ii
most	most	dat
prescription	prescription	nn1
drug	drug	nn1
products	product	nn2
because	because	cs
the	the	at
treating	treat	vvg
physician	physician	nn1
generally	generally	rr
does	do	vdz
not	not	xx
make	make	vvi
an	a	at1
intervening	intervening	jj
,	,	y
individualized	individualize	vvd
medical	medical	jj
judgment	judgment	nn1
in	in	ii
the	the	at
birth	birth	nn1
control	control	nn1
decision	decision	nn1
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n146	n146	fo
.	.	y
)	)	y
Lacy	lacy	jj_np1@
v.	xx_v	ii
G.D	g.d	np1
.	.	y
Searle	searle	np1
&;		null
Co.	co	np1
,	,	y
567	567	mc
A.2d	a.2d	fo
398	398	mc
,	,	y
400	400	mc
(	(	y
Del.	del	np1
1989	1989	mc
)	)	y
(	(	y
applying	apply	vvg
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
to	to	ii
IUD	iud	nn1
manufacturer	manufacturer	nn1
where	where	cs_rrq
patient	patient	nn1
was	be	vbdz
required	require	vvn
to	to	to
undergo	undergo	vvi
surgical	surgical	jj
removal	removal	nn1
of	of	io
her	her	appge
ovaries	ovary	nn2
and	and	cc
fallopian	fallopian	jj_nn1
tubes	tube	nn2
after	after	ii_cs
the	the	at
IUD	iud	nn1
perforated	perforate	vvd@_vvn@
her	her	appge
uterus	uterus	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n147	n147	fo
.	.	y
)	)	y
See	see	vv0
Doe	doe	np1_nn1@
v.	xx_v	ii
Solvay	solvay	np1
Pharm.	pharm	np1
,	,	y
Inc.	inc	jj
,	,	y
350	350	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
257	257	mc
,	,	y
273	273	mc
(	(	y
D.	d	np1
Me.	me	nn1
2004	2004	mc
)	)	y
(	(	y
rejecting	reject	vvg
application	application	nn1
of	of	io
learned	learned	jj@
intermediary	intermediary	nn1
exception	exception	nn1
for	for	if
oral	oral	jj_nn1
contraceptives	contraceptive	nn2
to	to	to
failure-to-warn	failure-to-warn	vvi
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
for	for	if
treatment	treatment	nn1
of	of	io
obsessive-compulsive	obsessive-compulsive	jj
disorder	disorder	nn1
(	(	y
OCD	ocd	np1
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n148	n148	fo
.	.	y
)	)	y
See	see	vv0
Mitchell	mitchell	np1
v.	xx_v	ii
VLI		np1
Corp.	corp	np1
,	,	y
786	786	mc
F.	f	np1_ra@
Supp.	supp	np1
966	966	mc
,	,	y
970	970	mc
(	(	y
M.D.	m.d	np1
Fla.	fla	np1
1992	1992	mc
)	)	y
(	(	y
concluding	conclude	vvg_jj
that	that	cst
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
did	do	vdd
not	not	xx
apply	apply	vvi
in	in	ii_rp@
products	product	nn2
liability	liability	nn1
action	action	nn1
brought	bring	vvn
by	by	ii
user	user	nn1
of	of	io
a	a	at1
nonprescription	nonprescription	nn1
contraceptive	contraceptive	nn1_jj
sponge	sponge	nn1
)	)	y
;	;	y
cf.	cf	vv0
Prager	prager	nn1_vv0_np1
v.	xx_v	ii
Allergan	allergan	np1
,	,	y
Inc.	inc	jj
,	,	y
No.	no	xx
89-C-6721	89-c-6721	mc
,	,	y
1990	1990	mc
WL	wl	np1
70875	70875	mc
,	,	y
at	at	ii
*4	*4	fo
(	(	y
N.D.	nd	np1
Ill	ill	z'
.	.	y
May	may	npm1
2	2	mc
,	,	y
1990	1990	mc
)	)	y
(	(	y
holding	hold	vvg
that	that	dd1_cst
doctrine	doctrine	nn1
did	do	vdd
not	not	xx
apply	apply	vvi
to	to	ii
manufacturer	manufacturer	nn1
of	of	io
a	a	at1
nonprescription	nonprescription	nn1
contact	contact	nn1
lens	lens	nn1
solution	solution	nn1
that	that	cst
allegedly	allegedly	rr
caused	cause	vvn_vvd
plaintiff	plaintiff	nn1
permanent	permanent	jj
eye	eye	nn1
damage	damage	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n149	n149	fo
.	.	y
)	)	y
See	see	vv0
supra	supra	nn1
notes	note	nn2
140-48	140-48	mcmc
and	and	cc
accompanying	accompanying	jj_vvg
text	text	nn1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n150	n150	fo
.	.	y
)	)	y
Edwards	edwards	np1
v.	xx_v	ii
Basel	basel	np1
Pharms.		np1
,	,	y
933	933	mc
P.2d	p.2d	fo
298	298	mc
,	,	y
301	301	mc
(	(	y
Okla.	okla	np1
1997	1997	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n151	n151	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
303	303	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n152	n152	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n153.		fo
)	)	y
734	734	mc
A.2d	a.2d	fo
1245	1245	mc
(	(	y
N.J.	nj	np1
1999	1999	mc
)	)	y
.	.	y
Until	until	cs_ii@
2007	2007	mc
,	,	y
the	the	at
closest	closest	jjt
resemblance	resemblance	nn1
to	to	ii
the	the	at
Perez	perez	np1
ruling	ruling	nn1
came	come	vvd
in	in	ii_rp@
an	a	at1
Oklahoma	oklahoma	np1
Supreme	supreme	jj
Court	court	nn1
ruling	ruling	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
where	where	cs_rrq
the	the	at
FDA	fda	nn1_np1
mandated	mandate	vvn_jj@
communication	communication	nn1
of	of	io
a	a	at1
particular	particular	jj
warning	warning	nn1
directly	directly	rr
to	to	ii
the	the	at
patient	patient	nn1_jj
as	as	ii31_rg
well	well	ii32_rr
as	as	ii33_csa
to	to	ii
the	the	at
physician	physician	nn1
.	.	y
See	see	vv0
McKee	mckee	np1
v.	xx_v	ii
Moore	moore	np1
,	,	y
648	648	mc
P.2d	p.2d	fo
21	21	mc
,	,	y
25	25	mc
(	(	y
Okla.	okla	np1
1982	1982	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Edwards	edwards	np1
,	,	y
933	933	mc
P.2d	p.2d	fo
at	at	ii
303	303	mc
(	(	y
FDA	fda	np1_nn1
compliance	compliance	nn1
does	do	vdz
not	not	xx
necessarily	necessarily	rr
satisfy	satisfy	vvi
state	state	nn1
requirements	requirement	nn2
which	which	ddq
may	may	vm
or	or	cc
may	may	vm
not	not	xx
conform	conform	vvi
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
)	)	y
;	;	y
Tansy	tansy	nn1
v.	xx_v	ii
Dacomed	dacomed	jj
Corp.	corp	np1
,	,	y
890	890	mc
P.2d	p.2d	fo
881	881	mc
,	,	y
886	886	mc
(	(	y
Okla.	okla	np1
1994	1994	mc
)	)	y
(	(	y
applying	apply	vvg
the	the	at
exception	exception	nn1
to	to	ii
a	a	at1
medical	medical	jj
device	device	nn1
)	)	y
.	.	y
This	this	dd1
exception	exception	nn1
for	for	if
FDA-required	fda-required	jj_nn1
patient	patient	jj_nn1
warnings	warning	nn2
is	be	vbz
not	not	xx
based	base	vvn
on	on	ii
an	a	at1
impression	impression	nn1
of	of	io
an	a	at1
altered	altered	jj
medical	medical	jj
landscape	landscape	nn1
,	,	y
nor	nor	cc
does	do	vdz
it	it	pph1
apply	apply	vvi
to	to	ii
all	all	db
prescription	prescription	nn1
drugs	drug	nn2
.	.	y
Rather	rather	rr@_rg
,	,	y
it	it	pph1
is	be	vbz
tied	tie	vvn
to	to	ii
compliance	compliance	nn1
with	with	iw
existing	existing	jj
laws	law	nn2
applicable	applicable	jj
to	to	ii
a	a	at1
limited	limited	jj
subset	subset	nn1
of	of	io
prescription	prescription	nn1
drugs	drug	nn2
.	.	y
See	see	vv0
Edwards	edwards	np1
,	,	y
933	933	mc
P.2d	p.2d	fo
at	at	ii
301	301	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n154	n154	fo
.	.	y
)	)	y
Perez	perez	np1
,	,	y
734	734	mc
A.2d	a.2d	fo
at	at	ii
1251	1251	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n155	n155	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
1248	1248	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n156	n156	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
1247	1247	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n157	n157	fo
.	.	y
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
1247	1247	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n159	n159	fo
.	.	y
)	)	y
See	see	vv0
In	in	rp@
re	re	ii
Meridia	meridia	np1
Prods	prod	nn2
.	.	y
Liab	liab	vv0_nn1_np1@
.	.	y
Litig.	litig	np1
,	,	y
328	328	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
791	791	mc
,	,	y
812	812	mc
n.19	n.19	fo
(	(	y
N.D.	nd	np1
Ohio	ohio	np1
2004	2004	mc
)	)	y
(	(	y
"	"	y
In	in	ii
the	the	at
intervening	intervening	jj
period	period	nn1
after	after	ii_cs
Perez	perez	np1
,	,	y
no	no	at
other	other	jj
state	state	nn1
has	have	vhz
followed	follow	vvn
New	new	np1
Jersey	jersey	np1
's	's	ge
lead	lead	nn1
.	.	y
"	"	y
)	)	y
;	;	y
see	see	vv0
also	also	rr
Corey	corey	np1
Schaecher	schaecher	np1_nn1
,	,	y
Comment	comment	vv0_nn1
,	,	y
"	"	y
Ask	ask	vv0
Your	your	appge
Doctor	doctor	nn1
if	if	cs
This	this	dd1
Product	product	nn1
is	be	vbz
Right	right	jj
for	for	if
You	you	ppy
"	"	y
:	:	y
Perez	perez	np1
v.	xx_v	ii
Wyeth	wyeth	np1
Laboratories	laboratory	nn2
,	,	y
Inc.	inc	jj
,	,	y
Direct-to-Consumer		np1
Advertising	advertising	nn1
and	and	cc
the	the	at
Future	future	nn1
of	of	io
the	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Doctrine	doctrine	nn1
in	in	ii
the	the	at
Face	face	nn1
of	of	io
the	the	at
Flood	flood	nn1
of	of	io
Vioxx	vioxx	np1_nn1
Claims	claim	vvz_nn2
,	,	y
26	26	mc
ST	st	np1
.		np1
LOUIS	louis	np1
U.	u	np1
PUB	pub	nn1
.	.	y
L.	l	np1_nnu@
REV.	rev	nnu
421	421	mc
,	,	y
443	443	mc
(	(	y
2007	2007	mc
)	)	y
(	(	y
stating	state	vvg
that	that	dd1_cst
post-Perez	post-perez	jj
courts	court	nn2
have	have	vh0
been	be	vbn
"	"	y
reluctant	reluctant	jj
,	,	y
at	at	rr21
best	best	rr22
,	,	y
...	...	...
to	to	to
delineate	delineate	vvi
an	a	at1
exception	exception	nn1
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n160	n160	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
In	in	rp@_ii
re	re	ii
Meridia	meridia	np1
,	,	y
328	328	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
at	at	ii
812	812	mc
n.19	n.19	fo
(	(	y
"	"	y
The	the	at
Court	court	nn1
thus	thus	rr
could	could	vm
not	not	xx
apply	apply	vvi
Perez	perez	np1
's	's	ge
logic	logic	nn1
even	even	cs21
if	if	cs22
it	it	pph1
desired	desire	vvd
to	to	to
do	do	vdi
so	so	rr
.	.	y
"	"	y
)	)	y
;	;	y
In	in	rp@_ii
re	re	ii
Norplant	norplant	np1_nn1
Contraceptive	contraceptive	jj_nn1
Prods	prod	nn2
.	.	y
Liab	liab	vv0_nn1_np1@
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
827	827	mc
(	(	y
E.D.	ed	nn1
Tex	tex	np1
.	.	y
2002	2002	mc
)	)	y
(	(	y
"	"	y
This	this	dd1
argument	argument	nn1
...	...	...
lacks	lack	vvz
merit	merit	nn1
in	in	ii
all	all	db
jurisdictions	jurisdiction	nn2
,	,	y
except	except	cs_ii
New	new	np1
Jersey	jersey	np1
.	.	y
...	...	...
Apart	apart	ii21
from	from	ii22
New	new	np1
Jersey	jersey	np1
,	,	y
direct-to-consumer	direct-to-consumer	jj_nn1
advertising	advertising	nn1
does	do	vdz
not	not	xx
negate	negate	vvi
the	the	at
applicability	applicability	nn1
of	of	io
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
doctrine	doctrine	nn1
.	.	y
"	"	y
)	)	y
;	;	y
Vitanza	vitanza	nn1_np1@
v.	xx_v	ii
Upjohn	upjohn	np1
Co.	co	np1
,	,	y
778	778	mc
A.2d	a.2d	fo
829	829	mc
(	(	y
Conn.	conn	np1
2001	2001	mc
)	)	y
;	;	y
McCombs	mccombs	np1
v.	xx_v	ii
Synthes	synthes	np1_nn2
(	(	y
U.S.A.	usa	np1
)	)	y
,	,	y
587	587	mc
S.E.2d	s.e.2d	fo
594	594	mc
(	(	y
Ga	ga	np1
.	.	y
2003	2003	mc
)	)	y
;	;	y
Larkin	larkin	np1
v.	xx_v	ii
Pfizer	pfizer	np1_nn1
,	,	y
Inc.	inc	jj
,	,	y
153	153	mc
S.W.3d	s.w.3d	fo
758	758	mc
(	(	y
Ky.	ky	np1
2004	2004	mc
)	)	y
;	;	y
Freeman	freeman	nn1
v.	xx_v	ii
Hoffman-La	hoffman-la	np1
Roche	roche	np1
,	,	y
Inc.	inc	jj
,	,	y
618	618	mc
N.W.2d	n.w.2d	fo
827	827	mc
(	(	y
Neb.	neb	np1
2000	2000	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n161	n161	fo
.	.	y
)	)	y
State	state	vv0_nn1
ex	ex	ii
rel	rel	nn1
.	.	y
Johnson	johnson	np1
&;		null
Johnson	johnson	np1
Corp	corp	npx
.	.	y
v.	xx_v	ii
Karl	karl	np1
,	,	y
647	647	mc
S.E.2d	s.e.2d	fo
899	899	mc
(	(	y
W.	w	np1
Va	va	fw
.	.	y
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
162	162	mc
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
906	906	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n163	n163	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
910	910	mc
(	(	y
quoting	quote	vvg
Lars	lars	np1
Noah	noah	np1
,	,	y
Advertising	advertising	nn1_vvg@
Prescription	prescription	nn1
Drugs	drug	nn2
to	to	ii
Consumers	consumer	nn2
:	:	y
Assessing	assess	vvg
the	the	at
Regulatory	regulatory	jj
and	and	cc
Liability	liability	nn1
Issues	issue	nn2
,	,	y
32	32	mc
GA	ga	np1
.	.	y
L.	l	np1_nnu@
REV.	rev	nnu
141	141	mc
,	,	y
160-61	160-61	mcmc
n.78		fo
(	(	y
1997	1997	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n164	n164	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
.	.	y
at	at	ii
908-09		mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n166	n166	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
913	913	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n167	n167	fo
.	.	y
)	)	y
See	see	vv0
supra	supra	nn1
notes	note	nn2
153--58		mcmc
and	and	cc
accompanying	accompanying	jj_vvg
text	text	nn1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n168	n168	fo
.	.	y
)	)	y
Karl	karl	np1
,	,	y
647	647	mc
S.E.2d	s.e.2d	fo
at	at	ii
917	917	mc
(	(	y
Albright	albright	np1_nn1
,	,	y
J.	xx_j	np1
,	,	y
dissenting	dissent	vvg
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n169	n169	fo
.	.	y
)	)	y
See	see	vv0
Am	am	ra@
.	.	y
Med	med	np1@_vvd
.	.	y
Ass'n	ass'n	vv0_nn1_np1@
,	,	y
Council	council	nn1
on	on	ii
Ethical	ethical	jj
&;		null
Judicial	judicial	jj
Affairs	affair	nn2
,	,	y
Code	code	nn1
of	of	io
Medical	medical	jj
Ethics	ethics	nn
,	,	y
Direct-to-Consumer		np1
Advertising	advertising	nn1
of	of	io
Prescription	prescription	nn1
Drugs	drug	nn2
,	,	y
Op.	op	nn1
5-015		mcmc
,	,	y
at	at	ii
126	126	mc
(	(	y
2006-2007	2006-2007	mcmc
)	)	y
(	(	y
"	"	y
Physicians	physician	nn2
must	must	vm
maintain	maintain	vvi
professional	professional	jj
standards	standard	nn2
of	of	io
informed	informed	jj@
consent	consent	nn1
when	when	cs
prescribing	prescribe	vvg
.	.	y
When	when	cs
a	a	at1
patient	patient	nn1
comes	come	vvz
to	to	ii
a	a	at1
physician	physician	nn1
with	with	iw
a	a	at1
request	request	nn1
for	for	if
a	a	at1
drug	drug	nn1
he	he	pphs1
or	or	cc
she	she	pphs1
has	have	vhz
seen	see	vvn
advertised	advertise	vvn_vvd_jj@
,	,	y
the	the	at
physician	physician	nn1
and	and	cc
the	the	at
patient	patient	nn1
should	should	vm
engage	engage	vvi
in	in	ii_rp@
a	a	at1
dialogue	dialogue	nn1
that	that	cst_dd1
would	would	vm
assess	assess	vvi
and	and	cc
enhance	enhance	vvi
the	the	at
patient	patient	nn1
's	's	ge
understanding	understanding	nn1
of	of	io
the	the	at
treatment	treatment	nn1
.	.	y
Although	although	cs
physicians	physician	nn2
should	should	vm
not	not	xx
be	be	vbi
biased	bias	vvn@
against	against	ii
drugs	drug	nn2
that	that	cst
are	be	vbr
advertised	advertise	vvn
,	,	y
physicians	physician	nn2
should	should	vm
resist	resist	vvi
commercially	commercially	rr
induced	induce	vvn_jj@_vvd
pressure	pressure	nn1
to	to	to
prescribe	prescribe	vvi
drugs	drug	nn2
that	that	cst_dd1
may	may	vm
not	not	xx
be	be	vbi
indicated	indicate	vvn
.	.	y
Physicians	physician	nn2
should	should	vm
deny	deny	vvi
requests	request	nn2
for	for	if
inappropriate	inappropriate	jj
prescriptions	prescription	nn2
and	and	cc
educate	educate	vvi
patients	patient	nn2
as	as	ii21
to	to	ii22
why	why	rrq
certain	certain	jj
advertised	advertised	jj@
drugs	drug	nn2
may	may	vm
not	not	xx
be	be	vbi
suitable	suitable	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
cost	cost	nn1
effectiveness	effectiveness	nn1
of	of	io
different	different	jj
options	option	nn2
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n170	n170	fo
.	.	y
)	)	y
See	see	vv0
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
OF	of	io
TORTS	tort	nn2
:	:	y
PRODUCTS	product	nn2
LIABILITY	liability	nn1
103	103	mc
(	(	y
Council	council	nn1
Draft	draft	nn1_vv0
No.	no	xx
1	1	mc1
,	,	y
1993	1993	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Noah	noah	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
163	163	mc
,	,	y
at	at	ii
162-63	162-63	mcmc
(	(	y
detailing	detail	vvg
the	the	at
Restatement	restatement	nn1
Reporters	reporter	nn2
'	'	ge
changes	change	nn2
regarding	regarding	ii
DTC	dtc	np1
advertising	advertising	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n171	n171	fo
.	.	y
)	)	y
See	see	vv0
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
OF	of	io
TORTS	tort	nn2
:	:	y
PRODUCTS	product	nn2
LIABILITY	liability	nn1
4(b)	4(b)	fo
(	(	y
3	3	mc
)	)	y
(	(	y
Council	council	nn1
Draft	draft	nn1_vv0
No.	no	xx
1A	1a	fo
,	,	y
1994	1994	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n172	n172	fo
.	.	y
)	)	y
Id.	id	z'
,	,	y
Memorandum	memorandum	nn1
at	at	ii
2	2	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n173	n173	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
(	(	y
"	"	y
We	we	ppis2
have	have	vh0
removed	remove	vvn
from	from	ii
the	the	at
black	black	jj
letter	letter	nn1
a	a	at1
special	special	jj
exception	exception	nn1
to	to	ii
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
for	for	if
direct	direct	jj
advertising	advertising	nn1
to	to	ii
patients	patient	nn2
.	.	y
Instead	instead	rr
we	we	ppis2
have	have	vh0
amended	amend	vvn
comment	comment	nn1_vv0
e	e	zz1
to	to	to
indicate	indicate	vvi
that	that	dd1_cst
,	,	y
where	where	cs_rrq
government	government	nn1
agencies	agency	nn2
mandate	mandate	nn1
that	that	cst
advertisements	advertisement	nn2
carry	carry	vv0
warnings	warning	nn2
to	to	ii
patients	patient	nn2
,	,	y
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
does	do	vdz
not	not	xx
apply	apply	vvi
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n174	n174	fo
.	.	y
)	)	y
The	the	at
learned	learned	jj@
intermediary	intermediary	nn1
exception	exception	nn1
relevant	relevant	jj
to	to	ii
advertisements	advertisement	nn2
was	be	vbdz
amended	amend	vvn
such	such	cs21
that	that	cs22
liability	liability	nn1
could	could	vm
exist	exist	vvi
if	if	csw@_cs
"	"	y
reasonable	reasonable	jj
instructions	instruction	nn2
or	or	cc
warnings	warning	nn2
regarding	regarding	ii_vvg
foreseeable	foreseeable	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
were	be	vbdr
not	not	xx
provided	provide	vvn
directly	directly	rr
to	to	ii
the	the	at
patient	patient	nn1_jj
when	when	cs_rrq
the	the	at
manufacturer	manufacturer	nn1
knew	know	vvd
or	or	cc
had	have	vhd_vhn@
reason	reason	nn1
to	to	to
know	know	vvi
that	that	cst
no	no	at
medical	medical	jj
provider	provider	nn1
would	would	vm
be	be	vbi
in	in	ii
the	the	at
position	position	nn1
"	"	y
to	to	to
reduce	reduce	vvi
the	the	at
risks	risk	nn2
of	of	io
harm	harm	nn1
through	through	ii
appropriate	appropriate	jj
warnings	warning	nn2
or	or	cc
instructions	instruction	nn2
.	.	y
"	"	y
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
OF	of	io
TORTS	tort	nn2
:	:	y
PRODUCTS	product	nn2
LIABILITY	liability	nn1
4(b)	4(b)	fo
(	(	y
3	3	mc
)	)	y
(	(	y
Tentative	tentative	jj
Draft	draft	nn1
No.	no	xx
1	1	mc1
,	,	y
1994	1994	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n175	n175	fo
.	.	y
)	)	y
See	see	vv0
Noah	noah	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
163	163	mc
,	,	y
at	at	ii
166	166	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n176	n176	fo
.	.	y
)	)	y
RESTATEMENT	restatement	nn1
(	(	y
THIRD	third	md
)	)	y
,	,	y
supra	supra	nn1
note	note	nn1_vv0
114	114	mc
,	,	y
at	at	ii
6	6	mc
cmt.	cmt	nnu
e	e	zz1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n177	n177	fo
.	.	y
)	)	y
See	see	vv0
Vitanza	vitanza	np1_nn1@
v.	xx_v	ii
Upjohn	upjohn	np1
Co.	co	np1
,	,	y
778	778	mc
A.2d	a.2d	fo
829	829	mc
(	(	y
Conn.	conn	np1
2001	2001	mc
)	)	y
;	;	y
McCombs	mccombs	np1
v.	xx_v	ii
Synthes	synthes	np1_nn2
(	(	y
U.S.A.	usa	np1
)	)	y
,	,	y
587	587	mc
S.E.2d	s.e.2d	fo
594	594	mc
(	(	y
Ga	ga	np1
.	.	y
2003	2003	mc
)	)	y
;	;	y
Larkin	larkin	np1
v.	xx_v	ii
Pfizer	pfizer	np1_nn1
,	,	y
Inc.	inc	jj
,	,	y
153	153	mc
S.W.3d	s.w.3d	fo
758	758	mc
(	(	y
Ky.	ky	np1
2004	2004	mc
)	)	y
;	;	y
Freeman	freeman	nn1
v.	xx_v	ii
Hoffman-La	hoffman-la	np1
Roche	roche	np1
,	,	y
Inc.	inc	jj
,	,	y
618	618	mc
N.W.2d	n.w.2d	fo
827	827	mc
(	(	y
Neb.	neb	np1
2000	2000	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n178	n178	fo
.	.	y
)	)	y
See	see	vv0
Rohrbough	rohrbough	nn1_vv0_np1
by	by	ii
Rohrbough	rohrbough	np1_nn1
v.	xx_v	ii
Wyeth	wyeth	np1
Labs.	lab	zz
,	,	y
719	719	mc
F.	f	np1_ra@
Supp.	supp	np1
470	470	mc
,	,	y
478	478	mc
(	(	y
N.D.	nd	np1
W.	w	np1
Va	va	fw
.	.	y
1989	1989	mc
)	)	y
(	(	y
finding	find	vvg_nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Toxoids	toxoids	nn2_np1
and	and	cc
Pertussis	pertussis	np1_nn1
Vaccine	vaccine	nn1
(	(	y
DTP	dtp	nn1
)	)	y
in	in	ii
a	a	at1
public	public	jj_nn1
health	health	nn1
clinic	clinic	nn1
qualified	qualify	vvn
as	as	ii
a	a	at1
learned	learned	jj@
intermediary	intermediary	nn1
)	)	y
,	,	y
aff	aff	nn1_vv0
'd	have	vhd_vm
on	on	ii
other	other	jj
grounds	ground	nn2
916	916	mc
F.2d	f.2d	fo
970	970	mc
(	(	y
4th	4th	md
Cir.	cir	np1
1990	1990	mc
)	)	y
;	;	y
Walker	walker	np1
v.	xx_v	ii
Merck	merck	np1
&;		null
Co.	co	np1_nn1
,	,	y
648	648	mc
F.	f	np1_ra@
Supp.	supp	np1
931	931	mc
,	,	y
934	934	mc
(	(	y
M.D.	m.d	np1
Ga	ga	np1
.	.	y
1986	1986	mc
)	)	y
;	;	y
Singleton	singleton	np1
v.	xx_v	ii
Airco	airco	np1
,	,	y
Inc.	inc	jj
,	,	y
314	314	mc
S.E.2d	s.e.2d	fo
680	680	mc
,	,	y
682	682	mc
(	(	y
Ga	ga	np1
.	.	y
Ct	ct	np1_nn1
.	.	y
App.	app	np1
1984	1984	mc
)	)	y
(	(	y
implying	imply	vvg
a	a	at1
nurse	nurse	nn1
anesthetist	anesthetist	nn1
qualified	qualify	vvn
as	as	ii
a	a	at1
learned	learned	jj@
intermediary	intermediary	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n179	n179	fo
.	.	y
)	)	y
See	see	vv0
Haste	haste	vv0_nn1
v.	xx_v	nnu_ii
Am	am	ra@
.	.	y
Home	home	nn1_rl
Prods	prod	nn2
.	.	y
Corp.	corp	np1
,	,	y
577	577	mc
F.2d	f.2d	fo
1122	1122	mc
,	,	y
1124	1124	mc
(	(	y
10th	10th	md
Cir.	cir	np1
1978	1978	mc
)	)	y
,	,	y
cert	cert	nn1
.	.	y
denied	deny	vvn_vvd
439	439	mc
U.S.	us	np1
955	955	mc
(	(	y
1978	1978	mc
)	)	y
(	(	y
suggesting	suggest	vvg
a	a	at1
veterinarian	veterinarian	nn1
could	could	vm
be	be	vbi
a	a	at1
learned	learned	jj@
intermediary	intermediary	nn1
in	in	ii
product	product	nn1
liability	liability	nn1
action	action	nn1
brought	bring	vvn_vvd
against	against	ii
the	the	at
manufacturer	manufacturer	nn1
of	of	io
an	a	at1
animal	animal	nn1
vaccine	vaccine	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n180	n180	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Smith	smith	np1
v.	xx_v	ii
Walter	walter	np1
C.	c	np1
Best	best	rrt
,	,	y
Inc.	inc	jj
,	,	y
927	927	mc
F.2d	f.2d	fo
736	736	mc
,	,	y
739	739	mc
(	(	y
3d	3d	nnu
Cir.	cir	np1
1990	1990	mc
)	)	y
(	(	y
using	use	vvg
the	the	at
term	term	nn1
"	"	y
knowledgeable	knowledgeable	jj
purchaser	purchaser	nn1
"	"	y
)	)	y
;	;	y
Higgins	higgins	np1
v.	xx_v	ii
E.I.	e.i	np1
DuPont	dupont	np1
de	de	np1
Nemours	nemours	np1_vvz
&;		null
Co.	co	np1_nn1
,	,	y
671	671	mc
F.	f	np1_ra@
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
referring	refer	vvg
to	to	ii
a	a	at1
"	"	y
knowledgeable	knowledgeable	jj
industrial	industrial	jj
purchaser	purchaser	nn1
"	"	y
)	)	y
;	;	y
Phillips	phillips	np1
v.	xx_v	ii
A.P	ap	np1
.	.	y
Green	green	np1@_jj
Refractories	refractories	np1
Co.	co	np1
,	,	y
630	630	mc
A.2d	a.2d	fo
874	874	mc
,	,	y
883	883	mc
(	(	y
Pa	pa	np1
.	.	y
Super	super	jj_nn1@
.	.	y
Ct	ct	np1_nn1
.	.	y
1993	1993	mc
)	)	y
(	(	y
using	use	vvg
the	the	at
term	term	nn1
"	"	y
knowledgeable	knowledgeable	jj
employer	employer	nn1
"	"	y
)	)	y
;	;	y
see	see	vv0
also	also	rr
Keith	keith	np1
Laughery	laughery	np1
,	,	y
Warnings	warning	nn2
in	in	ii
the	the	at
Workplace	workplace	nn1
:	:	y
Expanding	expand	vvg
the	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Rule	rule	nn1
to	to	to_ii
Include	include	vv0
Employers	employer	nn2
in	in	ii
the	the	at
Context	context	nn1
of	of	io
Product	product	nn1
**29;2188;TOOLONG		nn1
Relationship	relationship	nn1
,	,	y
46	46	mc
S.	s	np1
TEX	tex	np1
.	.	y
L.	l	np1_nnu@
REV.	rev	nnu
627	627	mc
(	(	y
2005	2005	mc
)	)	y
(	(	y
advocating	advocate	vvg
expansion	expansion	nn1
of	of	io
the	the	at
doctrine	doctrine	nn1
in	in	ii
certain	certain	jj
manufacturing	manufacturing	nn1
relationships	relationship	nn2
)	)	y
;	;	y
Victor	victor	np1
E.	e	np1
Schwartz	schwartz	np1
&;		null
Christopher	christopher	np1
E.	e	np1
Appel	appel	np1
,	,	y
Effective	effective	jj
Communication	communication	nn1
of	of	io
Warnings	warning	nn2
in	in	ii
the	the	at
Workplace	workplace	nn1
:	:	y
Avoiding	avoid	vvg
Injuries	injury	nn2
in	in	ii
Working	work	vvg
with	with	iw
Industrial	industrial	jj
Materials	material	nn2
,	,	y
73	73	mc
MO	mo	np1
.	.	y
L.	l	np1
REV.	rev	nnu_nnb
1	1	mc1
(	(	y
2008	2008	mc
)	)	y
(	(	y
discussing	discuss	vvg
the	the	at
parallels	parallel	nn2
and	and	cc
doctrinal	doctrinal	jj
interplay	interplay	nn1
of	of	io
the	the	at
learned	learned	jj@
intermediary	intermediary	nn1
rule	rule	nn1
with	with	iw
the	the	at
sophisticated	sophisticated	jj
user	user	nn1
doctrine	doctrine	nn1
in	in	ii
the	the	at
case	case	nn1
of	of	io
industrial	industrial	jj
materials	material	nn2
)	)	y
;	;	y
Carole	carole	np1
A.	a	zz
Cheney	cheney	np1
,	,	y
Comment	comment	vv0_nn1
,	,	y
Not	not	xx
Just	just	rr
For	for	if
Doctors	doctor	nn2
:	:	y
Applying	apply	vvg
the	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Doctrine	doctrine	nn1
to	to	ii
the	the	at
Relationship	relationship	nn1
Between	between	ii
Chemical	chemical	nn1_jj@
Manufacturers	manufacturer	nn2
,	,	y
Industrial	industrial	jj
Employers	employer	nn2
,	,	y
and	and	cc
Employees	employee	nn2
,	,	y
85	85	mc
NW	nw	nd1
.	.	y
U.	u	np1
L.	l	np1
REV.	rev	nnu
562	562	mc
,	,	y
575	575	mc
(	(	y
1991	1991	mc
)	)	y
(	(	y
discussing	discuss	vvg
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
prescription	prescription	nn1
drug	drug	nn1
context	context	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n181	n181	fo
.	.	y
)	)	y
See	see	vv0
supra	supra	nn1
notes	note	nn2
117-120	117-120	mcmc
and	and	cc
accompanying	accompanying	jj_vvg
text	text	nn1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n182	n182	fo
.	.	y
)	)	y
See	see	vv0
State	state	nn1
ex	ex	ii
rel	rel	nn1
.	.	y
Johnson	johnson	np1
&;		null
Johnson	johnson	np1
Co.	co	np1_nn1
v.	xx_v	ii
Karl	karl	np1
,	,	y
647	647	mc
S.E.2d	s.e.2d	fo
899	899	mc
,	,	y
917	917	mc
(	(	y
W.	w	np1
Va	va	fw
.	.	y
2007	2007	mc
)	)	y
(	(	y
Albright	albright	np1_nn1
,	,	y
J.	xx_j	np1
,	,	y
dissenting	dissent	vvg
)	)	y
(	(	y
"	"	y
But	but	ccb
to	to	to
presume	presume	vvi
,	,	y
as	as	csa_ii
the	the	at
majority	majority	nn1
appears	appear	vvz
to	to	to
,	,	y
that	that	cst
the	the	at
mere	mere	jj
presence	presence	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
advertising	advertising	nn1
in	in	ii
our	our	appge
society	society	nn1
relegates	relegate	vvz
the	the	at
role	role	nn1
of	of	io
the	the	at
physician	physician	nn1
to	to	ii
a	a	at1
mere	mere	jj
dispensary	dispensary	nn1
of	of	io
prescriptions	prescription	nn2
is	be	vbz
simply	simply	rr
not	not	xx
true	true	jj
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n183	n183	fo
.	.	y
)	)	y
The	the	at
Massachusetts	massachusetts	np1
Supreme	supreme	jj
Judicial	judicial	jj
Court	court	nn1
,	,	y
for	for	rex21
example	example	rex22
,	,	y
recently	recently	rr
held	hold	vvn_vvd
that	that	cst
a	a	at1
physician	physician	nn1
could	could	vm
be	be	vbi
liable	liable	jj
to	to	ii
third	third	md
parties	party	nn2
injured	injure	vvn_vvd
as	as	ii
a	a	at1
result	result	nn1
of	of	io
the	the	at
failure	failure	nn1
to	to	to
warn	warn	vvi
a	a	at1
patient	patient	nn1_jj
.	.	y
See	see	vv0
Coombes	coombes	np2
v.	xx_v	ii
Florio	florio	np1
,	,	y
877	877	mc
N.E.2d	n.e.2d	fo
567	567	mc
,	,	y
571-72	571-72	mcmc
(	(	y
Mass.	mass	np1
2007	2007	mc
)	)	y
(	(	y
holding	hold	vvg
that	that	cst
a	a	at1
doctor	doctor	nn1
may	may	vm
be	be	vbi
liable	liable	jj
when	when	cs
his	his	appge
patient	patient	nn1_jj
,	,	y
who	who	pnqs
alleged	allege	vvd
he	he	pphs1
was	be	vbdz
not	not	xx
adequately	adequately	rr
warned	warn	vvn_vvd
that	that	cst
the	the	at
medication	medication	nn1
he	he	pphs1
was	be	vbdz
on	on	rp@_ii
could	could	vm
cause	cause	vvi
drowsiness	drowsiness	nn1
or	or	cc
fainting	faint	vvg
,	,	y
injured	injure	vvd_vvn
the	the	at
plaintiff	plaintiff	nn1
in	in	ii
an	a	at1
automobile	automobile	nn1
accident	accident	nn1
)	)	y
.	.	y
<p>	<p>	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
751	751	mc
P.2d	p.2d	fo
470	470	mc
,	,	y
478-79	478-79	mcmc
(	(	y
Cal	calorie	nnu
.	.	y
1988	1988	mc
)	)	y
(	(	y
expressing	express	vvg
concern	concern	nn1
that	that	cst_dd1
increased	increased	jj_vvd
liability	liability	nn1
would	would	vm
drive	drive	vvi
prices	price	nn2
of	of	io
drugs	drug	nn2
too	too	rg
high	high	jj
and	and	cc
make	make	vv0
them	them	ppho2
less	less	rgr
available	available	jj
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n185	n185	fo
.	.	y
)	)	y
See	see	vv0
Richard	richard	np1
C.	c	np1
Ausness	ausness	np1
,	,	y
The	the	at
Case	case	nn1
for	for	if
a	a	at1
"	"	y
Strong	strong	jj
"	"	y
Regulatory	regulatory	jj
Compliance	compliance	nn1
Defense	defense	nn1
,	,	y
55	55	mc
MD	md	nn1_np1@
.	.	y
L.	l	np1_nnu@
REV.	rev	nnu
1210	1210	mc
,	,	y
1241	1241	mc
(	(	y
1996	1996	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n186	n186	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
1241-47		mcmc
(	(	y
1996	1996	mc
)	)	y
(	(	y
providing	provide	vvg
examples	example	nn2
of	of	io
cases	case	nn2
in	in	ii
which	which	ddq
courts	court	nn2
gave	give	vvd
little	little	da1_jj
weight	weight	nn1
to	to	ii
federal	federal	jj
safety	safety	nn1
regulations	regulation	nn2
spanning	span	vvg
a	a	at1
variety	variety	nn1
of	of	io
areas	area	nn2
,	,	y
such	such	ii21
as	as	ii22
flammability	flammability	nn1
standards	standard	nn2
for	for	if
clothing	clothing	nn1
,	,	y
pesticide	pesticide	nn1
warnings	warning	nn2
,	,	y
automobile	automobile	nn1
design	design	nn1
,	,	y
prescription	prescription	nn1
drug	drug	nn1
warnings	warning	nn2
,	,	y
aircraft	aircraft	nn
design	design	nn1_vv0@
,	,	y
and	and	cc
workplace	workplace	nn1
safety	safety	nn1
standards	standard	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n187	n187	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n188	n188	fo
.	.	y
)	)	y
See	see	vv0
2	2	mc
AM	am	ra@
.	.	y
LAW	law	nn1
INST.	inst	np1
,	,	y
REPORTER	reporter	nn1
'S	's	ge
STUDY	study	nn1
,	,	y
ENTERPRISE	enterprise	nn1
RESPONSIBILITY	responsibility	nn1
FOR	for	if
PERSONAL	personal	jj
INJURY	injury	nn1
95-97	95-97	mcmc
(	(	y
1991	1991	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Richard	richard	np1
B.	b	np1
Stewart	stewart	np1
,	,	y
Regulatory	regulatory	jj
Compliance	compliance	nn1
Preclusion	preclusion	nn1
of	of	io
Tort	tort	np1_nn1
Liability	liability	nn1
:	:	y
Limiting	limit	vvg
the	the	at
Dual-Track		np1
System	system	nn1
,	,	y
88	88	mc
GEO	geo	np1_nn1
.	.	y
L.J	lj	np1
.	.	y
2167	2167	mc
,	,	y
2168-70		mcmc
(	(	y
2000	2000	mc
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
)	)	y
,	,	y
supra	supra	nn1
note	note	nn1_vv0
114	114	mc
,	,	y
at	at	ii
4	4	mc
cmt.	cmt	nnu
e	e	zz1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n190	n190	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n191	n191	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
4	4	mc
Reporters	reporter	nn2
'	'	ge
Note	note	nn1_vv0
cmt.	cmt	nnu
d	d	zz1
(	(	y
citing	cite	vvg
as	as	ii
an	a	at1
example	example	nn1
Hawkins	hawkins	np1
v.	xx_v	ii
Evans	evans	np1
Cooperage	cooperage	np1
Co.	co	np1
,	,	y
766	766	mc
F.2d	f.2d	fo
904	904	mc
,	,	y
909	909	mc
(	(	y
5th	5th	md
Cir.	cir	np1
1985	1985	mc
)	)	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n192	n192	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Sims	sim	np1
v.	xx_v	ii
Washex		np1_nn1
Mach	mach	nnu
.	.	y
Corp.	corp	np1
,	,	y
932	932	mc
S.W.2d	s.w.2d	fo
559	559	mc
,	,	y
565	565	mc
(	(	y
Tex	tex	np1
.	.	y
App.	app	np1
1995	1995	mc
)	)	y
(	(	y
"	"	y
Compliance	compliance	nn1
with	with	iw
government	government	nn1
regulations	regulation	nn2
is	be	vbz
strong	strong	jj
evidence	evidence	nn1
,	,	y
although	although	cs
not	not	xx
conclusive	conclusive	jj
,	,	y
that	that	cst
a	a	at1
machine	machine	nn1
was	be	vbdz
not	not	xx
defectively	defectively	rr
designed	design	vvn_vvd
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n193	n193	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Lorenz	lorenz	np1
v.	xx_v	ii
Celotex	celotex	np1
Corp.	corp	np1
,	,	y
896	896	mc
F.2d	f.2d	fo
148	148	mc
,	,	y
152	152	mc
(	(	y
5th	5th	md
Cir.	cir	np1
1990	1990	mc
)	)	y
(	(	y
compliance	compliance	nn1
with	with	iw
safety	safety	nn1
regulation	regulation	nn1
is	be	vbz
strong	strong	jj
and	and	cc
substantial	substantial	jj
evidence	evidence	nn1
of	of	io
lack	lack	nn1
of	of	io
defect	defect	nn1
)	)	y
;	;	y
Dentson		np1
v.	xx_v	ii
Eddins	eddins	np1
&;		null
Lee	lee	np1
Bus	bus	nn1
Sales	sales	npx
,	,	y
Inc.	inc	jj
,	,	y
491	491	mc
So	so	rr
.	.	y
2d	2d	nnu
942	942	mc
,	,	y
944	944	mc
(	(	y
Ala.	ala	np1
1986	1986	mc
)	)	y
(	(	y
ruling	ruling	nn1_jj
that	that	cst
a	a	at1
school	school	nn1
bus	bus	nn1_vv0@
that	that	cst_dd1
is	be	vbz
not	not	xx
equipped	equip	vvn
with	with	iw
seatbelts	seatbelt	nn2
is	be	vbz
not	not	xx
defective	defective	jj
when	when	cs
the	the	at
legislature	legislature	nn1
has	have	vhz
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
863	863	mc
P.2d	p.2d	fo
167	167	mc
,	,	y
176	176	mc
(	(	y
Cal	calorie	nnu
.	.	y
1993	1993	mc
)	)	y
(	(	y
concluding	conclude	vvg_jj
that	that	cst
"	"	y
the	the	at
prudent	prudent	jj
course	course	nn1
is	be	vbz
to	to	to
adopt	adopt	vvi
for	for	if
tort	tort	nn1
purposes	purpose	nn2_vvz%
the	the	at
existing	existing	jj
legislative	legislative	jj
and	and	cc
administrative	administrative	jj
standard	standard	nn1
of	of	io
care	care	nn1
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n194	n194	fo
.	.	y
)	)	y
Beatty	beatty	np1
v.	xx_v	ii
Trailmaster		np1
Prods.	prods	np1
,	,	y
Inc.	inc	jj
,	,	y
625	625	mc
A.2d	a.2d	fo
1005	1005	mc
,	,	y
1014	1014	mc
(	(	y
Md.	md	np1
1993	1993	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n195	n195	fo
.	.	y
)	)	y
See	see	vv0
infra	infra	rr
note	note	vv0
203	203	mc
and	and	cc
accompanying	accompanying	jj_vvg
text	text	nn1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n196	n196	fo
.	.	y
)	)	y
See	see	vv0
States	state	np1_nn2@
v.	xx_v	ii
R.D.	r.d	nn1
Werner	werner	np1
Co.	co	np1
,	,	y
799	799	mc
P.2d	p.2d	fo
427	427	mc
,	,	y
430	430	mc
(	(	y
Colo	colo	np1
.	.	y
Ct	ct	np1_nn1
.	.	y
App.	app	np1
1990	1990	mc
)	)	y
(	(	y
ruling	ruling	nn1_jj
that	that	cst
the	the	at
trial	trial	nn1
court	court	nn1
did	do	vdd
not	not	xx
err	err	vvi
by	by	ii
admitting	admitting	jj_vvg
expert	expert	nn1_jj@
testimony	testimony	nn1
on	on	ii
a	a	at1
ladder	ladder	nn1
's	's	ge
compliance	compliance	nn1
with	with	iw
federal	federal	jj
regulations	regulation	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n197	n197	fo
.	.	y
)	)	y
See	see	vv0
Slisze	slisze	nn1_vv0_np1
v.	xx_v	ii
Stanley-Bostitch	stanley-bostitch	np1
,	,	y
979	979	mc
P.2d	p.2d	fo
317	317	mc
,	,	y
321	321	mc
(	(	y
Utah	utah	np1
1999	1999	mc
)	)	y
(	(	y
ruling	ruling	nn1_jj
that	that	cst_dd1
federal	federal	jj
OSHA	osha	nn1
standards	standard	nn2
regulating	regulate	vvg
the	the	at
design	design	nn1
of	of	io
a	a	at1
pneumatic	pneumatic	jj
nailer	nailer	nn1
were	be	vbdr
admissible	admissible	jj
as	as	csa_ii@
government	government	nn1
standards	standard	nn2
and	and	cc
established	establish	vvd_vvn
a	a	at1
rebuttable	rebuttable	jj
presumption	presumption	nn1
of	of	io
nondefectiveness	nondefectiveness	nn1
as	as	csa
they	they	pphs2
provided	provide	vvd
"	"	y
a	a	at1
legitimate	legitimate	jj
source	source	nn1
for	for	if
determining	determine	vvg
the	the	at
standard	standard	nn1
of	of	io
reasonable	reasonable	jj
care	care	nn1
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n198	n198	fo
.	.	y
)	)	y
See	see	vv0
Uptain	uptain	nn1_jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
222	222	mc
(	(	y
Colo	colo	np1
.	.	y
Ct	ct	np1_nn1
.	.	y
App.	app	np1
1984	1984	mc
)	)	y
(	(	y
finding	find	vvg
that	that	dd1_cst
manufacturer	manufacturer	nn1
of	of	io
a	a	at1
cleaning	cleaning	nn1
compound	compound	nn1
was	be	vbdz
entitled	entitle	vvn
to	to	ii
presumption	presumption	nn1
of	of	io
nondefectiveness	nondefectiveness	nn1
where	where	cs_rrq
an	a	at1
expert	expert	nn1
testified	testify	vvd
that	that	cst
the	the	at
product	product	nn1
label	label	nn1
's	's	ge
warnings	warning	nn2
complied	comply	vvn_vvd
with	with	iw
federal	federal	jj
and	and	cc
local	local	jj
laws	law	nn2
and	and	cc
was	be	vbdz
approved	approve	vvn
by	by	ii
the	the	at
Environmental	environmental	jj
Protection	protection	nn1
Agency	agency	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n199	n199	fo
.	.	y
)	)	y
See	see	vv0
Alvarado	alvarado	np1_nn1@
v.	xx_v	ii
J.C	jc	np1
.	.	y
Penney	penney	np1@_nn1_jj@
Co.	co	np1_nn1
,	,	y
735	735	mc
F.	f	np1_ra@
Supp.	supp	np1
371	371	mc
,	,	y
372-74		mcmc
(	(	y
D.	d	np1
Kan.	kan	np1
1990	1990	mc
)	)	y
.	.	y
In	in	ii
a	a	at1
case	case	nn1
involving	involve	vvg
a	a	at1
nightgown	nightgown	nn1
and	and	cc
robe	robe	nn1
that	that	cst
were	be	vbdr
ignited	ignite	vvn
by	by	ii
an	a	at1
open-flame	open-flame	jj_nn1
gas	gas	nn1
heater	heater	nn1
,	,	y
the	the	at
court	court	nn1
held	hold	vvd_vvn
that	that	cst
that	that	dd1
the	the	at
regulatory	regulatory	jj
compliance	compliance	nn1
provision	provision	nn1
of	of	io
the	the	at
Kansas	kansas	np1
Products	product	nn2
Liability	liability	nn1
Act	act	nn1
did	do	vdd
not	not	xx
create	create	vvi
a	a	at1
conclusive	conclusive	jj
presumption	presumption	nn1
and	and	cc
thus	thus	rr
a	a	at1
constitutional	constitutional	jj
challenge	challenge	nn1
by	by	ii
plaintiffs	plaintiff	nn2
was	be	vbdz
moot	moot	jj
.	.	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n200	n200	fo
.	.	y
)	)	y
See	see	vv0
Champlain	champlain	jj_nn1
Enters.		np1
,	,	y
Inc.	inc	jj
v.	xx_v	ii
United	united	np1
States	state	np1
,	,	y
957	957	mc
F.	f	np1_ra@
Supp.	supp	np1
26	26	mc
,	,	y
28	28	mc
(	(	y
N.D.N.Y.	n.d.n.y	np1
1997	1997	mc
)	)	y
(	(	y
ruling	ruling	nn1_jj
that	that	cst
the	the	at
regulatory	regulatory	jj
compliance	compliance	nn1
provision	provision	nn1
of	of	io
the	the	at
Kansas	kansas	np1
Products	product	nn2
Liability	liability	nn1
Act	act	nn1
would	would	vm
provide	provide	vvi
an	a	at1
airplane	airplane	nn1
manufacturer	manufacturer	nn1
with	with	iw
a	a	at1
defense	defense	nn1
against	against	ii
liability	liability	nn1
if	if	cs
it	it	pph1
established	establish	vvd
that	that	cst
the	the	at
aircraft	aircraft	nn
complied	comply	vvn_vvd
with	with	iw
government	government	nn1
safety	safety	nn1
standards	standard	nn2
,	,	y
unless	unless	cs
the	the	at
plaintiff	plaintiff	nn1
can	can	vm
show	show	vvi
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
have	have	vhi
taken	take	vvn
additional	additional	jj
precautions	precaution	nn2
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n201	n201	fo
.	.	y
)	)	y
See	see	vv0
Brand	brand	nn1_np1
v.	xx_v	ii
Mazda	mazda	np1
Motor	motor	nn1_vv0@
Corp.	corp	np1
,	,	y
978	978	mc
F.	f	np1_ra@
Supp.	supp	np1
1382	1382	mc
,	,	y
1387-88		mcmc
,	,	y
1391-93		mcmc
(	(	y
D.	d	np1
Kan.	kan	np1
1997	1997	mc
)	)	y
(	(	y
ruling	ruling	nn1_jj
that	that	cst_dd1
automobile	automobile	nn1
manufacturer	manufacturer	nn1
's	's	ge
compliance	compliance	nn1
with	with	iw
federal	federal	jj
regulatory	regulatory	jj
standards	standard	nn2
was	be	vbdz
not	not	xx
dispositive	dispositive	jj
of	of	io
liability	liability	nn1
or	or	cc
punitive	punitive	jj
damages	damage	nn2
absent	absent	vv0@_jj
clear	clear	jj
and	and	cc
convincing	convincing	jj
evidence	evidence	nn1
that	that	cst
the	the	at
manufacturer	manufacturer	nn1
acted	act	vvn_vvd
with	with	iw
reckless	reckless	jj
indifference	indifference	nn1
to	to	ii
consumer	consumer	nn1
safety	safety	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n202	n202	fo
.	.	y
)	)	y
COLO	colo	np1
.	.	y
REV	rev	nnu
.	.	y
STAT.	stat	np1
13-21-403(1)		nn1_jj
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n203	n203	fo
.	.	y
)	)	y
See	see	vv0
KAN	kan	nn1_jj_np1
.	.	y
STAT.	stat	np1
60-3304(a)		nn1_jj
(	(	y
2007	2007	mc
)	)	y
;	;	y
KY	ky	np1
.	.	y
REV	rev	nnu
.	.	y
STAT.	stat	np1
411.310(2)		fo
(	(	y
2008	2008	mc
)	)	y
;	;	y
MICH	mich	np1
.	.	y
COMP	comp	nn1
.	.	y
LAWS	law	nn2
600.2946(4)		fo
(	(	y
2000	2000	mc
)	)	y
;	;	y
TENN	tenn	np1
.	.	y
CODE	code	nn1_vv0@
29-28-104		mcmc
(	(	y
2008	2008	mc
)	)	y
;	;	y
TEX	tex	np1
.	.	y
CIV	civ	mc
.	.	y
PRAC	prac	np1_nn1_jj
.	.	y
&;		null
REM	rem	nn1
.	.	y
CODE	code	nn1_vv0@
82.008	82.008	mc
(	(	y
2008	2008	mc
)	)	y
;	;	y
UTAH	utah	np1
CODE	code	nn1
78B-6-703	78b-6-703	mc
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n204	n204	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Kernke		np1_vv0@
v.	xx_v	ii
The	the	at
Menninger	menninger	jjr@_np1_nn1@
Clinic	clinic	nn1
,	,	y
Inc.	inc	jj
,	,	y
173	173	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
1117	1117	mc
,	,	y
1121-22		mcmc
(	(	y
D.	d	np1
Kan.	kan	np1
2001	2001	mc
)	)	y
(	(	y
finding	find	vvg
insufficient	insufficient	jj
evidence	evidence	nn1
to	to	to
overcome	overcome	vvi
Kansas	kansas	np1
's	's	ge
presumption	presumption	nn1
of	of	io
nondefectiveness	nondefectiveness	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
clinical	clinical	jj
trial	trial	nn1
of	of	io
an	a	at1
experimental	experimental	jj
treatment	treatment	nn1
for	for	if
schizophrenia	schizophrenia	nn1
)	)	y
.	.	y
At	at	rr21
least	least	rr22
two	two	mc
additional	additional	jj
states	state	nn2
,	,	y
Arkansas	arkansas	np1
and	and	cc
Washington	washington	np1
,	,	y
specifically	specifically	rr
provide	provide	vv0
by	by	ii
statute	statute	nn1
that	that	cst
parties	party	nn2
may	may	vm
introduce	introduce	vvi
evidence	evidence	nn1
of	of	io
regulatory	regulatory	jj
compliance	compliance	nn1
to	to	to
show	show	vvi
that	that	cst
a	a	at1
product	product	nn1
is	be	vbz
not	not	xx
defective	defective	jj
or	or	cc
that	that	cst
its	its	z'
warnings	warning	nn2
are	be	vbr
not	not	xx
inadequate	inadequate	jj
.	.	y
See	see	vv0
ARK	ark	nn1
.	.	y
CODE	code	nn1_vv0@
16-116-105(a)		nn1_jj
(	(	y
2007	2007	mc
)	)	y
;	;	y
WASH	wash	vv0_nn1
.	.	y
REV	rev	nnu
.	.	y
CODE	code	nn1_vv0@
7.72.050(1)		fo
(	(	y
2008	2008	mc
)	)	y
.	.	y
These	these	dd2
statutes	statute	nn2
do	do	vd0
not	not	xx
assign	assign	vvi
any	any	dd
particular	particular	jj
evidentiary	evidentiary	jj_nn1
weight	weight	nn1
to	to	ii
compliance	compliance	nn1
with	with	iw
safety	safety	nn1
standards	standard	nn2
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n205	n205	fo
.	.	y
)	)	y
See	see	vv0
Henry	henry	np1
I.	i	np1
Miller	miller	np1
,	,	y
Failed	fail	vvd_jj@_vvn
FDA	fda	np1_nn1
Reform	reform	nn1
,	,	y
21	21	mc
REGULATION	regulation	nn1
24	24	mc
,	,	y
24	24	mc
(	(	y
1998	1998	mc
)	)	y
(	(	y
attributing	attribute	vvg
an	a	at1
increase	increase	nn1
in	in	ii
cost	cost	nn1
for	for	if
new	new	jj
drug	drug	nn1
development	development	nn1
and	and	cc
approval	approval	nn1
from	from	ii
$359	$359	nnu
million	million	m
to	to	ii
$500	$500	nnu
million--in	million--in	m1
pretax	pretax	nn1
1990	1990	mc
dollars--between		nnu2
1990	1990	mc
and	and	cc
1993	1993	mc
,	,	y
and	and	cc
an	a	at1
increase	increase	nn1
in	in	ii
the	the	at
time	time	nnt1
for	for	if
approval	approval	nn1
from	from	ii
8.1	8.1	mc
years	year	nnt2
to	to	ii
15.2	15.2	mc
years	year	nnt2
since	since	cs_ii@
the	the	at
1960s	1960s	mc2
,	,	y
to	to	ii
the	the	at
"	"	y
FDA	fda	np1_nn1
's	's	ge
regulatory	regulatory	jj
zeal	zeal	nn1
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n206	n206	fo
.	.	y
)	)	y
See	see	vv0
N.J.	nj	np1
STAT.	stat	np1
2A:58C-5c		fo
(	(	y
2008	2008	mc
)	)	y
;	;	y
OHIO	ohio	np1
REV	rev	nnu
.	.	y
CODE	code	nn1_vv0@
2307.80(C)		fo
(	(	y
2008	2008	mc
)	)	y
;	;	y
OR	or	cc
.	.	y
REV	rev	nnu
.	.	y
STAT.	stat	np1
30.927	30.927	mc
(	(	y
2007	2007	mc
)	)	y
.	.	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
statute	statute	nn1
to	to	to
include	include	vvi
medical	medical	jj
devices	device	nn2
and	and	cc
over-the-counter	over-the-counter	jj_vv0_nn1
drugs	drug	nn2
in	in	ii31
addition	addition	ii32
to	to	ii33
prescription	prescription	nn1
drugs	drug	nn2
.	.	y
OHIO	ohio	np1
LAWS	law	nn2
FILE	file	vv0@_nn1
144	144	mc
(	(	y
Am	am	ra@
.	.	y
Sub	sub	nn1_jj
.	.	y
S.B.	sb	np1
80	80	mc
)	)	y
(	(	y
amending	amend	vvg
OHIO	ohio	np1
REV	rev	nnu
.	.	y
CODE	code	nn1_vv0@
2307.80	2307.80	mc
)	)	y
(	(	y
effective	effective	jj
Apr.	apr	nn1
7	7	mc
,	,	y
2005	2005	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n207	n207	fo
.	.	y
)	)	y
See	see	vv0
ARIZ	ariz	np1
.	.	y
REV	rev	nnu
.	.	y
STAT.	stat	np1
12-701(A)		nn1_jj
(	(	y
2009	2009	mc
)	)	y
;	;	y
UTAH	utah	np1
CODE	code	nn1
78B-8-203(1)		nn1
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n208	n208	fo
.	.	y
)	)	y
See	see	vv0
MICH	mich	np1
.	.	y
COMP	comp	nn1
.	.	y
LAWS	law	nn2
600.2946(5)		fo
(	(	y
2000	2000	mc
)	)	y
.	.	y
The	the	at
Supreme	supreme	jj
Court	court	nn1
of	of	io
the	the	at
United	united	np1
States	state	np1
recently	recently	rr
found	find	vvn_vvd
that	that	cst
an	a	at1
exception	exception	nn1
in	in	ii
the	the	at
Michigan	michigan	np1
law	law	nn1
which	which	ddq
preserves	preserve	vvz
liability	liability	nn1
if	if	cs
the	the	at
drug	drug	nn1
company	company	nn1
withheld	withhold	vvn_vvd
or	or	cc
misrepresented	misrepresented	jj@_vvd
information	information	nn1
that	that	cst_dd1
would	would	vm
have	have	vhi
altered	alter	vvn
the	the	at
FDA	fda	np1_nn1
's	's	ge
decision	decision	nn1
to	to	to
approve	approve	vvi
the	the	at
drug	drug	nn1
product	product	nn1
(	(	y
i.e.	ie	rex
,	,	y
"	"	y
fraud-on-the-FDA		np1
"	"	y
)	)	y
was	be	vbdz
valid	valid	jj
and	and	cc
not	not	xx
preempted	preempt	vvn@_jj@
.	.	y
Warner-Lambert	warner-lambert	np1
Co.	co	np1_nn1
v.	xx_v	ii
Kent	kent	np1
,	,	y
128	128	mc
S.	s	np1
Ct	ct	np1_nn1
.	.	y
1168	1168	mc
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n209	n209	fo
.	.	y
)	)	y
See	see	vv0
OHIO	ohio	np1
REV	rev	nnu
.	.	y
CODE	code	vv0@_nn1
2307.80(B)-(C)		zz1
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n210	n210	fo
.	.	y
)	)	y
Compare	compare	vv0
OR	or	cc
.	.	y
REV	rev	nnu
.	.	y
STAT.	stat	np1
30.927	30.927	mc
(	(	y
2007	2007	mc
)	)	y
(	(	y
requiring	require	vvg
"	"	y
clear	clear	jj
and	and	cc
convincing	convincing	jj
"	"	y
evidence	evidence	nn1
of	of	io
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
(	(	y
2008	2008	mc
)	)	y
(	(	y
providing	provide	vvg
a	a	at1
preponderance	preponderance	nn1
of	of	io
the	the	at
evidence	evidence	nn1
standard	standard	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n211	n211	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
C.F.R.	c.f.r	np1
314.80(b)-(c)		zz1
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n212	n212	fo
.	.	y
)	)	y
See	see	vv0
generally	generally	rr
James	james	np1
P.	xx_p	np1
Muehlberger	muehlberger	np1
&;		null
Cary	cary	np1
Silverman	silverman	np1
,	,	y
Lawsuits	lawsuit	nn2
Without	without	iw
Injury	injury	nn1
:	:	y
The	the	at
Rise	rise	nn1
of	of	io
Consumer	consumer	nn1
Protection	protection	nn1
Claims	claim	nn2_vvz
,	,	y
LITIG	litig	np1_vv0_nn1
.	.	y
WATCH	watch	vv0_nn1
,	,	y
Oct.	oct	npm1
2006	2006	mc
,	,	y
at	at	ii
4	4	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n213	n213	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n214	n214	fo
.	.	y
)	)	y
See	see	vv0
N.J.	nj	np1
Citizen	citizen	nn1
Action	action	nn1
v.	xx_v	ii
Schering-Plough	schering-plough	np1
Corp.	corp	np1
,	,	y
842	842	mc
A.2d	a.2d	fo
174	174	mc
,	,	y
177	177	mc
(	(	y
N.J.	nj	np1
Super	super	jj_nn1@
.	.	y
Ct	ct	np1_nn1
.	.	y
App	app	vv0_nn1_np1@
.	.	y
Div.	div	mc
2003	2003	mc
)	)	y
(	(	y
holding	hold	vvg_jj@
plaintiffs	plaintiff	nn2
who	who	pnqs
claimed	claim	vvd
allergy	allergy	nn1
medication	medication	nn1
was	be	vbdz
not	not	xx
as	as	rg
effective	effective	jj
as	as	csa
advertised	advertise	vvn
failed	fail	vvn_vvd_jj@
to	to	to
establish	establish	vvi
a	a	at1
causal	causal	jj
nexus	nexus	nn1
between	between	ii
representations	representation	nn2
and	and	cc
any	any	dd
loss	loss	nn1
suffered	suffer	vvn_vvd
under	under	ii
the	the	at
New	new	np1
Jersey	jersey	np1
Consumer	consumer	nn1
Fraud	fraud	nn1
Act	act	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n215	n215	fo
.	.	y
)	)	y
See	see	vv0
Williams	williams	np1
v.	xx_v	ii
Purdue	purdue	np1
Pharma	pharma	np1
Co.	co	np1
,	,	y
297	297	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
171	171	mc
,	,	y
177-78	177-78	mcmc
(	(	y
dismissing	dismiss	vvg_jj@
District	district	nn1
of	of	io
Columbia	columbia	np1
's	's	ge
Consumer	consumer	nn1
Protection	protection	nn1
Procedures	procedure	nn2
Act	act	vv0@_nn1
claim	claim	vv0_nn1
that	that	cst
the	the	at
manufacturer	manufacturer	nn1
over-promoted		vvn_vvd@
the	the	at
drug	drug	nn1
as	as	csa_ii@
providing	provide	vvg
"	"	y
smooth	smooth	jj
and	and	cc
sustained	sustained	jj
"	"	y
pain	pain	nn1
relief	relief	nn1
for	for	if
twelve	twelve	mc
hours	hour	nnt2
with	with	iw
little	little	da1_jj
chance	chance	nn1
of	of	io
addiction	addiction	nn1
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n216	n216	fo
.	.	y
)	)	y
See	see	vv0
In	in	rp@
re	re	ii
Prempro	prempro	np1_nn1
Prods	prod	nn2
.	.	y
Liab	liab	vv0_nn1_np1@
.	.	y
Litig.	litig	np1
,	,	y
230	230	mc
F.R.D.	f.r.d	np1
555	555	mc
,	,	y
566-68	566-68	mcmc
(	(	y
E.D.	ed	nn1
Ark.	ark	np1
2005	2005	mc
)	)	y
(	(	y
denying	deny	vvg
certification	certification	nn1
of	of	io
a	a	at1
consumer-protection	consumer-protection	jj_nn1
class	class	nn1
due	due	ii21
to	to	ii22
material	material	nn1_jj@
variations	variation	nn2
in	in	ii
the	the	at
consumer	consumer	nn1
laws	law	nn2
of	of	io
the	the	at
twenty-nine	twenty-nine	mc
states	state	nn2_vvz
at	at	ii
issue	issue	nn1
and	and	cc
the	the	at
need	need	nn1
to	to	to
show	show	vvi
individual	individual	jj
plaintiffs	plaintiff	nn2
relied	rely	vvn_vvd
on	on	ii
the	the	at
allegedly	allegedly	rr
deceptive	deceptive	jj
advertisement	advertisement	nn1
and	and	cc
were	be	vbdr
injured	injure	vvn
as	as	ii
a	a	at1
result	result	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n217	n217	fo
.	.	y
)	)	y
See	see	vv0
In	in	rp@
re	re	ii
W.	w	np1
Va	va	fw
.	.	y
Rezulin	rezulin	np1@
Litig.	litig	np1
,	,	y
585	585	mc
S.E.2d	s.e.2d	fo
52	52	mc
,	,	y
62-65	62-65	mcmc
(	(	y
W.	w	np1
Va	va	fw
.	.	y
2003	2003	mc
)	)	y
(	(	y
ruling	ruling	nn1_jj
that	that	cst
the	the	at
statutory	statutory	jj
requirement	requirement	nn1
that	that	cst
a	a	at1
plaintiff	plaintiff	nn1
show	show	vv0_nn1
an	a	at1
"	"	y
ascertainable	ascertainable	jj
loss	loss	nn1
"	"	y
under	under	ii
West	west	np1
Virginia	virginia	np1
Consumer	consumer	nn1
Credit	credit	nn1
and	and	cc
Protection	protection	nn1
Act	act	nn1
did	do	vdd
not	not	xx
require	require	vvi
a	a	at1
showing	showing	nn1@
of	of	io
actual	actual	jj
damages	damage	nn2
and	and	cc
finding	find	vvg_nn1
that	that	cst
plaintiffs	plaintiff	nn2
needed	need	vvd_vvn
only	only	rr
to	to	to_ii
allege	allege	vvi
that	that	cst
they	they	pphs2
received	receive	vvd
a	a	at1
product	product	nn1
that	that	cst_dd1
was	be	vbdz
different	different	jj
or	or	cc
inferior	inferior	jj
to	to	ii
that	that	dd1
which	which	ddq
they	they	pphs2
believed	believe	vvd
they	they	pphs2
purchased	purchase	vvd
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n218	n218	fo
.	.	y
)	)	y
See	see	vv0
Int'l	int'l	nn1_np1_vv0
Union	union	nn1_np1
of	of	io
Operating	operating	nn1_vvg
Eng'rs		vvz_np1_nn2
Local	local	jj@_nn1
No.	no	xx
68	68	mc
Welfare	welfare	nn1
Fund	fund	nn1
v.	xx_v	ii
Merck	merck	np1
&;		null
Co.	co	np1_nn1
,	,	y
929	929	mc
A.2d	a.2d	fo
1076	1076	mc
,	,	y
1088	1088	mc
(	(	y
N.J.	nj	np1
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n219	n219	fo
.	.	y
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
of	of	io
Consumer	consumer	nn1
Protection	protection	nn1
Acts	act	nn2_vvz
,	,	y
54	54	mc
KAN	kan	jj_np1_nn1
.	.	y
L.	l	np1
REV.	rev	nnu_nnb
1	1	mc1
,	,	y
32-33	32-33	mcmc
(	(	y
2005	2005	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n220	n220	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
22-27	22-27	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n221	n221	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Victor	victor	np1
E.	e	np1
Schwartz	schwartz	np1
,	,	y
Cary	cary	np1
Silverman	silverman	np1
&;		null
Christopher	christopher	np1
E.	e	np1
Appel	appel	np1
,	,	y
"	"	y
That	that	dd1_cst
's	be	vbz
Unfair	unfair	jj
!	!	y
"	"	y
Says	say	vvz
Who--The		np1
Government	government	nn1
or	or	cc
Litigant		np1_nn1_jj
?	?	y
Consumer	consumer	nn1
Protection	protection	nn1
Claims	claim	nn2_vvz
Involving	involve	vvg
Regulated	regulated	jj@
Conduct	conduct	nn1
,	,	y
47	47	mc
WASHBURN	washburn	np1
L.J	lj	np1
.	.	y
93	93	mc
,	,	y
119	119	mc
(	(	y
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n222	n222	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
102	102	mc
.	.	y
Regulatory-compliance	regulatory-compliance	jj_nn1
exemptions	exemption	nn2
to	to	to
state	state	vvi
consumer	consumer	nn1
laws	law	nn2
vary	vary	vv0
from	from	ii
state	state	nn1
to	to	ii
state	state	nn1
but	but	ccb
generally	generally	rr
fit	fit	vv0_jj
within	within	ii
three	three	mc
categories	category	nn2
:	:	y
(	(	y
1	1	mc1
)	)	y
rules	rule	nn2
of	of	io
construction	construction	nn1
suggesting	suggest	vvg
or	or	cc
requiring	require	vvg
that	that	cst
courts	court	nn2
interpret	interpret	vv0
the	the	at
state	state	nn1
consumer	consumer	nn1
law	law	nn1
consistently	consistently	rr
with	with	iw
the	the	at
interpretations	interpretation	nn2
and	and	cc
policy	policy	nn1
of	of	io
the	the	at
FTC	ftc	np1
;	;	y
(	(	y
2	2	mc
)	)	y
exemptions	exemption	nn2
for	for	if
authorized	authorized	jj
or	or	cc
permitted	permitted	jj@_vvd_vvn
conduct	conduct	nn1
;	;	y
(	(	y
3	3	mc
)	)	y
exemptions	exemption	nn2
applicable	applicable	jj
to	to	ii
specific	specific	jj
regulated	regulated	jj@
industries	industry	nn2
or	or	cc
conduct	conduct	nn1_vv0
.	.	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
102-17	102-17	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n223	n223	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
106	106	mc
(	(	y
quoting	quote	vvg
Taylor	taylor	np1
v.	xx_v	ii
Bear	bear	nn1
Stearns	stearns	vvz_np1
&;		null
Co.	co	np1_nn1
,	,	y
572	572	mc
F.	f	np1_ra@
Supp.	supp	np1
667	667	mc
(	(	y
N.D.	nd	np1
Ga	ga	np1
.	.	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
See	see	vv0
id	id	z'
.	.	y
at	at	ii
119-22	119-22	mcmc
;	;	y
see	see	vv0
also	also	rr
Muehlberger	muehlberger	np1
&;		null
Silverman	silverman	np1_nn1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
212	212	mc
,	,	y
at	at	ii
5-6	5-6	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n225	n225	fo
.	.	y
)	)	y
U.S.	us	np1
CONST.	const	np1
art	art	nn1
.	.	y
VI	vi	mc_np1@
,	,	y
cl.	cl	mc
2	2	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n226	n226	fo
.	.	y
)	)	y
See	see	vv0
La	la	fu_np1_fw
.	.	y
Pub	pub	nn1
.	.	y
Serv	serv	nn1_np1@
.	.	y
Comm'n	comm'n	vv0_nn1
v.	xx_v	ii
FCC	fcc	np1
,	,	y
476	476	mc
U.S.	us	np1
355	355	mc
,	,	y
369	369	mc
(	(	y
1986	1986	mc
)	)	y
(	(	y
"	"	y
Pre-emption	preemption	nn1
may	may	vm
result	result	vvi
not	not	xx
only	only	rr
from	from	ii
action	action	nn1
taken	take	vvn
by	by	ii
Congress	congress	nn1
itself	itself	ppx1
;	;	y
a	a	at1
federal	federal	jj
agency	agency	nn1
action	action	nn1
within	within	ii
the	the	at
scope	scope	nn1
of	of	io
its	its	z'
congressionally	congressionally	rr
delegated	delegated	jj_vvn
authority	authority	nn1
may	may	vm
pre-empt	preempt	vvi
state	state	nn1
regulation	regulation	nn1
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n227	n227	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
U.S.C.	usc	np1
393(b)		fo
(	(	y
2006	2006	mc
)	)	y
(	(	y
charging	charge	vvg
the	the	at
FDA	fda	nn1
with	with	iw
ensuring	ensure	vvg
that	that	cst
drugs	drug	nn2
are	be	vbr
safe	safe	jj
and	and	cc
effective	effective	jj
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n228	n228	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
U.S.C.	usc	np1
360k(a)		fo
(	(	y
2006	2006	mc
)	)	y
(	(	y
providing	providing	cs21
that	that	cs22
a	a	at1
state	state	nn1
shall	shall	vm
not	not	xx
"	"	y
establish	establish	vv0
or	or	cc
continue	continue	vv0
in	in	ii_rp@
effect	effect	nn1
with	with	ii31
respect	respect	ii32
to	to	ii33
a	a	at1
device	device	nn1
intended	intend	vvn_vvd
for	for	if
human	human	nn1_jj
use	use	vv0_nn1
any	any	dd
requirement--(1)		mc1
which	which	ddq
is	be	vbz
different	different	jj
from	from	ii
,	,	y
or	or	cc
in	in	ii31
addition	addition	ii32
to	to	ii33
,	,	y
any	any	dd
requirement	requirement	nn1
applicable	applicable	jj
under	under	ii
federal	federal	jj
law	law	nn1
to	to	ii
the	the	at
device	device	nn1
,	,	y
and	and	cc
(	(	y
2	2	mc
)	)	y
which	which	ddq
relates	relate	vvz
to	to	ii
the	the	at
safety	safety	nn1
or	or	cc
effectiveness	effectiveness	nn1
of	of	io
the	the	at
device	device	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	ii
the	the	at
device	device	nn1
under	under	ii_rg@
"	"	y
relevant	relevant	jj
federal	federal	jj
law	law	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n229	n229	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Riegel	riegel	np1_vv0@
v.	xx_v	ii
Medtronic	medtronic	jj
,	,	y
Inc.	inc	jj
,	,	y
128	128	mc
S.	s	np1
Ct	ct	np1_nn1
.	.	y
999	999	mc
,	,	y
1006-08		mcmc
(	(	y
2008	2008	mc
)	)	y
(	(	y
discussing	discuss	vvg
the	the	at
scope	scope	nn1
of	of	io
the	the	at
MDA	mda	np1_nn1
's	's	ge
express	express	jj@
preemption	preemption	nn1
provision	provision	nn1
regarding	regarding	ii_vvg
medical	medical	jj
device	device	nn1
compliance	compliance	nn1
with	with	iw
FDA	fda	np1_nn1
pre-market	pre-market	jj_nn1
approval	approval	nn1
process	process	nn1
)	)	y
;	;	y
Sprietsma		np1
v.	xx_v	ii
Mercury	mercury	np1
Marine	marine	jj_nn1@
,	,	y
537	537	mc
U.S.	us	np1
51	51	mc
,	,	y
67-68	67-68	mcmc
(	(	y
2002	2002	mc
)	)	y
(	(	y
analyzing	analyze	vvg
the	the	at
confines	confine	nn2
of	of	io
an	a	at1
express	express	jj@
preemption	preemption	nn1
provision	provision	nn1
in	in	ii
the	the	at
Federal	federal	jj
Boat	boat	nn1
Safety	safety	nn1
Act	act	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n230	n230	fo
.	.	y
)	)	y
See	see	vv0
Crosby	crosby	np1
v.	xx_v	ii
Nat'l	nat'l	np1_nn1
Foreign	foreign	jj
Trade	trade	nn1
Council	council	nn1
,	,	y
530	530	mc
U.S.	us	np1
363	363	mc
,	,	y
372	372	mc
(	(	y
2000	2000	mc
)	)	y
(	(	y
"	"	y
Even	even	rr
without	without	iw
an	a	at1
express	express	jj@
provision	provision	nn1
for	for	if
preemption	preemption	nn1
,	,	y
we	we	ppis2
have	have	vh0
found	find	vvn
that	that	cst_dd1
state	state	vv0_nn1
law	law	nn1
must	must	vm
yield	yield	vvi
to	to	ii
a	a	at1
congressional	congressional	jj
Act	act	nn1
.	.	y
...	...	...
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n231	n231	fo
.	.	y
)	)	y
See	see	vv0
Rice	rice	nn1
v.	xx_v	ii
Santa	santa	np1
Fe	fe	np1
Elevator	elevator	nn1
Corp.	corp	np1
,	,	y
331	331	mc
U.S.	us	np1
218	218	mc
,	,	y
230-31	230-31	mcmc
(	(	y
1947	1947	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n232	n232	fo
.	.	y
)	)	y
Fla	fla	np1
.	.	y
Lime	lime	nn1
&;		null
Avocado	avocado	nn1
Growers	grower	nn2
,	,	y
Inc.	inc	jj
v.	xx_v	ii
Paul	paul	np1
373	373	mc
U.S.	us	np1
132	132	mc
,	,	y
142-43	142-43	mcmc
(	(	y
1963	1963	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Hillsborough	hillsborough	np1
County	county	nn1
v.	xx_v	ii
Automated	automated	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
713	713	mc
(	(	y
1985	1985	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n233	n233	fo
.	.	y
)	)	y
Geier	geier	nn1_jjr@_np1@
v.	xx_v	nnu_ii
Am	am	ra@
.	.	y
Honda	honda	np1
Motor	motor	nn1
Co.	co	nn1_np1
,	,	y
529	529	mc
U.S.	us	np1
861	861	mc
,	,	y
869-74		mcmc
(	(	y
2000	2000	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Gade	gade	vv0@_np1
v.	xx_v	ii_nnu
Nat'l	nat'l	np1_nn1
Solid	solid	jj_nn1@
Wastes	waste	nn2_vvz
Mgmt	mgmt	np1
.	.	y
Ass'n	ass'n	vv0_nn1_np1@
,	,	y
505	505	mc
U.S.	us	np1
88	88	mc
,	,	y
98	98	mc
(	(	y
1992	1992	mc
)	)	y
;	;	y
Hines	hines	np1
v.	xx_v	ii
Davidowitz	davidowitz	np1
,	,	y
312	312	mc
U.S.	us	np1
52	52	mc
,	,	y
67	67	mc
(	(	y
1941	1941	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n234	n234	fo
.	.	y
)	)	y
See	see	vv0
James	james	np1
O'Reilly	o'reilly	np1
,	,	y
A	a	zz1_at1@
State	state	nn1
of	of	io
Extinction	extinction	nn1
:	:	y
Does	do	vdz
Food	food	nn1
and	and	cc
Drug	drug	nn1
Administration	administration	nn1
Approval	approval	nn1
of	of	io
a	a	at1
Prescription	prescription	nn1
Drug	drug	nn1
Label	label	nn1_vv0
Extinguish	extinguish	vv0
State	state	nn1_vv0
Claims	claim	vvz_nn2
for	for	if
Inadequate	inadequate	jj
Warning	warning	nn1
?	?	y
,	,	y
58	58	mc
FOOD	food	nn1
&;		null
DRUG	drug	nn1
L.J	lj	np1
.	.	y
287	287	mc
,	,	y
291	291	mc
(	(	y
arguing	argue	vvg
that	that	cst
it	it	pph1
is	be	vbz
unlikely	unlikely	jj
that	that	cst
an	a	at1
implied	implied	jj@
field	field	nn1
preemption	preemption	nn1
claim	claim	nn1
could	could	vm
prevail	prevail	vvi
in	in	ii
the	the	at
prescription	prescription	nn1
drug	drug	nn1
field	field	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n235	n235	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Crosby	crosby	np1
,	,	y
530	530	mc
U.S.	us	np1
at	at	ii
372	372	mc
;	;	y
see	see	vv0
also	also	rr
Christine	christine	np1
H.	h	np1
Kim	kim	np1
,	,	y
The	the	at
Case	case	nn1
for	for	if
Preemption	preemption	nn1
of	of	io
Prescription	prescription	nn1
Drug	drug	nn1
Failure-to-Warn	failure-to-warn	vv0
Claims	claim	nn2
,	,	y
62	62	mc
FOOD	food	nn1
&;		null
DRUG	drug	nn1
L.J	lj	np1
.	.	y
399	399	mc
,	,	y
402	402	mc
(	(	y
2007	2007	mc
)	)	y
(	(	y
separating	separate	vvg
the	the	at
three	three	mc
distinct	distinct	jj
forms	form	nn2
of	of	io
implied	implied	jj@
preemption	preemption	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n236	n236	fo
.	.	y
)	)	y
See	see	vv0
Kim	kim	np1
,	,	y
supra	supra	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
increased	increased	jj
amicus	amicus	nn1
curiae	curia	nn2
filings	filing	nn2
in	in	ii
federal	federal	jj
preemption	preemption	nn1
cases	case	nn2
)	)	y
;	;	y
Mark	mark	np1
C.	c	np1
Levy	levy	np1
&;		null
Gregory	gregory	np1
J.	xx_j	np1
Wartman		np1
,	,	y
Amicus	amicus	np1
Curiae	curiae	np1
Efforts	effort	nn2
to	to	ii
Reform	reform	nn1
Product	product	nn1
Liability	liability	nn1
at	at	ii
the	the	at
Food	food	nn1
and	and	cc
Drug	drug	nn1
Administration	administration	nn1
:	:	y
FDA	fda	np1
's	's	ge
Influence	influence	nn1
on	on	ii
Federal	federal	jj
Preemption	preemption	nn1
of	of	io
Class	class	nn1
III	iii	mc
Medical	medical	jj
Devices	device	nn2
and	and	cc
Pharmaceuticals	pharmaceutical	nn2
,	,	y
60	60	mc
FOOD	food	nn1
&;		null
DRUG	drug	nn1
L.J	lj	np1
.	.	y
495	495	mc
,	,	y
497-99	497-99	mcmc
(	(	y
2005	2005	mc
)	)	y
;	;	y
Catherine	catherine	np1
M.	m	nn1
Sharkey	sharkey	np1_nn1@
,	,	y
Federalism	federalism	nn1
in	in	ii
Action	action	nn1
:	:	y
FDA	fda	np1_nn1
Regulatory	regulatory	jj
Preemption	preemption	nn1
in	in	ii
Pharmaceutical	pharmaceutical	jj
Cases	case	nn2
in	in	ii
State	state	nn1_np1@
Versus	versus	ii
Federal	federal	jj
Courts	court	nn2
,	,	y
15	15	mc
J.L.	jl	np1
&;		null
POL'Y	pol'y	np1_nn1
1013	1013	mc
,	,	y
1032-34		mcmc
(	(	y
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n237	n237	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Corrected	correct	vvd_vvn_jj@
Amicus	amicus	np1_nn1
Brief	brief	nn1_jj
for	for	if
the	the	at
United	united	np1
States	state	np1
,	,	y
Kallas	kalla	np2_nn2@
v.	xx_v	ii
Pfizer	pfizer	np1_nn1
,	,	y
Inc.	inc	jj
,	,	y
No.	no	xx
04-00998		mcmc
(	(	y
D.	d	np1
Utah	utah	np1
Sept.	sept	npm1
29	29	mc
,	,	y
2005	2005	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Sharkey	sharkey	np1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
236	236	mc
,	,	y
at	at	ii
1038	1038	mc
(	(	y
estimating	estimate	vvg
that	that	cst
the	the	at
FDA	fda	nn1_np1
is	be	vbz
directly	directly	rr
involved	involved	jj
in	in	ii
one	one	mc1
quarter	quarter	nn1
of	of	io
federal	federal	jj
court	court	nn1
drug	drug	nn1
preemption	preemption	nn1
cases	case	nn2
since	since	ii
2000	2000	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n238	n238	fo
.	.	y
)	)	y
See	see	vv0
Colacicco	colacicco	np1_nn1@
v.	xx_v	ii
Apotex	apotex	np1_nn1
,	,	y
Inc.	inc	jj
,	,	y
432	432	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
514	514	mc
,	,	y
528	528	mc
(	(	y
E.D.	ed	nn1
Pa.	pa	np1_nn1@
2006	2006	mc
)	)	y
(	(	y
citing	cite	vvg
21	21	mc
C.F.R.	c.f.r	np1
314.150	314.150	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
529	529	mc
U.S.	us	np1
861	861	mc
,	,	y
863	863	mc
(	(	y
2000	2000	mc
)	)	y
(	(	y
internal	internal	jj
quotation	quotation	nn1
marks	mark	nn2
omitted	omit	vvn
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n240	n240	fo
.	.	y
)	)	y
See	see	vv0
Requirements	requirement	nn2
on	on	ii
Content	content	nn1_jj
and	and	cc
Format	format	nn1
of	of	io
Labeling	label	vvg_np1
for	for	if
Human	human	jj_nn1
Prescription	prescription	nn1
Drug	drug	nn1
and	and	cc
Biological	biological	jj
Products	product	nn2
,	,	y
71	71	mc
Fed	feed	vvd_vvn
.	.	y
Reg.	reg	nn1
3922	3922	mc
,	,	y
3933-34		mcmc
(	(	y
Jan.	jan	npm1
24	24	mc
,	,	y
2006	2006	mc
)	)	y
(	(	y
effective	effective	jj
date	date	nn1
June	june	npm1
30	30	mc
,	,	y
2006	2006	mc
)	)	y
hereinafter	hereinafter	rr
"	"	y
FDA	fda	np1_nn1
Preamble	preamble	nn1
"	"	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n241	n241	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n242	n242	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
3935	3935	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n243	n243	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n244	n244	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
3935-36		mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n245	n245	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
3935	3935	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n246	n246	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
W.	w	np1
Wylie	wylie	np1
Blair	blair	np1
,	,	y
Implied	imply	vvd_jj@_vvn
Preemption	preemption	nn1
of	of	io
State	state	nn1_np1@
Tort	tort	nn1_np1
Law	law	nn1
Claims	claim	vvz_nn2
Against	against	ii
Prescription	prescription	nn1
Drug	drug	nn1
Manufacturers	manufacturer	nn2
Based	base	vvn
on	on	ii
FDA	fda	np1_nn1
Approval	approval	nn1
,	,	y
27	27	mc
J.	xx_j	np1
LEGAL	legal	jj
MED.	med	np1
289	289	mc
,	,	y
301	301	mc
(	(	y
2006	2006	mc
)	)	y
(	(	y
proposing	propose	vvg_jj@
amendment	amendment	nn1
of	of	io
the	the	at
Food	food	nn1
,	,	y
Drug	drug	nn1
,	,	y
and	and	cc
Cosmetic	cosmetic	jj
Act	act	nn1
,	,	y
enactment	enactment	nn1
of	of	io
state	state	nn1
statutes	statute	nn2
,	,	y
or	or	cc
the	the	at
use	use	nn1
of	of	io
judicial	judicial	jj
intervention	intervention	nn1
to	to	to
adopt	adopt	vvi
the	the	at
FDA	fda	np1_nn1
's	's	ge
interpretation	interpretation	nn1
of	of	io
the	the	at
scope	scope	nn1
of	of	io
implied	implied	jj@
preemption	preemption	nn1
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
the	the	at
Challenged	challenged	jj@
Role	role	nn1
of	of	io
Failure	failure	nn1
to	to	to_ii
Warn	warn	vv0
and	and	cc
Defective	defective	jj
Design	design	nn1
Pharmaceutical	pharmaceutical	jj
Cases	case	nn2
in	in	ii
Revealing	reveal	vvg_jj
Scientific	scientific	jj
Fraud	fraud	nn1
,	,	y
Marketing	marketing	nn1_vvg@
Mischief	mischief	nn1
,	,	y
and	and	cc
Conflicts	conflict	nn2
of	of	io
Interest	interest	nn1
,	,	y
35	35	mc
HOFSTRA	hofstra	np1
L.	l	np1
REV.	rev	nnu
1773	1773	mc
,	,	y
1778	1778	mc
(	(	y
2007	2007	mc
)	)	y
(	(	y
juxtaposing	juxtapose	vvg
the	the	at
FDA	fda	np1_nn1
's	's	ge
preemption	preemption	nn1
position	position	nn1
with	with	iw
deficiencies	deficiency	nn2
in	in	ii
the	the	at
agency	agency	nn1
's	's	ge_vbz
post-market	post-market	jj
regulatory	regulatory	jj
scheme	scheme	nn1
and	and	cc
suggesting	suggest	vvg
a	a	at1
possible	possible	jj
retreat	retreat	nn1
from	from	ii
the	the	at
FDA	fda	np1_nn1
's	's	ge
strong	strong	jj
stance	stance	nn1
on	on	ii
implied	implied	jj@
preemption	preemption	nn1
)	)	y
;	;	y
Margaret	margaret	np1
Gilhooley	gilhooley	np1
,	,	y
Addressing	address	vvg
Potential	potential	jj_nn1
Drug	drug	nn1
Risks	risk	nn2_vvz@
:	:	y
The	the	at
Limits	limit	nn2
of	of	io
Testing	testing	np1_nn1_vvg
,	,	y
Risk	risk	vv0_nn1
Signals	signal	nn2
,	,	y
Preemption	preemption	nn1_np1@
,	,	y
and	and	cc
the	the	at
Drug	drug	nn1
Reform	reform	nn1
Legislation	legislation	nn1
,	,	y
59	59	mc
S.C.L.		np1
REV.	rev	nnu
347	347	mc
,	,	y
388	388	mc
(	(	y
2008	2008	mc
)	)	y
(	(	y
recommending	recommend	vvg
the	the	at
FDA	fda	nn1_np1
change	change	vv0
its	its	z'
policy	policy	nn1
and	and	cc
require	require	vv0
that	that	dd1_cst
drug	drug	nn1
sponsors	sponsor	nn2
petition	petition	vv0@
the	the	at
agency	agency	nn1
for	for	if
a	a	at1
statement	statement	nn1
of	of	io
preemptive	pre-emptive	jj
effect	effect	nn1
on	on	ii
the	the	at
need	need	nn1
for	for	if
a	a	at1
warning	warning	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n247	n247	fo
.	.	y
)	)	y
Compare	compare	vv0
Howard	howard	np1
L.	l	np1
Dorfman	dorfman	np1
et	et	ra21
al.	al	ra22
,	,	y
Presumption	presumption	nn1
of	of	io
Innocence	innocence	nn1
:	:	y
FDA	fda	np1
's	's	ge
Authority	authority	nn1
to	to	to_ii
Regulate	regulate	vv0
the	the	at
Specifics	specific	nn2
of	of	io
Prescription	prescription	nn1
Drug	drug	nn1
Labeling	label	vvg_np1_nn1@
and	and	cc
the	the	at
Preemption	preemption	nn1
Debate	debate	nn1
,	,	y
61	61	mc
FOOD	food	nn1
&;		null
DRUG	drug	nn1
L.J	lj	np1
.	.	y
585	585	mc
,	,	y
610-11	610-11	mcmc
(	(	y
2006	2006	mc
)	)	y
(	(	y
advocating	advocate	vvg
substantial	substantial	jj
,	,	y
or	or	cc
Chevron	chevron	np1_nn1
level	level	nn1_jj
,	,	y
deference	deference	nn1
to	to	ii
the	the	at
Preamble	preamble	nn1
)	)	y
,	,	y
with	with	iw
Leslie	leslie	np1
C.	c	np1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
A	a	at1@_zz1
Role	role	nn1
for	for	if
Implied	implied	jj@
Preemption	preemption	nn1
,	,	y
62	62	mc
FOOD	food	nn1
&;		null
DRUG	drug	nn1
L.J	lj	np1
.	.	y
227	227	mc
,	,	y
247	247	mc
(	(	y
2007	2007	mc
)	)	y
(	(	y
concluding	conclude	vvg_jj
that	that	cst
the	the	at
Preamble	preamble	nn1
warrants	warrant	vvz
low	low	jj
level	level	nn1_jj
or	or	cc
Skidmore	skidmore	np1
deference	deference	nn1
)	)	y
.	.	y
See	see	vv0
also	also	rr
Catherine	catherine	np1
M.	m	nn1
Sharkey	sharkey	np1_nn1@
,	,	y
Preemption	preemption	nn1_np1@
by	by	ii
Preamble	preamble	nn1
:	:	y
Federal	federal	jj
Agencies	agency	nn2
and	and	cc
the	the	at
Federalization	federalization	nn1
of	of	io
Tort	tort	np1_nn1
Law	law	nn1
,	,	y
56	56	mc
DEPAUL	depaul	np1
L.	l	np1
REV.	rev	nnu
227	227	mc
,	,	y
243-45	243-45	mcmc
(	(	y
2007	2007	mc
)	)	y
(	(	y
examining	examine	vvg
increased	increased	jj
use	use	nn1
of	of	io
preemption	preemption	nn1
by	by	ii
federal	federal	jj
agencies	agency	nn2
and	and	cc
corresponding	corresponding	jj_vvg
judicial	judicial	jj
deference	deference	nn1
to	to	ii
agency	agency	nn1
determinations	determination	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n248	n248	fo
.	.	y
)	)	y
Compare	compare	vv0
In	in	rp@
re	re	ii
Bextra	bextra	np1
&;		null
Celebrex	celebrex	np1
Mktg	mktg	np1
.	.	y
Sales	sales	npx
Practices	practice	nn2
&;		null
Prod	prod	vv0_nn1
.	.	y
Liab	liab	vv0_nn1_np1@
.	.	y
Litig.	litig	np1
,	,	y
No.	no	xx
05-1699		mcmc
,	,	y
2006	2006	mc
WL	wl	np1
2374742	2374742	mc
(	(	y
N.D.	nd	np1
Cal	calorie	nnu
Aug.	aug	npm1
16	16	mc
,	,	y
2006	2006	mc
)	)	y
(	(	y
same	same	da
Celebrex	celebrex	nn1_np1
)	)	y
,	,	y
Conte	conte	np1_nn1
v.	xx_v	ii
Wyeth	wyeth	np1
,	,	y
Inc.	inc	jj
,	,	y
No.	no	xx
04-437382		mcmc
,	,	y
2006	2006	mc
WL	wl	np1
2692469	2692469	mc
(	(	y
Cal	calorie	nnu
.	.	y
App	app	vv0_nn1_np1@
.	.	y
Dep't	dep't	vv0
Super	super	jj_nn1@
.	.	y
Ct	ct	np1_nn1
.	.	y
Sept.	sept	npm1
14	14	mc
,	,	y
2006	2006	mc
)	)	y
(	(	y
same	same	da
metroclopramide	metroclopramide	nn1
)	)	y
,	,	y
and	and	cc
Abramowitz	abramowitz	np1_vv0@_nn1@
v.	xx_v	ii
Cephalon	cephalon	np1_nn1
,	,	y
Inc.	inc	jj
,	,	y
No	no	xx
.	.	y
BER-L-617-04		np1
,	,	y
2006	2006	mc
WL	wl	np1
560639	560639	mc
(	(	y
N.J.	nj	np1
Super	super	jj_nn1@
.	.	y
Ct	ct	np1_nn1
.	.	y
Law	law	nn1
Div	div	mc
.	.	y
Mar.	mar	npm1
3	3	mc
,	,	y
2006	2006	mc
)	)	y
(	(	y
finding	find	vvg_nn1
implied	implied	jj@_vvd_vvn
preemption	preemption	nn1
for	for	if
FDA	fda	np1_nn1
's	's	ge
approval	approval	nn1
of	of	io
risks	risk	nn2
associated	associate	vvn
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
&;		null
Co.	co	np1
,	,	y
467	467	mc
F.3d	f.3d	fo
85	85	mc
(	(	y
2d	2d	nnu
Cir.	cir	np1
2006	2006	mc
)	)	y
,	,	y
aff	aff	nn1
'd	have	vhd_vm
sub	sub	jj_nn1
.	.	y
nom	nom	vv0_nn1
,	,	y
Warner-Lambert	warner-lambert	np1
Co.	co	np1_nn1
v.	xx_v	ii
Kent	kent	np1
,	,	y
128	128	mc
S.	s	np1
Ct	ct	np1_nn1
.	.	y
1168	1168	mc
(	(	y
2008	2008	mc
)	)	y
,	,	y
Weiss	weiss	vv0_np1_nn1
v.	xx_v	ii
Fujisawa	fujisawa	np1
Pharm	pharm	np1_nn1
.	.	y
Co.	co	np1_nn1
,	,	y
464	464	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
666	666	mc
(	(	y
E.D.	ed	nn1
Ky.	ky	np1
2006	2006	mc
)	)	y
,	,	y
Jackson	jackson	np1
v.	xx_v	ii
Pfizer	pfizer	np1_nn1
,	,	y
Inc.	inc	jj
,	,	y
432	432	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
964	964	mc
(	(	y
D.	d	np1
Neb.	neb	np1
2006	2006	mc
)	)	y
,	,	y
and	and	cc
Levine	levine	np1_vv0@_nn1@
v.	xx_v	ii
Wyeth	wyeth	np1
,	,	y
944	944	mc
A.2d	a.2d	fo
179	179	mc
(	(	y
Vt.	vt	np1
2006	2006	mc
)	)	y
,	,	y
cert	cert	nn1
.	.	y
granted	grant	vvn_vvd
,	,	y
128	128	mc
S.	s	np1
Ct	ct	np1_nn1
.	.	y
1118	1118	mc
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n249	n249	fo
.	.	y
)	)	y
Medtronic	medtronic	np1@_jj
,	,	y
Inc.	inc	jj
v.	xx_v	ii
Lohr	lohr	np1_nn1
,	,	y
518	518	mc
U.S.	us	np1
470	470	mc
,	,	y
505	505	mc
(	(	y
1996	1996	mc
)	)	y
(	(	y
Breyer	breyer	np1_nn1
,	,	y
J.	xx_j	np1
,	,	y
concurring	concur	vvg
)	)	y
;	;	y
see	see	vv0
also	also	rr
Chevron	chevron	nn1_np1
v.	xx_v	ii
Nat'l	nat'l	np1_nn1
Res	res	nn2_jj
.	.	y
Def	def/	vv0_nn1_np1@
.	.	y
Council	council	nn1
467	467	mc
U.S.	us	np1
837	837	mc
,	,	y
863-64	863-64	mcmc
(	(	y
1984	1984	mc
)	)	y
(	(	y
"	"	y
The	the	at
fact	fact	nn1
that	that	cst
the	the	at
agency	agency	nn1
has	have	vhz
from	from	rr41
time	time	rr42
to	to	rr43
time	time	rr44
changed	change	vvn
its	its	z'
interpretation	interpretation	nn1
..	...	...
,	,	y
does	do	vdz
not	not	xx
..	...	...
,	,	y
lead	lead	vv0
us	us	ppio2
to	to	to
conclude	conclude	vvi
that	that	cst
no	no	at
deference	deference	nn1
should	should	vm
be	be	vbi
accorded	accord	vvn
the	the	at
agency	agency	nn1
's	's	ge
interpretation	interpretation	nn1
of	of	io
the	the	at
statute	statute	nn1
.	.	y
An	a	at1
initial	initial	jj_nn1
agency	agency	nn1
interpretation	interpretation	nn1
is	be	vbz
not	not	xx
instantly	instantly	rr
carved	carve	vvn_vvd
in	in	ii
stone	stone	nn1
.	.	y
"	"	y
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
471	471	mc
U.S.	us	np1
707	707	mc
,	,	y
718	718	mc
(	(	y
1985	1985	mc
)	)	y
;	;	y
see	see	vv0
also	also	rr
Dowhal	dowhal	jj_np1
v.	xx_v	ii
SmithKline	smithkline	np1
Beecham	beecham	np1
Consumer	consumer	nn1
,	,	y
88	88	mc
P.3d	p.3d	fo
1	1	mc1
,	,	y
5-6	5-6	mcmc
,	,	y
9-10	9-10	mcmc
(	(	y
Cal	calorie	nnu
.	.	y
2004	2004	mc
)	)	y
(	(	y
according	accord	vvg_ii_cs_jj@
deference	deference	nn1
to	to	ii
FDA	fda	np1_nn1
position	position	nn1
expressed	express	vvn_vvd
in	in	ii
letters	letter	nn2
issued	issue	vvn_vvd
in	in	ii31
response	response	ii32
to	to	ii33
a	a	at1
manufacturer	manufacturer	nn1
inquiry	inquiry	nn1
and	and	cc
citizen	citizen	nn1
petition	petition	nn1
stating	state	vvg
that	that	cst
California	california	np1
law	law	nn1
was	be	vbdz
preempted	preempt	vvn@
to	to	ii
the	the	at
extent	extent	nn1
it	it	pph1
required	required	jj_vvd@
warnings	warning	nn2
on	on	ii
nicotine	nicotine	nn1
replacement	replacement	nn1
devices	device	nn2
that	that	cst
conflicted	conflict	vvd
with	with	iw
the	the	at
FDA	fda	np1_nn1
's	's	ge
determination	determination	nn1
that	that	cst
a	a	at1
manufacturer	manufacturer	nn1
could	could	vm
include	include	vvi
only	only	rr_jj
approved	approved	jj_vvn
warnings	warning	nn2
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
251	251	mc
.	.	y
)	)	y
Levine	levine	vv0_nn1
v.	xx_v	ii
Wyeth	wyeth	np1
,	,	y
944	944	mc
A.2d	a.2d	fo
179	179	mc
(	(	y
Vt.	vt	np1
2006	2006	mc
)	)	y
,	,	y
cert	cert	nn1
.	.	y
granted	grant	vvn_vvd
,	,	y
128	128	mc
S.	s	np1
Ct	ct	np1_nn1
.	.	y
1118	1118	mc
(	(	y
2008	2008	mc
)	)	y
(	(	y
No.	no	xx
06-1249		mcmc
)	)	y
.	.	y
The	the	at
Court	court	nn1
also	also	rr
decided	decide	vvd_vvn
two	two	mc
other	other	jj
cases	case	nn2
this	this	dd1
term	term	nn1
considering	considering	ii_vvg_cs
preemption	preemption	nn1
in	in	ii
the	the	at
FDA	fda	nn1_np1
context	context	nn1
.	.	y
See	see	vv0
Riegel	riegel	np1_nn1@
v.	xx_v	ii
Medtronic	medtronic	jj
,	,	y
Inc.	inc	jj
,	,	y
128	128	mc
S.	s	np1
Ct	ct	np1_nn1
.	.	y
999	999	mc
(	(	y
2008	2008	mc
)	)	y
;	;	y
Warner-Lambert	warner-lambert	np1
Co.	co	np1_nn1
v.	xx_v	ii
Kent	kent	np1
,	,	y
128	128	mc
S.	s	np1
Ct	ct	np1_nn1
.	.	y
1168	1168	mc
(	(	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n252	n252	fo
.	.	y
)	)	y
See	see	vv0
Levine	levine	np1
,	,	y
944	944	mc
A.2d	a.2d	fo
at	at	ii
182	182	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n253	n253	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
183	183	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
--		nn1_jj
(	(	y
n255	n255	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
188	188	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n256	n256	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n257	n257	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
194	194	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n258	n258	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
192	192	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n259	n259	fo
.	.	y
)	)	y
See	see	vv0
Brief	brief	nn1_jj
for	for	if
the	the	at
United	united	np1
States	state	np1
as	as	csa_ii@
Amicus	amicus	np1
Curiae	curiae	np1
Supporting	supporting	jj_vvg
Petitioner	petitioner	nn1
,	,	y
Wyeth	wyeth	vvz_np1
v.	xx_v	ii
Levine	levine	np1
,	,	y
No.	no	xx
06-1249		mcmc
(	(	y
U.S.	us	np1
filed	file	vvd
Dec.	dec	np
2007	2007	mc
)	)	y
,	,	y
available	available	jj
at	at	ii
http		nnu
:	:	y
**63;2219;TOOLONG		fu
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n260	n260	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
9-11	9-11	mcmc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n261	n261	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
9	9	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n262	n262	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
11	11	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n263	n263	fo
.	.	y
)	)	y
See	see	vv0
Colacicco	colacicco	np1_nn1@
v.	xx_v	ii
Apotex	apotex	np1_nn1
,	,	y
Inc.	inc	jj
,	,	y
432	432	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
514	514	mc
(	(	y
E.D.	ed	nn1
Pa.	pa	np1_nn1@
2006	2006	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n264	n264	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
529	529	mc
;	;	y
see	see	vv0
also	also	rr
Sykes	sykes	np1
v.	xx_v	ii
Glaxo-SmithKline		np1
,	,	y
484	484	mc
F.	f	np1_ra@
Supp.	supp	np1
2d	2d	nnu
289	289	mc
,	,	y
308-10	308-10	mcmc
(	(	y
E.D.	ed	nn1
Pa.	pa	np1_nn1@
2007	2007	mc
)	)	y
(	(	y
preempting	preempt	vvg_jj@
state	state	nn1
tort	tort	nn1_vv0
actions	action	nn2_vvz@
against	against	ii
pediatric	pediatric	jj
vaccine	vaccine	nn1
manufacturers	manufacturer	nn2
under	under	ii
the	the	at
National	national	jj
Childhood	childhood	nn1
Vaccine	vaccine	nn1
Injury	injury	nn1
Compensation	compensation	nn1
Act	act	nn1
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n265	n265	fo
.	.	y
)	)	y
See	see	vv0
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Prod	prod	vv0_nn1
.	.	y
Liab	liab	vv0_nn1_np1@
.	.	y
Litig.	litig	np1
,	,	y
MDL	mdl	mc
No.	no	xx
1699	1699	mc
,	,	y
2006	2006	mc
WL	wl	np1
2374742	2374742	mc
,	,	y
at	at	ii
*9	*9	fo
(	(	y
N.D.	nd	np1
Cal	calorie	nnu
.	.	y
Aug.	aug	npm1
16	16	mc
,	,	y
2006	2006	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n266.		fo
)	)	y
499	499	mc
F.3d	f.3d	fo
239	239	mc
,	,	y
241	241	mc
(	(	y
3d	3d	nnu
Cir.	cir	np1
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n267	n267	fo
.	.	y
)	)	y
See	see	vv0
DEL	del	fw_np1@
.	.	y
CODE	code	vv0@_nn1
tit.	tit	nnu
6	6	mc
2513(b)		fo
(	(	y
2009	2009	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n268	n268	fo
.	.	y
)	)	y
See	see	vv0
Pennsylvania	pennsylvania	np1
Employees	employee	nn2
,	,	y
499	499	mc
F.3d	f.3d	fo
at	at	ii
243	243	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n269	n269	fo
.	.	y
)	)	y
Id	id	z'
.	.	y
at	at	ii
251	251	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n270	n270	fo
.	.	y
)	)	y
See	see	vv0
id	id	z'
.	.	y
at	at	ii
252	252	mc
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n271	n271	fo
.	.	y
)	)	y
See	see	vv0
Richard	richard	np1
Epstein	epstein	np1
,	,	y
Why	why	rrq
the	the	at
FDA	fda	nn1_np1
Must	must	vm
Preempt	preempt	np1_vv0
Tort	tort	np1_nn1
Litigation	litigation	nn1
:	:	y
A	a	at1@_zz1
Critique	critique	nn1
of	of	io
Chevron	chevron	np1_nn1
Deference	deference	nn1
and	and	cc
a	a	at1
Response	response	nn1
to	to	ii
Richard	richard	np1
Nagareda	nagareda	np1
,	,	y
1	1	mc1
J.	xx_j	np1
TORT	tort	np1
L.	l	np1
1	1	mc1
,	,	y
1	1	mc1
(	(	y
2006	2006	mc
)	)	y
(	(	y
"	"	y
Federal	federal	jj
preemption	preemption	nn1
of	of	io
state	state	nn1
tort	tort	nn1_vv0
actions	action	nn2
for	for	if
pharmaceuticals	pharmaceutical	nn2
is	be	vbz
long	long	rr
overdue	overdue	jj
,	,	y
both	both	rr_db2
under	under	rg@_ii
current	current	jj
law	law	nn1
and	and	cc
as	as	ii
a	a	at1
matter	matter	nn1
of	of	io
sound	sound	jj@_nn1
legal	legal	jj
policy	policy	nn1
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n272	n272	fo
.	.	y
)	)	y
See	see	vv0
Buckman	buckman	np1_nn1
Co.	co	np1_nn1
v.	xx_v	ii
Plaintiffs	plaintiff	nn2
'	'	ge
Legal	legal	jj
Comm.	comm	np1
,	,	y
531	531	mc
U.S.	us	np1
341	341	mc
,	,	y
350	350	mc
(	(	y
2001	2001	mc
)	)	y
(	(	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
's	's	ge_vbz
detailed	detailed	jj
regulatory	regulatory	jj
regime	regime	nn1
in	in	ii
the	the	at
shadow	shadow	nn1
of	of	io
50	50	mc
States	state	np1
'	'	ge
tort	tort	nn1
regimes	regime	nn2
will	will	vm
dramatically	dramatically	rr
increase	increase	vvi
the	the	at
burdens	burden	nn2
facing	face	vvg
potential	potential	jj_nn1
applicants-burdens		nn2
not	not	xx
contemplated	contemplate	vvn
by	by	ii
Congress	congress	nn1
in	in	ii
enacting	enact	vvg
the	the	at
FDCA	fdca	nn1_np1
.	.	y
...	...	...
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n273	n273	fo
.	.	y
)	)	y
See	see	vv0
FDA	fda	nn1_np1
Preamble	preamble	nn1
,	,	y
supra	supra	nn1
note	note	nn1_vv0
240	240	mc
,	,	y
at	at	ii
3934	3934	mc
(	(	y
"	"	y
In	in	ii
order	order	nn1
to	to	ii
more	more	rgr
fully	fully	rr
address	address	vv0@
the	the	at
comments	comment	nn2
expressing	express	vvg
concern	concern	nn1
about	about	ii
the	the	at
product	product	nn1
liability	liability	nn1
implications	implication	nn2
of	of	io
revising	revise	vvg
the	the	at
labeling	labeling	nn1@_jj@_vvg
for	for	if
prescription	prescription	nn1
drugs	drug	nn2
,	,	y
we	we	ppis2
believe	believe	vv0
it	it	pph1
would	would	vm
be	be	vbi
useful	useful	jj
to	to	to
set	set	vvi
forth	forth	rr
in	in	ii
some	some	dd
detail	detail	nn1_vv0@
the	the	at
arguments	argument	nn2
made	make	vvn_vvd
in	in	ii
those	those	dd2
amicus	amicus	nn1
briefs	brief	nn2
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n274	n274	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
U.S.C.	usc	np1
301	301	mc
(	(	y
2006	2006	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n275	n275	fo
.	.	y
)	)	y
See	see	vv0
21	21	mc
U.S.C.	usc	np1
360k(a)		fo
(	(	y
2006	2006	mc
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n276	n276	fo
.	.	y
)	)	y
See	see	vv0
supra	supra	nn1
Part	part	nn1
III.A	iii.a	np1
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n277	n277	fo
.	.	y
)	)	y
See	see	vv0
supra	supra	nn1
Part	part	nn1
III.B	iii.b	np1
;	;	y
see	see	vv0
also	also	rr
Dorfman	dorfman	np1
et	et	ra21
al.	al	ra22
,	,	y
supra	supra	nn1
note	note	nn1_vv0
247	247	mc
,	,	y
at	at	ii
622	622	mc
(	(	y
"	"	y
The	the	at
public	public	jj_nn1
policy	policy	nn1
balance	balance	nn1
weighs	weigh	vvz
in	in	ii31
favor	favor	ii32
of	of	ii33
a	a	at1
uniform	uniform	jj
federal	federal	jj
scheme	scheme	nn1
to	to	to
provide	provide	vvi
for	for	if
the	the	at
introduction	introduction	nn1
of	of	io
urgently	urgently	rr
needed	need	vvn_vvd
medical	medical	jj
therapies	therapy	nn2
without	without	iw
compromising	compromise	vvg_jj@
FDA	fda	np1_nn1
's	's	ge
role	role	nn1
of	of	io
ensuring	ensure	vvg
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
scientifically	scientifically	rr
sound	sound	vv0@_jj@
precautionary	precautionary	jj
language	language	nn1
with	with	ii31
regard	regard	ii32
to	to	ii33
adverse	adverse	jj
events	event	nn2
,	,	y
and	and	cc
allow	allow	vv0
for	for	if
clear	clear	jj
understanding	understanding	nn1
by	by	ii
the	the	at
recipients	recipient	nn2
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
--		nn1_jj
(	(	y
n278	n278	fo
.	.	y
)	)	y
See	see	vv0
,	,	y
e.g.	eg	rex
,	,	y
Jennifer	jennifer	np1
Girod	girod	np1
,	,	y
The	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Doctrine	doctrine	nn1
:	:	y
An	a	at1
Efficient	efficient	jj
Protection	protection	nn1
for	for	if
Patients	patient	nn2
,	,	y
Past	past	jj_nn1_rl
and	and	cc
Present	present	nn1_jj
,	,	y
40	40	mc
IND	ind	nn1
.	.	y
L.	l	np1_nnu@
REV.	rev	nnu
397	397	mc
,	,	y
398	398	mc
,	,	y
416	416	mc
(	(	y
2007	2007	mc
)	)	y
(	(	y
discussing	discuss	vvg
the	the	at
potential	potential	jj_nn1
benefits	benefit	nn2
of	of	io
DTC	dtc	np1
advertising	advertising	nn1
)	)	y
;	;	y
Jack	jack	np1
B.	b	np1
Harrison	harrison	np1
&;		null
Mina	mina	np1
J.	xx_j	np1
Jerrerson		np1
,	,	y
"	"	y
Some	some	dd
Accurate	accurate	jj
Information	information	nn1
is	be	vbz
Better	better	jjr_rrr
Than	than	csn
No	no	xx
Information	information	nn1
at	at	rr21
All	all	rr22
"	"	y
:	:	y
Arguments	argument	nn2
Against	against	ii
An	a	at1
Exception	exception	nn1
to	to	ii
the	the	at
Learned	learned	jj@
Intermediary	intermediary	nn1
Doctrine	doctrine	nn1
Based	base	vvn
on	on	ii
Direct-to-Consumer		np1
Advertising	advertising	nn1
,	,	y
78	78	mc
OR	or	cc
.	.	y
L.	l	np1_nnu@
REV.	rev	nnu
605	605	mc
,	,	y
606	606	mc
(	(	y
1999	1999	mc
)	)	y
(	(	y
"	"	y
DTC	dtc	np1
advertising	advertising	nn1
increases	increase	vvz_nn2
consumer	consumer	nn1
awareness	awareness	nn1
of	of	io
illnesses	illness	nn2
and	and	cc
their	their	appge
symptoms	symptom	nn2
,	,	y
empowers	empower	vvz
consumers	consumer	nn2
to	to	to
take	take	vvi
charge	charge	nn1
of	of	io
their	their	appge
healthcare	health-care	nn1
decisions	decision	nn2
,	,	y
and	and	cc
enhances	enhance	vvz
the	the	at
quality	quality	nn1
of	of	io
the	the	at
dialogue	dialogue	nn1
between	between	ii
physicians	physician	nn2
and	and	cc
patients	patient	nn2
.	.	y
"	"	y
)	)	y
.	.	y
<p>	<p>	y
GRAPH	graph	nn1
:	:	y
Figure	figure	nn1_vv0%
1	1	mc1
Ads	ad	nn2
Rank	rank	np1_vv0@
Low	low	np1_jj_rr@
as	as	ii_csa
a	a	at1
Source	source	nn1
of	of	io
Information	information	nn1
for	for	if
Rx	rx	np1
Drugs	drug	nn2
<p>	<p>	y
By	by	ii
Victor	victor	np1
E.	e	np1
Schwartz	schwartz	np1
;	;	y
Cary	cary	np1
Silverman	silverman	np1_nn1
;	;	y
Michael	michael	np1
J.	xx_j	np1
Hulka	hulka	np1
and	and	cc
Christopher	christopher	np1
E.	e	np1
Appel	appel	np1
<p>	<p>	y
Victor	victor	np1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
Hardy	hardy	np1
&;		null
Bacon	bacon	np1
L.L.P.	l.l.p	np1
(	(	y
Washington	washington	np1
,	,	y
D.C.	d.c	np1
)	)	y
;	;	y
Co-Author	co-author	nn1
,	,	y
PROSSER	prosser	np1
,	,	y
WADE	wade	np1_vv0
AND	and	cc
SCHWARTZ	schwartz	np1_nn1
'S	's	ge
TORTS	tort	nn2
(	(	y
11th	11th	md
ed.	ed	nn1
2005	2005	mc
)	)	y
;	;	y
Member	member	nn1
,	,	y
Advisory	advisory	jj
Committees	committee	nn2
of	of	io
the	the	at
American	american	jj
Law	law	nn1
Institute	institute	nn1
's	's	ge
Restatement	restatement	nn1
of	of	io
the	the	at
Law	law	nn1
(	(	y
Third	third	md_np1%
)	)	y
Torts	torts	vvz_np1
:	:	y
Products	product	nn2
Liability	liability	nn1
,	,	y
Apportionment	apportionment	nn1
of	of	io
Liability	liability	nn1
,	,	y
General	general	jj_nn1
Principles	principle	nn2
,	,	y
Liability	liability	nn1
for	for	if
Physical	physical	jj
and	and	cc
Emotional	emotional	jj
Harm	harm	nn1
projects	project	nn2
;	;	y
J.D.	jd	np1
,	,	y
Columbia	columbia	np1
University	university	nn1
(	(	y
magna	magna	rr31
cum	cum	rr32
laude	laude	rr33
)	)	y
;	;	y
B.A.	ba	np1
,	,	y
Boston	boston	np1
University	university	nn1
(	(	y
summa	summa	rr31
cum	cum	rr32
laude	laude	rr33
)	)	y
.	.	y
<p>	<p>	y
Cary	cary	np1
Silverman	silverman	np1
,	,	y
Of	of	io
Counsel	counsel	np1
,	,	y
Shook	shake	vvd_vvn
,	,	y
Hardy	hardy	np1
&;		null
Bacon	bacon	np1
L.L.P.	l.l.p	np1
(	(	y
Washington	washington	np1
,	,	y
D.C.	d.c	np1
)	)	y
;	;	y
J.D.	jd	np1
,	,	y
M.P.A.	mpa	np1
,	,	y
The	the	at
George	george	np1
Washington	washington	np1
University	university	nn1
Law	law	nn1
School	school	nn1
(	(	y
2000	2000	mc
)	)	y
(	(	y
with	with	iw
honors	honor	nn2
)	)	y
;	;	y
B.S.	bs	np1
,	,	y
Management	management	nn1
Science	science	nn1
,	,	y
State	state	vv0_nn1_np1@
University	university	nn1
of	of	io
New	new	np1
York	york	np1
College	college	nn1
at	at	ii
Geneseo	geneseo	np1
(	(	y
n1997		fo
)	)	y
.	.	y
<p>	<p>	y
Michael	michael	np1
J.	xx_j	np1
Hulka	hulka	np1
,	,	y
Counsel	counsel	np1
,	,	y
Eli	eli	np1
Lilly	lilly	np1
and	and	cc
Company	company	nn1
;	;	y
Law	law	nn1
Clerk	clerk	nn1
,	,	y
Judge	judge	np1@_vv0
Michael	michael	np1
S.	s	np1
Kanne	kanne	np1
,	,	y
U.S.	us	np1
Court	court	nn1
of	of	io
Appeals	appeal	nn2
for	for	if
the	the	at
Seventh	seventh	md
Circuit	circuit	nn1
;	;	y
J.D.	jd	np1
,	,	y
Indiana	indiana	np1
University	university	nn1
Bloomington	bloomington	np1_nn1@
School	school	nn1
of	of	io
Law	law	nn1
(	(	y
magna	magna	rr31
cum	cum	rr32
laude	laude	rr33
)	)	y
;	;	y
Editor-in-Chief	editor-in-chief	nn1_jj
,	,	y
Indiana	indiana	np1
Law	law	nn1
Journal	journal	nn1
.	.	y
The	the	at
views	view	nn2
expressed	express	vvn_vvd
herein	herein	rr
do	do	vd0
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
.	.	y
<p>	<p>	y
Christopher	christopher	np1
E.	e	np1
Appel	appel	np1
,	,	y
Attorney	attorney	nn1
,	,	y
Public	public	jj_nn1
Policy	policy	nn1
Group	group	nn1
,	,	y
Shook	shake	vvd_vvn
,	,	y
Hardy	hardy	np1
&;		null
Bacon	bacon	np1
L.L.P.	l.l.p	np1
(	(	y
Washington	washington	np1
,	,	y
D.C.	d.c	np1
)	)	y
;	;	y
J.D.	jd	np1
,	,	y
Wake	wake	vv0_nn1
Forest	forest	nn1
University	university	nn1
School	school	nn1
of	of	io
Law	law	nn1
;	;	y
B.S.	bs	np1
,	,	y
University	university	nn1
of	of	io
Virginia	virginia	np1
.	.	y
<p>	<p>	y
